<SEC-DOCUMENT>0000886163-19-000063.txt : 20190424
<SEC-HEADER>0000886163-19-000063.hdr.sgml : 20190424
<ACCEPTANCE-DATETIME>20190423180858
ACCESSION NUMBER:		0000886163-19-000063
CONFORMED SUBMISSION TYPE:	DEF 14A
PUBLIC DOCUMENT COUNT:		10
CONFORMED PERIOD OF REPORT:	20190606
FILED AS OF DATE:		20190424
DATE AS OF CHANGE:		20190423
EFFECTIVENESS DATE:		20190424

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			LIGAND PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0000886163
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				770160744
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEF 14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33093
		FILM NUMBER:		19762329

	BUSINESS ADDRESS:	
		STREET 1:		3911 SORRENTO VALLEY BLVD
		STREET 2:		SUITE 110
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		858-550-7500

	MAIL ADDRESS:	
		STREET 1:		3911 SORRENTO VALLEY BLVD
		STREET 2:		SUITE 110
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEF 14A
<SEQUENCE>1
<FILENAME>lgnd-2019annualmeetingproxy.htm
<DESCRIPTION>DEF 14A
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sF3941A1C39635ECB90E05C1FEBE214C6"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">UNITED STATES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">WASHINGTON, D.C. 20549</font></div><div style="line-height:120%;padding-top:13px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SCHEDULE 14A INFORMATION</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Rule 14a-101)</font></div><div style="line-height:120%;padding-top:9px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PROXY STATEMENT PURSUANT TO SECTION 14(a) OF</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">THE SECURITIES EXCHANGE ACT OF 1934</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Filed by the Registrant </font><font style="font-family:Wingdings;font-size:10pt;">x</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Filed by a Party other than the Registrant </font><font style="font-family:Wingdings;font-size:10pt;">&#168;</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Check the appropriate box:  </font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:6%;"></td><td style="width:94%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">&#168;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:21px;text-align:left;padding-left:26px;text-indent:-27px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Preliminary Proxy Statement</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:8px;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">&#168;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:5px;text-align:left;padding-left:26px;text-indent:-27px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">x</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:5px;text-align:left;padding-left:26px;text-indent:-27px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Definitive Proxy Statement</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">&#168;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:5px;text-align:left;padding-left:26px;text-indent:-27px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Definitive Additional Materials</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:8px;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">&#168;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:5px;text-align:left;padding-left:26px;text-indent:-27px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Soliciting Material under 240.14a-12</font></div></td></tr></table></div><img src="ligandlogo41719.jpg" alt="ligandlogo41719.jpg" style="height:65px;width:149px;"></div><div style="line-height:120%;padding-top:5px;text-align:center;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-weight:bold;">LIGAND PHARMACEUTICALS INCORPORATED</font></div><div style="line-height:120%;padding-top:13px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Name of Registrant as Specified In Its Charter</font></div><div style="line-height:120%;padding-top:21px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Name of Person(s) Filing Proxy Statement, if other than the Registrant</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Payment of Filing Fee (Check the appropriate box):</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:6%;"></td><td style="width:94%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">x</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:17px;text-align:left;padding-left:26px;text-indent:-27px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">No fee required.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">&#168;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:17px;text-align:left;padding-left:26px;text-indent:-27px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1)&#160;&#160;&#160;&#160;Title of each class of securities to which transaction applies:</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2)&#160;&#160;&#160;&#160;Aggregate number of securities to which transaction applies:</font></div><div style="padding-left:36px;text-indent:-36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3)&#160;&#160;&#160;&#160;Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the filing fee is calculated and state how it was determined):</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4)&#160;&#160;&#160;&#160;Proposed maximum aggregate value of transaction:</font></div><div style="padding-bottom:1px;padding-left:36px;text-indent:-36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5)      Total fee paid:</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:6%;"></td><td style="width:94%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">&#168;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:17px;text-align:left;padding-left:26px;text-indent:-27px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fee paid previously with preliminary materials.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">&#168;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:17px;text-align:left;padding-left:36px;text-indent:-36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1)          Amount Previously Paid:</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2)&#160;&#160;&#160;&#160;Form, Schedule or Registration Statement No.:</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3)&#160;&#160;&#160;&#160;Filing Party:</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4)&#160;&#160;&#160;&#160;Date Filed:</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:4pt;"><font style="font-family:inherit;font-size:4pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:4pt;"><font style="font-family:inherit;font-size:4pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:4pt;"><font style="font-family:inherit;font-size:4pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="s0039158CA46052BDB763E34BF0F07956"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><img src="ligandlogo41719a01.jpg" alt="ligandlogo41719a01.jpg" style="height:65px;width:149px;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:20pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:5px;text-align:left;font-size:20pt;"><font style="font-family:inherit;font-size:20pt;font-weight:bold;">Notice of Annual Meeting of Stockholders</font></div></td></tr></table></div></div><div style="line-height:100%;padding-top:5px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:63.67521367521367%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:31%;"></td><td style="width:69%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#acacac;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Meeting Date</font></div></td><td style="vertical-align:bottom;background-color:#acacac;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Thursday, June 6, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#3595dd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Time</font></div></td><td style="vertical-align:bottom;background-color:#3595dd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">8:30 a.m. (Pacific Time)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#ff7724;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Location</font></div></td><td style="vertical-align:bottom;background-color:#ff7724;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3911 Sorrento Valley Boulevard, Suite 110</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">San Diego, CA 92121</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#80c9ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Record Date</font></div></td><td style="vertical-align:bottom;background-color:#80c9ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Friday, April 10, 2019</font></div></td></tr></table></div></div><div style="line-height:100%;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dear Stockholder:</font></div><div style="line-height:100%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The annual meeting of stockholders of Ligand Pharmaceuticals Incorporated (&#8220;Ligand&#8221; or the &#8220;Company&#8221;) will be held at 3911 Sorrento Valley Boulevard, Suite 110, San Diego, CA 92121, on June 6, 2019 at 8:30 a.m. local time, for the following purposes:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:57px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:100%;font-size:10pt;padding-left:33px;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To elect a board of directors for the forthcoming year. Our board of directors has nominated the following eight persons, each to serve for a one year term to expire at the 2020 annual meeting of stockholders: Jason Aryeh, Todd Davis, Nancy Gray, John Higgins, John Kozarich, John LaMattina, Sunil Patel and Stephen Sabba.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:57px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:100%;font-size:10pt;padding-left:33px;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To ratify the selection of Ernst &amp; Young LLP as the Company&#8217;s independent registered accounting firm for the fiscal year ending December 31, 2019.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:57px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:100%;font-size:10pt;padding-left:33px;"><font style="font-family:inherit;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To consider and vote upon, on an advisory basis, the compensation of our named executive officers as disclosed in this proxy statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission (the "SEC").</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:57px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:33px;"><font style="font-family:inherit;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To approve the amendment and restatement of the Company's 2002 Stock Incentive Plan.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:57px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:33px;"><font style="font-family:inherit;font-size:10pt;">5. </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To approve the amendment and restatement of the Company's Employee Stock Purchase Plan.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:57px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:33px;"><font style="font-family:inherit;font-size:10pt;">6.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To transact such other business as may properly come before the meeting or any adjournment(s) thereof.</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stockholders of record at the close of business on April 10, 2019 will be entitled to vote at the annual meeting. We have elected to use the internet as our primary means of providing our proxy materials to stockholders. Most stockholders will receive only a Notice of Internet Availability of Proxy Materials with instructions for accessing the proxy materials, including our Proxy Statement and annual report, and for voting via the internet. The Notice of Internet Availability of Proxy Materials also provides information on how stockholders may obtain paper copies of our proxy materials free of charge, if they so choose.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The stock transfer books of the Company will remain open between the record date, April 10, 2019, and the date of the meeting. A list of stockholders entitled to vote at the annual meeting will be available for inspection at the offices of the Company and at the meeting. Whether or not you plan to attend the annual meeting in person, please vote by internet or telephone as described in the enclosed proxy materials or, if you request that the proxy materials be mailed to you, by signing, dating and returning the proxy card enclosed with those materials. If you attend the annual meeting and vote by ballot, your proxy will be revoked automatically and only your vote at the annual meeting will be counted. The prompt return of your proxy will assist us in preparing for the annual meeting.</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:40.38461538461539%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By Order of the Board of Directors,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/&#160;&#160;&#160;&#160;C</font><font style="font-family:inherit;font-size:8pt;">HARLES</font><font style="font-family:inherit;font-size:10pt;">&#160;S. B</font><font style="font-family:inherit;font-size:8pt;">ERKMAN</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Charles S. Berkman</font></div><div style="padding-bottom:1px;text-align:center;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;font-style:italic;">Senior Vice President, General Counsel&#160;&amp; Secretary</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">San Diego, California</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">April 24, 2019</font></div><div><br></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="s06AC24283F525ABE91BF59B745350BDF"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:20pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:top;background-color:#727272;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:5px;text-align:left;padding-left:9px;font-size:20pt;"><font style="font-family:inherit;font-size:20pt;color:#ffffff;font-weight:bold;">Table of Contents</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-indent:0px;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:94%;"></td><td style="width:6%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:12pt;"><a style="font-family:inherit;font-size:12pt;" href="#s8A7E2DB1CF2055A88D98009D322150ED"><font style="font-family:inherit;font-size:12pt;">Introduction</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8A7E2DB1CF2055A88D98009D322150ED">1</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:11pt;"><a style="font-family:inherit;font-size:11pt;" href="#s45D6E0A5A26458818B77D65B69CCB035"><font style="font-family:inherit;font-size:11pt;">Proposal No.&#160;1: Election of Directors</font></a><font style="font-family:inherit;font-size:11pt;">&#160;&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;padding-left:4px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s45D6E0A5A26458818B77D65B69CCB035">8</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:11pt;"><a style="font-family:inherit;font-size:11pt;" href="#s9015A77D08FF5D2391F54D5DEC13E785"><font style="font-family:inherit;font-size:11pt;">Proposal No.&#160;2: Ratification of Independent Registered Public Accounting Firm</font></a><font style="font-family:inherit;font-size:11pt;">&#160;&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;padding-left:4px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s9015A77D08FF5D2391F54D5DEC13E785">12</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:11pt;"><a style="font-family:inherit;font-size:11pt;" href="#sFE82CB747F735B35A613FEC4864CE830"><font style="font-family:inherit;font-size:11pt;">Proposal No.&#160;3: Approval of the Compensation of the Named Executive Officers</font></a><font style="font-family:inherit;font-size:11pt;">&#160;&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;padding-left:4px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFE82CB747F735B35A613FEC4864CE830">15</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:11pt;"><a style="font-family:inherit;font-size:11pt;" href="#s27810da5d5dd4d4ebb413db40b387007"><font style="font-family:inherit;font-size:11pt;">Proposal No. 4: Approval of the Amended and Restated Ligand Pharmaceuticals Incorporated 2002 Stock Incentive Plan</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;padding-left:4px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s27810da5d5dd4d4ebb413db40b387007">16</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:11pt;"><a style="font-family:inherit;font-size:11pt;" href="#s89f0aeadb89c46af909604944f0665e7"><font style="font-family:inherit;font-size:11pt;">Proposal No. 5: Approval of the Amended and Restated Ligand Pharmaceuticals Incorporated Employee Stock Purchase Plan</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;padding-left:4px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s89f0aeadb89c46af909604944f0665e7">30</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:11pt;"><a style="font-family:inherit;font-size:11pt;" href="#sFFC042B667F65DE3B8D7755606230864"><font style="font-family:inherit;font-size:11pt;">Executive Officers</font></a><font style="font-family:inherit;font-size:11pt;">&#160;&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;padding-left:4px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFFC042B667F65DE3B8D7755606230864">36</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:11pt;"><a style="font-family:inherit;font-size:11pt;" href="#s96DF54CB30FD53BEB4DAA846F2B49036"><font style="font-family:inherit;font-size:11pt;">Security Ownership of Certain Beneficial Owners, Directors and Management</font></a><font style="font-family:inherit;font-size:11pt;">&#160;&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;padding-left:4px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s96DF54CB30FD53BEB4DAA846F2B49036">37</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:11pt;"><a style="font-family:inherit;font-size:11pt;" href="#sBBC729F5D0835632AA6B61CEB6548584"><font style="font-family:inherit;font-size:11pt;">Compensation Discussion and Analysis</font></a><font style="font-family:inherit;font-size:11pt;">&#160;&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;padding-left:4px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sBBC729F5D0835632AA6B61CEB6548584">39</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:11pt;"><a style="font-family:inherit;font-size:11pt;" href="#sB108D3B503915A4DB33A504E8F90501D"><font style="font-family:inherit;font-size:11pt;">Compensation Tables</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;padding-left:4px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sB108D3B503915A4DB33A504E8F90501D">53</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:11pt;"><a style="font-family:inherit;font-size:11pt;" href="#sFBCFDB06F44B5D43814BCFECAD6706ED"><font style="font-family:inherit;font-size:11pt;">Pay Ratio Disclosure</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;padding-left:4px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s48523a2b11c74f64a57deb8e2185f9c1">60</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:11pt;"><a style="font-family:inherit;font-size:11pt;" href="#s46773984bc2a4c55b6166c7b148c7265"><font style="font-family:inherit;font-size:11pt;">Compensation Committee Interlocks and Insider Participation</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;padding-left:4px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s46773984bc2a4c55b6166c7b148c7265">61</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:11pt;"><a style="font-family:inherit;font-size:11pt;" href="#s7bf315575fe9493e9f5327fa58372728"><font style="font-family:inherit;font-size:11pt;">Compensation Committee Report</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;padding-left:4px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s7bf315575fe9493e9f5327fa58372728">61</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:11pt;"><a style="font-family:inherit;font-size:11pt;" href="#s0a9b3ecf53a147db9471487be10b18a9"><font style="font-family:inherit;font-size:11pt;">Audit Committee Report</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;padding-left:4px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0a9b3ecf53a147db9471487be10b18a9">62</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:11pt;"><a style="font-family:inherit;font-size:11pt;" href="#s79102963a14c4c14b116ba8b8fd2aed7"><font style="font-family:inherit;font-size:11pt;">Equity Compensation Plans</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;padding-left:4px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s79102963a14c4c14b116ba8b8fd2aed7">62</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:11pt;"><a style="font-family:inherit;font-size:11pt;" href="#sBB12C6C817DA5DE7BEEA68AEFBF539F7"><font style="font-family:inherit;font-size:11pt;">Certain Relationships and Related Transactions</font></a><font style="font-family:inherit;font-size:11pt;">&#160;&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;padding-left:4px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sBB12C6C817DA5DE7BEEA68AEFBF539F7">62</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:11pt;"><a style="font-family:inherit;font-size:11pt;" href="#sB7F767AC82045D6C813627B1880342BC"><font style="font-family:inherit;font-size:11pt;">Section&#160;16(a) Beneficial Ownership Reporting Compliance</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;padding-left:4px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sB7F767AC82045D6C813627B1880342BC">63</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:11pt;"><a style="font-family:inherit;font-size:11pt;" href="#s17035A5382BC543280C4FDA369123EBA"><font style="font-family:inherit;font-size:11pt;">Deadline for Proposals for Next Annual Meeting</font></a><font style="font-family:inherit;font-size:11pt;">&#160;&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;padding-left:4px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s17035A5382BC543280C4FDA369123EBA">63</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:11pt;"><a style="font-family:inherit;font-size:11pt;" href="#s2BA095B5EA3356B39D795A0C3793E211"><font style="font-family:inherit;font-size:11pt;">Annual Report on Form 10-K</font></a><font style="font-family:inherit;font-size:11pt;">&#160;&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;padding-left:4px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s2BA095B5EA3356B39D795A0C3793E211">63</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:11pt;"><a style="font-family:inherit;font-size:11pt;" href="#s9A113BA2D2D65CBEA338225FC3ED185A"><font style="font-family:inherit;font-size:11pt;">Solicitation of Proxies</font></a><font style="font-family:inherit;font-size:11pt;">&#160;&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;padding-left:4px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s9A113BA2D2D65CBEA338225FC3ED185A">64</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:11pt;"><a style="font-family:inherit;font-size:11pt;" href="#s690011C0DEA053CE9E88DD75AADACCF8"><font style="font-family:inherit;font-size:11pt;">Householding of Proxy Materials</font></a><font style="font-family:inherit;font-size:11pt;">&#160;&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;padding-left:4px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s690011C0DEA053CE9E88DD75AADACCF8">64</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:11pt;"><a style="font-family:inherit;font-size:11pt;" href="#sA29B7E02171656789901370479754AFD"><font style="font-family:inherit;font-size:11pt;">Other Business</font></a><font style="font-family:inherit;font-size:11pt;">&#160;&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;padding-left:4px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sA29B7E02171656789901370479754AFD">64</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:11pt;"><a style="font-family:inherit;font-size:11pt;" href="#s28368a12ab9640cf90a65408e98ba370"><font style="font-family:inherit;font-size:11pt;">Appendix A - Amendment and Restatement of the Ligand Pharmaceuticals Incorporated 2002 Stock Incentive Plan</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;padding-left:4px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s28368a12ab9640cf90a65408e98ba370">65</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:11pt;"><a style="font-family:inherit;font-size:11pt;" href="#sb6e62536bc644ccb9ea4178e9b4c6808"><font style="font-family:inherit;font-size:11pt;">Appendix B - Amendment and Restatement of the Ligand Pharmaceuticals Incorporated Employee Stock Purchase Plan</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;padding-left:4px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sb6e62536bc644ccb9ea4178e9b4c6808">86</a></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="s8A7E2DB1CF2055A88D98009D322150ED"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-left:0px;text-indent:0px;font-size:20pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:top;background-color:#727272;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:5px;padding-left:9px;font-size:20pt;"><font style="font-family:inherit;font-size:20pt;color:#ffffff;font-weight:bold;">Ligand Pharmaceuticals Incorporated</font></div><div style="padding-left:9px;font-size:20pt;"><font style="font-family:inherit;font-size:20pt;color:#ffffff;font-weight:bold;">3911 Sorrento Valley Boulevard, Suite 110</font></div><div style="padding-left:9px;font-size:20pt;"><font style="font-family:inherit;font-size:20pt;color:#ffffff;font-weight:bold;">San Diego, CA 92121</font></div><div style="padding-left:9px;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;color:#ffffff;font-weight:bold;">Proxy Statement</font></div><div style="padding-left:9px;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;color:#ffffff;font-weight:bold;">For the Annual Meeting of Stockholders</font></div></td></tr></table></div></div><div style="line-height:150%;padding-top:21px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On behalf of the board of directors of Ligand, we are asking for your proxy, to be used at the annual meeting of stockholders to be held on June 6, 2019. The annual meeting will be held at 8:30 a.m. local time at 3911 Sorrento Valley Boulevard, Suite 110, San Diego, CA 92121. Stockholders of record on April 10, 2019 (the &#8220;Record Date&#8221;) are entitled to notice of and to vote at the annual meeting. If you need directions to the location of the annual meeting, please contact us at (858)&#160;550-7500. On or about April 24, 2019, we will mail to stockholders a Notice of Internet Availability of Proxy Materials containing instructions on how to access our proxy statement and 2018 annual report online and how to vote online. If you receive such a Notice by mail, you will not receive a printed copy of the materials unless you specifically request one. However, the Notice contains instructions on how to request to receive printed copies of these materials and a proxy card by mail.</font></div><div style="line-height:120%;padding-top:21px;text-align:left;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-weight:bold;">Important Notice Regarding the Availability of Proxy Materials for the Stockholder Meeting to Be Held on Thursday, June 6, 2019.</font></div><div style="line-height:150%;padding-top:21px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This proxy statement and the Company&#8217;s annual report are available electronically at www.envisionreports.com/LGND. </font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ligand Pharmaceuticals Incorporated 2019 Proxy Statement </font><font style="font-family:Wingdings;font-size:8pt;">l</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">1</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-left:0px;text-indent:0px;font-size:18pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:top;background-color:#727272;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:5px;text-align:left;padding-left:9px;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;color:#ffffff;font-weight:bold;">General Information about the Annual Meeting and Voting</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:13px;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:18%;"></td><td style="width:82%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#b4b4b4;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#b4b4b4;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">What is the purpose of the annual meeting?</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At our annual meeting, stockholders will act on the items outlined in the notice of meeting that is attached to this proxy statement. These include the election of directors, the ratification of the selection of Ernst &amp; Young LLP as the Company&#8217;s independent registered public accounting firm, the approval, on an advisory basis, of the compensation of the named executive officers as disclosed in this proxy statement, the approval of the amendment and restatement of the Company's 2002 Stock Incentive Plan and the approval of the amendment and restatement of the Company's Employee Stock Purchase Plan.</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#b4b4b4;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#b4b4b4;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Who can vote at the meeting?</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:8px;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Only stockholders of record as of the close of business on the Record Date are entitled to vote the shares of stock they held on that date. Stockholders may vote in person or by proxy (see &#8220;How do I vote by proxy?&#8221; below). Each holder of shares of common stock is entitled to one vote for each share of stock held on the proposals presented in this proxy statement. Our amended and restated bylaws provide that a majority of all of the shares of the stock entitled to vote, whether present in person or represented by proxy, will be a quorum for the transaction of business at the meeting.</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#b4b4b4;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#b4b4b4;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:8px;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">How many votes do I have?</font></div><div style="padding-top:18px;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:8px;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Each share of our common stock that you own as of April 10, 2019 entitles you to one vote. The Notice of Internet Availability of Proxy Materials that is sent to you, or the proxy card or voting instruction form that is included in the proxy materials mailed to you if you have requested delivery by mail, will show the number of shares that you are entitled to vote.</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#b4b4b4;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#b4b4b4;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">What is a &#8220;broker non-vote&#8221;?</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:8px;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A broker non-vote occurs when a broker holding shares for a beneficial owner, commonly known as holding shares in &#8220;street name,&#8221; does not vote on a particular proposal because the broker does not have discretionary voting power with respect to that proposal and has not received instructions from the beneficial owner.  </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#b4b4b4;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#b4b4b4;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:8px;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">How are votes counted?</font></div><div style="padding-top:8px;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:8px;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Directors will be elected by a favorable vote of a plurality of the aggregate votes present, in person or by proxy, at the annual meeting. Accordingly, abstentions will not affect the outcome of the election of candidates for director. Absent instructions from the beneficial owner of such shares, a broker is not entitled to vote shares held for a beneficial owner on certain non-routine items, such as the election of directors, the approval, on an advisory basis, of the compensation of the named executive officers as disclosed in this proxy statement and any stockholder proposals. Thus, if the beneficial owner does not give a broker specific instructions, the beneficially owned shares may not be voted on this proposal and will not be counted in determining the number of shares necessary for approval, although they will count for purposes of determining whether a quorum exists. Stockholders are not permitted to cumulate their shares for the purpose of electing directors or otherwise.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:8px;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The proposal to ratify the selection of Ernst &amp; Young LLP as our independent registered public accounting firm for the fiscal year ending December&#160;31, 2019 requires the affirmative vote of a majority of the aggregate votes present, in person or by proxy, and entitled to vote at the annual meeting. Abstentions will have the same effect as a vote against this proposal. However, ratification of the selection of Ernst &amp; Young LLP is considered a routine matter on which a broker or other nominee is empowered to vote. Accordingly, no broker non-votes will result from this proposal.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:8px;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Approval of the non-binding advisory resolution on our executive compensation requires the affirmative vote of a majority of the aggregate votes present, in person or by proxy, and entitled to vote at the annual meeting. Abstentions will have the same effect as a vote against this proposal. Absent instructions from the beneficial owner of such shares, a broker is not entitled to vote shares held for a beneficial owner on the resolution to approve the compensation of our named executive officers. As a result, broker non-votes will have no effect on the outcome of the vote.</font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ligand Pharmaceuticals Incorporated 2019 Proxy Statement </font><font style="font-family:Wingdings;font-size:8pt;">l</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">2</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;padding-left:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:18%;"></td><td style="width:82%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Approval of the amendment and restatement of our 2002 Stock Incentive Plan requires the affirmative vote of a majority of the aggregate votes present, in person or by proxy, and entitled to vote at the annual meeting. Abstentions will have the same effect as a vote against this proposal. Absent instructions from the beneficial owner of such shares, a broker is not entitled to vote shares held for a beneficial owner on the resolution to approve the amendment and restatement of our 2002 Stock Incentive Plan. As a result, broker non-votes will have no effect on the outcome of the vote.</font></div><div style="padding-bottom:8px;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:2px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Approval of the amendment and restatement of our Employee Stock Purchase Plan requires the affirmative vote of a majority of the aggregate votes present, in person or by proxy, and entitled to vote at the annual meeting. Abstentions will have the same effect as a vote against this proposal. Absent instructions from the beneficial owner of such shares, a broker is not entitled to vote shares held for a beneficial owner on the resolution to approve the amendment and restatement of our Employee Stock Purchase Plan. As a result, broker non-votes will have no effect on the outcome of the vote.</font></div><div style="padding-bottom:8px;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:8px;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All votes will be counted by an inspector of elections appointed for the meeting. The inspector will count separately &#8220;yes&#8221; votes, &#8220;no&#8221; votes, abstentions and broker non-votes. Shares represented by proxies that reflect abstentions or broker non-votes will be counted as shares that are present and entitled to vote for purposes of determining the presence of a quorum.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:8px;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Voting results will be tabulated and certified by our mailing and tabulating agent, Computershare.</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#b4b4b4;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#b4b4b4;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:8px;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Why did I receive a one-page notice in the mail regarding the Internet availability of proxy materials instead of a full set of proxy materials?</font></div><div style="padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:8px;padding-top:8px;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to rules adopted by the SEC, we have elected to provide access to our proxy materials over the internet. Accordingly, we are sending a Notice of Internet Availability of Proxy Materials to our stockholders who have not previously requested the receipt of paper proxy materials advising them that they can access this proxy statement, the 2018 annual report and voting instructions over the internet at http://www.envisionreports.com/LGND, by calling toll-free (866) 641-4276, or by sending an e-mail to investorvote@computershare.com with &#8220;Proxy Materials Ligand Pharmaceuticals&#8221; in the subject line. Include in the message your full name and address, plus the number located in the shaded bar on the reverse, and state in the email that you want a paper copy of current meeting materials. You can also state your preference to receive a paper copy for future meetings. There is no charge for you requesting a copy. Please make your request for a copy on or before May 23, 2019 to facilitate timely delivery. In addition, stockholders may request to receive proxy materials electronically by email or in printed form by mail on an ongoing basis. All stockholders will have the ability to access the proxy materials on the website referred to in the Notice of Internet Availability of Proxy Materials or request to receive a printed set of the proxy materials. We encourage stockholders to take advantage of the availability of the proxy materials on the internet to help reduce the environmental impact of the annual meeting.</font></div></td></tr></table></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:18%;"></td><td style="width:6%;"></td><td style="width:76%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#828282;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#828282;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#828282;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td rowspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:4px;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">How do I vote by proxy?</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:4px;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Record Holders</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If you are a stockholder of record on the Record Date, you may vote in one of the following four ways:</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;padding-top:4px;padding-left:36px;text-indent:-36px;"><img src="image1a01.gif" alt="image1a01.gif" style="height:29px;width:30px;"></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">By the internet.</font><font style="font-family:inherit;font-size:10pt;">&#160;You may go to </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">www.envisionreports.com/LGND</font><font style="font-family:inherit;font-size:10pt;">&#160;24 hours a day, 7 days a week, and follow the instructions. You will need the 15-digit control number that is included in the Notice of Internet Availability of Proxy Materials, proxy card or voting instructions form that is sent to you. The internet voting system allows you to confirm that the system has properly recorded your votes. This method of voting will be available up until 11:59 p.m. EDT, on June 5, 2019.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;padding-top:4px;padding-left:36px;text-indent:-36px;font-size:10pt;"><img src="image2.gif" alt="image2.gif" style="height:30px;width:30px;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">By telephone. </font><font style="font-family:inherit;font-size:10pt;">On a touch-tone telephone, you may call toll-free 1-800-652-8683, 24 hours a day, 7 days a week, and follow the instructions. You will need the 15 digit control number that is included in the Notice of Internet Availability of Proxy Materials, proxy card or voting instructions form that is sent to you. As with internet voting, you will be able to confirm that the system has properly recorded your votes. This method of voting will be available up until 11:59 p.m. EDT, on June 5, 2019.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;padding-top:4px;padding-left:36px;text-indent:-36px;font-size:10pt;"><img src="image3.gif" alt="image3.gif" style="height:30px;width:30px;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">By mail</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">. </font><font style="font-family:inherit;font-size:10pt;">If you are a stockholder of record, and you elect to receive your proxy materials by mail, you may vote by proxy by marking, dating, and signing your proxy card exactly as your name appears on the card and returning it by mail in the postage-paid envelope that will be provided to you. You should mail the proxy card form in plenty of time to allow delivery prior to the meeting. Do not mail the proxy card or voting instruction form if you are voting over the internet or by telephone.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;padding-top:4px;padding-left:36px;text-indent:-36px;"><img src="image4.gif" alt="image4.gif" style="height:29px;width:30px;"></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">At the annual meeting</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">. </font><font style="font-family:inherit;font-size:10pt;">You may vote your shares at the annual meeting if you attend in person.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Even if you plan to attend the annual meeting, we encourage you to vote over the internet or by telephone prior to the meeting. It is fast and convenient, and votes are recorded and confirmed immediately.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Beneficial Owners: Shares Registered in the Name of a Broker or Bank </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If you are a beneficial owner of shares registered in the name of your broker, bank or other agent, you should have received a proxy card and voting instructions with these proxy materials from that organization rather than directly from us. Simply complete and mail the proxy card to ensure that your vote is counted. You may be eligible to vote your shares electronically over the Internet or by telephone. A large number of banks and brokerage firms offer Internet and telephone voting. If your bank or brokerage firm does not offer Internet or telephone voting information, please complete and return your proxy card in the self-addressed, postage-paid envelope provided. To vote in person at the annual meeting, you must obtain a valid proxy from your broker, bank or other agent. Follow the instructions from your broker or bank included with these proxy materials, or contact your broker or bank to request a proxy form. </font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ligand Pharmaceuticals Incorporated 2019 Proxy Statement </font><font style="font-family:Wingdings;font-size:8pt;">l</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">3</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;padding-left:0px;"></div><div><br></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ligand Pharmaceuticals Incorporated 2019 Proxy Statement </font><font style="font-family:Wingdings;font-size:8pt;">l</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">4</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:18%;"></td><td style="width:82%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#b4b4b4;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#b4b4b4;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:8px;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">May I revoke my proxy?</font></div><div style="padding-top:8px;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:8px;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If you give us your proxy, you may revoke it at any time before it is exercised. You may revoke your proxy by sending in another signed proxy with a later date, by notifying our corporate secretary, Charles S. Berkman, in writing before the annual meeting that you have revoked your proxy, or by attending the annual meeting and voting in person.</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#b4b4b4;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#b4b4b4;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:13px;padding-bottom:8px;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">What is the quorum requirement?</font></div><div style="padding-top:8px;padding-bottom:8px;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:13px;padding-bottom:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A quorum of stockholders is necessary to hold a valid meeting. A quorum will be present if the holders of a majority in voting power of the shares of common stock issued, outstanding and entitled to vote are present in person or represented by proxy at the annual meeting. On the Record Date, there were 19,663,929 shares outstanding and entitled to vote. Accordingly, 9,831,965 shares must be represented by stockholders present at the annual meeting or by proxy to have a quorum.</font></div><div style="padding-top:8px;padding-bottom:8px;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Your shares will be counted towards the quorum only if you submit a valid proxy vote or vote at the annual meeting. Abstentions and broker non-votes will be counted towards the quorum requirement. If there is no quorum, either the chairperson of the annual meeting or a majority in voting power of the stockholders entitled to vote at the annual meeting, present in person or represented by proxy, may adjourn the annual meeting to another time or place.</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#b4b4b4;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#b4b4b4;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:8px;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">I share an address with another stockholder, and we received only one paper copy of the proxy materials and annual report. How may I obtain an additional copy of these materials?</font></div><div style="padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:8px;padding-top:8px;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The rules of the SEC permit us, under certain circumstances, to send a single set of the Notice of Internet Availability of Proxy Materials, proxy materials, and annual reports to any household at which two or more stockholders reside. This procedure, known as householding, reduces the volume of duplicate information you receive and helps to reduce our expenses.<br>In order to take advantage of this opportunity, we have delivered only one Notice of Internet Availability of Proxy Materials or, if you previously requested to receive paper proxy materials by mail, one proxy statement and annual report to stockholders who share an address (unless we received contrary instructions from the affected stockholders prior to the mailing date). We will mail a separate copy of any of these documents, if requested. Requests for separate copies of any of these documents, either now or in the future, as well as requests for single copies in the future by stockholders who share an address and are currently receiving multiple copies, can be made by stockholders of record by contacting our corporate secretary at Ligand Pharmaceuticals Incorporated, 3911 Sorrento Valley Boulevard, Suite 110, San Diego, CA  92121, or by telephone at (858) 550-7500. Such requests by street name holders should be made through their bank, broker or other holder of record.</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#b4b4b4;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#b4b4b4;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:8px;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">How do I obtain an Annual Report on Form 10-K?</font></div><div style="padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If you would like a copy of our annual report on Form 10-K for the fiscal year ended December&#160;31, 2018 that we filed with the SEC, we will send you one without charge. Please write to: </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ligand Pharmaceuticals Incorporated<br>3911 Sorrento Valley Boulevard,  Suite 110<br>San Diego, CA 92121<br>Attn: Corporate Secretary</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All of our SEC filings are also available in the Investors section of our website at www.ligand.com.</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#b4b4b4;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#b4b4b4;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:8px;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">How can I find out the results of the voting at the annual meeting?</font></div><div style="padding-top:8px;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:8px;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Preliminary voting results will be announced at the annual meeting. Final voting results will be published in a Current Report on Form 8-K to be filed with the SEC within four business days after the annual meeting. If final voting results are not available to us in time to file a Form&#160;8-K within four business days after the meeting, we intend to file a Form&#160;8-K to publish preliminary results and, within four business days after the final results are known to us, file an amendment to the Form&#160;8-K to publish the final results.</font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ligand Pharmaceuticals Incorporated 2019 Proxy Statement </font><font style="font-family:Wingdings;font-size:8pt;">l</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">5</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="s570e0d318f9d43c3860c655350db07cc"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:18pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.20634920634922%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:20%;"></td><td style="width:20%;"></td><td style="width:20%;"></td><td style="width:20%;"></td><td style="width:20%;"></td></tr><tr><td colspan="5" style="vertical-align:top;background-color:#727272;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:5px;padding-top:5px;text-align:left;padding-left:9px;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;color:#ffffff;font-weight:bold;">Proxy Statement Summary</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The summary below highlights certain information that may be found elsewhere in this proxy statement. We encourage you to read the entire proxy statement before casting your vote. Our proxy statement and related materials are first being made available to our shareholders on or about April 24, 2019.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#007dd8;font-weight:bold;text-decoration:underline;">Director Nominees</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Please find a list of director nominees to the Board of Directors (the "Board") of Ligand Pharmaceuticals Incorporated (the "Company" or "Ligand") below. Additional information for each nominees can be found under "Proposal 1: Election of Directors".</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:24%;"></td><td style="width:6%;"></td><td style="width:13%;"></td><td style="width:57%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#40aeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Name</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#40aeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Age*</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#40aeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Director Since</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#40aeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Professional Background</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:2px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">John W. Kozarich, Ph.D. (N)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">69</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2003</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:2px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Distinguished Scientist and Executive Advisor of ActivX Biosciences, Inc.</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#e2e2e2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:2px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">John L. Higgins</font></div></td><td style="vertical-align:bottom;background-color:#e2e2e2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">49</font></div></td><td style="vertical-align:bottom;background-color:#e2e2e2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2007</font></div></td><td style="vertical-align:bottom;background-color:#e2e2e2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:2px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Chief Executive Officer of Ligand Pharmaceuticals Incorporated</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:2px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Jason M. Aryeh (C)(N)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">50</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2006</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:2px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Founder and Managing General Partner of JALAA Equities, LP</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#e2e2e2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:2px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Todd C. Davis (C) </font></div></td><td style="vertical-align:bottom;background-color:#e2e2e2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">58</font></div></td><td style="vertical-align:bottom;background-color:#e2e2e2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2007</font></div></td><td style="vertical-align:bottom;background-color:#e2e2e2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:2px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Founder and Managing Partner of RoyaltyRx Capital</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:2px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Nancy Ryan Gray, Ph.D. (A) </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">59</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:2px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">President and CEO of Gordon Research Conferences</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#e2e2e2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:2px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">John L. LaMattina, Ph.D. (C)</font></div></td><td style="vertical-align:bottom;background-color:#e2e2e2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">69</font></div></td><td style="vertical-align:bottom;background-color:#e2e2e2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2011</font></div></td><td style="vertical-align:bottom;background-color:#e2e2e2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:2px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Senior Partner at PureTech Ventures</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:2px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Sunil Patel(A)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">47</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2010</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:2px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Former Executive Vice President and Chief Financial Officer for OncoMed Pharmaceuticals</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#e2e2e2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:2px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Stephen L. Sabba, M.D. (A)(N)</font></div></td><td style="vertical-align:bottom;background-color:#e2e2e2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">59</font></div></td><td style="vertical-align:bottom;background-color:#e2e2e2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2008</font></div></td><td style="vertical-align:bottom;background-color:#e2e2e2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:2px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Leading Bio/Pharma Analyst and Fund Manager for Knott Partners, L.P</font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:8pt;padding-left:36px;"><font style="font-family:inherit;font-size:8pt;">*&#160;</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#32;&#32;&#32;As of April 10, 2019</font></div></td></tr></table><div style="line-height:150%;text-align:left;padding-left:48px;text-indent:-12px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(A)  Member of the audit committee</font></div><div style="line-height:150%;text-align:left;padding-left:48px;text-indent:-12px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(C)  Member of the compensation committee</font></div><div style="line-height:150%;text-align:left;padding-left:48px;text-indent:-12px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(N)  Member of the nominating and corporate governance committee</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#007dd8;font-weight:bold;text-decoration:underline;">Our Key Executive Compensation Practices</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.20634920634922%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:20%;"></td><td style="width:20%;"></td><td style="width:20%;"></td><td style="width:20%;"></td><td style="width:20%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#acacac;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Practice</font></div></td><td colspan="4" style="vertical-align:bottom;background-color:#acacac;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Description</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Balanced Approach to Performance-Based Pay</font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Performance-based awards are tied to the achievement of financial and operating objectives, including, revenue, number of newly acquired shots-on-goal and acquisitions</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#e2e2e2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Two to Three Year Performance Periods and Three Year Vest Schedules</font></div></td><td colspan="4" style="vertical-align:bottom;background-color:#e2e2e2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">The two to three year performance periods and three year vest schedules for our equity awards promotes a long-term approach to the achievement of strategic and financial objectives</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Balanced Mix of Pay Components</font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Target compensation mix is not overly weighted toward annual incentive awards and balances cash and long-term equity awards in accordance with certain financial or non-financial metrics that align with our short and long-term strategic goals</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#e2e2e2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Executive Compensation at Risk</font></div></td><td colspan="4" style="vertical-align:bottom;background-color:#e2e2e2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">We ensure a significant portion of the total compensation opportunity for executives is "at-risk" through both our short- and long-term incentive awards, the payout of which is directly related to the achievement of pre-established performance metrics directly tied to our business goals and strategies </font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Executive Compensation Philosophy</font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">We have an executive compensation philosophy that clearly articulates our commitment to equal pay principles and promoting a values-based culture</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#e2e2e2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">"Double-Trigger" Change-in-Control Arrangements</font></div></td><td colspan="4" style="vertical-align:bottom;background-color:#e2e2e2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">We provide for double-trigger acceleration of our equity awards (requiring both a change in control and a qualifying termination of an executive&#8217;s employment before vesting is accelerated)</font></div><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ligand Pharmaceuticals Incorporated 2019 Proxy Statement </font><font style="font-family:Wingdings;font-size:8pt;">l</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">6</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#007dd8;font-weight:bold;text-decoration:underline;">Our Board's Voting Recommendations</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:6%;"></td><td style="width:52%;"></td><td style="width:20%;"></td><td style="width:15%;"></td><td style="width:7%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#3f96f9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item </font></div></td><td style="vertical-align:bottom;background-color:#3f96f9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Description of Proposal</font></div></td><td style="vertical-align:bottom;background-color:#3f96f9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">For</font></div></td><td style="vertical-align:bottom;background-color:#3f96f9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Against</font></div></td><td style="vertical-align:bottom;background-color:#3f96f9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Page</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Election of directors</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:12pt;"><font style="font-family:Wingdings;font-size:12pt;color:#5b9a04;font-weight:bold;">&#254;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s45D6E0A5A26458818B77D65B69CCB035">8</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:#e2e2e2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2</font></div></td><td style="vertical-align:bottom;background-color:#e2e2e2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Ratification of independent registered public accounting firm</font></div></td><td style="vertical-align:bottom;background-color:#e2e2e2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:12pt;"><font style="font-family:Wingdings;font-size:12pt;color:#5b9a04;font-weight:bold;">&#254;</font></div></td><td style="vertical-align:bottom;background-color:#e2e2e2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#e2e2e2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s9015A77D08FF5D2391F54D5DEC13E785">12</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Approval of compensation of named executive officers</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:12pt;"><font style="font-family:Wingdings;font-size:12pt;color:#5b9a04;font-weight:bold;">&#254;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFE82CB747F735B35A613FEC4864CE830">15</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:#e2e2e2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">4</font></div></td><td style="vertical-align:bottom;background-color:#e2e2e2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Approval of Amendment and Restatement of the Ligand Pharmaceuticals Incorporated 2002 Stock Incentive Plan</font></div></td><td style="vertical-align:bottom;background-color:#e2e2e2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:12pt;"><font style="font-family:Wingdings;font-size:12pt;color:#5b9a04;font-weight:bold;">&#254;</font></div></td><td style="vertical-align:bottom;background-color:#e2e2e2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#e2e2e2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s27810da5d5dd4d4ebb413db40b387007">16</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">5</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Approval of Amendment and Restatement of the Ligand Pharmaceuticals Incorporated Employee Stock Purchase Plan</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:12pt;"><font style="font-family:Wingdings;font-size:12pt;color:#5b9a04;font-weight:bold;">&#254;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s89f0aeadb89c46af909604944f0665e7">30</a></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ligand Pharmaceuticals Incorporated 2019 Proxy Statement </font><font style="font-family:Wingdings;font-size:8pt;">l</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">7</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="s45D6E0A5A26458818B77D65B69CCB035"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-left:0px;text-indent:0px;font-size:18pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:top;background-color:#727272;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:5px;padding-top:5px;text-align:left;padding-left:9px;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;color:#ffffff;font-weight:bold;">Proposal No. 1 Election of Directors </font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The persons named below have been nominated by our board of directors to serve as directors of the Company until the next annual meeting of stockholders and until their successors have been elected and qualified. The eight candidates receiving the highest number of affirmative votes of the shares entitled to vote at the annual meeting will be elected directors of the Company. As of the date of this proxy statement, our board of directors is not aware of any nominee who is unable to or will decline to serve as a director. If, however, any of those named are unable to serve at the time of the annual meeting, the proxyholders may exercise discretionary authority to vote for substitutes.</font></div><div style="line-height:120%;padding-top:20px;text-align:left;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-weight:bold;">Business Experience of Director Nominees</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Jason M.&#160;Aryeh</font><font style="font-family:inherit;font-size:10pt;">&#160;has served as a member of Ligand&#8217;s board of directors since September 2006. Mr. Aryeh has more than twenty years of equity investment experience focused on the life sciences industry. He is the founder and Managing General Partner of JALAA Equities, LP, a private investment fund focused on the biotechnology and medical device sectors, and has served in such capacity since 1997. Mr. Aryeh currently serves on the Board of Directors of Orchestra BioMed, a private company where he is chairman of Orchestra&#8217;s Nominating &amp; Governance Committee and on its Audit Committee. Mr. Aryeh previously served as a director of Novelion Therapeutics Inc. (formerly QLT Inc.), a publicly traded company, from 2012 through 2018. Since 2006, Mr. Aryeh has served as Executive Chairman, on the board of directors or as a consultant to many public and private life sciences companies and charitable foundations, including the Cystic Fibrosis Foundation&#8217;s Therapeutics Board. Mr. Aryeh earned a B.A. in economics, with honors, from Colgate University, and is a member of the Omnicron Delta Epsilon Honor Society in economics. In selecting Mr. Aryeh to serve as a director, the board considered, among other things, his valuable capital markets experience, including his service as managing general partner of a hedge fund focused on the life sciences sector.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Todd C. Davis</font><font style="font-family:inherit;font-size:10pt;">&#32;has served as a member of Ligand's board of director since March 2007. He is the&#160;Founder and Managing Partner of RoyaltyRx Capital, a special opportunities investment firm founded in 2018. From 2006 until 2018, Mr. Davis was a Founder &amp; Managing Partner&#160;of Cowen/HealthCare Royalty Partners, a global healthcare investment firm. He has almost thirty years of experience in both operations and investing in the biopharmaceutical and life science industries. Mr. Davis has been involved in over $3 billion in healthcare financings including growth equity, public equity turnarounds, structured debt and royalty acquisitions. He has also led, structured and closed over 40 additional intellectual property licenses, as well as hybrid royalty-debt deals. Previously, Mr. Davis was a partner at Paul Capital Partners, where he co-managed that firm's royalty investments as a member of the Royalty Management Committee. He also served as a partner responsible for biopharmaceutical growth equity investments at Apax Partners. Mr. Davis began his business career in sales at Abbott Laboratories where he held several commercial roles of increasing responsibility. He subsequently held general management, business development, and licensing roles at Elan Pharmaceuticals. Mr. Davis is a navy veteran and holds a B.S. from the U.S. Naval Academy and an M.B.A. from Harvard University. He currently serves on the board&#160;of Palvella Therapeutics Inc., BioDelivery Sciences, and Ligand Pharmaceuticals. He is also a board member of the Harvard Business School Healthcare Alumni Association. </font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nancy Ryan Gray, Ph.D., </font><font style="font-family:inherit;font-size:10pt;">has served as a member of Ligand's board of directors since of August 2017. Dr. Gray has acted as the President and CEO of Gordon Research Conferences, a nonprofit organization focused on organizing international scientific conferences, since 2003. From December 1997 until August 2003 she served as the Director of Membership for the American Chemical Society. Prior to that, Dr. Gray worked as a Senior Research Scientist at Exxon/Mobil Research and Engineering, a subsidiary of Exxon Mobil Corporation focused on researching oil and gas. Dr. Gray is a Fellow of the Royal Society of Chemistry, a Fellow of the American Association for the Advancement of Science and a member of the American Chemical Society. She was a Research Fellow at the Foundation on Matter Institute for Atomic and Molecular Physics in Amsterdam, and completed the Harvard Executive Education Finance for Senior Executives program. She also has authored or co-authored numerous scientific articles. Dr. Gray received her B.S. in Chemistry from the University of Notre Dame in 1981 and her Ph.D. in Fuel Science from The Pennsylvania State University in 1985. In selecting Dr. Gray to serve as a director, the board considered, among other things, her scientific background and knowledge of the biotechnology industry.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">John L. Higgins</font><font style="font-family:inherit;font-size:10pt;">&#32;is the Chief Executive Officer of Ligand Pharmaceuticals Incorporated, a position he has held since January 2007 and he has been a member of Ligand&#8217;s board of directors since March 2007. Prior to joining Ligand, Mr. Higgins served as Chief Financial Officer at Connetics Corporation, a specialty pharmaceutical company, since 1997, and also served as Executive Vice President, Finance and Administration and Corporate Development at Connetics until its acquisition by </font></div><div><br></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ligand Pharmaceuticals Incorporated 2019 Proxy Statement </font><font style="font-family:Wingdings;font-size:8pt;">l</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">8</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stiefel Laboratories, Inc. in December 2006. Before joining Connetics, he was a member of the executive management team at BioCryst Pharmaceuticals. Prior to BioCryst, Mr. Higgins was a member of the healthcare banking team of Dillon, Read &amp; Co. Inc., an investment banking firm. Mr. Higgins serves on the board, audit and governance committees of BioTechne Corporation, a company which develops and manufactures proteins. Mr. Higgins serves as a director on several private company boards and has served as a director of numerous public and private companies. He graduated Magna Cum Laude from Colgate University with an A.B. in economics. In selecting Mr. Higgins to serve as a director, the board considered, among other things, his valuable experience operating and managing public biotechnology companies, his prior service on other company boards and his financial transaction experience as an investment banker. Ligand also benefits from Mr. Higgins' financial experience in leadership roles at companies within the biopharmaceutical industry.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">John W. Kozarich, Ph.D.,</font><font style="font-family:inherit;font-size:10pt;">&#32;has served as a member of Ligand&#8217;s board since March 2003. Dr. Kozarich currently serves as Distinguished Scientist and Executive Advisor of ActivX Biosciences, Inc., and previously served as ActivX&#8217;s Chairman and President from 2004 through March 2017. From 1992 to 2001, he was vice president at Merck Research Laboratories and previously held professorships at the University of Maryland and Yale University School of Medicine. Dr. Kozarich is also an adjunct professor of Chemical Physiology at the Scripps Research Institute and serves on boards, including Retrophin, Inc. and Intec Pharma Ltd. Previously, Dr. Kozarich served as a director of ActiveX Biosciences Inc., Corium Intl and Novelion Therapeutics. He is also a recent recipient of the Distinguished Scientist Award from the San Diego Section of the American Chemical Society. Dr. Kozarich earned his B.S. in chemistry, summa cum laude, from Boston College, his Ph.D. in biological chemistry from the Massachusetts Institute of Technology, and was an NIH Postdoctoral Fellow at Harvard. In selecting Dr.&#160;Kozarich to serve as a director, the board considered, among other things, his valuable pharmaceutical and international experience, including his service at Merck Research Laboratories, which is part of one of the world&#8217;s largest pharmaceutical companies, and his service with ActivX Biosciences, Inc., Novelion Therapeutics Inc. and Corium Intl. Ligand also benefits from Dr.&#160;Kozarich&#8217;s financial and accounting experience in the pharmaceutical and biotechnology industries.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">John L. LaMattina, Ph.D.,</font><font style="font-family:inherit;font-size:10pt;">&#32;has served as a member of Ligand&#8217;s board since February 2011. He spent 30 years at Pfizer Inc. beginning as a medicinal chemist in 1977. During his career, he was appointed to various positions of increasing responsibility for Pfizer Central Research, including Vice President of U.S. Discovery Operations in 1993, Senior Vice President of Worldwide Discovery Operations in 1998, Senior Vice President of Worldwide Development in 1999, and President, Pfizer Global R&amp;D in 2004. Dr. LaMattina graduated with cum laude honors from Boston College with a B.S. in Chemistry. He received a Ph.D. from the University of New Hampshire in Organic Chemistry and subsequently was at Princeton University in the National Institutes of Health Postdoctoral Fellowship program. Dr. LaMattina is currently a senior partner at PureTech Ventures and serves on the boards of directors of PureTech Health plc, Gelesis Inc., Immunome Inc., Vedanta Biosciences,&#160;Inc. and Zafgen, Inc., which is a Nasdaq-listed company. In selecting Dr. LaMattina to serve as a director, the board considered, among other things, his valuable pharmaceutical and experience and experience as director of several biotech companies which provides the board with a broad leadership perspective. Ligand also benefits from Dr.&#160;LaMattina&#8217;s expert knowledge of the biopharmaceutical industry and his experience as strategic and scientific advisor.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Sunil Patel</font><font style="font-family:inherit;font-size:10pt;">&#32;has served as a member of Ligand&#8217;s board of directors since October 2010. He has more than 20 years of senior management and R&amp;D experience in the biotechnology industry. Mr. Patel most recently was Executive Vice President and Chief Financial Officer for OncoMed Pharmaceuticals, a development-stage company focused on therapeutics targeting cancer stem cells. Mr. Patel has held senior management positions in corporate development, marketing, and strategy with BiPar Sciences, Allos Therapeutics, Connetics, Abgenix and Gilead Sciences. Mr. Patel also worked at McKinsey &amp; Company serving biotech and pharmaceutical clients and has held scientific research positions at ZymoGenetics and ProCyte. Mr. Patel received his undergraduate degree in Chemistry at the University of California, Berkeley, and master&#8217;s degree in Molecular Bioengineering/Biotechnology at the University of Washington. In selecting Mr.&#160;Patel to serve as a director, the board considered, among other things, his valuable pharmaceutical and corporate development experience, including his service at OncoMed Pharmaceuticals. Ligand also benefits from Mr.&#160;Patel&#8217;s experience in serving as a senior member of management at both public and private biotechnology companies.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Stephen L. Sabba, M.D.,</font><font style="font-family:inherit;font-size:10pt;">&#32;has served as a member of Ligand&#8217;s board of directors since August 2008. Dr. Sabba has been a leading Bio/Pharma Analyst and Fund Manager for Knott Partners, L.P., an investment fund company, since November 2006. Previously he was a Partner and Director of Research with Kilkenny Capital Management, a Chicago-based biomedical hedge fund. Prior to that, Dr. Sabba was Director of Research at Sturza&#8217;s Medical Research, and previously was a gastroenterologist and internist in private practice at Phelps Memorial Hospital in North Tarrytown, New York. He received his medical degree from the New York University School of Medicine, and completed a residency in internal medicine and a fellowship in gastroenterology at the Veterans Administration Medical Center in New York City. He earned a B.S. with honors at Cornell University. Dr. Sabba has served as a member of the board of the directors for Novelion Therapeutics Inc., </font></div><div><br></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ligand Pharmaceuticals Incorporated 2019 Proxy Statement </font><font style="font-family:Wingdings;font-size:8pt;">l</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">9</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a leading Canadian biotech company, since June 2012. In selecting Dr.&#160;Sabba to serve as a director, the board considered, among other things, his capital markets and accounting expertise gained from his prior experience working in the hedge fund and investment fund industries. Ligand also benefits from his background as a medical doctor and from his understanding of medicine.</font></div><div style="line-height:120%;padding-top:20px;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-weight:bold;">Director Independence</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our board of directors has determined that, with the exception of Mr.&#160;Higgins, each of the directors is an independent director under the Nasdaq Global Market listing standards. The independent directors have two or more regularly scheduled executive sessions per year at which only the independent directors are present.</font></div><div style="line-height:120%;padding-top:16px;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-weight:bold;">Board Meetings and Committees</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our board of directors held ten meetings, with two in-person and eight by telephone, and acted by unanimous written consent two times during the year ended December&#160;31, 2018. During such year, each incumbent director attended 75% of the aggregate number of meetings of our board of directors and of each the committees on which he or she served which were held during the periods in which he or she served.  </font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our board of directors has an audit committee, a nominating and corporate governance committee and a compensation committee. Each committee is described below. Each of these committees has a written charter approved by our board of directors. A copy of each charter can be found in the &#8220;Investors&#8212;Governance&#8221; section of our website at www.ligand.com. Our board of directors has determined that each member of these committees meets the applicable rules and regulations regarding independence and that each member is free of any relationship that would interfere with his or her individual exercise of independent judgment with regard to the Company.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The audit committee is primarily responsible for overseeing the Company&#8217;s accounting and financial reporting processes, auditing of financial statements, systems of internal control, and financial compliance programs. The audit committee currently consists of Dr. Gary, Mr. Patel and Dr. Sabba (chair). The audit committee held five meetings with one in-person and four by telephone. After reviewing the qualifications of all current committee members and any relationship they may have that might affect their independence from the Company, our board of directors has determined that (i)&#160;all current committee members are &#8220;independent&#8221; as defined under Section&#160;10A of the Securities Exchange Act of 1934, as amended, (ii)&#160;all current committee members are &#8220;independent&#8221; as defined under the applicable Nasdaq Global Market listing standards, (iii)&#160;all current committee members have the ability to read and understand financial statements and (iv)&#160;Dr.&#160;Sabba qualifies as an &#8220;audit committee financial expert.&#8221; The latter determination is based on a qualitative assessment of his level of knowledge and experience based on a number of factors, including his formal education and experience.  </font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The nominating and corporate governance committee is responsible for identifying and recommending candidates for director of the Company. The nominating and corporate governance committee currently consists of Mr.&#160;Aryeh (chair) and Drs. Kozarich and Sabba. Each member of the nominating and corporate governance committee is an independent director under the Nasdaq Global Market listing standards. The nominating and corporate governance committee held zero in-person meeting and four telephonic meetings during 2018.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The nominating and corporate governance committee considers nominees recommended by stockholders, if submitted in writing to the Secretary at the Company&#8217;s principal executive offices and accompanied by the author&#8217;s full name, current address and telephone number. The nominating and corporate governance committee has set no specific minimum qualifications for candidates it recommends, but considers each individual&#8217;s qualifications, such as high personal integrity and ethics, relevant expertise and professional experience, as a whole. The nominating and corporate governance committee and the board as a whole consider it beneficial to the Company to have directors with a diversity of backgrounds and skills. The nominating and corporate governance committee and the board as a whole have no formal policy with regard to the consideration of diversity in identifying director nominees. The nominating and corporate governance committee considers candidates throughout the year and makes recommendations as vacancies occur or the size of our board of directors expands. Candidates are identified from a variety of sources including recommendations by stockholders, current directors, management, and other parties. The nominating and corporate governance committee considers all such candidates in the same manner, regardless of source. Under its charter, the nominating and corporate governance committee may retain a search firm to identify and recommend candidates but has not done so to date.</font></div><div><br></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ligand Pharmaceuticals Incorporated 2019 Proxy Statement </font><font style="font-family:Wingdings;font-size:8pt;">l</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">10</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The compensation committee reviews and approves the Company&#8217;s compensation policies, sets executive officers&#8217; compensation and administers the Company&#8217;s stock option and stock purchase plans. The compensation committee consists of Messrs. Aryeh and Davis (chair) and Dr.&#160;LaMattina. Each member is an independent director under the Nasdaq Global Market listing standards. The compensation committee held four meetings with zero in-person and four by telephone, and acted by unanimous written consent two times during 2018.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company does not have a policy regarding attendance of the directors at the annual meeting. At our 2018 annual meeting of stockholders, none of our then-current directors was in attendance.</font></div><div style="line-height:120%;padding-top:20px;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-weight:bold;">Board Leadership Structure</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our board of directors has nominated eight persons to serve as directors of the Company until the next annual meeting of stockholders, seven of whom are independent. We separate the roles of chief executive officer and chairman of our board of directors in recognition of the differences between the two roles. The chief executive officer is responsible for setting the strategic direction for the Company and the day-to-day leadership and performance of the Company, while the chairman of our board of directors provides guidance to the chief executive officer and presides over meetings of the full board of directors. We believe that this separation of responsibilities provides a balanced approach to managing the board of directors and overseeing the Company.</font></div><div style="line-height:120%;padding-top:20px;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-weight:bold;">Board&#8217;s Role in Risk Oversight</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our board of directors is actively involved in oversight of risks that could affect the Company. The board&#8217;s role in our risk oversight process includes receiving regular reports from members of senior management on areas of material risk to the Company, including risks associated with our operational, financial, legal and regulatory functions. The full board (or the appropriate board committee in the case of risks that are under the purview of a particular committee) receives these reports from the appropriate &#8220;risk owner&#8221; within the organization to enable it to understand our risk identification, risk management and risk mitigation strategies. When a board committee engages in a discussion related to areas of material risk to the Company, the chairperson of the relevant committee reports on the discussion to the full board during the committee reports portion of the next board meeting. This enables the board and its committees to coordinate the risk oversight role.</font></div><div style="line-height:120%;padding-top:20px;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-weight:bold;">Communicating with the Board of Directors</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stockholders may communicate with our board of directors or individual directors by mail, in care of the Secretary, at the Company&#8217;s principal executive offices. Letters are distributed to the board of directors, or to any individual director or directors as appropriate, depending on the content of the letter. However, items that are unrelated to the duties and responsibilities of the board of directors will be excluded. In addition, material that is illegal, inappropriate or similarly unsuitable will be excluded. Any letter that is filtered out under these standards, however, will be made available to any director upon request.</font></div><div style="line-height:120%;padding-top:20px;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-weight:bold;">Recommendation of the Board of Directors</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The board of directors unanimously recommends a vote </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">FOR</font><font style="font-family:inherit;font-size:10pt;">&#32;the nominees listed above.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ligand Pharmaceuticals Incorporated 2019 Proxy Statement </font><font style="font-family:Wingdings;font-size:8pt;">l</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">11</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="s9015A77D08FF5D2391F54D5DEC13E785"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:24px;font-size:18pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:top;background-color:#727272;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:5px;text-align:left;padding-left:9px;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;color:#ffffff;font-weight:bold;">Proposal No. 2 Ratification of Independent Registered Public Accounting Firm</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:20px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On April 2, 2019, the Audit Committee of the Company&#8217;s Board approved the selection of Ernst &amp; Young LLP as its independent registered public accounting firm. You are being asked to ratify the selection of Ernst &amp; Young LLP as the Company&#8217;s independent registered public accounting firm for the fiscal year ending December&#160;31, 2019. Neither the firm nor any of its members has any relationship with the Company or any of its affiliates, except in the firm&#8217;s capacity as the Company&#8217;s independent registered public accounting firm.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stockholder ratification of the selection of Ernst &amp; Young LLP as the Company&#8217;s independent registered public accounting firm is not required by Delaware law, the Company&#8217;s certificate of incorporation, the Company&#8217;s amended and restated bylaws, or otherwise. However, the board of directors is submitting the selection of Ernst &amp; Young LLP to the stockholders for ratification as a matter of good corporate practice. In the event the stockholders fail to ratify the selection, the board of directors will reconsider its selection. Even if the selection is ratified, the board of directors or its audit committee, in its discretion, may direct the appointment of a different independent auditing firm at any time during the year if such a change would be in the Company&#8217;s and its stockholders&#8217; best interests.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Representatives of Ernst &amp; Young LLP are expected to be present at the annual meeting, and will have the opportunity to make a statement if they desire to do so and are expected to be available to respond to appropriate questions. The affirmative vote of the holders of a majority of the shares represented and voting at the annual meeting will be required to ratify the selection of Ernst &amp; Young LLP.</font></div><div><br></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ligand Pharmaceuticals Incorporated 2019 Proxy Statement </font><font style="font-family:Wingdings;font-size:8pt;">l</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">12</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-weight:bold;">Independent Auditor&#8217;s Fees</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following is a summary of the fees incurred by the Company from Ernst &amp; Young LLP, the Company&#8217;s independent registered public accounting firm for the fiscal year ended December&#160;31, 2018 and 2017:</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:97.81746031746032%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"></td></tr><tr><td style="width:50%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:21%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:22%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:2px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fee Category</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fiscal Year<br>2018 Fees</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fiscal Year<br>2017 Fees</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:2px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Audit Fees</font><font style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">968,528</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">903,385</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:2px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Audit-related fees</font><font style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(2)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">157,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">150,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:2px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Tax Fees</font><font style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(3)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">622,121</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">273,843</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:2px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total Fees</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,747,649</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,327,228</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1) &#160;&#160;&#160;&#160;Audit fees consist of amounts for professional services rendered in connection with the integrated audit of our consolidated financial statements and related schedule and internal control over financial reporting, review of the interim condensed consolidated financial statements included in quarterly reports. We note that for fiscal year 2017, $150,000 of the fees were reclassified from the audit fees to the audit-related fees to conform to the current year presentation. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2)&#160;&#160;&#160;&#160;For the fiscal years ended December&#160;31, 2018 and 2017, audit-related fees were primarily incurred for accounting consultations. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3)&#160;&#160;&#160;&#160;Tax fees for the fiscal years ended December&#160;31, 2018 and 2017, related to services rendered for federal, state and international tax compliance and tax consulting projects including the analysis of our net operating loss carryforwards, Research and Development tax credit analysis, international tax planning, issuance of the 2018 convertible notes and business combination.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In considering the nature of the services provided by Ernst &amp; Young LLP during the 2018 fiscal year, the audit committee determined that such services are compatible with the provision of independent audit services.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The audit committee discussed these services with Ernst &amp; Young LLP and the Company&#8217;s management to determine that they are permitted under the rules and regulation concerning auditor independence promulgated by the SEC to implement the Sarbanes-Oxley Act of 2002, as well as the American Institute of Certified Public Accountants.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All services performed by Ernst &amp; Young LLP in 2018 and 2017 were pre-approved in accordance with the requirements of the audit committee charter.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Except as stated above, there were no other fees charged by Ernst &amp; Young LLP for 2018 or 2017. The audit committee considers the provision of these services to be compatible with maintaining the independence of Ernst &amp; Young LLP. None of the fees paid to Ernst &amp; Young LLP under the category &#8220;Tax Fees&#8221; described above were approved by the audit committee after services were rendered pursuant to the </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">de minimis</font><font style="font-family:inherit;font-size:10pt;">&#32;exception established by the SEC.</font></div><div style="line-height:120%;padding-top:20px;text-align:left;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-weight:bold;">Audit Committee Policy Regarding Pre-Approval of Audit and Permissible Non-Audit Services of Our Independent Registered Public Accounting Firm</font></div><div style="line-height:120%;padding-top:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our audit committee has established a policy that all audit and permissible non-audit services provided by our independent registered public accounting firm will be pre-approved by the audit committee. These services may include audit services, audit-related services, tax services and other services. The audit committee considers whether the provision of each non-audit service is compatible with maintaining the independence of our auditors. Pre-approval is detailed as to the particular service or category of services and is generally subject to a specific budget. Our independent registered public accounting firm and management are required to periodically report to the audit committee regarding the extent of services provided by the independent registered public accounting firm in accordance with this pre-approval, and the fees for the services performed to date.</font></div><div><br></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ligand Pharmaceuticals Incorporated 2019 Proxy Statement </font><font style="font-family:Wingdings;font-size:8pt;">l</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">13</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:20px;text-align:left;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-weight:bold;">Recommendation of the Board of Directors</font></div><div style="line-height:120%;padding-top:20px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our board of directors unanimously recommends that stockholders vote </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">FOR</font><font style="font-family:inherit;font-size:10pt;">&#32;the ratification of the selection of Ernst &amp; Young LLP to serve as the Company&#8217;s independent registered public accounting firm for the year ending December&#160;31, 2019.</font></div><div><br></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ligand Pharmaceuticals Incorporated 2019 Proxy Statement </font><font style="font-family:Wingdings;font-size:8pt;">l</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">14</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="sFE82CB747F735B35A613FEC4864CE830"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:24px;font-size:18pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:top;background-color:#727272;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:5px;text-align:left;padding-left:9px;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;color:#ffffff;font-weight:bold;">Proposal No. 3 Approval of Compensation of the Named Executive Officers</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 (the "Dodd-Frank Act"), our stockholders are entitled to vote at the annual meeting to provide advisory approval of the compensation of our named executive officers as disclosed in this proxy statement pursuant to the compensation disclosure rules of the SEC. This proposal, commonly known as a &#8220;say-on-pay&#8221; proposal, gives our stockholders the opportunity to express their views on our named executive officers&#8217; compensation. This vote is not intended to address any specific item of compensation, but rather the overall compensation of our named executive officers and the philosophy, policies and practices described in this proxy statement. Pursuant to the Dodd-Frank Act, the stockholder vote on executive compensation is an advisory vote only, and it is not binding on us or our board of directors.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Although the vote is non-binding, our compensation committee and board of directors value the opinions of the stockholders and will consider the outcome of the vote when making future compensation decisions. As described more fully in the Compensation Discussion and Analysis section of this proxy statement, our executive compensation program is designed to attract, retain and motivate individuals with superior ability, experience and leadership capability to deliver on our annual and long-term business objectives necessary to create stockholder value. We urge stockholders to read the Compensation Discussion and Analysis section of this proxy statement, which describes in detail how our executive compensation policies and procedures operate and are intended to operate in the future. The compensation committee and the board of directors believe that our executive compensation program fulfills these goals and is reasonable, competitive and aligned with our performance and the performance of our executives.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are asking our stockholders to indicate their support for our named executive officer compensation as described in this proxy statement. Accordingly, we ask that our stockholders vote &#8220;FOR&#8221; the following resolution:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;RESOLVED, that Ligand Pharmaceuticals Incorporated stockholders approve, on an advisory basis, the compensation of the named executive officers, as disclosed in Ligand Pharmaceuticals Incorporated&#8217;s Proxy Statement for the 2019 annual meeting of stockholders, pursuant to the compensation disclosure rules of the SEC, including the Compensation Discussion and Analysis, the 2018 Summary Compensation Table and the other related tables and disclosure.&#8221;</font></div><div style="line-height:120%;padding-top:20px;text-align:left;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-weight:bold;">Recommendation of the Board of Directors</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our board of directors unanimously recommends that stockholders vote </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">FOR</font><font style="font-family:inherit;font-size:10pt;">&#32;the approval, on an advisory basis, of the compensation of the named executive officers as disclosed in this proxy statement pursuant to the compensation disclosure rules of the SEC.</font></div><div><br></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ligand Pharmaceuticals Incorporated 2019 Proxy Statement </font><font style="font-family:Wingdings;font-size:8pt;">l</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">15</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="s27810da5d5dd4d4ebb413db40b387007"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:18pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.0079365079365%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:top;background-color:#727272;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:5px;text-align:left;padding-left:9px;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;color:#ffffff;font-weight:bold;">Proposal No. 4: Amendment and Restatement of the Ligand Pharmaceuticals Incorporated 2002 Stock Incentive Plan</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are asking our stockholders to approve the amendment and restatement of the Ligand Pharmaceuticals Incorporated 2002 Stock Incentive Plan, or the Existing Plan. The amendment and restatement of the Existing Plan is referred to herein as the Restated Equity Plan. The Restated Equity Plan was adopted by our board on March 28, 2019, subject to stockholder approval. The Restated Equity Plan will become effective if it is approved by the stockholders at the annual meeting. </font></div><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The proposed amendments to the Existing Plan would: </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Increase the Share Reserve</font><font style="font-family:inherit;font-size:10pt;">. We are asking our stockholders to approve an increase of 820,000 in the number of shares available for issuance under the Restated Equity Plan over the existing share reserve under the Existing Plan. Accordingly, the Restated Equity Plan authorizes the issuance of an aggregate of 6,299,254 shares of common stock. As of April 10, 2019, awards covering a total of 2,032,707 shares were subject to outstanding awards under the Existing Plan (with performance awards counted assuming "target" performance) and 213,646 shares remained available for future grants under the Existing Plan (with performance awards counted assuming "target" performance, which number drops to 191,549 shares remaining available for issuance under the Existing Plan if performance awards are counted assuming "maximum" performance).</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the terms of the Restated Equity Plan, the shares available for issuance may be used for all types of awards under a fungible pool formula. Pursuant to this fungible pool formula, the authorized share limit will be reduced by one share of common stock for every one share subject to an option or stock appreciation right, or SAR, outstanding under the Restated Equity Plan and 1.5 shares of common stock for every one share subject to a &#8220;full-value award&#8221; under the Restated Equity Plan. For purposes of the Restated Equity Plan, a full-value award is an award pursuant to which shares of our common stock are issuable that is granted with a per-share exercise or purchase price less than 100% of the fair market value of a share of our common stock on the date of grant. </font></div><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The proposed increase in shares available for issuance under the Restated Equity Plan (over the existing share reserve under the Existing Plan) has been reviewed and approved by our board. In the process, the board determined that the existing number of shares available for issuance under the Existing Plan was insufficient to meet our ongoing needs to provide long-term incentive grants on an ongoing and regular basis to motivate, reward and retain key employees who create stockholder value. The increase in shares has been necessitated by the hiring of new employees, and by granting additional stock awards to current employees as long-term incentives. The increase will enable us to continue our policy of equity ownership by employees and directors as an incentive to contribute to our continued success.</font></div><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Limit on Incentive Stock Options.</font><font style="font-family:inherit;font-size:10pt;">&#32;&#32;Under the Restated Equity Plan, no more than 6,299,254 shares may be issued upon the exercise of incentive stock options, or ISOs, subject to adjustment for changes in our capitalization and certain corporate transactions, as described below under the heading &#8220;Adjustments.&#8221;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Extend the Term</font><font style="font-family:inherit;font-size:10pt;">. The Restated Equity Plan will have a term of ten years from the date it was adopted by our board.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Limitations on Dividend Payments on Unvested Awards</font><font style="font-family:inherit;font-size:10pt;">. The Restated Equity Plan provides that dividends and dividend equivalents may not be paid on awards subject to vesting conditions unless and until such conditions are met. Under the Restated Equity Plan, dividend equivalents may not be paid on stock options or SARs.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Removal of Section 162(m) Provisions</font><font style="font-family:inherit;font-size:10pt;">. Section 162(m) of the Internal Revenue Code, or the Code, prior to the Tax Cuts and Jobs Act of 2017 (the &#8220;TCJA&#8221;), allowed performance-based compensation that met certain requirements to be tax deductible regardless of amount.  This qualified performance-based compensation exception was repealed as part of the TCJA.  We have removed certain provisions from the Restated Equity Plan which were otherwise required for awards to qualify as performance-based compensation under the Section 162(m) exception prior to its repeal, including, without limitation, the limit on the number of awards that could be granted to an individual in any calendar year.  </font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ligand Pharmaceuticals Incorporated 2019 Proxy Statement </font><font style="font-family:Wingdings;font-size:8pt;">l</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">16</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Tax Withholding</font><font style="font-family:inherit;font-size:10pt;">. The Restated Equity Plan permits the plan administrator to allow for the withholding or delivery of shares in satisfaction of tax withholding with respect to awards with a value up to the maximum individual statutory tax rate in the applicable jurisdiction at the time of such withholding (or such other rate as may be required to avoid the liability classification of the applicable award under generally accepted accounting principles in the United States of America). Shares withheld or delivered in excess of the minimum applicable statutory rate will not, however, become available for issuance under the Restated Equity Plan.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Each of these aspects of the Restated Equity Plan is discussed below. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Restated Equity Plan is not being materially amended in any respect other than to reflect the changes described above. </font></div><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Why the Stockholders Should Vote to Approve the Restated Equity Plan </font></div><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Equity Incentive Awards Are an Important Part of Our Compensation Philosophy</font><font style="font-family:inherit;font-size:10pt;">. Our equity compensation plans are critical to our ongoing effort to build stockholder value. As discussed in the Compensation Discussion and Analysis section of this proxy statement, equity incentive awards are central to our compensation program. Our board and its compensation committee believe that our ability to grant equity incentive awards to new and existing employees, directors and eligible consultants has helped us attract, retain and motivate world-class talent. Historically, we have primarily issued stock options and restricted stock units because these forms of equity compensation provide a strong retention value and incentive for employees to work to grow the business and build stockholder value, and are attractive to employees who share the entrepreneurial spirit that has made us a success.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Also, our equity incentive programs are broad-based. The equity incentive programs we have in place have worked to build stockholder value by attracting and retaining talented employees. We believe we must continue to offer a competitive equity compensation plan in order to attract and motivate the talent necessary for our continued growth and success. As of April 10, 2019, 53 of our 109 employees, all of our 7 non-employee directors and 2 of our 18 consultants held outstanding equity awards.</font></div><div style="line-height:120%;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">The Existing Plan Will No Longer Have Shares Available for Grant</font><font style="font-family:inherit;font-size:10pt;">. Under our current forecasts, the Existing Plan will run out of shares available for grant within the next nine months, and we will not be able to continue to issue equity to our employees and directors unless our stockholders approve the Restated Equity Plan. This assumes we continue to grant awards consistent with our historical usage and current practices, as reflected in our historical burn rate discussed below, and noting that future circumstances may require us to change our current equity grant practices. While we could increase cash compensation if we are unable to grant equity incentives, we anticipate that we will have difficulty attracting, retaining and motivating our employees and directors if we are unable to make equity grants to them.</font></div></td></tr></table><div style="line-height:174%;text-align:left;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">We Manage Our Equity Incentive Award Use Carefully. </font><font style="font-family:inherit;font-size:10pt;">We manage our long-term stockholder dilution by limiting the number of equity awards granted annually. Our compensation committee carefully monitors our total dilution and equity expense to ensure that we maximize stockholder value by granting only the appropriate number of equity awards necessary to attract, reward and retain employees. The following table summarizes the awards outstanding and shares available for grant under the Existing Plan as of April 10, 2019, and the proposed increase in shares authorized for issuance under the Restated Equity Plan:</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ligand Pharmaceuticals Incorporated 2019 Proxy Statement </font><font style="font-family:Wingdings;font-size:8pt;">l</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">17</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.0079365079365%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:54%;"></td><td style="width:3%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:2%;"></td><td style="width:14%;"></td><td style="width:2%;"></td><td style="width:13%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Number</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">of Shares</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As a % of Shares</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Outstanding</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Dollar</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Value</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(3)</sup></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bababa;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bababa;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,905,655</font></div></td><td style="vertical-align:bottom;background-color:#bababa;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bababa;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bababa;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bababa;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.7%</font></div></td><td style="vertical-align:bottom;background-color:#bababa;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bababa;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$244,190,632</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average exercise price of outstanding options</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$77.11</font></div></td><td style="vertical-align:bottom;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bababa;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average remaining term (in years) of outstanding options</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bababa;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.99</font></div></td><td style="vertical-align:bottom;background-color:#bababa;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bababa;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bababa;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bababa;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bababa;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bababa;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted stock units</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(4)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">127,052</font></div></td><td style="vertical-align:bottom;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.6%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$16,280,443</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bababa;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares available for grant</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(5)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bababa;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">213,646</font></div></td><td style="vertical-align:bottom;background-color:#bababa;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bababa;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bababa;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bababa;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.1%</font></div></td><td style="vertical-align:bottom;background-color:#bababa;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bababa;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$27,376,598</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Proposed increase in shares available for issuance under Restated Equity Plan (over existing share reserve under Existing Plan)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">820,000</font></div></td><td style="vertical-align:bottom;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.2%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$105,074,800</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:4px;padding-top:4px;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1) Excludes the shares available for grant under our Employee Stock Purchase Plan, or the Existing ESPP. For more information about our Existing ESPP and the shares remaining available for issuance thereunder, see Proposal 5 below.</font></div><div style="line-height:120%;padding-bottom:4px;padding-top:4px;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2) Based on 19,663,929 shares of our common stock outstanding as of April 10, 2019. </font></div><div style="line-height:120%;padding-bottom:4px;padding-top:4px;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3) Based on the closing price of our common stock on April 10, 2019, of $128.14 per share. </font></div><div style="line-height:120%;padding-bottom:4px;padding-top:4px;text-align:left;padding-left:24px;text-indent:-22px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">(4) Restricted stock units that are subject to performance-based vesting are reflected assuming &#8220;target&#8221; performance.</font><font style="font-family:Arial;font-size:12pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">Performance-based awards granted prior to 2018 may be eligible to vest in up to 137.5% of the &#8220;target&#8221; award levels at &#8220;maximum&#8221; performance. Performance-based awards granted beginning in 2018 may be eligible to vest in up to 150% of the &#8220;target&#8221; award levels at &#8220;maximum&#8221; performance. The number of performance-based restricted stock units outstanding as of April 10, 2019 assuming "maximum" performance is 44,200.</font></div><div style="line-height:120%;padding-bottom:4px;padding-top:4px;text-align:left;padding-left:24px;text-indent:-22px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5)  Shares remaining available for issuance under the Existing Plan calculated assuming performance-based awards are counted against the share reserve at &#8220;target&#8221; levels.  If performance-based awards are counted against the share reserve assuming "maximum" performance, only 191,549 shares remained available for issuance under the Existing Plan as of April 10, 2019.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In determining whether to approve the Restated Equity Plan, including the proposed increase to the share reserve under the Restated Equity Plan over the share reserve under the Existing Plan, our board considered the following: </font></div><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The 6,299,254 shares to be reserved for issuance under the Restated Equity Plan will represent an increase of 820,000 shares from the aggregate number of shares reserved for issuance and that remain available for future grant under the Existing Plan as of April 10, 2019.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In determining the size of the share reserve under the Restated Equity Plan, our board considered the number of equity awards we granted during the past three calendar years. In calendar years 2016, 2017 and 2018, our annual equity burn rates (calculated by dividing (1) the number of shares subject to equity awards granted during the year by (2) the weighted-average number of diluted shares outstanding at the end of the applicable year) under the Existing Plan were 2.4%, 1.5% and 1.2%, respectively. If each &#8220;full-value award&#8221; is multiplied by 1.5 (consistent with the methodology employed pursuant to the fungible share ratio in the Restated Equity Plan), the &#8220;adjusted&#8221; annual burn rate under the Existing Plan would be 3.0%, 1.6% and 1.3%, for calendar years 2016, 2017 and 2018, respectively. </font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:50px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:26px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In fiscal years 2016, 2017 and 2018, the number of stock options and time-vesting restricted stock units granted and the number of performance-based restricted stock units earned, was as follows:</font></div></td></tr></table><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:90.87301587301587%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:34%;"></td><td style="width:22%;"></td><td style="width:22%;"></td><td style="width:22%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#87baff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#87baff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#87baff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#87baff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Stock Options/SARs granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">228,362</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">273,353</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">263,489</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Time-based RSUs granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43,812</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43,042</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,987</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Performance-based RSUs earned</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,783</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">143,691</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We expect the proposed aggregate share reserve under the Restated Equity Plan to provide us with enough shares for awards for approximately one to two years, assuming we continue to grant awards consistent with our current </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ligand Pharmaceuticals Incorporated 2019 Proxy Statement </font><font style="font-family:Wingdings;font-size:8pt;">l</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">18</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-left:48px;text-align:left;"><font style="font-family:inherit;font-size:10pt;">practices and historical usage, as reflected in our historical burn rate, and further dependent on the price of our shares and hiring activity during the next few years, forfeitures of outstanding awards under the Existing Plan, and noting that future circumstances may require us to change our current equity grant practices. We cannot predict our future equity grant practices, the future price of our shares or future hiring activity with any degree of certainty at this time, and the share reserve under the Restated Equity Plan could last for a shorter or longer time. </font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In calendar years 2016, 2017 and 2018, the end of year overhang rate (calculated by dividing (1) the sum of the number of shares subject to equity awards outstanding at the end of the calendar year plus shares remaining available for issuance for future awards at the end of the calendar year by (2) the number of shares outstanding at the end of the calendar year) was 14.6%, 13.3% and 11.7%, respectively. If the Restated Equity Plan is approved, we expect our overhang at the end of 2019 will be approximately 11.4% (excluding the 64,008 shares that remain available for issuance under the Employee Stock Purchase Plan as of April 10, 2019).</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Analysis by our compensation consultant, which was based on generally accepted evaluation methodologies used by proxy advisory firms, that the additional number of shares to be reserved under the Restated Equity Plan is within generally accepted standards as measured by an analysis of the Restated Equity Plan cost relative to industry standards.</font></div></td></tr></table><div style="line-height:174%;text-align:justify;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In light of the factors described above, and the fact that the ability to continue to grant equity compensation is vital to our ability to continue to attract and retain highly qualified individuals in the extremely competitive labor markets in which we compete, our board has determined that the size of the share reserve under the Restated Equity Plan is reasonable and appropriate at this time. Our board will not create a subcommittee to evaluate the risk and benefits for issuing shares under the Restated Equity Plan.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">The Restated Equity Plan Contains Equity Compensation Best Practices </font></div><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Restated Equity Plan authorizes the issuance of equity-based compensation in the form of stock options, SARs, restricted shares, restricted stock units, dividend equivalents, stock payments and performance-based awards structured by the compensation committee within parameters set forth in the Restated Equity Plan, for the purpose of providing our directors, officers, employees and consultants equity compensation, incentives and rewards for superior performance. Some of the key features of the Restated Equity Plan that reflect our commitment to effective management of incentive compensation and that are consistent with best practices in equity compensation to protect our stockholders&#8217; interests are as follows:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Broad-based eligibility for equity awards</font><font style="font-family:inherit;font-size:10pt;">. We grant equity awards to all our full-time US employees and key international employees. By doing so, we link employee interests with stockholder interests throughout the organization and motivate our employees to act as owners of the business. As of April 10, 2019, 53 of our 109 employees, all of our 7 non-employee directors and 2 of our 18 consultants had received grants of equity awards. </font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Stockholder approval is required for additional shares</font><font style="font-family:inherit;font-size:10pt;">. The Restated Equity Plan does not contain an annual &#8220;evergreen&#8221; provision. The Restated Equity Plan authorizes a fixed number of shares, so that stockholder approval is required to increase the maximum number of securities which may be issued under the Restated Equity Plan. </font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">No Re-pricing or Replacement of Options or Stock Appreciation Rights</font><font style="font-family:inherit;font-size:10pt;">. The Restated Equity Plan prohibits, without stockholder approval: (1) the amendment of awards to reduce the exercise price, and (2) the replacement of an option or SAR with cash, any other award or an option or SAR with an exercise price that is less than the exercise price per share of the original option or SAR. </font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">No In-the-Money Option or Stock Appreciation Right Grants</font><font style="font-family:inherit;font-size:10pt;">. The Restated Equity Plan prohibits the grant of options or SARs with an exercise or base price less than the fair market value of our common stock, generally the closing price of our common stock, on the date of grant. </font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Limitations on Dividend Payments on Performance Awards</font><font style="font-family:inherit;font-size:10pt;">. Dividends and dividend equivalents may be paid on awards subject to vesting conditions only to the extent such conditions are met.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ligand Pharmaceuticals Incorporated 2019 Proxy Statement </font><font style="font-family:Wingdings;font-size:8pt;">l</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">19</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Limitations on Grants</font><font style="font-family:inherit;font-size:10pt;">. No one person participating in the Restated Equity Plan may receive awards for more than 1,000,000 shares of common stock in the aggregate per calendar year.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Non-Employee Director Compensation Limit</font><font style="font-family:inherit;font-size:10pt;">. The sum of any cash compensation, or other compensation, and the grant date fair value of awards granted to a non-employee director for services as a non-employee director during any calendar year, generally may not exceed $550,000 (which limit will be increased to $850,000 in the calendar year of his or her initial service as a non-employee director).</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">No Tax Gross-Ups</font><font style="font-family:inherit;font-size:10pt;">. The Restated Equity Plan does not provide for any tax gross-ups.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Independent Administration</font><font style="font-family:inherit;font-size:10pt;">. The compensation committee of the board, which consists of only independent directors, will administer the Restated Equity Plan if it is approved by stockholders.</font></div></td></tr></table><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Stockholder Approval Requirement</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stockholder approval of the Restated Equity Plan is necessary in order for us to (1) meet the stockholder approval requirements of Nasdaq and (2) grant ISOs thereunder.</font></div><div style="line-height:120%;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If the Restated Equity Plan is not approved by our stockholders, the Restated Equity Plan will not become effective, the Existing Plan will continue in full force and effect, and we may continue to grant awards under the Existing Plan, subject to its terms, conditions and limitations, using the shares available for issuance thereunder.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Summary of the Restated Equity Plan </font></div><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following is a summary of the principal features of the Restated Equity Plan, assuming approval of this proposal. The summary, however, is not a complete description of all the provisions of the Restated Equity Plan. The proposed Restated Equity Plan is attached to this proxy statement as</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#32;Appendix A</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Plan Structure </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Restated Equity Plan contains three separate equity programs; the Discretionary Option Grant Program, the Stock Issuance Program and the Other Stock Awards Program. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Administration </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Restated Equity Plan will be administered by the compensation committee of the board. This committee has complete discretion, subject to the provisions of the Restated Equity Plan, to authorize awards under the Restated Equity Plan to all eligible persons other than non-employee members of our board. However, the board may also appoint a secondary committee of one or more members of our board of directors to have separate but concurrent authority to make awards under those programs to all eligible individuals other than our executive officers and non-employee members of our board of directors. The full board will administer the Restated Equity Plan with respect to awards to the non-employee members of our board of directors. The term &#8220;Plan Administrator,&#8221; as used in this proxy statement, will mean the board, the compensation committee or any secondary committee, to the extent each such entity is acting within the scope of its duties under the Restated Equity Plan. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Eligibility </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Officers and employees of Ligand and its subsidiaries, whether now existing or subsequently established, non-employee members of our board of directors and consultants and independent contractors of Ligand and its parent and subsidiaries are eligible to participate in the Restated Equity Plan. </font></div><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of April 10, 2019, all 109 of our employees, all 7 non-employee members of our board of directors and all 18 of our consultants were eligible to receive awards under the Existing Plan, and would have been eligible to receive awards under the Restated Equity Plan had it been in effect on such date. </font></div><div><br></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ligand Pharmaceuticals Incorporated 2019 Proxy Statement </font><font style="font-family:Wingdings;font-size:8pt;">l</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">20</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Shares Available</font><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are asking our stockholders to approve an increase of 820,000 in the number of shares available for issuance under the Restated Equity Plan over the share reserve under the Existing Plan. The Restated Equity Plan will authorize the issuance of an aggregate of 6,299,254 shares of common stock, reduced by (1) one share for each share subject to a stock option or SAR and (2) 1.5 shares for each share subject to a full-value award. As of April 10, 2019, 213,646 shares of common stock remained available for future issuance under the Existing Plan and 2,032,707 shares were subject to outstanding awards under the Existing Plan.  In no event may more than 6,299,254 shares of common stock be issued upon the exercise of ISOs under the Restated Equity Plan.</font></div><div style="line-height:120%;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If (1) any award is forfeited or expires or such award is settled for cash, (2) any shares subject to a full-value award are forfeited by the holder or repurchased by us at a price not greater than the price paid by the holder of such shares, or (3) any shares are tendered or withheld to satisfy any tax withholding obligation with respect to a full-value award, then the shares subject to such award may, to the extent of such forfeiture, expiration, cash settlement or repurchase, be used again for new grants under the Restated Equity Plan; provided, however, that, notwithstanding the foregoing, in the event shares subject to a full-value award are delivered by a participant or withheld by us to satisfy any tax withholding obligation at a tax withholding rate in excess of the minimum statutory withholding rates, such shares tendered or withheld to satisfy the tax withholding obligation at a rate in excess of the minimum statutory withholding rates shall not be available for future grants of awards under the Restated Equity Plan and shall continue to be counted against the share reserve in an amount corresponding to the reduction in the share reserve previously made with respect to such award. Any shares that again become available for grant will be added back as (1) one share if such shares were subject to an option or SAR, and (2) as 1.5 shares if such shares were subject to full-value awards. The payment of dividend equivalents in cash in conjunction with any outstanding awards will not be counted against the shares available for issuance under the Restated Equity Plan. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Notwithstanding the foregoing, the following shares will not be added to the shares authorized for grant under the Restated Equity Plan: (1) any shares tendered or withheld to satisfy the exercise price of an option or any tax withholding obligation with respect to an option or SAR, (2) any shares subject to a SAR that are not issued in connection with the stock settlement of the SAR on its exercise, and (3) any shares purchased on the open market with the cash proceeds from the exercise of options. </font></div><div style="line-height:174%;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Adjustments </font></div><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Should any change be made to the common stock issuable under the Restated Equity Plan by reason of any stock split, stock dividend, recapitalization, combination of shares, exchange of shares or other change affecting the outstanding common stock as a class without our receipt of consideration, or as a result of a change in ownership or control of Ligand, then appropriate adjustments will be made to: </font></div><div style="line-height:174%;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:46px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the maximum number and/or class of securities issuable under the Restated Equity Plan and the maximum number of shares that may be issued upon exercise of ISOs under the Restated Equity Plan;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:96px;text-indent:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:96px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:46px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the maximum number and/or class of securities for which any one person may be granted awards per calendar year under the Restated Equity Plan;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:96px;text-indent:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:96px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:46px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the number and/or class of securities for which grants are subsequently to be made under an automatic option grant program to new and continuing non-employee members of the board of directors;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:96px;text-indent:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:96px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:46px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the number and/or class of securities and price per share in effect under each outstanding award; and</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:96px;text-indent:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:96px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:46px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">terms and conditions of any outstanding awards (including, without limitation, any applicable performance </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ligand Pharmaceuticals Incorporated 2019 Proxy Statement </font><font style="font-family:Wingdings;font-size:8pt;">l</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">21</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-left:96px;text-align:left;"><font style="font-family:inherit;font-size:10pt;">targets or criteria with respect thereto).</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, equitable adjustments will be made to outstanding awards in the event a large non-recurring cash dividend is paid to our stockholders, which affects the common stock or share price of the common stock underlying the awards subject to the Restated Equity Plan. Such adjustments to the outstanding awards will be effected in a manner which will preclude the enlargement or dilution of rights and benefits under those awards. </font></div><div style="line-height:174%;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Valuation </font></div><div style="line-height:120%;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair market value per share of common stock on any relevant date under the Restated Equity Plan will be deemed to be equal to the closing selling price per share on that date on the NASDAQ Global Market. If there is no reported selling price for such date, then the fair market value per share will be the closing selling price on the last preceding date for which such quotation exists. On April 10, 2019, the closing selling price per share of our common stock was $128.14. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Discretionary Grant Program </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Grants </font></div><div style="line-height:120%;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Plan Administrator has complete discretion under the Discretionary Option Grant Program to determine which eligible individuals are to receive option grants, the time or times when those grants are to be made, the number of shares subject to each such grant, the status of any granted option as either an ISO or a non-statutory option under the federal tax laws, the time or times when each option is to become exercisable, the vesting schedule (if any) to be in effect for the option grant and the maximum term (up to 10 years) for which any granted option is to remain outstanding. </font></div><div style="line-height:120%;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Price and Exercisability </font></div><div style="line-height:120%;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Each granted option will have an exercise price per share not less than 100% of the fair market value per share of common stock on the option grant date, and no granted option will have a term in excess of 10 years. The shares subject to each option will generally become exercisable for fully-vested shares in a series of installments over a specified period of service measured from the grant date. However, one or more options may be structured so that they are immediately exercisable for any or all of the option shares. The shares acquired under such immediately-exercisable options will normally be unvested and subject to repurchase by us, at the lower of (1) the exercise price paid per share or (2) the fair market value per share of common stock at the time of cessation of service if the optionee ceases service with us prior to vesting in those shares. </font></div><div style="line-height:120%;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The exercise price may be paid in cash or check, in shares of common stock or, in the Plan Administrator&#8217;s discretion, by issuance of a promissory note. Outstanding options may also be exercised through a same-day sale program pursuant to which a designated brokerage firm is to effect an immediate sale of the shares purchased under the option and pay to us, out of the sale proceeds available on the settlement date, sufficient funds to cover the exercise price for the purchased shares plus all applicable withholding taxes. </font></div><div style="line-height:120%;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">No optionee has any stockholder rights with respect to the option shares until such optionee has exercised the option and paid the exercise price for the purchased shares. Options are generally not assignable or transferable other than by will or the laws of inheritance and, during the optionee&#8217;s lifetime, the option may be exercised only by such optionee. However, the Plan Administrator may allow non-statutory options to be transferred or assigned during the optionee&#8217;s lifetime to one or more members of the optionee&#8217;s immediate family or to a trust established exclusively for one or more such family members or to the optionee&#8217;s former spouse, to the extent such transfer or assignment is in furtherance of the optionee&#8217;s estate plan or pursuant to a domestic relations order. The optionee may also designate one or more beneficiaries to automatically receive his or her outstanding options at death. </font></div><div style="line-height:174%;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Termination of Service </font></div><div style="line-height:120%;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upon cessation of service, the optionee will have a limited period of time in which to exercise his or her outstanding options for any shares in which the optionee is vested at that time. The Plan Administrator has discretion to extend the period following the optionee&#8217;s cessation of service during which his or her outstanding options may be exercised, up to the date of the option&#8217;s expiration and/or to accelerate the exercisability or vesting of such options in whole or in part. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ligand Pharmaceuticals Incorporated 2019 Proxy Statement </font><font style="font-family:Wingdings;font-size:8pt;">l</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">22</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Stock Issuance Program </font></div><div style="line-height:120%;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares may be issued under the Stock Issuance Program at a price per share, if any, determined by the Plan Administrator. The Plan Administrator has complete discretion under this program to determine which eligible individuals are to receive such stock issuances, the time or times when such issuances or awards are to be made, the number of shares subject to each such issuance or award and the vesting schedule, if any, to be in effect for the stock issuance. </font></div><div style="line-height:120%;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The shares issued may be fully and immediately vested upon issuance or may vest upon the recipient&#8217;s completion of a designated service period or upon our attainment of pre-established performance goals. The Plan Administrator has, however, the discretionary authority at any time to accelerate the vesting of any and all unvested shares outstanding under the Stock Issuance Program. </font></div><div style="line-height:120%;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any unvested shares for which the requisite service requirement or performance objective is not obtained must be surrendered to us for cancellation or repurchase, and the participant will not have any further stockholder rights with respect to those shares. Recipients of restricted shares under the Stock Issuance Program may have voting rights and may receive dividends, if any, prior to the time when the restrictions lapse, provided that any dividends paid on unvested shares will be subject to the same vesting conditions as the underlying unvested shares.</font></div><div style="line-height:120%;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Other Stock Awards Program </font></div><div style="line-height:120%;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Plan Administrator has complete discretion under the Other Stock Awards Program to make awards of stock appreciation rights, restricted stock units or dividend equivalents to eligible persons under the Plan. </font></div><div style="line-height:120%;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Stock Appreciation Rights </font></div><div style="line-height:120%;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">SARs may be granted in connection with stock options or other awards, or separately. SARs granted by the Plan Administrator in connection with stock options or other awards typically will provide for payments to the holder based upon increases in the price of our common stock over the exercise price of the SAR or a related option or other awards. Each granted SAR will have an exercise or base price per share not less than 100% of the fair market value per share of common stock on the SAR grant date, and no granted SAR will have a term in excess of 10 years. There are no restrictions specified in the plan on the exercise of SARs or the amount of gain realizable therefrom, although restrictions may be imposed by the Plan Administrator in the SAR agreements. The Plan Administrator may elect to pay SARs in cash or in shares of our common stock or in a combination of both. </font></div><div style="line-height:174%;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Restricted Stock Units</font></div><div style="line-height:120%;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted stock units may be awarded to participants, typically without payment of consideration, but subject to vesting conditions based on continued employment or on performance criteria established by our compensation committee. Like stock issuances that are subject to vesting, restricted stock units may not be sold, or otherwise transferred or hypothecated, until vesting conditions are removed or expire. Unlike stock issuances, shares issuable pursuant to a restricted stock unit award will not be issued until the restricted stock unit award has vested, and recipients of restricted stock unit awards generally will have no voting or dividend rights prior to the time when vesting conditions are satisfied. </font></div><div style="line-height:120%;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Dividend Equivalents </font></div><div style="line-height:120%;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dividend equivalents represent the value of the dividends, if any, per share paid by us, calculated with reference to the number of shares covered by the stock options, SARs or other awards held by the participant. Dividend and dividend equivalents may not be paid on awards subject to vesting conditions unless and until such conditions are met.</font></div><div style="line-height:174%;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Equity Awards to Non-Employee Directors </font></div><div style="line-height:120%;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-employee members of our board of directors are eligible for automatic equity awards under the Restated Equity Plan pursuant to the terms of our Director Compensation Policy, which is described below under &#8220;Compensation Discussion and Analysis-Narrative to Director Compensation Table.&#8221; </font></div><div style="line-height:120%;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the Restated Equity Plan, the sum of any cash compensation, or other compensation, and the grant date fair value of </font></div><div><br></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ligand Pharmaceuticals Incorporated 2019 Proxy Statement </font><font style="font-family:Wingdings;font-size:8pt;">l</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">23</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">awards granted to a non-employee director for services as a non-employee director during any calendar year, generally may not exceed $550,000 (which limit will be increased to $850,000 in the calendar year of his or her initial service as a non-employee director). The plan administrator may make exceptions to this limit for individual non-employee directors in extraordinary circumstances, as the plan administrator may determine in its discretion, provided that the non-employee director receiving such additional compensation may not participate in the decision to award such compensation or in other contemporaneous compensation decisions involving non-employee directors.</font></div><div style="line-height:174%;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">General Plan Provisions </font></div><div style="line-height:120%;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Change in Ownership or Control </font></div><div style="line-height:120%;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the event that we are acquired by merger or asset sale, or if there is a change in ownership or control, the Plan Administrator may provide for any or all of the following alternatives: </font></div><div style="line-height:120%;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:46px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">require participants to surrender their outstanding awards for a cash payment;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:46px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">replace outstanding awards with other rights or property; </font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:46px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">accelerate the vesting of all or a portion of the awards; </font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:46px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">require that the successor or survivor corporation assume the awards or replace them with equivalent awards; or</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:46px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">adjust the terms and conditions of outstanding awards.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, in the event that we are acquired by merger or asset sale, or if there is a change in ownership or control, then awards granted under the Restated Equity Plan may: </font></div><div style="line-height:120%;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:46px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">vest or accelerate in full when such awards are not to be assumed by any successor corporation;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:2px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:46px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">vest or accelerate in full when such awards are to be assumed by any successor corporation; or</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:46px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">vest or accelerate in full when such awards are to be assumed by any successor corporation and the employee holding such options is involuntarily terminated.</font></div></td></tr></table><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Tax Withholding</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Restated Equity Plan permits the plan administrator to allow for the withholding or surrender of shares in satisfaction of tax withholding with respect to awards with a value up to the maximum individual statutory tax rate in the applicable jurisdiction at the time of such withholding (or such other rate as may be required to avoid the liability classification of the applicable award under generally accepted accounting principles in the United States of America). </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Amendment and Termination </font></div><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The board may amend or modify the Restated Equity Plan at any time, subject to any required stockholder approval pursuant to applicable laws and regulations. Unless sooner terminated by the board, the Restated Equity Plan will terminate on the earliest of: </font></div><div style="line-height:120%;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March 28, 2029; or</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:96px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the termination of all outstanding options in connection with certain changes in control or ownership of the Company.</font></div></td></tr></table><div style="line-height:174%;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Repricing Prohibited </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><br></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ligand Pharmaceuticals Incorporated 2019 Proxy Statement </font><font style="font-family:Wingdings;font-size:8pt;">l</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">24</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Restated Equity Plan prohibits, without stockholder approval: (1) the amendment of awards to reduce the exercise price, and (2) the replacement of an option or SAR with cash, any other award or an option or SAR with an exercise price that is less than the exercise price per share of the original option or SAR. </font></div><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Performance-Based Awards</font><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><div style="line-height:120%;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any awards granted pursuant to the Restated Equity Plan may be subject to performance-based vesting conditions. The value of performance awards may be linked to any one or more of the performance criteria listed below, or other specific criteria determined by the Plan Administrator, in each case on a specified date or dates or over any period or periods determined by the Plan Administrator. The goals are established and evaluated by the Plan Administrator and may relate to performance over any periods as determined by the Plan Administrator. </font></div><div style="line-height:120%;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These pre-established performance goals may be based on one or more performance criteria determined by the Plan Administrator, which may include, but are not limited to, the following performance criteria: </font></div><div style="line-height:174%;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:49px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">net earnings (either before or after interest, taxes, depreciation and amortization); </font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:96px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:49px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">gross or net sales or revenue; </font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:96px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:49px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">adjusted net income;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:96px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:49px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">operating earnings or profit; </font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:96px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:49px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">cash flow (including, but not limited to, operating cash flow and free cash flow); </font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:96px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:49px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">return on assets; </font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:96px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:49px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">return on capital; </font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:96px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:49px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">return on stockholders&#8217; equity; </font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:96px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:49px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">total stockholder return; </font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:96px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:49px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">return on sales; </font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:96px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:49px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">gross or net profit or operating margin; </font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:96px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:49px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">expenses; </font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:96px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:49px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">working capital; </font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:96px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:49px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">earnings per share or adjusted earnings per share </font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:96px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:49px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">price per share of our common stock; </font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:96px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:49px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">regulatory body approval for commercialization of a product; and</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:96px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:49px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">implementation or completion of critical projects; </font></div></td></tr></table><div style="line-height:174%;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">any of which may be measured with respect to us, or any subsidiary, affiliate or other business unit, either in absolute terms, terms of growth or as compared to any incremental increase or decrease or as compared to results of a peer group or to market performance indicators or indices. The compensation committee will define in an objective fashion the manner of calculating the performance criteria it selects to use for such awards. With regard to a particular performance period, the compensation committee will have the discretion to select the length of the performance period, the type of performance-based awards to be granted, and the goals that will be used to measure the performance for the period. In determining the </font></div><div><br></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ligand Pharmaceuticals Incorporated 2019 Proxy Statement </font><font style="font-family:Wingdings;font-size:8pt;">l</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">25</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">actual size of an individual performance-based award for a performance period, the compensation committee may reduce or eliminate (but not increase) the initial award. Generally, a participant will have to be employed by or providing services to us or any of our subsidiaries or affiliates on the date the performance-based award is paid to be eligible for a performance-based award for any period. </font></div><div style="line-height:120%;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Plan Administrator may, in its sole discretion, provide that one or more adjustments shall be made to one or more of the performance goals. Such adjustments may include, but are not limited to, one or more of the following:</font></div><div style="line-height:174%;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:49px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">items related to a change in accounting principle; </font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:96px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:49px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">items relating to financing activities; </font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:96px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:49px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">expenses for restructuring or productivity initiatives; </font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:96px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:49px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">other non-operating items; </font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:96px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:49px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">items related to acquisitions; </font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:96px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:49px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">items attributable to the business operations of any entity acquired by us during the performance period;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:96px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:49px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">items related to the disposal of a business or segment of a business;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:96px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:49px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">items related to discontinued operations that do not qualify as a segment of a business under applicable accounting standards; </font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:96px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:49px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">items attributable to any stock dividend, stock split, combination or exchange of stock occurring during the performance period; </font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:96px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:49px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">other items of significant income or expense which are determined to be appropriate adjustments; </font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:96px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:49px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">items relating to unusual or extraordinary corporate transactions, events or developments; </font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:96px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:49px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">items related to amortization of acquired intangible assets; </font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:96px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:49px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">items that are outside the scope of our core, on-going business activities; </font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:96px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:49px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">items related to acquired in-process research and development; </font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:96px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:49px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">items relating to changes in tax laws;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:96px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:49px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">items relating to major licensing or partnership arrangements; </font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:49px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">items relating to asset impairment charges;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:96px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:49px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">items relating to gains or losses for litigation, arbitration and contractual settlements; or</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:96px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:49px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">items relating to any other unusual or nonrecurring events or changes in applicable laws, accounting principles or business conditions.</font></div></td></tr></table><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The maximum number of shares which may be subject to awards granted under the Restated Equity Plan to any individual in any calendar year may not exceed 1,000,000 shares of common stock. </font></div><div style="line-height:120%;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Securities Laws</font><font style="font-family:inherit;font-size:10pt;">. The Restated Equity Plan is intended to conform to all provisions of the Securities Act of 1933, as amended, and the Exchange Act and any and all regulations and rules promulgated by the SEC thereunder, including, without limitation, Rule 16b-3. The Restated Equity Plan will be administered, and awards will be granted and may be exercised, only in such a manner as to conform to such laws, rules and regulations. </font></div><div><br></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ligand Pharmaceuticals Incorporated 2019 Proxy Statement </font><font style="font-family:Wingdings;font-size:8pt;">l</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">26</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Material U.S. Federal Income Tax Consequences </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following is a general summary under current law of the material federal income tax consequences to an employee, consultant or non-employee director granted an award under the Restated Equity Plan. This summary deals with the general federal income tax principles that apply and is provided only for general information. Some kinds of taxes, such as state, local and foreign income taxes and federal employment taxes, are not discussed. Tax laws are complex and subject to change and may vary depending on individual circumstances and from locality to locality. The summary does not discuss all aspects of federal income taxation that may be relevant in light of a holder&#8217;s personal circumstances. This summarized tax information is not tax advice and a holder of an award should rely on the advice of his or her legal and tax advisors. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Option Grants </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options granted under the Restated Equity Plan may be either ISOs which satisfy the requirements of Section 422 of the Code or non-statutory options which are not intended to meet such requirements. The Federal income tax treatment for the two types of options differs as follows: </font></div><div style="line-height:174%;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Incentive Options</font><font style="font-family:inherit;font-size:10pt;">. The optionee recognizes no taxable income at the time of the option grant, and no taxable income is generally recognized at the time the option is exercised. However, the amount by which the fair market value (at the time of exercise) of the purchased shares exceeds the exercise price will be included in the optionee&#8217;s income for purposes of the alternative minimum tax. The optionee will, however, recognize taxable income in the year in which the purchased shares are sold or otherwise made the subject of a taxable disposition. For Federal tax purposes, dispositions are divided into two categories: (1) qualifying and (2) disqualifying. A qualifying disposition occurs if the sale or other disposition is made after the optionee has held the shares for more than two years after the option grant date and more than one year after the exercise date. If either of these two holding periods is not satisfied, then a disqualifying disposition will result.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upon a qualifying disposition, the optionee will recognize long-term capital gain in an amount equal to the excess of (1) the amount realized upon the sale or other disposition of the purchased shares over (2) the exercise price paid for the shares. If there is a disqualifying disposition of the shares, then the excess of (1) the lesser of the fair market value of those shares on the exercise date or the sale date over (2) the exercise price paid for the shares will be taxable as ordinary income to the optionee. Any additional gain or loss recognized upon the disposition will be recognized as a capital gain or loss by the optionee. </font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If the optionee makes a disqualifying disposition of the purchased shares, then we will be entitled to an income tax deduction, for the taxable year in which such disposition occurs, equal to the excess of (1) the fair market value of such shares on the option exercise date or the sale date, if less, over (2) the exercise price paid for the shares. In no other instance will we be allowed a deduction with respect to the optionee&#8217;s disposition of the purchased shares. </font></div><div style="line-height:174%;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:49px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Non-Statutory Options</font><font style="font-family:inherit;font-size:10pt;">. No taxable income is recognized by an optionee upon the grant of a non-statutory option. The optionee will in general recognize ordinary income in the year in which the option is exercised, equal to the excess of the fair market value of the purchased shares on the exercise date over the exercise price paid for the shares, and the optionee will be required to satisfy the tax withholding requirements applicable to such income.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are entitled to an income tax deduction equal to the amount of ordinary income recognized by the optionee with respect to the exercised non-statutory option. The deduction is in general allowed for the taxable year of Ligand in which such ordinary income is recognized by the optionee. </font></div><div style="line-height:174%;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Stock Appreciation Rights </font></div><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">No taxable income is recognized upon receipt of a SAR. The holder recognizes ordinary income, in the year in which the SAR is exercised, in an amount equal to the excess of the fair market value of the underlying shares of common stock on the </font></div><div><br></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ligand Pharmaceuticals Incorporated 2019 Proxy Statement </font><font style="font-family:Wingdings;font-size:8pt;">l</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">27</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">exercise date over the base price in effect for the exercised right, and the holder is required to satisfy the tax withholding requirements applicable to such income. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are entitled to an income tax deduction equal to the amount of ordinary income recognized by the holder in connection with the exercise of the SAR. The deduction generally is allowed for the taxable year in which such ordinary income is recognized. </font></div><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Direct Stock Issuance </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">An employee to whom unvested shares are issued generally will not recognize taxable income upon such issuance and we generally will not then be entitled to a deduction unless an election is made by the participant under Section 83(b) of the Code. However, when the restrictions on the shares of stock lapse, such that the shares are no longer subject to a substantial risk of forfeiture, the employee generally will recognize ordinary income and we generally will be entitled to a deduction for an amount equal to the excess of the fair market value of the shares at the date such restrictions lapse over the purchase price. If a timely election is made under Section 83(b) with respect to unvested stock, the participant generally will recognize ordinary income on the date of the issuance equal to the excess, if any, of the fair market value of the shares at that date over the purchase price therefore, and we will be entitled to a deduction for the same amount. A participant who receives stock in lieu of a cash payment that would otherwise have been made will generally be taxed as if the cash payment has been received, and we generally will be entitled to a deduction for the same amount. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Restricted Stock Units </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">An individual to whom restricted stock units are issued will not have taxable income upon issuance and we will not then be entitled to a deduction. An individual to whom restricted stock units are issued will generally realize ordinary income at the time the shares issuable with respect to the restricted stock unit award are distributed to the individual in an amount equal to the fair market value of such shares (less any purchase price), and we will be entitled to a corresponding deduction. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Dividend Equivalents </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A recipient of a dividend equivalent award generally will not recognize taxable income at the time of grant, and we will not be entitled to a deduction at that time. When a dividend equivalent is paid, the participant generally will recognize ordinary income, and we will be entitled to a corresponding deduction. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Section 409A of the Code </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain awards under the Restated Equity Plan may be considered &#8220;nonqualified deferred compensation&#8221; subject to Section 409A of the Code, which imposes additional requirements on the payment of deferred compensation. Generally, if at any time during a taxable year a nonqualified deferred compensation plan fails to meet the requirements of Section 409A, or is not operated in accordance with those requirements, all amounts deferred under the nonqualified deferred compensation plan for the current taxable year and all preceding taxable years, by or for any participant with respect to whom the failure relates, are includible in the gross income of the participant for the taxable year to the extent not subject to a substantial risk of forfeiture and not previously included in gross income. If a deferred amount is required to be included in income under Section 409A, the amount will be subject to income tax at regular income tax rates plus an additional 20 percent tax, as well as potential premium interest tax. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Section 162(m) Limitation</font><font style="font-family:inherit;font-size:10pt;">.    </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In general, under Section 162(m), income tax deductions of publicly-held corporations may be limited to the extent total compensation (including base salary, annual bonus, stock option exercises and non-qualified benefits paid) for certain executive officers exceeds $1 million (less the amount of any &#8220;excess parachute payments&#8221; as defined in Section 280G of the Code) in any one year. Prior to the TCJA, covered employees generally consisted of our Chief Executive Officer and each of the next three highest compensated officers serving at the end of the taxable year other than our Chief Financial Officer, and compensation that qualified as &#8220;performance-based&#8221; under Section 162(m) was exempt from this $1 million deduction limitation.  As part of the TCJA, the ability to rely on this exemption was, with certain limited exceptions, eliminated; in addition, the definition of covered employees was expanded to generally include all named executive officers.  Certain awards under the Existing Plan granted prior to November 2, 2017 may be grandfathered from the changes made by the TCJA under certain limited transition </font></div><div><br></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ligand Pharmaceuticals Incorporated 2019 Proxy Statement </font><font style="font-family:Wingdings;font-size:8pt;">l</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">28</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">relief, however, for grants after that date and any grants which are not grandfathered, we will no longer be able to take a deduction for any compensation in excess of $1 million that is paid to a covered employee.  There is no guarantee that we will be able to take a deduction for any compensation in excess of $1 million that is paid to a covered employee under the Existing Plan or the Restated Equity Plan.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">New Plan Benefits </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our non-employee directors will be eligible to receive automatic option grants under the Restated Equity Plan pursuant to our director compensation policy, as described below under &#8220;Compensation of Directors.&#8221; All other future grants under the Restated Equity Plan are within the discretion of the Plan Administrator and the benefits of such grants are, therefore, not determinable.  No shares of common stock have been issued with respect to the 820,000 share increase for which stockholder approval is sought under this Proposal 4.</font></div><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Plan Benefits </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The table below shows, as to our named executive officers and the various indicated groups, the number of shares of common stock subject to awards granted under the Existing Plan to date that were outstanding as of April 10, 2019: </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.20634920634922%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:64%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:2%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:2%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Name and Position</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Number of Shares Subject to Stock Option Awards</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Number of Shares Subject to Restricted Stock Awards/RSUs</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">John L. Higgins, Chief Executive Officer</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">747,621</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,542</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Matthew W. Foehr, President and Chief Operating Officer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">308,699</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,429</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Matthew Korenberg, Executive Vice President, Finance and Chief Financial Officer</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">92,497</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,499</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Charles S. Berkman, Senior Vice President and General Counsel </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,965</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,050</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Executive Officers, as a group</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,186,782</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">76,520</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-Employee Directors, as a group</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#160;(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">131,326</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,059</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nominees for election as Directors</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">131,326</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,059</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Each associate of any of any such directors, executive officers or nominees</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Each Other Person Who Received or Is To Receive 5% of Such Options, Warrants or Rights</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Employees other than Executive Officers, as a group</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">607,547</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46,473</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1) All of the non-employee members of our board of directors will, upon re-election to the board at the Annual Meeting, receive an automatic award of restricted stock units and options to purchase shares of common stock under the Restated Equity Plan pursuant to our director compensation policy, as described [below] under &#8220;Compensation of Directors.&#8221; Each option will have an exercise price per share equal to the fair market value per share of common stock on the grant date.</font></div><div style="line-height:120%;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2) Restricted stock units that are subject to performance-based vesting are reflected assuming &#8220;target&#8221; performance.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All other future grants under the Restated Equity Plan are within the discretion of the Plan Administrator and the benefits of such grants are, therefore, not determinable. </font></div><div style="line-height:174%;padding-top:20px;text-align:left;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-weight:bold;">Recommendation of the Board of Directors</font></div><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our board of directors unanimously recommends that stockholders vote </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">FOR</font><font style="font-family:inherit;font-size:10pt;">&#32;the approval of the amendment and restatement of the Ligand Pharmaceuticals Incorporated 2002 Stock Incentive Plan.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ligand Pharmaceuticals Incorporated 2019 Proxy Statement </font><font style="font-family:Wingdings;font-size:8pt;">l</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">29</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="s89f0aeadb89c46af909604944f0665e7"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:18pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:top;background-color:#727272;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:5px;text-align:left;padding-left:9px;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;color:#ffffff;font-weight:bold;">Proposal No. 5: Amendment and Restatement of the Ligand Pharmaceuticals Incorporated Employee Stock Purchase Plan</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">We are asking our stockholders to approve the amendment and restatement of our Employee Stock Purchase Plan, or the Existing ESPP. The proposed amendment and restatement of the Existing ESPP is referred to herein as the Restated ESPP. The Restated ESPP was adopted by our board in April 2019, subject to stockholder approval. The Restated ESPP will become effective on June 6, 2019</font><font style="font-family:inherit;font-size:12pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">if it is approved by the stockholders at the annual meeting. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Existing ESPP expires on June 28, 2019.  We are asking stockholders to approve the Restated ESPP to remove the fixed expiration date and the limit on the number of shares purchasable by participants during any calendar year.  Although stockholder approval is not required for these amendments, the board of directors is submitting the Restated ESPP to our stockholders for approval as a matter of good corporate practice.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Restated ESPP is not being amended in any material respect other than to reflect the changes described above.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We believe the Restated ESPP, including the amendment to remove the fixed term of the Existing ESPP, is necessary to ensure that the Restated ESPP will continue to be available to our eligible employees. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The principal features of the Restated ESPP are summarized below for the convenience and information of our stockholders. This description is qualified in its entirety by reference to the Restated ESPP, which is attached to this proxy statement as </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Appendix B</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Determination to Approve Restated ESPP</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The table below presents information about the number of shares remaining available for issuance under the Existing ESPP at April 10, 2019. The table below does not include information about the number of shares that were subject to outstanding equity awards or that may be available for future issuance under our other equity compensation plans. Information related to our other equity compensation plans is further described in the table under the heading &#8220;Why the Stockholders Should Vote to Approve the Restated Equity Plan&#8221; in Proposal 4 to this proxy statement. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.01587301587301%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:40%;"></td><td style="width:19%;"></td><td style="width:1%;"></td><td style="width:19%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#acacac;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#acacac;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Number of Shares</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#acacac;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As a % of Shares Outstanding</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#acacac;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Dollar Value</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Existing ESPP Shares available for issuance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64,008</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.03</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,201,985</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1) Based on 19,663,929 shares of our common stock outstanding as of April 10, 2019.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2) Based on the closing price of our common stock on April 10, 2019, of $128.14 per share. </font></div><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In determining whether to approve the Restated ESPP, our board considered the following:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The 218,374 shares reserved for issuance under the Restated ESPP will not represent an increase from the aggregate number of shares reserved for issuance and that remain available for future grant under the Existing ESPP as of April 10, 2019.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In determining not to increase the size of the share reserve under the Restated ESPP, our board considered the number of shares issued under the Existing ESPP during the past three calendar years. In calendar years 2016, 2017 and 2018, our annual equity burn rates (calculated by dividing (1) the number of shares issued under the Existing ESPP by (2) the weighted-average number of diluted shares outstanding during the applicable year) under the Existing ESPP were 0.01%, 0.01% and 0.02%, respectively. </font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We expect the aggregate share reserve under the Restated ESPP to provide us with enough shares for awards for at least ten years, assuming employee participation in the Restated ESPP consistent with historical levels, as reflected in our three-year burn rate for the Existing ESPP, and further dependent on the price of our shares and hiring activity during the next few years. We cannot predict our future share usage under the Restated ESPP, the future price of our </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ligand Pharmaceuticals Incorporated 2019 Proxy Statement </font><font style="font-family:Wingdings;font-size:8pt;">l</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">30</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-left:48px;text-align:left;"><font style="font-family:inherit;font-size:10pt;">shares or future hiring activity with any degree of certainty at this time, and the share reserve under the Restated ESPP could last for a shorter or longer time. </font></div><div style="line-height:174%;text-align:left;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In calendar years 2016, 2017 and 2018, the end of year overhang rate (calculated by dividing (1)&#160;the shares remaining available for issuance for future awards at the end of the calendar year under the Existing ESPP by (2)&#160;the number of shares outstanding at the end of the calendar year) was 0.34%, 0.32% and 0.31%, respectively. If the Restated ESPP is approved, we expect our overhang at the end of 2019 attributable to the Restated ESPP will be approximately 1.10%.</font></div></td></tr></table><div style="line-height:174%;text-align:left;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In light of the factors described above, and the fact that the ability to continue to offer eligible employees the ability to participate in the Restated ESPP is vital to our ability to continue to attract and retain employees in the extremely competitive labor markets in which we compete, our board of directors has determined that adopting the Restated ESPP is reasonable and appropriate at this time. Our board of directors will not create a subcommittee to evaluate the risk and benefits for issuing shares under the Restated ESPP. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:232%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Summary of the Restated ESPP</font></div><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following is a summary of the principal features of the Restated ESPP, assuming approval of this proposal. The summary, however, is not a complete description of all the provisions of the Restated ESPP. The proposed Restated ESPP is attached to this proxy statement as</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#32;Appendix B</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:18px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">General </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Restated ESPP is intended to comply with the requirements of Section&#160;423 of the Code, thereby assuring the participants the associated tax advantages. These tax advantages are described below under &#8220;Material Federal Income Tax Consequences.&#8221; </font></div><div style="line-height:120%;padding-top:18px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Administration </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Restated ESPP will be administered by the compensation committee of the board or directors, which committee we shall refer to in this proposal as the Plan Administrator. The Plan Administrator will have full authority to administer the Restated ESPP, including the authority to interpret and construe any provision of the Restated ESPP. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Eligibility and Participation </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any individual who is employed by us or any of our parent or subsidiary corporations on a basis under which he or she is regularly expected to work for more than 20 hours per week and more than five months per calendar year (including any corporation which subsequently becomes a parent or subsidiary during the term of the Restated ESPP) will be eligible to participate in the Restated ESPP. An individual must be an eligible employee on the start date of any offering period in order to join that offering period. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of April 10, 2019, 41 of our 109 employees, including our 4 executive officers, were eligible to participate in the Existing ESPP.  Upon the effective date of the Restated ESPP, these 41 employees will also be eligible to participate in the Restated ESPP, subject to the terms and conditions of the Restated ESPP. </font></div><div style="line-height:120%;padding-top:18px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Shares Available </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">An aggregate of 218,374 shares of common stock are reserved for issuance under the Existing ESPP, which is the same share reserve in effect under the Existing ESPP. As of April 10, 2019, 154,366 shares of common stock had been issued under the Existing ESPP, and 64,008 shares remained available for future issuance. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Should any change be made to our outstanding common stock by reason of any stock dividend, stock split, exchange or combination of shares or other similar change affecting the outstanding common stock as a class without the company&#8217;s receipt of consideration, appropriate adjustments will be made to: </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the class and maximum number of securities issuable over the term of the Restated ESPP,</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the class and maximum number of securities purchasable per participant on any purchase date, and </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ligand Pharmaceuticals Incorporated 2019 Proxy Statement </font><font style="font-family:Wingdings;font-size:8pt;">l</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">31</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the class and number of securities and the price per share in effect under each outstanding purchase right. </font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Such adjustments are designed to preclude the dilution or enlargement of rights and benefits under the Restated ESPP. </font></div><div style="line-height:120%;padding-top:18px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Offering Periods and Purchase Rights </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our common stock will be offered for purchase under the Restated ESPP through a series of successive offering periods. Offering periods under the Restated ESPP will be six months long, unless otherwise determined by the Plan Administrator. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At the time a participant joins an offering period, he or she will be granted a purchase right to acquire shares of common stock during that offering period. Each participant may authorize periodic payroll deductions in any multiple of 1% (up to a maximum of 10%) of his or her total cash earnings to be applied to the acquisition of common stock at semi-annual intervals. The purchase dates will occur on the last trading day of each offering period (e.g., the last trading day of June and December of each year), and all payroll deductions collected from the participant for the offering period will automatically be applied to the purchase of common stock on that date provided the participant remains an eligible employee and does not withdraw from the Restated ESPP prior to that date. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A participant may suspend his or her payroll deductions under the Restated ESPP. A participant may also withdraw from the Restated ESPP at any time, and his or her accumulated payroll deductions will be refunded immediately. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A participant&#8217;s purchase right will immediately terminate upon his or her cessation of employment or loss of eligible employee status. Any payroll deductions which the participant may have made for the offering period in which such cessation of employment or loss of eligibility occurs will be refunded and will not be applied to the purchase of common stock. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">No participant will have any stockholder rights with respect to the shares covered by his or her purchase rights until the shares are actually purchased on the participant&#8217;s behalf. No adjustment will be made for dividends, distributions or other rights for which the record date is prior to the date of such purchase. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">No purchase rights will be assignable or transferable by the participant, and the purchase rights will be exercisable only by the participant. </font></div><div style="line-height:120%;padding-top:18px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Purchase Price </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The purchase price of our common stock acquired on each semi-annual purchase date will be equal to 85% of the lower of: </font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the fair market value per share of common stock on the start date of the offering period in which the individual is enrolled, or </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the fair market value on the last trading day of such offering period. </font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair market value per share of common stock on any particular date under the Restated ESPP will be deemed to be equal to the closing selling price per share on such date on the Nasdaq Global Market. If there is no closing selling price for the common stock on that date, then the fair market value per share shall be the closing selling price on the last preceding date for which such quotation exists. On April 10, 2019, the closing selling price per share of our common stock on the Nasdaq Global Market was $128.14. </font></div><div style="line-height:120%;padding-top:18px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Special Limitations </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Restated ESPP imposes certain limitations upon a participant&#8217;s rights to acquire common stock, including the following limitations: </font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">purchase rights granted to a participant may not permit such individual to purchase more than $25,000 worth of common stock (valued at the time each purchase right is granted) for each calendar year those purchase rights are outstanding at any time, </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">purchase rights may not be granted to any individual if such individual would, immediately after the grant, own or hold outstanding options or other rights to purchase, stock possessing 5% or more of the total combined voting power or value of all classes of our stock or the stock of any of our parent or subsidiary corporations, and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">no participant may purchase more than 1,250 shares of common stock during any offering period. </font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ligand Pharmaceuticals Incorporated 2019 Proxy Statement </font><font style="font-family:Wingdings;font-size:8pt;">l</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">32</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Any payroll deductions not applied because of these limitations will be refunded to the employee. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Plan Administrator will have the discretionary authority to increase or decrease the per participant and total participant purchase limitations as of the start date of any new offering period under the Restated ESPP, with the new limits to be in effect for that offering period and each subsequent offering period. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Effect of a Change in Control </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Should we be acquired by merger, sale of substantially all of its assets or sale of securities representing more than 50% of the total combined voting power of our outstanding securities, then all outstanding purchase rights will automatically be exercised immediately prior to the effective date of such acquisition (or on such other date as is determined by the Plan Administrator). The purchase price will be equal to 85% of the lower of: </font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the fair market value per share of common stock on the start date of the offering period in which the individual is enrolled at the time such acquisition occurs, or </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the fair market value per share of common stock on such purchase date. </font></div></td></tr></table><div style="line-height:120%;padding-top:18px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Share Proration </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Should the total number of shares of common stock which are to be purchased under outstanding purchase rights on any particular date exceed the number of shares then available for issuance under the Restated ESPP, the Plan Administrator shall make a pro rata allocation of the available shares on a uniform and nondiscriminatory basis, and the payroll deductions of each participant, to the extent in excess of the aggregate purchase price payable for the common stock prorated to such individual, shall be refunded to such participant. </font></div><div style="line-height:120%;padding-top:18px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Amendment and Termination </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Restated ESPP will continue in effect until terminated by our board of directors.  Our board of directors may terminate, suspend or amend the Restated ESPP at any time. However, our board of directors may not, without stockholder approval: </font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">increase the number of shares issuable under the Restated ESPP, </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">alter the purchase price formula so as to reduce the purchase price to an amount below 85% of the lower of (1)&#160;the fair market value per share of common stock on the start date of an offering period, or (2)&#160;the fair market value per share of common stock on the purchase date, or </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">modify the requirements for eligibility to participate in the Restated ESPP. </font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Securities Laws</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Restated ESPP is intended to conform to all provisions of the Securities Act of 1933, as amended, and the Exchange Act and any and all regulations and rules promulgated by the SEC thereunder, including, without limitation, Rule 16b-3. The Restated ESPP will be administered, and shares will be issued thereunder, only in such a manner as to conform to such laws, rules and regulations.</font></div><div style="line-height:120%;padding-top:18px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Material U.S. Federal Income Tax Consequences </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following is a general summary under current law of the material federal income tax consequences to an employee who participates in the Restated ESPP. This summary deals with the general federal income tax principles that apply and is provided only for general information. Some kinds of taxes, such as state, local and foreign income taxes and federal employment taxes, are not discussed. Tax laws are complex and subject to change and may vary depending on individual circumstances and from locality to locality. The summary does not discuss all aspects of federal income taxation that may be relevant in light of a holder&#8217;s personal circumstances. This summarized tax information is not tax advice and a holder of an award should rely on the advice of his or her legal and tax advisors. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Restated ESPP, and the right of participants to make purchases thereunder, is intended to qualify under the provisions of Section&#160;423 of the Code. Under the applicable Code provisions, no income will be taxable to a participant until the sale or other disposition of the shares purchased under the Restated ESPP. Upon such sale or disposition, the participant will generally be subject to tax in an amount that depends upon the length of time such shares are held by the participant prior to disposing of them. </font></div><div><br></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ligand Pharmaceuticals Incorporated 2019 Proxy Statement </font><font style="font-family:Wingdings;font-size:8pt;">l</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">33</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If the shares are sold or disposed of more than two years from the first day of the offering period during which the shares were purchased and one year from the date of purchase, or if the participant dies while holding the shares, the participant (or his or her estate) will recognize ordinary income measured as the lesser of (1)&#160;the excess of the fair market value of the shares at the time of such sale or disposition over the purchase price or (2)&#160;an amount equal to 15% of the fair market value of the shares as of the first day of the offering period. Any additional gain will be treated as long-term capital gain. If the shares are held for the holding periods described above but are sold for a price that is less than the purchase price, there is no ordinary income and the participating employee has a long-term capital loss for the difference between the sale price and the purchase price. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If the shares are sold or otherwise disposed of before the expiration of the holding periods described above, the participant will recognize ordinary income generally measured as the excess of the fair market value of the shares on the date the shares are purchased over the purchase price. Any additional gain or loss on such sale or disposition will be long-term or short-term capital gain or loss, depending on how long the shares were held following the date they were purchased by the participant prior to disposing of them. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are not entitled to a deduction for amounts taxed as ordinary income or capital gain to a participant except to the extent of ordinary income recognized upon a sale or disposition of shares prior to the expiration of the holding periods described above. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:18px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">New Plan Benefits </font></div><div style="line-height:120%;padding-top:18px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Benefits under the Restated ESPP will depend on the employees&#8217; enrollment and contribution elections, and the fair market value of the shares at various future dates. Therefore, it is not possible to determine the benefits that will be received in the future by participants in the Restated ESPP.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:18px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Plan Benefits under the Existing ESPP</font></div><div style="line-height:120%;padding-top:18px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of April 10, 2019, each of our named executive officers and the various indicated groups have purchased the following shares under the Existing ESPP:</font></div><div style="line-height:120%;padding-bottom:9px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:90.47619047619048%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:68%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Name and Position</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Number of Shares Purchased</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Aggregate Purchase Price</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">John L. Higgins, Chief Executive Officer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,502</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$23,182</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Matthew W. Foehr, President and Chief Operating Officer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,117</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$67,320</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Matthew Korenberg, Executive Vice President, Finance and Chief Financial Officer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">659</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$62,908</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Charles S. Berkman, Senior Vice President and General Counsel</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,468</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$203,093</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Executive Officers, as a group </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,051</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$479,636</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;padding-top:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-Employee Directors, as a group</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1) </sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;padding-top:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nominees for election as Directors</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Each associate of any of any such directors, executive officers or nominees</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Each Other Person Who Received or Is To Receive 5% of Such Options, Warrants or Rights</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Employees other than Executive Officers, as a group</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">135,315</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$4,496,916</font></div></td></tr></table></div></div><div style="line-height:174%;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1) Directors who are not Company employees are not eligible to participate in the Existing ESPP. </font></div><div><br></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ligand Pharmaceuticals Incorporated 2019 Proxy Statement </font><font style="font-family:Wingdings;font-size:8pt;">l</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">34</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:232%;padding-top:20px;text-align:left;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-weight:bold;">Recommendation of the Board of Directors</font></div><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our board of directors unanimously recommends that stockholders vote </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">FOR</font><font style="font-family:inherit;font-size:10pt;">&#32;the approval of the amendment and restatement of the Ligand Pharmaceuticals Incorporated Employee Stock Purchase Plan.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ligand Pharmaceuticals Incorporated 2019 Proxy Statement </font><font style="font-family:Wingdings;font-size:8pt;">l</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">35</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="sFFC042B667F65DE3B8D7755606230864"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:24px;font-size:18pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:top;background-color:#727272;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:5px;text-align:left;padding-left:9px;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;color:#ffffff;font-weight:bold;">Executive Officers</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The names of the executive officers of the Company and their ages, titles and biographies as of April 10, 2019 are set forth below.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">John L. Higgins,</font><font style="font-family:inherit;font-size:10pt;">&#32;49, is being considered for the position of director of the Company. See &#8220;Election of Directors&#8221; for a discussion of Mr.&#160;Higgins' business experience.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Charles S. Berkman, J.D.,</font><font style="font-family:inherit;font-size:10pt;">&#32;50, has served as our Senior Vice President, General Counsel and Secretary since January 2018 and prior that as our Vice President, General Counsel and Secretary since April 2007. Mr. Berkman joined the Company in November 2001 and previously served as Associate General Counsel and Chief Patent Counsel for the Company (and Secretary since March 2007). Prior to joining the Company, Mr. Berkman was an attorney at the international law firm of Baker &amp; McKenzie from November 2000 to November 2001. Before that he served as an attorney at the law firm of Lyon &amp; Lyon from 1993 to November 2000, where he specialized in intellectual property law. Mr. Berkman earned a B.S. in chemistry from the University of Texas and a J.D. from the University of Texas School of Law.</font></div><div style="line-height:120%;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Matthew W. Foehr,</font><font style="font-family:inherit;font-size:10pt;">&#32;46, has been our President and Chief Operating Officer since January 2015.  Prior to that time, Mr. Foehr served as our Executive Vice President and Chief Operating Officer since 2011, and has more than 20 years of experience managing global research and development programs. Prior to joining Ligand in 2011, he was Vice President and Head of Consumer Dermatology R&amp;D, as well as Acting Chief Scientific Officer of Dermatology, in the Stiefel division of GlaxoSmithKline (GSK). Following GSK's $3.6 billion acquisition of Stiefel in 2009, Mr. Foehr led the R&amp;D integration of Stiefel into GSK. At Stiefel Laboratories, Inc., Mr. Foehr served as Senior Vice President of Global R&amp;D Operations, Senior Vice President of Product Development &amp; Support, and Vice President of Global Supply Chain Technical Services. Prior to Stiefel, Mr. Foehr held various executive roles at Connetics Corporation including Senior Vice President of Technical Operations and Vice President of Manufacturing. Mr. Foehr serves on the Board of Directors of Viking Therapeutics, Inc. and Ritter Pharmaceuticals, Inc.  Mr. Foehr is the author of multiple scientific publications and is named on numerous U.S. patents. He received his B.S. degree in biology from Santa Clara University.</font></div><div style="line-height:120%;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Matthew Korenberg,</font><font style="font-family:inherit;font-size:10pt;">&#32;44, has served as our Executive Vice President, Finance and Chief Financial Officer since January 2018 and prior to that as our Vice President, Finance and Chief Financial Officer since August 2015.  Prior to joining Ligand, commencing in September 2013, Mr. Korenberg was the founder, Chief Executive Officer and a director of NeuroCircuit Therapeutics, a company focused on developing drugs to treat genetic disorders of the brain with an initial focus on Down syndrome. Prior to founding NeuroCircuit Therapeutics, Mr. Korenberg was a Managing Director and member of the healthcare investment banking team at Goldman Sachs from July 1999 through August 2013. During his 14 year tenure at Goldman Sachs, Mr. Korenberg was focused on advising and financing companies in the biotechnology and pharmaceutical sectors and was based in New York, London and San Francisco. Prior to Goldman Sachs, Mr. Korenberg was a healthcare investment banker at Dillon, Read &amp; Co. Inc. where he spent two years working with healthcare companies in the biotechnology and pharmaceutical sectors and industrial companies. Mr. Korenberg holds a B.B.A. in Finance and Accounting from The University of Michigan.</font></div><div><br></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ligand Pharmaceuticals Incorporated 2019 Proxy Statement </font><font style="font-family:Wingdings;font-size:8pt;">l</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">36</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="s96DF54CB30FD53BEB4DAA846F2B49036"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:174%;padding-top:24px;text-align:center;font-size:18pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:top;background-color:#727272;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:5px;text-align:left;padding-left:9px;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;color:#ffffff;font-weight:bold;">Security Ownership of Certain Beneficial Owners, Directors and Management</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table shows, based on information we have, the beneficial ownership of our common stock as of April 10, 2019, by:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">all persons who are beneficial owners of 5% or more of our outstanding common stock;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">each of our current directors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">each of our named executive officers (as defined below in &#8220;Compensation Discussion and Analysis &#8211; Summary Compensation Table&#8221;);&#160;and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">all of our executive officers and directors as a group.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unless otherwise indicated, each of the stockholders has sole voting and investment power with respect to the shares beneficially owned, subject to community property laws, where applicable. Percentage of ownership is based on approximately 19,663,929 shares of common stock outstanding on April 10, 2019. Shares of common stock underlying options include options which are currently exercisable or will become exercisable within 60&#160;days after April 10, 2019, are deemed outstanding for computing the percentage of the person or group holding such options, but are not deemed outstanding for computing the percentage of any other person or group. The address for individuals for whom an address is not otherwise indicated is 3911 Sorrento Valley Boulevard, Suite 110, San Diego, CA 92121.</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:49%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:16%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfbfbf;padding-left:1px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Beneficial Owner</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Number of</font></div><div style="padding-top:1px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares</font></div><div style="padding-top:1px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Beneficially</font></div><div style="padding-top:1px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Owned</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares Beneficially</font></div><div style="padding-top:1px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Owned via Options,</font></div><div style="padding-top:1px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrants or</font></div><div style="padding-top:1px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Convertible Notes</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Percent of</font></div><div style="padding-top:1px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Class Owned</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">BlackRock, Inc.</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div><div style="padding-top:1px;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55 East 52</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">nd</sup></font><font style="font-family:inherit;font-size:10pt;">&#160;Street</font></div><div style="padding-top:1px;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">New York, NY 10055</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,761,861</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14.0%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Vanguard Group</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></font></div><div style="padding-top:1px;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100 Vanguard Blvd.</font></div><div style="padding-top:1px;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Malvern, PA 19355</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,929,850</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.8%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Renaissance Technologies LLC</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(3)</sup></font></div><div style="padding-top:1px;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">800 Third Avenue</font></div><div style="padding-top:1px;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">New York, NY 10022</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,480,819</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.5%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Directors and Executive Officers</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Jason M. Aryeh</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#160;(4)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">115,244</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,851</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Charles S. Berkman</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60,546</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,524</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Todd C. Davis</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47,639</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,456</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Matthew W. Foehr</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">155,448</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">241,372</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.0%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nancy Ryan Gray</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,151</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">John L. Higgins</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">141,399</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">625,235</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.8%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Matthew Korenberg</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45,767</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,888</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">John W. Kozarich</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,142</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,356</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">John L. LaMattina</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,449</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,186</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Sunil Patel</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,524</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,851</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stephen L. Sabba</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,856</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,856</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Directors and executive officers as a group (11 people)</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">665,014</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,025,726</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.4%</font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ligand Pharmaceuticals Incorporated 2019 Proxy Statement </font><font style="font-family:Wingdings;font-size:8pt;">l</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">37</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:5%;"></td><td style="width:95%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;padding-left:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;*</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less than one percent.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Represents shares of common stock owned by funds affiliated with BlackRock, Inc. at December 31, 2018, as indicated in the entity&#8217;s Schedule 13G/A filed with the SEC on February 11, 2019.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Represents shares of common stock beneficially owned by The Vanguard Group at December 31, 2018 as indicated in the entity&#8217;s Schedule 13G/A filed with the SEC on February 12, 2019.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Represents shares of common stock beneficially owned by Renaissance Technologies LLC at December 31, 2018 as indicated in the entity&#8217;s Schedule 13G filed with the SEC on February 12, 2019.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares held by Jason Aryeh are owned by certain funds managed by JALAA Equities, LP (&#8220;JALAA&#8221;) and affiliates (collectively, the &#8220;Funds&#8221;).  Mr. Aryeh  is the general partner of JALAA and a partner of JLV.  Mr. Aryeh individually has the sole power to vote 101,344 shares and dispose of 101,344 shares beneficially owned by Mr. Aryeh and the Funds.</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ligand Pharmaceuticals Incorporated 2019 Proxy Statement </font><font style="font-family:Wingdings;font-size:8pt;">l</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">38</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="sBBC729F5D0835632AA6B61CEB6548584"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:174%;padding-top:20px;text-align:center;padding-left:30px;text-indent:-30px;font-size:18pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:top;background-color:#727272;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:5px;text-align:left;padding-left:9px;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;color:#ffffff;font-weight:bold;">Compensation Discussion and Analysis</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This Compensation Discussion and Analysis (&#8220;CD&amp;A&#8221;) describes our compensation philosophy and programs, the compensation decisions the compensation committee made under those programs, and the factors considered in making those decisions.  This CD&amp;A focuses on the compensation of our named executive officers or &#8220;NEOs&#8221;, who for 2018 were: </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:35%;"></td><td style="width:65%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Name</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Title</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">John L. Higgins</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Executive Officer</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Matthew W. Foehr</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">President and Chief Operating Officer</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Matthew Korenberg</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Executive Vice President, Finance and Chief Financial Officer</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Charles S. Berkman</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Senior Vice President and General Counsel</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:20px;text-align:left;padding-left:30px;text-indent:-30px;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-weight:bold;">Executive Summary</font></div><div style="line-height:120%;padding-top:20px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Overview and Objectives of Our Executive Compensation Program</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The compensation committee has designed our executive compensation program to provide compensation opportunities that:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">attract, motivate and retain individuals of superior ability and managerial talent critical to its long-term success;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">align executives&#8217; interests with the Company&#8217;s corporate strategies, business objectives and the long-term interests of the Company&#8217;s stockholders;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">create incentives to achieve key strategic and corporate performance objectives; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">enhance the executives&#8217; incentive to increase the Company&#8217;s stock price and maximize stockholder value.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Within this framework our compensation program has been developed with the following key principles in mind: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">We Intend to Pay for Performance</font><font style="font-family:inherit;font-size:10pt;">. The majority of our named executive officers&#8217; total compensation as shown in our Summary Compensation Table below ties compensation directly to the achievement of corporate objectives, increases in our stock price or both. We emphasize pay for performance in order to align executive compensation with our business strategy and the creation of long-term stockholder value.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Our Compensation Program Supports Our Corporate Objectives and Stockholder Interests</font><font style="font-family:inherit;font-size:10pt;">. Our compensation program is designed to align executive officer compensation with our corporate strategies, business objectives and the long-term interests of our stockholders by rewarding successful execution of our business plan and tying a significant portion of total compensation opportunities to equity incentives.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Key Elements of Our Compensation Program</font><font style="font-family:inherit;font-size:10pt;">. Our compensation program is designed to achieve these objectives through a combination of the following types of compensation:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:20px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#9702;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">base salary;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#9702;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">annual variable performance bonus awards payable in cash;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#9702;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">long-term stock-based incentive awards comprised of a significant portion of performance-based equity; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#9702;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">employee benefits and perquisites, including change in control severance arrangements.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The compensation committee uses competitive compensation data from the annual total compensation study of peer companies to inform its decisions about overall compensation opportunities and specific compensation elements, including base salary. Additionally, the compensation committee uses multiple reference points when establishing targeted compensation levels. The compensation committee has adopted a philosophy that is intended to emphasize </font></div><div><br></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ligand Pharmaceuticals Incorporated 2019 Proxy Statement </font><font style="font-family:Wingdings;font-size:8pt;">l</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">39</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">equity over cash while ensuring total compensation is competitive. The Committee applies judgment and discretion in establishing targeted pay levels, taking into account not only competitive market data, but also factors such as Company, business and individual performance, scope of responsibility, critical needs and skill sets, leadership potential and succession planning. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Each element of our executive compensation program is discussed in greater detail below.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Ligand's Strong 2018 Corporate Performance</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our Company&#8217;s fiscal year 2018 accomplishments, guided by our named executive officers, illustrate the success of our executive compensation program, and included, among other things, the following:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Successful Business Development:</font><font style="font-family:inherit;font-size:10pt;">&#160; The Company&#8217;s shots on goal portfolio increased through licensing and acquisitions by more than 40 during 2018, finishing the year with over 200 shots on goal. In October 2018, the Company acquired Vernalis, a structure-based drug discovery biotechnology company with a broad pipeline of partnered programs and ongoing collaborations, which provides a platform to help efficiently pursue investment and acquisition activities in Europe and the United Kingdom.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:-7px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Continued Optimization of Captisol Business:</font><font style="font-family:inherit;font-size:10pt;">&#32;In 2018, the Company entered into 85 new Captisol research contracts and had expanded the distribution capacity on Captisol. In addition to shipping commercial and clinical material out of the contract manufacturing sites in both Portugal and Ireland, the Company also established a new distribution capability in Ireland in 2018.&#160;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Research and Development:  </font><font style="font-family:inherit;font-size:10pt;">In 2018, the Company continued to advance its product pipeline, including final preparations for making the Clinical Trial Application submission to the health authorities in Canada where its first in-human trial will be run this year. The Company manufactured the clinical batches of Captisol-enabled(CE)-iohexol and has received Institutional Review Board approval to initiate the clinical trial in the first quarter of 2019 and we plan to have Phase 1 bioavailability data on CE-iohexol in 2019. In addition, the Company also initiated five internal antibody-related programs in 2018.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Operational Achievements:</font><font style="font-family:inherit;font-size:10pt;">&#32;During 2018, the Company had its seventh consecutive year of being cash flow positive with solid financial growth.&#160;The Company successfully contained costs while integrating the Vernalis business within the organization. </font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Performance Graph</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The graph below shows the five-year cumulative total stockholder return assuming the investment of $100 and is based on the returns of the component companies weighted monthly according to their market capitalizations. The graph compares total stockholder returns of our common stock, of all companies traded on the Nasdaq Stock market, as represented by the Nasdaq Composite&#174; Index, and of the NASDAQ Biotechnology Stock Index, as prepared by The Nasdaq Stock Market Inc. </font></div><div style="line-height:150%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The stockholder return shown on the graph below is not necessarily indicative of future performance and we will not make or endorse any predictions to future stockholder returns.</font></div><div><br></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ligand Pharmaceuticals Incorporated 2019 Proxy Statement </font><font style="font-family:Wingdings;font-size:8pt;">l</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">40</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;"><img src="graph.jpg" alt="graph.jpg" style="height:325px;width:672px;"></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018 Compensation Programs and Decisions </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In line with our executive compensation program&#8217;s emphasis on pay for performance, compensation awarded to our named executive officers for 2018 reflected our financial results and overall compensation philosophy:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Base Salary Adjustments:</font><font style="font-family:inherit;font-size:10pt;">&#32;During 2018, our named executive officers received increases to their base salaries of between 2% and 11%. The Company provides its named executive officers with a base salary that approximates the 25th percentile for similar positions at our peer group, and these increases were determined to be appropriate by our compensation committee to ensure that the base salaries of our named executive officers continued to be generally consistent with this pay positioning philosophy.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Pay-for-Performance Annual Incentive Bonuses:</font><font style="font-family:inherit;font-size:10pt;">&#32;For 2018, our Company focused on certain key business development objectives and objectives related to business development, the Captisol business, the OmniAb business and operational goals. Our compensation program for 2018 was designed to support the Company&#8217;s focus on these areas and together achievement in these areas represented the criteria upon which our named executive officer&#8217;s bonus opportunity was based. Based on corporate performance in these four areas during 2018, as summarized above, our compensation committee determined that our executive officers should be paid their bonuses at 110% of targeted levels.  The annual bonuses awarded to our named executive officers for 2018 are discussed below under &#8220;Annual Performance-Based Cash Compensation.&#8221; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Equity Emphasis on Performance-Based Equity Awards:</font><font style="font-family:inherit;font-size:10pt;">&#160;Our compensation committee continued its practice of ensuring that a substantial portion of our named executive officers&#8217; total compensation is awarded in the form of long-term equity incentive awards.  In 2018, at least 25% of each named executive officer&#8217;s equity awards were granted in the form of performance-based stock awards.  </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#9702;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Stock Options:</font><font style="font-family:inherit;font-size:10pt;">&#32;Fifty percent of each named executive officer&#8217;s annual awards was granted in the form of stock options, which we consider to be performance based awards as they provide value to our executives only if our stock price increases.  These stock options are subject to our standard four year vesting schedule.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#9702;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Performance-Based Restricted Stock Units:</font><font style="font-family:inherit;font-size:10pt;">&#160; In 2018, the compensation committee also awarded performance-based restricted stock units to our named executive officers, which awards represented approximately 25% of the total value of the long-term equity incentive awards granted to our named executive officers in 2018.  These performance-based restricted stock units will vest based on objectives related to the Company's revenue for the two year performance period commencing January 1, 2018 and ending December 31, 2019 and new shots on goal and revenue generated from acquisitions completed </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ligand Pharmaceuticals Incorporated 2019 Proxy Statement </font><font style="font-family:Wingdings;font-size:8pt;">l</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">41</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-left:96px;padding-top:12px;"><font style="font-family:inherit;font-size:10pt;">during the performance period commencing January 1, 2018 and ending December 31, 2020, with each such objective equally weighted (and a possible performance multiplier of 150% for "maximum" performance relative to both objectives).&#160;The compensation committee selected the foregoing performance measures because they represent the key financial and operational performance metrics for which the executives are responsible, thereby creating the clearest link between executive actions, corporate results and continued long-term success for the Company.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#9702;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Time-Based Restricted Stock Units: </font><font style="font-family:inherit;font-size:10pt;">The remainder of the long-term equity incentive awards granted to our named executive officers was granted in the form of restricted stock units that are subject to our standard three year vesting schedule.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In light of the Company&#8217;s overall performance during 2018, the compensation committee believes that the named executive officers&#8217; 2018 compensation was appropriate.</font></div><div><br></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ligand Pharmaceuticals Incorporated 2019 Proxy Statement </font><font style="font-family:Wingdings;font-size:8pt;">l</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">42</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;padding-left:30px;text-indent:-30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Ligand's Executive Compensation Best Practices</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We regularly review and refine our executive compensation program to ensure that it continues to reflect practices and policies that are aligned with our pay-for-performance philosophy.  The following practices and policies we believe are in line with current best practices for aligning executive and shareholder interests and sound corporate governance practices:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:24%;"></td><td style="width:5%;"></td><td style="width:71%;"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Compensation Practice</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Ligand Policy</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:8px;text-align:left;padding-left:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Pay for Performance</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#008000;font-weight:bold;">YES</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:8px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have a historical practice of granting a meaningful portion of equity compensation for our executives and a majority of our executives&#8217; total direct compensation is performance-based.</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:8px;text-align:left;padding-left:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Annual &#8220;Say on Pay&#8221; Vote</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#008000;font-weight:bold;">YES</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:8px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We seek an annual non-binding advisory vote from our shareholders to approve the executive compensation programs disclosed in our CD&amp;A, tabular disclosure and related narrative in our proxy.</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:8px;text-align:left;padding-left:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Independent Compensation Consultant</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#008000;font-weight:bold;">YES</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:8px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The compensation committee retains an independent compensation consultant.</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:8px;text-align:left;padding-left:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Annual Compensation Risk Assessment</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#008000;font-weight:bold;">YES</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:8px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Each year we perform an assessment of any risks that could result from our compensation plans and programs.</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:8px;text-align:left;padding-left:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Employment Agreements</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#008000;font-weight:bold;">NO</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:8px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We do not provide our executive officers with employment agreements.</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:8px;text-align:left;padding-left:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Excise Tax Gross-ups</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#008000;font-weight:bold;">NO</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:8px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We do not provide tax gross ups to our executives for "excess parachute payments".</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:8px;text-align:left;padding-left:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Repricing or Exchange of Underwater Stock Options</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#008000;font-weight:bold;">NO</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:8px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We prohibit option repricing without stockholder approval.</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:8px;text-align:left;padding-left:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Single Trigger Change in Control Vesting/Benefits</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#008000;font-weight:bold;">NO</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:8px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We do not provide for single-trigger vesting or payment of benefits for our executives upon a change in control. Rather, we provide double-trigger (or both a change in control and termination of an executive&#8217;s employment) before vesting is accelerated.</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;padding-left:30px;text-indent:-30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Response to 2018 Say on Pay Vote</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2018, we held a stockholder advisory vote on the compensation of our named executive officers, commonly referred to as a say-on-pay vote. Our stockholders overwhelmingly approved the compensation of our named executive officers, with approximately 98% of stockholder votes cast in favor of our 2018 say-on-pay resolution (excluding abstentions and broker non-votes). As we evaluated our compensation practices and talent needs throughout 2018, we were mindful of the strong support our stockholders expressed for our compensation philosophy. As a result, following our annual review of our executive compensation philosophy, the compensation committee decided to generally retain our existing approach to executive compensation for our continuing executives, with an emphasis on short- and long-term incentive compensation that rewards our senior executives when they deliver value for our stockholders. </font></div><div style="line-height:120%;padding-top:20px;text-align:left;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-weight:bold;">The Role of the Compensation Committee and Executive Officers in Setting Compensation</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The compensation committee has the primary authority to determine the Company&#8217;s compensation philosophy and to establish compensation for the Company&#8217;s executive officers. In determining each level of compensation and the total package, the compensation committee reviewed a variety of sources, to determine and set compensation.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The chief executive officer aids the compensation committee by providing annual recommendations regarding the compensation of all executive officers, other than himself. Each named executive officer and senior executive management team member, in turn, participates in an annual performance review with the chief executive officer to provide input about his contributions to the Company&#8217;s success for the period being assessed. The performance of our chief executive officer and senior executive management team as a group is reviewed annually by the compensation committee.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2018, the compensation committee retained Radford, a part of Aon plc, a national executive compensation consulting firm, to assist it in the formulation of the peer group used to determine executive equity compensation during 2018 and to advise regarding the determination of the other key elements of the executive compensation program. Radford reports to and is accountable to the compensation committee, and may not conduct any other work for us without the authorization of the compensation committee. Radford did not provide any services to us in 2018 beyond its engagement as an advisor to the </font></div><div><br></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ligand Pharmaceuticals Incorporated 2019 Proxy Statement </font><font style="font-family:Wingdings;font-size:8pt;">l</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">43</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">compensation committee on executive compensation matters. After review and consultation with Radford, the compensation committee has determined that Radford is independent and there is no conflict of interest resulting from retaining Radford currently or during the year ended December 31, 2018. In reaching these conclusions, the compensation committee considered the factors set forth in Exchange Act Rule 10C-1 and Nasdaq listing standards.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As in prior years, the compensation committee and the Company&#8217;s management also consulted several independent compensation surveys to assist them in determining market pay practices for compensating executive officers. These surveys were reviewed to compare the Company&#8217;s compensation levels to the market compensation levels, taking into consideration the other companies&#8217; size, the industry, the individual executive&#8217;s level of responsibility and his years of experience. For 2018, the current executive salaries were evaluated against the Radford Global Life Sciences Survey using data from comparable U.S. public biotechnology companies with revenue under $500 million and market capitalization between $1.0 billion and $8.0 billion as of September 2017 when survey data was compiled. These surveys were used due to the competitiveness in hiring employees within the biotechnology industry as well as in our geographic location and we believe they represent the types of companies with which we compete for executive talent. With respect to the foregoing survey data, the identities of the individual companies included in the surveys were not provided to the compensation committee, and the compensation committee did not refer to individual compensation information for such companies. Instead, the compensation committee only referred to the statistical summaries of the compensation information for the companies included in such surveys.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additionally, the compensation committee worked with Radford to confirm a peer group of companies in the United States for which compensation information can be provided to the compensation committee. This is necessary so the Company can offer compensation that is competitive within that group of companies. The peer group companies for 2018 compensation included ACADIA Pharmaceuticals, Acorda Therapeutics, Eagle Pharmaceuticals, Exelixis, Halozyme Therapeutics, Horizon Pharma, Innoviva, Ironwood Pharmaceuticals, Ionis Pharmaceuticals, Lexicon Pharmaceuticals, Momenta Pharmaceuticals, Nektar Therapeutics, Neurocrine Biosciences, Pacira Pharmaceuticals, PDL BioPharma, Portola Pharmaceuticals, Repligen, Supernus Pharmaceuticals and Theravance Biopharma.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The selected companies in our peer group are companies that fall within a reasonable range of comparison factors and/or that we may compete with for executive talent. In addition to the criteria related to finding companies with similar business models and at a similar stage of development as Ligand, the other criteria used in the identification and selection of the peer group included business/labor market competitors in the biotechnology industry similar in size and complexity to us, companies with revenue under $500 million, companies with market values between $1.0 billion and $8.0 billion (based on trading values in November 2017 when the peer group was selected) and companies with products in comparable stages of development to our products. We also focused on companies with multiple product candidates, as opposed to single product companies. The peer group was not selected on the basis of executive compensation levels. The peer group revisions from the 2017 peer group were intended to ensure that the peer group more accurately reflects companies that are our peers in terms of our current business model and stage of development, including the number of programs maintained by the Company and the importance of licensing to the Company's business model.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The peer group compensation data is limited to publicly available information and therefore does not provide precise comparisons by position as offered by more comprehensive survey data. The survey data, however, can be used to provide pooled compensation data for positions closely akin to those held by each named executive officer. In addition, the pool of senior executive talent from which we draw and against which we compare ourselves extends beyond the limited community of our immediate peer group and includes a wide range of other organizations outside of our traditional competitors, which range is represented by such surveys. As a result, the compensation committee uses peer group data to analyze the overall competitiveness of our compensation with our direct publicly traded peers in the United States and our general compensation philosophy, and to determine equity award levels for the named executive officers, but also relies on industry survey data in determining actual executive compensation. For purposes of this compensation discussion and analysis, references to our &#8220;peer group&#8221; include both the peer group of companies listed above and the survey data reviewed by our compensation committee.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The compensation committee has adopted a compensation philosophy that places a greater emphasis on long-term equity incentive compensation for our named executive officers than cash compensation. As a result, the compensation committee generally sets target total cash compensation below the median of executive officers performing similar job functions at companies in our peer group to ensure a greater emphasis is placed on long-term incentives while ensuring total compensation is competitive with market.&#160; At the same time, the compensation committee emphasizes long-term equity incentive compensation by setting target equity compensation above the median of executive officers performing similar job </font></div><div><br></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ligand Pharmaceuticals Incorporated 2019 Proxy Statement </font><font style="font-family:Wingdings;font-size:8pt;">l</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">44</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">junctions at companies in our peer group.&#160; However, we strongly believe in retaining the best talent among our senior executive management team and while we believe that comparisons to market data are a useful tool, we do not believe that it is appropriate to establish executive compensation levels based solely on a comparison to data from these companies.&#160; Therefore, the compensation committee may approve total compensation packages for senior executive management that vary from the foregoing positioning based on several factors, including overall experiences, accumulated years of service with us, level of responsibilities and/or performance ratings.&#160; Our 2018 total compensation for our named executive officers was generally consistent with the foregoing compensation philosophy. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, the mix of compensation paid to our named executive officers is intended to ensure that total compensation reflects our overall success or failure, including our long-term stock performance, and to motivate executive officers to meet appropriate performance measures. In determining each element of compensation for any given year, our compensation committee considers and determines each element individually and then reviews the resulting total compensation and determines whether it is reasonable and competitive. We do not have a pre-established policy or target for the allocation between either cash and non-cash or short-term and long-term incentive compensation.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The compensation levels of our named executive officers reflect to a significant degree their varying roles and responsibilities. Mr.&#160;Higgins, in his role as chief executive officer, has the greatest level of responsibility among our named executive officers and, therefore, receives the highest level of pay. This is also consistent with the practices of the companies in our peer group and the summary compensation data included in the summaries of comparable companies reviewed by our compensation committee.</font></div><div style="line-height:120%;padding-top:20px;text-align:left;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-weight:bold;">Base Compensation</font></div><div style="line-height:100%;padding-top:21px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As discussed above, the Company provides its named executive officers with a base salary that approximates the 25</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">th</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;percentile for similar positions at our peer group, but may vary from such level based on:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">industry experience, knowledge and qualifications;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the salary levels in effect for comparable positions within the Company&#8217;s principal industry marketplace competitors; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">internal comparability considerations.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As a general matter, the base salary for each executive officer is initially established through negotiation at the time the officer is hired, taking into account the officer&#8217;s qualifications, experience, prior salary and competitive salary information. Increases in base salary from year to year are based upon the performance of the executive officers as well as market positioning considerations, as assessed by the chief executive officer (for executives other than himself) and approved by the compensation committee. The compensation committee assesses these factors with respect to the chief executive officer.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For 2018, our named executive officers received increases to their base salaries of between 2% and 11%, as follows:  Mr. Higgins, 2.3% increase; Mr. Foehr, 3.9% increase; Mr. Korenberg, 6.2% increase; and Mr. Berkman, 11.0% increase. These increases were determined to be appropriate by our compensation committee to ensure that the base salaries of our named executive officers continued to be generally consistent with our pay positioning philosophy, as described above. Base salaries paid to our named executive officers for 2018 are disclosed below in the table entitled &#8220;Summary Compensation Table.&#8221;</font></div><div style="line-height:120%;padding-top:21px;text-align:left;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-weight:bold;">Performance-Based Compensation</font></div><div style="line-height:120%;padding-top:21px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Annual Performance-Based Cash Compensation</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">It is the compensation committee&#8217;s objective to have a substantial portion of each named executive officer&#8217;s compensation contingent upon the Company&#8217;s performance. For each of our named executive officers, all of his annual bonus compensation is dependent on the Company&#8217;s performance relative to specified performance objectives.  </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The annual performance-based bonus program consists of a cash award if certain corporate performance objectives are satisfied. The Company sets annual incentive targets so that each executive&#8217;s total target cash compensation (inclusive of base salary) approximates the 25th percentile of target total cash opportunities offered by our peer group. Under the Company&#8217;s </font></div><div><br></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ligand Pharmaceuticals Incorporated 2019 Proxy Statement </font><font style="font-family:Wingdings;font-size:8pt;">l</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">45</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018 program, the target performance bonus for the chief executive officer is 75% of base salary, 50% of base salary for Messrs. Foehr and Korenberg, and 40% of base salary for Mr. Berkman. The target incentive opportunities remained flat year over year for executives for 2018.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In determining the performance compensation awarded to each named executive officer, the Company evaluates the Company&#8217;s performance in a number of areas. At the beginning of each year, our board of directors sets corporate objectives for the year. These objectives are set by the board of directors after considering management input and our overall strategic objectives. These objectives generally relate to factors such as strategic objectives, achievement of product development objectives, establishment of new collaborative arrangements and general operational goals. Following the conclusion of each year, the compensation committee determines the level of achievement for each year relative to these corporate objectives. This achievement level is then applied to each named executive officer&#8217;s target bonus to determine that year&#8217;s total annual bonus. The compensation committee retains the discretion to reduce the final bonus payout to a named executive officer.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At the beginning of 2018, our board of directors, with input provided by our named executive officers, established our Company goals for the year. The compensation committee then reviewed and considered a proposed Company-wide (including named executive officers) bonus program in view of the Company goals, including the proportional emphasis to be placed on each objective annual bonus determination purposes.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company goals approved by the compensation committee for 2018 for purposes of annual bonus achievement included:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.21428571428571%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:89%;"></td><td style="width:11%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#80c9ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Goals</font></div></td><td style="vertical-align:bottom;background-color:#80c9ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Status</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#acacac;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Business Development Goals (35% Weighting)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Complete at least nine new licensing deals</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Met</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Close Series B financing for Nucorion Pharmaceuticals, Inc. or assist Seelos Therapeutics, Inc. in closing next financing</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Met</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Evaluate and, if appropriate, pursue potential acquisitions</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Met</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#acacac;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Goals Related to OmniAb Business (35% Weighting)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Complete OmniChicken license expansions to generate at least five new program campaigns</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Met</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Increase customer service and awareness of OmniAb platform via successful partner meetings, publications and presentations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Met</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Launch next-generation OmniChicken with expanded repertoire</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Met</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#acacac;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Goals Related to Optimization of Captisol Business (20% Weighting)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepare IND for CE-Iohexol and position for clinical initiation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Met</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expand existing relationships and generate at least 35 new research contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Met</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Optimize sample processing and logistics/operations to create long-term business efficiencies</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Met</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Manage business to maximize annual revenue and manage competitive threats</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Met</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Establish new distribution site, facilitating annual tax savings</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Met</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#acacac;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Operational Goals (10% Weighting)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deliver superior partner customer service focused on information timeliness, technical support, issue resolution and commercial planning</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Met</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Organizational staff planning and expansion and improvement of data management systems</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Met</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Complete facility and lab improvements at office and laboratory space located in Emeryville, California</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Met</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effective financial, legal and administrative management and tax planning</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Met</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In evaluating management&#8217;s performance against our 2018 corporate objectives in January 2019, our compensation committee determined to award a corporate achievement level of 110% relative to those objectives. This determination was made in the discretion of the compensation committee after its review of our overall corporate performance relative to each of the objectives listed above. In general, quantitative objectives were not established for most of the corporate objectives during 2018. Instead these performance objectives were used as a guide by the compensation committee in determining overall corporate performance as they represented those areas in which the named executive officers and our employees generally were expected to focus their efforts.</font></div><div><br></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ligand Pharmaceuticals Incorporated 2019 Proxy Statement </font><font style="font-family:Wingdings;font-size:8pt;">l</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">46</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">With respect to the business development goals, the compensation committee awarded an achievement level of 110%, noting that in 2018, the Company completed thirteen new licensing deals that increased the Company&#8217;s shots-on-goal portfolio and acquired Vernalis. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">With respect to the goals related to our OmniAb business, the compensation committee awarded full credit, for an achievement level of 110%, noting our successful acquisition and integration of Vernalis.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">With respect to the goals related to the optimization of our Captisol business, the compensation committee awarded an achievement level of 110%, noting that the Company entered into 85 new Captisol research contracts. The Company worked with key vendors and partners to maximize revenue potential and volatility, had new patents issued and expanded key manufacturing relationships and improved manufacturing efficiencies. In addition, the Company established a new distribution site in Ireland to facilitate annual tax savings.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">With respect to the operational goals, which were entirely qualitative goals and not objectively determinable, the compensation committee determined an overall achievement level of 110% was appropriate given its subjective determination of the Company&#8217;s overall performance in this area during 2018. The compensation committee noted that in 2018, the Company was cash-flow positive for the seventh consecutive year. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As a result of the foregoing determinations, all of our named executive officers received bonus awards equal to 110% of their target awards. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The actual bonus awards paid to our named executive officers for 2018 are disclosed below in the table entitled &#8220;Summary Compensation Table.&#8221;</font></div><div style="line-height:120%;padding-top:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Long-Term Performance-Based Equity Incentive Program </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In accordance with our compensation philosophy, the Company&#8217;s longer-term performance-based compensation is based on equity ownership. The Company believes that equity ownership in the Company is important to tie the ultimate level of an executive officer&#8217;s compensation to the performance of the Company&#8217;s stock and stockholder gains while creating an incentive for sustained growth.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We generally provide equity compensation to our named executive officers through grants of stock options, performance stock units and restricted stock units. The grants are designed to align the interests of our named executive officers with those of the stockholders and provide each individual with a significant incentive to manage the Company from the perspective of an owner with an equity stake in the business. The compensation committee views granting options and restricted stock unit awards as a retention device and therefore also reviews the status of vesting and number of vested verses unvested options and restricted stock unit awards at the time of grant. Guidelines for the number of stock options and restricted stock unit awards granted to each executive officer are determined using a procedure approved by the compensation committee based upon several factors, including the executive officer&#8217;s level of responsibility, salary grade, performance and the value of the stock option and restricted stock unit awards at the time of grant. With respect to our named executive officers, we generally make awards to such officers at the time of initial hire based on an evaluation of the foregoing factors. Additional grants, other than the annual awards to executives, may be made following a significant change in job responsibility or in recognition of a significant achievement. Annual awards are made to our named executive officers when such awards are deemed appropriate by the compensation committee based on an evaluation of the foregoing factors.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Given the position of executive cash compensation relative to market (which is set at approximately the 25th percentile), our compensation committee has emphasized long-term equity incentive compensation to ensure total compensation is competitive. The long-term equity incentive awards granted to the named executive officers in 2018 were set at approximately the 75th percentile level of equity awards for similar positions at our peer group companies, adjusted using the above factors and taking into consideration such equivalency factors as our number of shares outstanding and market capitalization, compared to the peer group companies.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Time-based stock options granted under our 2002 Stock Incentive Plan, as amended (the "2002 Plan"), generally have a four-year vesting schedule designed to provide an incentive for continued employment. The options generally expire ten years from the date of the grant. This provides a reasonable time frame during which executive officers and other employees who receive grants can benefit from the appreciation of the Company&#8217;s shares. The exercise price of options granted under our </font></div><div><br></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ligand Pharmaceuticals Incorporated 2019 Proxy Statement </font><font style="font-family:Wingdings;font-size:8pt;">l</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">47</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2002 Plan, is equal to 100% of the fair market value of the underlying stock on the date of grant. Accordingly, the option will provide a return to the executive officer only if the market price of the shares appreciates over the option term. Time-based restricted stock unit awards generally vest in equal installments over three years. We also grant performance-based equity awards to our named executive officers.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Since 2015, performance-based restricted stock units have been a significant component of our annual long-term equity incentive awards for our named executive officers.&#160;The &#8220;target&#8221; number of performance-based restricted stock units granted to our named executive officers each year represents approximately 25% of the total value of the long-term equity incentive awards granted to our named executive officers.&#160; Of the remainder of the long-term equity incentive awards granted to our named executive officers, 50% of the total value of the long-term incentive awards is granted in the form of stock options that are subject to our standard four year vesting schedule, as described above, and 25% of the total value of the long-term incentive awards is granted in the form of restricted stock units that are subject to our standard three year vesting schedule, as described above. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">2018 Long-Term Incentive Awards.</font><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March and May 2018, our compensation committee approved long-term incentive awards to our named executive officers as described in the Grants of Plan-Based Awards table below. The Company will disclose the actual revenue goals/targets relative to actual performance at the conclusion of the performance period. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The time-based stock options and restricted stock units vest in accordance with the standard vesting schedules described above.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">With respect to the performance-based restricted stock units granted in 2018, a named executive officer may earn up to 150% of the &#8220;target&#8221; number of performance-based restricted stock units based on performance relative to the performance objectives established for these awards. The performance-based restricted stock units will vest based on objectives related to the Company's revenue for the two year performance period commencing January 1, 2018 and ending December 31, 2019 and our new shots on goal and revenue generated from acquisitions during the performance period commencing January 1, 2018 and ending December 31, 2020, with each such objective equally weighted . Threshold performance levels, below which no vesting will be awarded, were also established for each performance objective. The compensation committee selected the foregoing performance measures because they represent the key financial and operational performance metrics for which the executives are responsible, thereby creating the clearest link between executive actions, corporate results and continued long-term success for the Company.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All of the equity awards granted to our named executive officers in 2018 are disclosed below in the table entitled &#8220;Grants of Plan-Based Awards in Fiscal Year 2018.&#8221;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Vesting of 2017 Performance-Based Restricted Stock Units.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2017, our named executive officers were granted performance-based restricted stock units. A named executive officer may earn up to 137.5% of the &#8220;target&#8221; number of performance-based restricted stock units based on performance relative to the performance objectives established for these awards. The performance-based restricted stock units will vest based on objectives related to our cash flow for the two year performance period commencing January 1, 2017 and ending December 31, 2018 and our new licensing deals during the performance period commencing April 1, 2017 and ending December 31, 2019, with each such objective equally weighted (and a possible performance multiplier of 150% for "maximum" performance relative to the cash flow objective and a possible performance multiplier of 125% for "maximum" performance relative to the new licensing deals objective).</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;In January 2019, the compensation committee certified our achievement relative to the cash flow objective for purposes of the 2017 performance-based restricted stock units.&#160; The threshold, target and maximum performance levels for the cash flow component of the awards were as follows:&#160; less than $195 million, 0% payout; $195 million, 75% payout; $216.6 million, 100% payout; and equal to or greater than $238.3 million, 125% payout.&#160;The compensation committee determined that our cash flow for purposes of determining the vesting of the portion of the 2017 performance-based restricted stock units eligible to vest based on our cash flow for the two year performance period commencing January 1, 2017 and ending December 31, 2018 exceeded $300.0 million, resulting in a 125% payout with respect to these units.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Vesting of 2016 Performance-Based Restricted Stock Units.</font></div><div><br></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ligand Pharmaceuticals Incorporated 2019 Proxy Statement </font><font style="font-family:Wingdings;font-size:8pt;">l</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">48</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2016, our named executive officers were granted performance-based restricted stock units. A named executive officer may earn up to 137.5% of the &#8220;target&#8221; number of performance-based restricted stock units based on performance relative to the performance objectives established for these awards. The performance-based restricted stock units were eligible to vest based on objectives related to our revenues for the two year performance period commencing January 1, 2016 and ending December 31, 2017 and our new OmniAb shots on goal transactions during the three year performance period commencing January 1, 2016 and ending December 31, 2018, with each such objective equally weighted (and a possible performance multiplier of 150% for &#8220;maximum&#8221; performance relative to the revenue objective and a possible performance multiplier of 125% for &#8220;maximum&#8221; performance relative to the new OmniAb shots-on-goal transactions objectives). Threshold performance levels, below which no vesting will be awarded, were also established for each performance objective. The compensation committee selected the foregoing performance measures because they represent the key financial and operational performance metrics for which the executives are responsible, thereby creating the clearest link between executive actions, corporate results and continued long-term success for the Company.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2018, the compensation committee certified our achievement relative to the revenue objective for purposes of the 2016 performance-based restricted stock units (i.e. 150% vesting for revenue over $300 million, 100% vesting for revenue between $275 million and $300 million, 50% for revenue between $250 million and $275 million, and no vesting for revenue below $250 million) for purposes of the 2016 performance-based restricted stock units and approved a 104% payout with respect to these units.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2019, the compensation committee certified our achievement relative to the new OmniAb shots on goal transactions objective for purposes of the 2016 performance-based restricted stock units. The threshold, target and maximum performance levels for the new shots on goal transactions component of the awards were as follows:  less than 8, 0% payout; 8, 75% payout; 12, 100% payout; and equal to or greater than 16, 125% payout.  We had 18 new OmniAb shots on goal transactions for purposes of the 2016 performance-based restricted stock units for the three year performance period commencing January 1, 2016 and ending December 31, 2018, resulting in a 125% payout with respect to these units. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All of the equity awards granted to our named executive officers and outstanding as of December 31, 2018 are disclosed below in the table entitled &#8220;Outstanding Equity Awards At Fiscal Year End.&#8221;</font></div><div style="line-height:120%;padding-top:24px;text-align:left;padding-left:30px;text-indent:-30px;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-weight:bold;">Other Elements of Compensation and Perquisites</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We also provide our named executive officers and other employees the following benefits and perquisites.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Medical Insurance.</font><font style="font-family:inherit;font-size:10pt;">&#32;The Company provides to each named executive officer, the named executive officer&#8217;s spouse and children such health, dental and vision insurance coverage as the Company may from time to time make available to its other executives of the same level of employment. The Company pays a portion of the premiums for this insurance for all employees.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Life and Disability Insurance.</font><font style="font-family:inherit;font-size:10pt;">&#32;The Company provides each named executive officer such disability and/or life insurance as the Company in its sole discretion may from time to time make available to its other executive employees of the same level of employment.  The Company pays the premiums for this life insurance coverage for the named executive officers.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Defined Contribution Plan.</font><font style="font-family:inherit;font-size:10pt;">&#32;The Company and its designated affiliates offer the Section&#160;401(k) Savings/Retirement Plan (the "401(k) Plan"), a tax-qualified retirement plan, to their eligible employees. The 401(k) Plan permits eligible employees to defer from 1% to 90% of their annual eligible compensation, subject to certain limitations imposed by the Internal Revenue Code. The employees&#8217; elective deferrals are immediately vested and non-forfeitable in the 401(k) Plan.  The Company also makes matching contributions to the 401(k) Plan. In 2018, the match was equal to $0.40 per each $1.00 contributed by an employee up to an annual maximum of $4,800 per year.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Employee Stock Purchase Plan.</font><font style="font-family:inherit;font-size:10pt;">&#32;The Company&#8217;s 2002 Employee Stock Purchase Plan, as amended, which is intended to qualify under Section&#160;423 of the Internal Revenue Code, permits participants to purchase Company stock on favorable terms. Plan participants are granted a purchase right to acquire shares of common stock at a price that is 85% of the stock price on either the first day of the six month offering period or the stock price on the last day of the six month offering period, whichever is lower. The purchase dates occur on the last business days of December and June of each year. To pay for the shares, each participant may authorize periodic payroll deductions from 1% to 10% of his or her cash compensation, subject </font></div><div><br></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ligand Pharmaceuticals Incorporated 2019 Proxy Statement </font><font style="font-family:Wingdings;font-size:8pt;">l</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">49</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">to certain limitations imposed by the Internal Revenue Code. All payroll deductions collected from the participant in an offering period are automatically applied to the purchase of common stock on that offering period&#8217;s purchase date provided the participant remains an eligible employee and has not withdrawn from the employee stock purchase plan prior to that date.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Other.</font><font style="font-family:inherit;font-size:10pt;">&#32;The Company makes available certain other perquisites or fringe benefits to executive officers and other employees, such as tuition reimbursement, professional society dues and food and recreational fees incidental to official company functions, including board meetings. The aggregate of these other benefits was less than $10,000 for each executive officer in the last fiscal year.</font></div><div style="line-height:120%;padding-top:20px;text-align:left;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-weight:bold;">Severance and Change in Control Arrangements</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We believe that reasonable severance benefits for our named executive officers are important because it may be difficult for our executive officers to find comparable employment within a short period of time following an involuntary termination of employment. We also believe that it is important to protect our named executive officers in the event of a change in control transaction involving us. In addition, it is our belief that the interests of stockholders will be best served if the interests of our senior management are aligned with them, and providing change in control severance benefits should eliminate, or at least reduce, the reluctance of senior management to pursue potential change in control transactions that may be in the best interests of stockholders. Accordingly, the severance arrangements we have entered into with each of our executive officers provide for severance benefits in specified circumstances, as well as benefits in connection with an involuntary termination following a change in control.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Change in Control Arrangements</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has a change in control severance agreement with each of the named executive officers. In the event a named executive officer&#8217;s employment is terminated by us without cause or he or she resigns for good reason within 24 months following a change in control of the Company, he or she will be eligible to receive a severance benefit equal to:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">one times (two times for Mr.&#160;Higgins) the annual rate of base salary in effect for such officer at the time of involuntary termination; plus</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">one times (two times for Mr.&#160;Higgins) the greater of: (a)&#160;the maximum target bonus for the fiscal year in which the termination occurs; or (b)&#160;the maximum target bonus for the fiscal year in which the change in control occurs, if different; plus</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">twelve (twenty-four for Mr.&#160;Higgins) multiplied by the monthly premium the executive would be required to pay for continued health coverage for himself or herself and his or her eligible dependents.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The foregoing severance amount will be payable in a lump sum following the officer&#8217;s termination of employment, subject to the officer&#8217;s execution of a general release of claims acceptable to us.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The change in control severance agreements also provide that all of a named executive officer&#8217;s outstanding stock awards will vest in the event of such a termination. In addition, the post-termination exercise period of a named executive officer&#8217;s stock options will be extended from three&#160;months to the date that is nine months following the date of termination (but in no event beyond the original expiration date of such options).</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For purposes of the change in control severance agreements, an involuntary termination is either a termination of a named executive officer&#8217;s employment by us without cause or his resignation for good reason. &#8220;Cause&#8221; is generally defined as an officer&#8217;s conviction of, or plea of &#8220;guilty&#8221; or &#8220;no contest&#8221; to, a felony under the laws of the United States or any state thereof, an officer&#8217;s willful and material breach of any obligation or duty under the employment agreement, the Company&#8217;s confidentiality and proprietary rights agreement or the Company&#8217;s written employment or other written policies that have previously been furnished to the officer, which breach is not cured within 30 days after written notice thereof is received by the officer, if such breach is capable of cure, the officer&#8217;s gross negligence or willful misconduct, including without limitation, fraud, dishonesty or embezzlement, in the performance of his duties, or the officer&#8217;s continuing failure or refusal to perform his assigned duties or to comply with reasonable directives of the board of directors that are consistent with the officer&#8217;s job duties (which directives are not in conflict with applicable law), which failure is not cured within 30 days after written notice thereof is received by the officer.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ligand Pharmaceuticals Incorporated 2019 Proxy Statement </font><font style="font-family:Wingdings;font-size:8pt;">l</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">50</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For purposes of the change in control severance agreements, &#8220;good reason&#8221; is generally defined as a material diminution in the officer&#8217;s authority, duties or responsibilities, a material diminution in the officer&#8217;s base compensation, a material change in the geographic location at which the officer must perform his duties, or any other action or inaction that constitutes a material breach by the Company or any successor or affiliate of its obligations to the officer under the employment agreement. An officer must provide written notice to the Company of the occurrence of any of the foregoing events or conditions without his written consent within 90 days of the occurrence of such event. The Company will have a period of 30 days to cure such event or condition after receipt of written notice of such event from the officer. Any voluntary termination of an officer&#8217;s employment for &#8220;good reason&#8221; must occur no later than the date that is six months following the initial occurrence of one of the foregoing events or conditions.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For purposes of the change in control severance agreements, a &#8220;change in control&#8221; has generally the same definition as given to such term under our 2002 Plan, as described below.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Amended and Restated Severance Plan</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We maintain the Ligand Pharmaceuticals Incorporated Amended and Restated Severance Plan to provide severance payments to our employees and the employees of our subsidiaries upon an involuntary termination of employment without cause. Each of the named executive officers is eligible to participate in the severance plan, provided that he or she is not subject to disciplinary action or a formal performance improvement plan at the time of termination. However, if, as a result of his or her involuntary termination by us without &#8220;cause,&#8221; a named executive officer would be eligible to receive severance under any individual change in control severance agreement, employment agreement or other arrangement providing severance benefits, as approved by our board of directors or a committee thereof, such named executive officer will not be eligible for benefits under the severance plan.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the terms of the severance plan, a named executive officer will be eligible to receive (1)&#160;a lump sum payment in cash for his fully earned but unpaid base salary and accrued but unused vacation through the date of termination, (2)&#160;an amount equal to his base salary for the severance period, which period will be equal to (a)&#160;two months plus (b)&#160;one week for each year of service as of the date of termination and (c)&#160;continued health coverage at the same cost as was in effect for the named executive officer at the date of termination throughout such severance period, provided that such named executive officer elects continued coverage under COBRA. The foregoing cash severance benefit will be payable in a lump sum following the officer&#8217;s termination of employment, subject to the officer&#8217;s execution of a general release of claims acceptable to us.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For purposes of the severance plan, &#8220;cause&#8221; is generally defined as an officer&#8217;s conviction of (or entry of a plea of no contest to) any felony or any other criminal act, an officer&#8217;s commission of any act of fraud or embezzlement, an officer&#8217;s unauthorized use or disclosure of confidential or proprietary information or trade secrets of the Company or our subsidiaries, or an officer&#8217;s commission of any material violation of the Company&#8217;s policies, or an officer&#8217;s commission of any other intentional misconduct which adversely affects the business or affairs of the Company in a material manner.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Change in Control Acceleration of Equity Awards</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity awards granted under the 2002 Plan to the named executive officers may be subject to accelerated vesting in the event of a &#8220;change in control.&#8221;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity award agreements under the 2002 Plan, which cover each of the named executive officers, provide that such equity awards will automatically vest in the event of a &#8220;change in control&#8221; where the option is not assumed or replaced by a successor.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the 2002 Plan, a &#8220;change in control&#8217; is generally defined as:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a merger, consolidation or reorganization of the Company in which 50% or more of its voting securities change ownership;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the sale, transfer or other disposition of all or substantially all of the Company&#8217;s assets in complete liquidation or dissolution of the Company; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a change in control of the Company effected through a successful tender offer for more than 50% of the Company&#8217;s outstanding common stock or through a change in the majority of our board of directors as a result of one or more contested elections for board membership.</font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ligand Pharmaceuticals Incorporated 2019 Proxy Statement </font><font style="font-family:Wingdings;font-size:8pt;">l</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">51</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, the performance-based restricted stock units granted to the named executive officers in 2018 contain additional vesting provisions that will apply in the event of a change in control. In the event of a change in control prior to December 31, 2019, the number of performance-based restricted stock units in which a named executive will be eligible to vest under each performance-based restricted stock unit will be set at the &#8220;target&#8221; number of restricted stock units, which &#8220;target&#8221; restricted stock units will continue to be eligible to vest based solely on the participant&#8217;s continued employment or service, with 50% of such &#8220;target&#8221; units vesting on December 31, 2019 and 50% of such &#8220;target&#8221; units vesting on December 31, 2020. In the event of a change in control after December 31, 2019 but prior to December 31, 2020, the remaining number of restricted stock units in which a participant will be eligible to vest under each performance-based restricted stock unit will be set at 50% of the &#8220;target&#8221; number of restricted stock units, which &#8220;target&#8221; restricted stock units will continue to be eligible to vest based solely on the participant&#8217;s continued employment or service through December 31, 2020.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Further, the performance-based restricted stock units granted to the named executive officers in 2017 contain</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">additional vesting provisions that will apply in the event of a change in control. In the event a change in control had occurred prior to December 31, 2018, the number of performance-based restricted stock units in which a named executive would have been eligible to vest under each performance-based restricted stock unit would have been set at the &#8220;target&#8221; number of restricted stock units, which &#8220;target&#8221; restricted stock units would have continued to be eligible to vest based solely on the participant&#8217;s continued employment or service, with 50% of such &#8220;target&#8221; units vesting on December 31, 2018 and 50% of such &#8220;target&#8221; units vesting on December 31, 2019. In the event of a change in control after December 31, 2018 but prior to December 31, 2019, the remaining number of restricted stock units in which a participant will be eligible to vest under each performance-based restricted stock unit will be set at 50% of the &#8220;target&#8221; number of restricted stock units, which &#8220;target&#8221; restricted stock units will continue to be eligible to vest based solely on the participant&#8217;s continued employment or service through December 31, 2019.</font></div><div style="line-height:120%;padding-top:20px;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-weight:bold;">Policies Regarding Tax Deductibility of Compensation</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Section&#160;162(m) of the Internal Revenue Code restricts the ability of publicly held companies to take a federal income tax deduction for compensation paid to &#8220;covered employees&#8221; to the extent that compensation exceeds $1.0&#160;million per covered employee in any fiscal year. Prior to the Tax Cuts and Jobs Act of 2017, covered employees generally consisted of a company&#8217;s chief executive officer and its three most highly compensated executive officers serving at the end of the taxable year (other than its chief financial officer), and compensation that qualified as &#8220;performance-based&#8221; under Section 162(m) was exempt from this $1 million deduction limitation. As part of the Tax Cuts and Jobs Act of 2017, the ability to rely on this exemption was, with certain limited exceptions, eliminated; in addition, the definition of covered employees was expanded to generally include all named executive officers. Although we historically maintained plans that were intended to permit the payment of deductible compensation under Section 162(m) of the Code if the requirements of Section 162(m) were satisfied, subject to the limited transition relief rules in the Tax Cuts and Jobs Act of 2017, we may no longer be able to take a deduction for any compensation in excess of $1 million that is paid to a covered employee. While we consider the tax deductibility of each element of executive compensation as a factor in our overall compensation program, the compensation committee retains the discretion to approve compensation that may not qualify for the compensation deduction if, in light of all applicable circumstances, it would be in our best interest for such compensation to be paid without regard to whether it may be tax deductible.</font></div><div style="line-height:120%;padding-top:20px;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-weight:bold;">Risk Assessment of Compensation Policies and Programs</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2019, management and Radford assessed our compensation policies and programs for all employees for purposes of determining the relationship of such policies and programs and the enterprise risks faced by the Company and presented its assessment to our compensation committee. Based on these assessments, management recommended, and the compensation committee concluded, that none of our compensation policies or programs create risks that are reasonably likely to have a material adverse effect on the Company. In connection with their review, management and the compensation committee noted certain key attributes of our compensation policies and programs that help to reduce the likelihood of excessive risk taking, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The program design provides a balanced mix of cash and equity compensation, fixed and variable compensation and annual and long-term incentives.</font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ligand Pharmaceuticals Incorporated 2019 Proxy Statement </font><font style="font-family:Wingdings;font-size:8pt;">l</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">52</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate performance objectives are designed to be consistent with the Company&#8217;s overall business plan and strategy, as approved by the board of directors.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The determination of executive incentive awards is based on a review of a variety of indicators of performance, reducing the risk associated with any single indicator of performance.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s equity awards generally vest over multi-year periods.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The compensation committee has the right to exercise negative discretion over executive annual incentive plan payments.</font></div></td></tr></table><div style="line-height:130%;text-align:left;padding-left:48px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div><a name="sB108D3B503915A4DB33A504E8F90501D"></a></div><div style="line-height:120%;text-align:center;font-size:18pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:top;background-color:#727272;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:5px;text-align:left;padding-left:9px;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;color:#ffffff;font-weight:bold;">Compensation Tables</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;"><br></font></div><div style="line-height:120%;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-weight:bold;">Summary Compensation Table</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table provides information regarding the compensation earned by our named executive officers during the fiscal years ended December&#160;31, 2018, 2017 and 2016.</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:18%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:8%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:2px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Name and Principal Position</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Year</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Salary($)</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Bonus ($)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Stock</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Awards ($)</font><font style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Option</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Awards ($)</font><font style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Non-Equity</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Incentive Plan</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Compensation ($)</font><font style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(2)</sup></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">All Other</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Compensation ($)</font><font style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(3)</sup></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:2px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">John L. Higgins,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">627,413</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">-</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2,779,081</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2,376,729</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">517,615</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">5,965</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">6,306,803</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-style:italic;">&#160;&#160;&#160;&#160;&#160;&#160;Chief Executive Officer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">611,656</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">30,000</font><font style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(2)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2,111,154</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2,202,412</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">550,491</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">7,494</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">5,513,207</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">573,958</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">-</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,992,215</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2,393,068</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">387,421</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">5,978</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">5,352,640</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:2px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Matthew W. Foehr,</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2018</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">458,931</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">-</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,361,147</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,164,133</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">252,412</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">87,517</font><font style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(4)</sup></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3,236,623</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:14px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-style:italic;">President and Chief Operating Officer</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2017</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">442,094</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">30,000</font><font style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(2)</sup></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,387,985</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,280,493</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">265,256</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">52,675 </font><font style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(5)</sup></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3,458,503</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:14px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-style:italic;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2016</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">429,292</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">-</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">973,888</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,169,942</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">193,181</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">74,954</font><font style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(6)</sup></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2,841,257</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:2px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Matthew Korenberg,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">428,438</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">-</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,077,560</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">921,591</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">235,641</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">5,400</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2,668,630</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:14px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-style:italic;">Executive Vice President, Finance and Chief Financial Officer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">403,438</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">30,000</font><font style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(2)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">736,550</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">768,266</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">242,063</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">5,400</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2,185,717</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">378,750</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">-</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">664,015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">797,704</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">118,500</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">7,872</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,966,841</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:2px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Charles S. Berkman,</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2018</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">402,500</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">-</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">623,961</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">533,547</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">177,100</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">6,471</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,743,579</font></div></td></tr><tr><td rowspan="2" style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;padding-left:14px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-style:italic;">Senior Vice President and General Counsel</font></div><div style="padding-top:1px;padding-left:14px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-style:italic;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2017</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">362,812</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">-</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">466,461</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">486,593</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">174,150</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">8,803</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,498,819</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2016</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">329,167</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">-</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">376,275</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">452,035</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">136,350</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">6,343</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,300,170</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:2pt;"><font style="font-family:inherit;font-size:2pt;"><br></font></div><div style="line-height:120%;padding-left:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-top:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:130%;font-size:8pt;padding-left:30px;"><font style="font-family:inherit;font-size:8pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:130%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Reflects the grant date fair value for stock and option awards granted in 2016, 2017 and 2018, calculated in accordance with FASB ASC Topic 718, </font><font style="font-family:inherit;font-size:8pt;font-style:italic;">Compensation - Stock Compensation</font><font style="font-family:inherit;font-size:8pt;">, ("Topic 718"). The assumptions used to calculate the value of stock and option awards are set forth under Note 8 of the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December&#160;31, 2018, filed with the SEC on February 28, 2019. With respect to the restricted stock unit awards included in the Summary Compensation Table that were granted during 2018 with performance-based vesting conditions, these amounts include the grant date fair value of such performance-based restricted stock units granted to each of the named executive officers based on the estimated probable outcome of  the performance based objectives applicable to such awards on the grant date. The full grant date fair value of the performance-based restricted stock units awarded to our named executive officers during fiscal year 2018, assuming maximum achievement of the applicable performance objectives is as follows: Mr. Higgins $2,277,675, Mr. Foehr $1,115,566 Mr. Korenberg $883,145, and Mr. Berkman $511,385.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:130%;font-size:8pt;padding-left:30px;"><font style="font-family:inherit;font-size:8pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:130%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Represents performance bonus awards under the management bonus plan earned in 2016, 2017 and 2018, but paid in the subsequent year.  For 2017 for Messrs. Higgins, Foehr and Korenberg, the "Bonus" column reflects a $30,000 discretionary increase to their annual bonuses approved by the compensation committee.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:130%;font-size:8pt;padding-left:30px;"><font style="font-family:inherit;font-size:8pt;">(3)</font></div></td><td style="vertical-align:top;"><div style="line-height:130%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">With the exception of Mr. Foehr, represents life insurance premiums paid by the Company for each year represented in the table and $4,800 in 401(k) matching funds paid by the Company for each named executive officer. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:30px;"><font style="font-family:inherit;font-size:8pt;">(4)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Pursuant to the management rights letter between Viking Therapeutics, Inc. ("Viking"), and the Company dated May 21, 2014, the Company nominated Mr. Foehr to serve as a member of Viking&#8217;s board of directors.  During 2018, in connection with Mr. Foehr&#8217;s service as a director of Viking, Mr. Foehr received (1) $33,170 in cash payments and (2) $48,647 in option awards (representing the aggregate grant date fair value of the option awards as reported by Viking, computed in accordance with authoritative accounting guidance).  Additionally, Mr. Foehr received life insurance premiums paid by the Company for 2018 of $900 and $4,800 in 401(k) matching funds paid by the Company in 2018.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:-19px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(5)  During 2017, in connection with Mr. Foehr&#8217;s service as a director of Viking, Mr. Foehr received (1) $33,170 in cash payments and (2) $13,278 in option awards (representing the aggregate grant date fair value of the option awards as reported by Viking, computed in </font></div><div><br></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ligand Pharmaceuticals Incorporated 2019 Proxy Statement </font><font style="font-family:Wingdings;font-size:8pt;">l</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">53</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">accordance with authoritative accounting guidance).  Additionally, Mr. Foehr received life insurance premiums paid by the Company for 2017 of $900, taxable fringe benefits of $527 and $4,800 in 401(k) matching funds paid by the Company in 2017.</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:-19px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(6)  During 2016, in connection with Mr. Foehr&#8217;s service as a director of Viking, Mr. Foehr received (1) $33,170  in cash payments and (2) $36,084  in option awards (representing the aggregate grant date fair value of the option awards as reported by Viking, computed in accordance with authoritative accounting guidance).  Additionally, Mr. Foehr received life insurance premiums paid by the Company for 2016 of $600, taxable fringe benefits of $419 and $4,800 in 401(k) matching funds paid by the Company in 2016.</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:-19px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-weight:bold;">Grants of Plan-Based Awards in Fiscal Year 2018</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes plan-based awards granted to our named executive officers during the last fiscal year.  </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="23"></td></tr><tr><td style="width:7%;"></td><td style="width:6%;"></td><td style="width:8%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:2px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Name</font></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;padding-left:2px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Grant Date</font></div></td><td rowspan="2" style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;padding-left:2px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Date&#160;of Board&#160;</font></div><div style="text-align:center;padding-left:2px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Action </font></div><div style="text-align:center;padding-left:2px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">approving</font></div><div style="text-align:center;padding-left:2px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Award</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Estimated Future Payouts Under</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Non-Equity Incentive Plan</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Awards </font><font style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></font></div></td><td colspan="6" style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Estimated Future Payouts Under Equity Incentive Plan Awards </font><font style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(2)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">All Other</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Stock</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Awards:</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Number of</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Shares of</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Stock or</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Units </font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(#)</font><font style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(3)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">All&#160;Other</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Option</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Awards:</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Number of</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Securities</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Underlying</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Options </font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(#)</font><font style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(4)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Exercise&#160;or</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Base&#160;Price</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">of&#160;Option</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Awards</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">($/Sh)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Grant&#160;Date</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Fair Value </font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">of</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Stock and</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Option</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Awards </font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">($)</font><font style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(5)</sup></font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Threshold ($)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Target ($)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Maximum ($)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Threshold (#)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Target (#)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Maximum (#)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:2px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">John&#160;L.&#160;</font></div><div style="text-align:left;padding-left:2px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Higgins</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1/23/18</font></div></td><td style="vertical-align:bottom;padding-left:1px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1/23/18</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">487,500</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">5/30/18</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">5/30/18</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3,964</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">7,928</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">11,892</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,518,450</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3/2/18</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3/2/18</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">7,928</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,260,631</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3/2/18</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3/2/18</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">41,392</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">159.01</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2,376,729</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:2px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Matthew&#160;</font></div><div style="text-align:left;padding-left:2px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">W. Foehr</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1/23/18</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1/23/18</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">245,000</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">5/30/18</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">5/30/18</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,942</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3,883</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">5,825</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">743,711</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3/2/18</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3/2/18</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3,883</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">617,436</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3/2/18</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3/2/18</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">20,274</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">159.01</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,164,133</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:2px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Matthew Korenberg</font></div></td><td style="vertical-align:bottom;padding-left:1px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1/23/18</font></div></td><td style="vertical-align:bottom;padding-left:1px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1/23/18</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">235,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">5/30/18</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">5/30/18</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,537</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3,074</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">4,611</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">588,763</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3/2/18</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3/2/18</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3,074</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">488,797</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3/2/18</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3/2/18</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">16,050</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">159.01</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">921,591</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:2px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Charles S. Berkman</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1/23/18</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1/23/18</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">172,000</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">5/30/18</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">5/30/18</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">890</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,780</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2,670</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">340,923</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3/2/18</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3/2/18</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,780</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">283,038</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3/2/18</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3/2/18</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">9,292</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">159.01</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">533,547</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:2pt;"><font style="font-family:inherit;font-size:2pt;"><br></font></div><div style="line-height:120%;padding-left:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:53px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:130%;font-size:8pt;padding-left:29px;"><font style="font-family:inherit;font-size:3pt;">&#32;</font><font style="font-family:inherit;font-size:8pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:130%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Represents the target cash bonus awards granted under our annual performance bonus program. Actual bonus amounts paid are reflected in the Summary Compensation Table above.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:53px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:130%;font-size:8pt;padding-left:29px;"><font style="font-family:inherit;font-size:8pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:130%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">The performance-based restricted stock units will vest based on objectives related to the Company's revenue for the two year performance period commencing January 1, 2018 and ending December 31, 2019 and new shots-on-goal and revenue generated from acquisitions completed during the performance period commencing January 1, 2018 and ending December 31, 2020, with each such objective equally weighted (and a possible performance multiplier of 150% for &#8220;maximum&#8221; performance relative to both objectives. Threshold performance levels, below which no vesting will be awarded, were also established for each performance objective.  For a description of the change in control provisions applicable to the foregoing equity award, see &#8220;Severance and Change in Control Arrangements&#8221; above.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:53px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:130%;font-size:8pt;padding-left:29px;"><font style="font-family:inherit;font-size:8pt;">(3)</font></div></td><td style="vertical-align:top;"><div style="line-height:130%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">The restricted stock unit awards granted to the named executive officers vest in equal installments over a three year period on each of February 15, 2019, 2020 and 2021. For a description of the change in control provisions applicable to the foregoing equity awards, see &#8220;Severance and Change in Control Arrangements&#8221; above.</font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ligand Pharmaceuticals Incorporated 2019 Proxy Statement </font><font style="font-family:Wingdings;font-size:8pt;">l</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">54</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:53px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:130%;font-size:8pt;padding-left:29px;"><font style="font-family:inherit;font-size:8pt;">(4)</font></div></td><td style="vertical-align:top;"><div style="line-height:130%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Each option grant to the named executive officers vests 12.5% on August 15, 2018 and the remainder in 42 equal monthly installments. For a description of the change in control provisions applicable to the foregoing equity awards, see &#8220;Severance and Change in Control Arrangements&#8221; above.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:53px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:130%;font-size:8pt;padding-left:29px;"><font style="font-family:inherit;font-size:8pt;">(5)</font></div></td><td style="vertical-align:top;"><div style="line-height:130%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Represents the fair value of the stock option or stock award at the time of grant as determined in accordance with the provisions of FASB ASC Topic 718. The assumptions used to calculate the value of stock and option awards are set forth under Note 8 of the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December&#160;31, 2018, filed with the SEC on February 28, 2019. With respect to awards, the vesting of which is performance-based, the grant date fair value is based on the estimated probable outcome of the performance objectives applicable to such awards on the grant date.</font></div></td></tr></table><div style="line-height:120%;padding-top:21px;text-align:left;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-weight:bold;">Outstanding Equity Awards at Fiscal Year-End</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table provides information on all stock and option awards held by the named executive officers of the Company as of December&#160;31, 2018. All outstanding equity awards are in shares of the Company&#8217;s common stock. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ligand Pharmaceuticals Incorporated 2019 Proxy Statement </font><font style="font-family:Wingdings;font-size:8pt;">l</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">55</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"></td></tr><tr><td style="width:9%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Option Awards</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Stock Awards</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:2px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Name</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Number of</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Securities</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Underlying</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unexercised</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Options (#)</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercisable</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Number of</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Securities</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Underlying</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unexercised</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Options (#)</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unexercisable</font><font style="font-family:inherit;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Equity</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Incentive Plan</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Awards:</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Number of</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Securities</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Underlying</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unexercised</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unearned</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Options&#160;(#)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Option Exercise Price</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Option</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Expiration</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Date</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Number&#160;of</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares or</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Units of</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Stock That</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Have Not</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Vested&#160;(#)</font><font style="font-family:inherit;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(2)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Market&#160;</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Value&#160;of Shares or&#160;Units of&#160;Stock That</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Have Not</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Vested&#160;($)</font><font style="font-family:inherit;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(3)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Equity</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Incentive</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Plan</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Awards:</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Number&#160;of</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unearned</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares,</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unit&#160;or&#160;</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Other</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Rights&#160;That</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Have Not</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Vested&#160;(#)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Equity</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">incentive</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Plan</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Awards:</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Market</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">or Payout</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Value of</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unearned</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares,</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Units&#160;or&#160;Other</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Rights&#160;That</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Have Not</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Vested&#160;($)</font><font style="font-family:inherit;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(3)</sup></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:2px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">John&#160;L.&#160;</font></div><div style="text-align:left;padding-left:2px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Higgins</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">33,790</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">16.14</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2/14/2019</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">48,125</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">9.96</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2/14/2020</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">94,657</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">10.05</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2/16/2021</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">144,666</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">14.47</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2/8/2022</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">95,616</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">21.92</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2/15/2023</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">14,334</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">32.00</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">6/3/2023</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">75,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">74.42</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2/11/2024</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">20,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">74.42</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2/11/2024</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">53,856</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2,342</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">56.26</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2/10/2025</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">39,235</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">16,156</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">85.79</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2/11/2026</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">20,005</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">23,641</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">100.38</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2/23/2027</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">7,761</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">33,631</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">159.01</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3/2/2028</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">18,614</font><font style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(4)</sup></font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2,525,920</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">11,502</font><font style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(5)</sup></font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,560,821</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">7,928</font><font style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(6)</sup></font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,075,830</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:2px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Matthew W. Foehr</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">14,894</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">9.97</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">4/17/2021</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">21,675</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">14.47</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2/8/2022</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">73,000</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">21.92</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2/14/2023</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">65,000</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">74.42</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2/11/2024</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">40,358</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,755</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">56.26</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2/9/2025</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">19,182</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">7,898</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">85.79</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2/10/2026</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">11,631</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">13,745</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">100.38</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2/23/2027</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3,802</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">16,472</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">159.01</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3/1/2028</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">10,804</font><font style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(7)</sup></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,466,103</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">6,687</font><font style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(5)</sup></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">907,426</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3,883</font><font style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(6)</sup></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">526,923</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:2px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Matthew Korenberg</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">20,833</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">4,167</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">104.59</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">8/5/2025</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,539</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">5,385</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">85.79</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2/11/2026</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">6,979</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">8,246</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">100.38</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2/23/2027</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3,010</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">13,040</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">159.01</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3/1/2028</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">6,742 </font><font style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(8)</sup></font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">914,889</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">4,013</font><font style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(5)</sup></font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">544,564</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3,074</font><font style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(6)</sup></font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">417,142</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:2px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Charles S. Berkman</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">224</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">21.92</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2/14/2023</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2,623</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">56.26</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2/9/2025</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,525</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3,052</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">85.79</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2/10/2026</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,607</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">5,223</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">100.38</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2/23/2027</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,743</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">7,549</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">159.01</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3/1/2028</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">4,017</font><font style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#160;(9)</sup></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">545,107</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2,542</font><font style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(5)</sup></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">344,949</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,780</font><font style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(6)</sup></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">241,546</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:2pt;"><font style="font-family:inherit;font-size:2pt;"><br></font></div><div style="line-height:120%;padding-left:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ligand Pharmaceuticals Incorporated 2019 Proxy Statement </font><font style="font-family:Wingdings;font-size:8pt;">l</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">56</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:53px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:29px;"><font style="font-family:inherit;font-size:8pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Each option grant to the named executive officers has a ten year term from the date of grant. Except as described below, each option vests 12.5% after six months from grant and the remainder in 42 equal monthly installments. For a description of the change in control provisions applicable to the stock option awards, see &#8220;Severance and Change in Control Arrangements&#8221; above.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:53px;text-indent:-24px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:53px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:29px;"><font style="font-family:inherit;font-size:8pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Except as described in footnotes 5 and 6 b</font><font style="font-family:inherit;font-size:8pt;background-color:#ffffff;">elow, t</font><font style="font-family:inherit;font-size:8pt;">he restricted stock unit awards granted to the named executive officers vest in equal installments over a three year period following the date of grant. For a description of the change in control provisions applicable to the stock awards, see &#8220;Severance and Change in Control Arrangements&#8221; above.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:53px;text-indent:-24px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:53px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:29px;"><font style="font-family:inherit;font-size:8pt;">(3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Computed by multiplying the closing market price of our common stock on December&#160;31, 2018, the last trading day of 2018, of $135.70, by the number of shares of common stock subject to such award.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:53px;text-indent:-24px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:53px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:29px;"><font style="font-family:inherit;font-size:8pt;">(4)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">The table above reflects the remaining unvested restricted stock units from the following grants of restricted stock units to Mr. Higgins, which vest in equal installments over a three year period from the date of grant: 3,870 unvested restricted stock units granted on February 11, 2016, 6,816 unvested restricted stock units granted on February 24, 2017, and 7,982 unvested restricted stock units granted on March 2, 2018. For a description of the change in control provisions applicable to the stock awards, see &#8220;Severance and Change in Control Arrangements&#8221; above.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:53px;text-indent:-24px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:53px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:29px;"><font style="font-family:inherit;font-size:8pt;">(5)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Represents the performance-based restricted stock units granted to the named executive officer in 2017. A named executive officer was eligible to earn up to 137.5% of the &#8220;target&#8221; number of performance-based restricted stock units based on performance relative to the performance objectives established for these awards.  </font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:53px;text-indent:-24px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:53px;text-indent:48px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">The performance-based restricted stock units granted in 2017 were eligible to vest based on objectives related to the Company's cash flow for the two year performance period commencing January 1, 2017 and ending December 31, 2018 and our new licensing deals during the performance period commencing April 1, 2017 and ending December 31, 2019 with each such objective equally weighted (and a possible performance multiplier of 125% for &#8220;maximum&#8221; performance relative to the cash flow objective and a possible performance multiplier of 150% for &#8220;maximum&#8221; performance relative to the new licensing deals objective).</font></div><div style="line-height:120%;text-align:left;padding-left:53px;text-indent:-24px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:53px;text-indent:48px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">In January 2019, the compensation committee certified our achievement relative to the cash flow objectives for purposes of the 2017 performance-based restricted stock units. The threshold, target and maximum performance levels for the cash flow-based component of the awards were as follows: less than $195 million, 0% payout; $195 million, 75% payout; $216.6 million, 100% payout; and equal to or greater than $238.3 million, 125% payout. Our cash flow for purposes of the 2017 performance-based restricted stock units for the two year performance period commencing January 1, 2017 and ending December 31, 2018 exceeded $300 million, resulting in a 125% of &#8220;target&#8221; payout with respect to the units eligible to vest based on the cash flow objective.  The performance condition applicable to these awards were satisfied and vested upon our compensation committee&#8217;s certification of such results in January 2019.  The actual number of units that vested in January 2019 are reported above with respect to the portion of the 2017 awards tied to cash flow as follows:  Mr. Higgins, 6,390; Mr. Foehr, 3,715; Mr. Korenberg, 2,230; and Mr. Berkman, 1,413.  </font></div><div style="line-height:120%;text-align:left;padding-left:53px;text-indent:-24px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:53px;text-indent:48px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">The &#8220;target&#8221; number of performance-based restricted stock units granted to the named executive officers in 2017 that remain eligible to vest based on the new licensing deals objective are reported in the column titled &#8220;Equity Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights That Have Not Vested&#8221; above as follows:  Mr. Higgins, 5,112; Mr. Foehr, 2,972; Mr. Korenberg, 1,783; and Mr. Berkman, 1,129.</font></div><div style="line-height:120%;text-align:left;padding-left:53px;text-indent:-24px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:53px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:29px;"><font style="font-family:inherit;font-size:8pt;">(6)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Represents the &#8220;target&#8221; number of performance-based restricted stock units granted to the named executive officer in 2018. The performance-based restricted stock units granted in 2018 will vest based on objectives related to the Company's revenue for the two year performance period commencing January 1, 2018 and ending December 31, 2019 and new shots on goal and revenue generated from acquisitions completed during the performance period commencing January 1, 2018 and ending December 31, 2020, with each such objective equally weighted (and a possible performance multiplier of 150% for &#8220;maximum&#8221; performance relative to both objectives).  Threshold performance levels, below which no vesting will be awarded, were also established for each performance objective. For a description of the change in control provisions applicable to the foregoing equity awards, see &#8220;Severance and Change in Control Arrangements&#8221; above. The &#8220;target&#8221; number of performance-based restricted stock units granted to each of the named executive officers reflected in the column above are as follows:  Mr. Higgins, 7,928; Mr. Foehr, 3,833; Mr. Korenberg, 3,074; and Mr. Berkman, 1,780. </font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:53px;text-indent:-24px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:53px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:29px;"><font style="font-family:inherit;font-size:8pt;">(7)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">The table above reflects the remaining unvested restricted stock units from the following grants of restricted stock units to Mr. Foehr, which vest in equal installments over a three year period: 1,892 unvested restricted stock units granted on February 11, 2016, 5,029 unvested restricted stock units granted on February 24, 2017, and 3,883 unvested restricted stock units granted on March 2, 2018. For a description of the change in control provisions applicable to the stock awards, see &#8220;Severance and Change in Control Arrangements&#8221; above.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:53px;text-indent:-24px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:53px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:29px;"><font style="font-family:inherit;font-size:8pt;">(8)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">The table above reflects the remaining unvested restricted stock units from the following grants of restricted stock units to Mr. Korenberg: 1,290 unvested restricted stock units granted on February 11, 2016, 2,378 unvested restricted stock units granted February 24, 2017, and 3,074 unvested restricted stock units granted on March 2, 2018. For a description of the change in control provisions applicable to the stock awards, see &#8220;Severance and Change in Control Arrangements&#8221; above.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:53px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:29px;"><font style="font-family:inherit;font-size:8pt;">(9)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">The table above reflects the remaining unvested restricted stock units from the following grants of restricted stock units to Mr. Berkman, which vest in equal installments over a three year period: 731 unvested restricted stock units granted on February 11, 2016, 1,506 unvested restricted stock units granted on February 24, 2017, and 1,780 unvested restricted stock units granted on March 2, 2018. For a description of the change in control provisions applicable to the stock awards, see &#8220;Severance and Change in Control Arrangements&#8221; above.</font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ligand Pharmaceuticals Incorporated 2019 Proxy Statement </font><font style="font-family:Wingdings;font-size:8pt;">l</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">57</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:21px;text-align:left;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-weight:bold;">Option Exercises and Stock Vested During Fiscal Year 2018</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table provides information on stock option exercises and stock vesting in fiscal 2018 by the named executive officers of the Company.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:31%;"></td><td style="width:17%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:17%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Option Awards</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Stock Awards</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:2px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Name</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">No. of Shares</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Acquired&#160;on&#160;Exercise&#160;(#)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Value&#160;Realized&#160;Upon</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercise&#160;($)</font><font style="font-family:inherit;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Number&#160;of&#160;Shares</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Acquired&#160;on&#160;Vesting&#160;(#)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Value&#160;Realized&#160;on</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Vesting&#160;($)</font><font style="font-family:inherit;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(2)</sup></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:2px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">John L. Higgins</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">44,654</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">7,948,120</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">18,608</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2,977,076</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:2px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Matthew W. Foehr</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">51,515</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">8,113,543</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">11,717</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,867,227</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:2px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Matthew Korenberg</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">11,540</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,972,178</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">6,483</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,175,533</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:2px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Charles S. Berkman</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">24,453</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2,608,699</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">4,138</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">660,283</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:2pt;"><font style="font-family:inherit;font-size:2pt;"><br></font></div><div style="line-height:120%;padding-left:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:130%;font-size:8pt;padding-left:30px;"><font style="font-family:inherit;font-size:8pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:130%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">The value realized upon exercise of stock options reflects the price at which shares acquired upon exercise of the stock options were sold or valued for income tax purposes, net of the exercise price for acquiring the shares.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:130%;font-size:8pt;padding-left:30px;"><font style="font-family:inherit;font-size:8pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:130%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Computed by multiplying the closing market price of our common stock on the vesting date by the number of restricted stock units subject to such award vesting on the applicable vesting date.</font></div></td></tr></table><div style="line-height:120%;padding-top:21px;text-align:left;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-weight:bold;">Potential Payments Upon Termination or Change in Control</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes potential change in control and severance payments to each named executive officer as of December 31, 2018. The three right-hand columns describe the payments that would apply in three different potential scenarios&#8212;a termination without cause prior to a change in control or more than 24 months following a change in control; a change in control without a termination of employment; or a termination of employment as a result of the named executive officer&#8217;s resignation for good reason or termination of employment by us other than for cause, in each case within 24 months following a change in control. The table assumes that the termination or change in control occurred on December&#160;31, 2018. For purposes of estimating the value of accelerated equity awards to be received in the event of a termination of employment or change in control, we have assumed a price per share of our common stock of $135.70, which represents the closing market price of our common stock as reported on the Nasdaq Global Market on December&#160;31, 2018, the last trading day of 2018. All cash severance benefits will be paid in a lump sum.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:22%;"></td><td style="width:1%;"></td><td style="width:20%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:21%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:2px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Name</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Benefit</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Termination Without Cause; No Change of Control ($)</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Change of Control; No&#160;Termination ($)</font><font style="font-family:inherit;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Termination&#160;Without Cause&#160;or&#160;Resignation for Good Reason within 24 Months Following a Change&#160;of&#160;Control ($)</font><font style="font-family:inherit;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(2)</sup></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:2px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">John L. Higgins</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Salary</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">249,709</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,256,600</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Bonus</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">942,450</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Option acceleration</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">4,314,871</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">4,314,871</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Stock Award acceleration</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">6,177,460</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">6,177,460</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Benefits continuation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">14,393</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">69,087</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Total value:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">264,102</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">10,492,331</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">12,760,468</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:2px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Matthew W. Foehr</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Salary</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">147,436</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">460,000</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Bonus</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">230,000</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Option acceleration</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2,592,450</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2,592,450</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Stock Award acceleration</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3,740,654</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3,740,654</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Benefits continuation</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">11,515</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">34,544</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Total value:</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">158,951</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">6,333,104</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">7,057,648</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:2px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Matthew Korenberg</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Salary</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">104,744</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">430,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Bonus</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">215,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Option acceleration</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,288,838</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,288,838</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Stock Award acceleration</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2,133,917</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2,133,917</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Benefits continuation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">8,636</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">34,544</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Total value:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">113,380</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3,422,755</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">4,102,299</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:2px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Charles S. Berkman</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Salary</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">199,904</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">405,000</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Bonus</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">162,000</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Option acceleration</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">998,645</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">998,645</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Stock Award acceleration</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,326,989</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,326,989</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Benefits continuation</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">17,272</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">34,544</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Total value:</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">217,176</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2,325,634</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2,927,178</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:2pt;"><font style="font-family:inherit;font-size:2pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ligand Pharmaceuticals Incorporated 2019 Proxy Statement </font><font style="font-family:Wingdings;font-size:8pt;">l</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">58</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-left:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:130%;font-size:8pt;padding-left:30px;"><font style="font-family:inherit;font-size:8pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:130%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">The 2002 Plan provides that options or restricted stock units will vest in the event of a change in control and the options or restricted stock units are not assumed or replaced by a successor. This disclosure assumes that the successor does not assume or replace the options or restricted stock units.  For purposes of calculating the values in the table above, performance-based restricted stock units are included at "target" performance levels.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:130%;font-size:8pt;padding-left:30px;"><font style="font-family:inherit;font-size:8pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:130%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">The change in control severance agreements with each of our named executive officers provide that all of a named executive officer&#8217;s outstanding stock awards will vest in the event of an involuntary termination.  For purposes of calculating the values in the table above, performance-based restricted stock units are included at "target" performance levels.</font></div></td></tr></table><div style="line-height:120%;padding-top:20px;text-align:left;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-weight:bold;">Compensation of Directors</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table provides information related to the compensation of each of our non-employee directors for fiscal 2018.</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:39%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:2px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Name</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Cash Fees ($)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Stock Awards ($)</font><font style="font-family:inherit;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(8)</sup></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Option Awards ($)</font><font style="font-family:inherit;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(8)</sup></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total ($)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:2px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Jason M. Aryeh</font><font style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:1px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">62,685</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:1px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">96,584</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:1px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">186,596</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:1px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">345,865</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:2px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Todd Davis</font><font style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(2)</sup></font></div></td><td style="vertical-align:top;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:1px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">60,185</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:1px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">96,584</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:1px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">186,596</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:1px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">343,365</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:2px;font-size:9pt;"><font style="font-family:inherit;font-size:8pt;">Nancy Gray</font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(3)</sup></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:1px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">55,185</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:1px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">96,584</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:1px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">186,596</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:1px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">338,365</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:2px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">John W. Kozarich</font><font style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(4)</sup></font></div></td><td style="vertical-align:top;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:1px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">80,185</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:1px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">96,584</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:1px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">186,596</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:1px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">363,365</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:2px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Sunil Patel</font><font style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(5)</sup></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:1px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">55,185</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:1px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">96,584</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:1px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">186,596</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:1px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">338,365</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:2px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Stephen L. Sabba</font><font style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(6)</sup></font></div></td><td style="vertical-align:top;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:1px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">70,185</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:1px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">96,584</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:1px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">186,596</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:1px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">353,365</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:2px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">John L. LaMattina</font><font style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(7)</sup></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:1px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">52,685</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:1px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">96,584</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:1px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">186,596</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:1px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">335,865</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:2pt;"><font style="font-family:inherit;font-size:2pt;"><br></font></div><div style="line-height:120%;padding-left:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:30px;"><font style="font-family:inherit;font-size:8pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">As of December&#160;31, 2018, Mr.&#160;Aryeh held options to purchase 13,325 shares of our common stock and 493 restricted stock units. During 2018, Mr.&#160;Aryeh received 493 restricted stock units with a grant date fair value of $96,584 and 2,474 stock options with a grant date fair value of $186,596. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:30px;"><font style="font-family:inherit;font-size:8pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">As of December&#160;31, 2018, Mr.&#160;Davis held options to purchase 4,930 shares of our common stock and 493 restricted stock units. During 2018, Mr.&#160;Davis received 493 restricted stock units with a grant date fair value of $96,584 and 2,474 stock options with a grant date fair value of $186,596. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:29px;"><font style="font-family:inherit;font-size:8pt;">(3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">As of December 31, 2018, Dr. Gray held options to purchase 5,926 shares of our common stock and 1,101 restricted stock units.  During 2018, Dr. Gray received 493 restricted stock units with a grant date fair value of $96,584 and 2,474 stock options with a grant date fair value of $186,596. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:29px;"><font style="font-family:inherit;font-size:8pt;">(4)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">As of December&#160;31, 2018, Dr.&#160;Kozarich held options to purchase 37,830 shares of our common stock and 493 restricted stock units. During 2018, Dr. Kozarich received 493 restricted stock units with a grant date fair value of $96,584 and 2,456 stock options with a grant date fair value of $186,596.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:29px;"><font style="font-family:inherit;font-size:8pt;">(5)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">As of December&#160;31, 2018, Mr.&#160;Patel held options to purchase 13,325 shares of our common stock and 493 restricted stock units. During 2018, Mr. Patel received 493 restricted stock units with a grant date fair value of $96,584 and 2,474 stock options with a grant date fair value of $186,596.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:29px;"><font style="font-family:inherit;font-size:8pt;">(6)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">As of December&#160;31, 2018, Dr.&#160;Sabba held options to purchase 35,330 shares of our common stock and 493 restricted stock units. During 2018, Dr. Sabba received 493 restricted stock units with a grant date fair value of $96,584 and 2,474 stock options with a grant date fair value of $186,596.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:29px;"><font style="font-family:inherit;font-size:8pt;">(7)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">As of December&#160;31, 2018, Dr.&#160;LaMattina held options to purchase 20,660 shares of our common stock and 493 restricted stock units. During 2018, Dr. LaMattina received 493 restricted stock units with a grant date fair value of $96,584 and 2,474 stock options with a grant date fair value of $186,596.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:29px;"><font style="font-family:inherit;font-size:8pt;">(8)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Reflects the grant date fair value for stock and option awards granted in 2018, calculated in accordance with FASB ASC Topic 718. The assumptions used to calculate the value of stock and option awards are set forth under Note 8 of the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December&#160;31, 2018, filed with the SEC on February 28, 2019. </font></div></td></tr></table><div style="line-height:120%;padding-top:20px;text-align:left;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-weight:bold;">Narrative to Director Compensation Table</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-employee members of our board of directors are paid fees for their service as a director and are reimbursed for expenses incurred in connection with such service.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under our director compensation policy in effect during 2018, each director was eligible to receive an annual retainer of $45,000. No meeting fees are paid. In addition, the chairperson of the board will received an additional annual retainer of $30,000, the chairperson of the audit committee received an additional annual retainer fee of $20,000, the chairperson of the compensation committee received an additional annual retainer of $15,000 and the chairperson of the nominating and corporate governance committees received an additional annual retainer fee of $10,000. Members of the audit committee </font></div><div><br></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ligand Pharmaceuticals Incorporated 2019 Proxy Statement </font><font style="font-family:Wingdings;font-size:8pt;">l</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">59</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">received an additional annual retainer of $10,000, members of the compensation committee received an additional annual retainer of $7,500 and members of the nominating and corporate governance committee received an additional annual retainer of $5,000.  Directors may elect to receive their retainers in cash or vested shares of our common stock, which shares are issued under our 2002 Plan.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At the 2018 annual meeting, non-employee directors were automatically granted (i) that number of restricted stock units determined by dividing (a) $95,000, by (b) the average closing price per share of the Company&#8217;s common stock on the Nasdaq Global Market (or such other established stock exchange or national quotation system on which the stock is quoted) for the 30-calendar day period prior to the date of grant, and (ii) that number of stock options having a value of $190,000, calculated on the grant date in accordance with the Black-Scholes option pricing model (utilizing the same assumptions that the Company utilizes in preparation of its financial statements).  The foregoing awards will vest in full on the earlier of (i) the date of the annual meeting of the Company&#8217;s stockholders next following the grant date, and (ii) on the first anniversary of the date of grant.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upon initial election to the board of directors, each non-employee director will automatically be granted (i) that number of restricted stock units determined by dividing (a) $145,000, by (b) the average closing price per share of the Company&#8217;s common stock on the Nasdaq Global Market (or such other established stock exchange or national quotation system on which the stock is quoted) for the 30-calendar day period prior to the date of grant, and (ii) that number of stock options having a value of $280,000, calculated on the grant date in accordance with the Black-Scholes option pricing model (utilizing the same assumptions that the Company utilizes in preparation of its financial statements). The foregoing awards will vest in three equal annual installments on each of the first three anniversaries following the date of grant.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All awards will vest in full in the event of a change in control or a hostile take-over, each as defined under our 2002 Plan. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Non-Employee Director Ownership Guidelines</font><font style="font-family:inherit;font-size:10pt;">. In addition, the director compensation policy contains an ownership guideline so that members of the board are required to own shares with a value of at least three times the then-current annual retainer after they had completed three years of board service. As of the date of this proxy statement, all non-employee directors were in compliance with these guidelines.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s48523a2b11c74f64a57deb8e2185f9c1"></a></div><div style="line-height:120%;padding-top:24px;text-align:center;font-size:18pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:top;background-color:#727272;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:5px;text-align:left;padding-left:9px;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;color:#ffffff;font-weight:bold;">Pay Ratio Disclosure</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2015, pursuant to a mandate of the Dodd-Frank Wall Street Reform and Consumer Protection Act, the SEC adopted a rule requiring annual disclosure of the ratio of the median employee&#8217;s annual total compensation to the total annual compensation of the&#160;principal executive officer.&#160;We are providing the following information to comply with Item 402(u) of Regulation&#160;S-K:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total compensation of our CEO in 2018 was $6,306,833 as reported above in our Summary Compensation Table. The total compensation for the median employee, other than our CEO, was $262,940.  The total compensation for the median employee was calculated according to the requirements of the Summary Compensation Table which includes base salary, bonus, equity awards and 401(k) matching contributions.  The ratio of our CEO&#8217;s compensation to the compensation of the median employee was 24 to 1. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The&#160;pay&#160;ratio&#160;reported above is a reasonable estimate calculated in a manner consistent with SEC rules based on our internal records and the methodology described above. The SEC rules for identifying the median compensated employee and calculating the&#160;pay&#160;ratio&#160;based on that employee's annual total&#160;compensation allow companies to adopt a variety of methodologies, to apply certain exclusions, and to make reasonable estimates and assumptions that reflect their employee populations and compensation practices. Therefore, the&#160;pay&#160;ratio&#160;reported by other companies may not be comparable to the&#160;pay&#160;ratio&#160;reported above, as other companies have different employee populations and compensation practices and&#160;may utilize different methodologies, exclusions, estimates and assumptions in calculating their own&#160;pay&#160;ratios. In addition, under the disclosure instructions 2 to Item 402(u), the median-paid employee may be identified once every three years if there is no significant impact to the pay ratio disclosure. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ligand Pharmaceuticals Incorporated 2019 Proxy Statement </font><font style="font-family:Wingdings;font-size:8pt;">l</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">60</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our employee population data described above does not include approximately 70 employees of Vernalis, which we acquired in October 2018. Other than the Vernalis acquisition, there had been no material changes to our employee population or to the median-paid employee's compensation arrangements in 2018 that would significantly affect the pay ratio disclosure, the employee representing the median-paid employee is the same employee selected for the 2018 Proxy Statement.  </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s46773984bc2a4c55b6166c7b148c7265"></a></div><div style="line-height:120%;text-align:center;font-size:18pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:top;background-color:#727272;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:5px;text-align:left;padding-left:9px;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;color:#ffffff;font-weight:bold;">Compensation Committee Interlocks and Insider Participation</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Relationships and Independence of the Compensation Committee Members</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During fiscal 2018, the compensation committee was composed of Messrs. Aryeh and Davis and Dr.&#160;LaMattina. No executive officer of the Company served on the board of directors or compensation committee of any entity which has one or more executive officers serving as members of the Company&#8217;s board of directors or compensation committee.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s7bf315575fe9493e9f5327fa58372728"></a></div><div style="line-height:120%;text-align:center;font-size:18pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:top;background-color:#727272;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:5px;text-align:left;padding-left:9px;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;color:#ffffff;font-weight:bold;">Compensation Committee Report</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">The compensation committee of the Company&#8217;s board of directors has submitted the following report for inclusion in this proxy statement:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The compensation committee reviewed this Compensation Discussion and Analysis and discussed its contents with the Company&#8217;s management. Based on the review and discussions, the compensation committee has recommended to the board of directors that this Compensation Discussion and Analysis be included in this proxy statement and our annual report for the year ended December&#160;31, 2018.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This report of the compensation committee shall not be deemed incorporated by reference by any general statement incorporating by reference this proxy statement into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except to the extent that we specifically incorporate this information by reference, and shall not otherwise be deemed filed under such acts.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The foregoing report has been furnished by the compensation committee.</font></div><div><br></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ligand Pharmaceuticals Incorporated 2019 Proxy Statement </font><font style="font-family:Wingdings;font-size:8pt;">l</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">61</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:150%;padding-top:21px;text-align:left;padding-left:42px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Todd C. Davis, Chairperson of the Compensation Committee</font></div><div style="line-height:150%;text-align:left;padding-left:42px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Jason M. Aryeh</font></div><div style="line-height:150%;text-align:left;padding-left:42px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">John L. LaMattina, Ph.D.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s0a9b3ecf53a147db9471487be10b18a9"></a></div><div style="line-height:120%;text-align:center;font-size:18pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:top;background-color:#727272;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:5px;text-align:left;padding-left:9px;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;color:#ffffff;font-weight:bold;">Audit Committee Report</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">The following is the report delivered by the audit committee of the Company&#8217;s board of directors with respect to the principal factors considered by such committee in its oversight of the accounting, auditing and financial reporting practices of the Company for 2018.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The audit committee oversees the Company&#8217;s financial reporting process on behalf of the board of directors. Management has the primary responsibility for the financial statements and the reporting process including the systems of internal controls. In fulfilling its oversight responsibilities, the audit committee reviewed and discussed the audited financial statements in the Company&#8217;s annual report with management, including a discussion of any significant changes in the selection or application of accounting principles, the reasonableness of significant judgments, the clarity of disclosures in the financial statements and the effect of any new accounting initiatives.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The audit committee reviewed and discussed with Ernst &amp; Young LLP, who is responsible for expressing an opinion on the conformity of the Company&#8217;s audited consolidated financial statements with generally accepted accounting principles, their judgments as to the quality, not just the acceptability, of the Company&#8217;s accounting principles and such other matters as are required to be discussed with the audit committee under generally accepted auditing standards, including those matters required under Auditing Standard 1301 (Communications with Audit Committees). In addition, the audit committee has discussed with Ernst &amp; Young LLP their independence from management and the Company, and has received from Ernst &amp; Young LLP the written disclosures and the letter required by the Public Company Accounting Oversight Board Rule 3526.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The audit committee met with Ernst &amp; Young LLP to discuss the overall scope of their services, the results of their audit and reviews, its evaluation of the Company&#8217;s internal controls and the overall quality of the Company&#8217;s financial reporting. Ernst &amp; Young LLP, as the Company&#8217;s independent registered public accounting firm, also periodically updates the audit committee about new accounting developments and their potential impact on the Company&#8217;s reporting. The audit committee&#8217;s meetings with Ernst &amp; Young LLP were held with and without management present. The audit committee is not employed by the Company, nor does it provide any expert assurance or professional certification regarding the Company&#8217;s financial statements. The audit committee relies, without independent verification, on the accuracy and integrity of the information provided, and representations made, by management and the Company&#8217;s independent registered public accounting firm.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In reliance on the reviews and discussions referred to above, the audit committee has recommended to the Company&#8217;s board of directors that the audited consolidated financial statements be included in this proxy statement and in our annual report for the year ended December&#160;31, 2018.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This report of the audit committee shall not be deemed incorporated by reference by any general statement incorporating by reference this proxy statement into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except to the extent that we specifically incorporate this information by reference, and shall not otherwise be deemed filed under such acts.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The foregoing report has been furnished by the audit committee.</font></div><div style="line-height:150%;padding-top:21px;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stephen L. Sabba, M.D., Chairperson of the Audit Committee</font></div><div style="line-height:150%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nancy Ryan Gray, Ph.D.</font></div><div style="line-height:150%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Sunil Patel</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s79102963a14c4c14b116ba8b8fd2aed7"></a></div><div style="line-height:120%;padding-top:20px;text-align:center;font-size:18pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.63492063492063%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:top;background-color:#727272;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:5px;text-align:left;padding-left:9px;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;color:#ffffff;font-weight:bold;">Equity Compensation Plans</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have two compensation plans approved by our stockholders under which our equity securities are authorized for issuance to employees and directors for goods or services, the 2002 Plan and the Employee Stock Purchase Plan.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes information about our equity compensation plans as of December 31, 2018:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"></td></tr><tr><td style="width:55%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(a)</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Number of</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">securities to be</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">issued upon</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">exercises of</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">outstanding</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">options,</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">warrants</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">and rights</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(b)</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted-</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">average</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">exercise&#160;price&#160;of</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">outstanding</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">options,</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">warrants</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">and rights</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(c)</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Number of</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">securities</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">remaining available</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">for future issuance</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">under equity</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">compensation</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">plans</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(excluding</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">securities</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">reflected in</font></div><div style="padding-top:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">column(a))</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:2px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Equity compensation plans approved by security holders</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,313,374</font><font style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">47.03</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">614,704</font><font style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(2)</sup></font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:2px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Equity compensation plans not approved by security holders</font><font style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(3)</sup></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfbfbf;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,313,374(1)</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">47.03</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">614,704</font><font style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(2)</sup></font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:2pt;"><font style="font-family:inherit;font-size:2pt;"><br></font></div><div style="line-height:120%;padding-left:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:130%;font-size:8pt;padding-left:30px;"><font style="font-family:inherit;font-size:8pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:130%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Includes options and restricted stock units outstanding under the 2002 Plan, with performance-based restricted stock units included at "target" levels.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:130%;font-size:8pt;padding-left:30px;"><font style="font-family:inherit;font-size:8pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:130%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">At December 31, 2018, 550,696 and 64,008 shares were available under the 2002 Plan and the Employee Stock Purchase Plan, respectively, for future grants of awards (calculated by including performance-based restricted stock units at the "target" level).</font><font style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:8pt;">Of the shares available under the Employee Stock Purchase Plan at December 31, 2018, 999 of the 36,250 share that were eligible for purchase were purchased during the offering period in effect on such date.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:130%;font-size:8pt;padding-left:30px;"><font style="font-family:inherit;font-size:8pt;">(3)</font></div></td><td style="vertical-align:top;"><div style="line-height:130%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">There are no equity compensation plans (including individual compensation arrangements) not approved by the Company&#8217;s security holders.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sBB12C6C817DA5DE7BEEA68AEFBF539F7"></a></div><div style="line-height:120%;padding-top:24px;text-align:center;font-size:20pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:top;background-color:#727272;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:5px;text-align:left;padding-left:9px;font-size:20pt;"><font style="font-family:inherit;font-size:20pt;color:#ffffff;font-weight:bold;">Certain Relationships and Related Transactions</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We describe below transactions and series of similar transactions, since the beginning of fiscal year 2018, with respect to which we were a party, will be a party, or otherwise benefited, in which:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the amounts involved exceeded or will exceed $120,000; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a director, nominee for director, executive officer, holder of more than 5% of our common stock or any member of their immediate family had or will have a direct or indirect material interest.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to our audit committee charter, the audit committee of our board of directors is responsible for reviewing and approving all transactions with related parties. We have not adopted written procedures for review of, or standards for approval of, these transactions, but instead the audit committee of our board of directors intends to review such transactions on a case by case basis. In addition, the compensation committee of our board of directors and/or our board of directors will review approve all compensation-related policies involving our directors and executive officers.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The severance arrangements we have entered into with each of our executive officers provide for severance benefits in specified circumstances, as well as benefits in connection with a change in control. See &#8220;Compensation Discussion and Analysis&#8212;Severance and Change in Control Arrangements.&#8221;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our certificate of incorporation and our amended and restated bylaws provide that we will indemnify each of our directors and officers to the fullest extent permitted by the Delaware General Corporation Law. Further, we have entered into </font></div><div><br></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ligand Pharmaceuticals Incorporated 2019 Proxy Statement </font><font style="font-family:Wingdings;font-size:8pt;">l</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">62</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">indemnification agreements with each of our directors and officers, and we have purchased a policy of directors&#8217; and officers&#8217; liability insurance that insures our directors and officers against the cost of defense, settlement or payment of a judgment under certain circumstances.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the management rights letter between Viking Therapeutics, Inc. ("Viking"), and the Company dated May 21, 2014, the Company nominated Mr. Foehr to serve as a member of Viking&#8217;s board of directors. During 2018, in connection with Mr. Foehr&#8217;s service as a director of Viking, Mr. Foehr received (1) $33,170 in cash payments and (2) $48,647 in option awards (representing the aggregate grant date fair value of the option awards as reported by Viking, computed in accordance with authoritative accounting guidance).</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All future transactions between the Company and its officers, directors, principal stockholders and affiliates will be approved by the audit committee or a majority of the independent and disinterested members of the board of directors.</font></div><div><a name="sB7F767AC82045D6C813627B1880342BC"></a></div><div style="line-height:120%;padding-top:24px;text-align:center;font-size:18pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:top;background-color:#727272;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:5px;text-align:left;padding-left:9px;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;color:#ffffff;font-weight:bold;">Section 16(a) Beneficial Ownership Reporting Compliance</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Section&#160;16(a) of the Securities Exchange Act of 1934, as amended, requires the Company&#8217;s executive officers and directors, and persons who own more than 10% of a registered class of the Company&#8217;s equity securities, to file reports of ownership and changes in ownership with the SEC. Executive officers, directors and greater than 10% stockholders are required by SEC regulation to furnish the Company with copies of all Section&#160;16(a) forms they file.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based solely on review of the copies of such forms furnished to the Company, or written representations from certain reporting persons, we have determined that all Section&#160;16(a) filing requirements applicable to its officers, directors and greater than 10% beneficial owners were satisfied during the fiscal year ended December&#160;31, 2018.</font></div><div><a name="s17035A5382BC543280C4FDA369123EBA"></a></div><div style="line-height:120%;padding-top:24px;text-align:center;font-size:18pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:top;background-color:#727272;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:5px;text-align:left;padding-left:9px;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;color:#ffffff;font-weight:bold;">Deadline For Proposals For Next Annual Meeting</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The deadline for submitting a stockholder proposal for inclusion in our proxy statement and form of proxy for the 2019 annual meeting of stockholders is December 26, 2019 (120 calendar days in advance of the anniversary of the date of this proxy statement). Stockholders wishing to submit proposals or director nominations that are to be included in such proxy statement and proxy must also do so by December 26, 2019. Stockholders are advised to review our amended and restated bylaws, which contain additional requirements with respect to advance notice of stockholder proposals and director nominations. Our current amended and restated bylaws are available at the SEC&#8217;s website, www.sec.gov, or upon written request to our Corporate Secretary at the address listed below. Stockholder proposals and director nominations should be directed to Corporate Secretary, Ligand Pharmaceuticals Incorporated, 3911 Sorrento Valley Boulevard, Suite 110, San Diego CA, 92121.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, the proxy solicited by the board of directors for the next annual meeting of stockholders will confer discretionary authority to vote on any stockholder proposal presented at that meeting, unless the Company receives notice of such proposal no later than a reasonable period of time prior to the mailing of proxy materials for such annual meeting.</font></div><div><a name="s2BA095B5EA3356B39D795A0C3793E211"></a></div><div style="line-height:120%;padding-top:24px;text-align:center;font-size:18pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:top;background-color:#727272;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:5px;text-align:left;padding-left:9px;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;color:#ffffff;font-weight:bold;">Annual Report on Form 10-K</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stockholders that received the Notice of Internet Availability of Proxy Materials can access this Proxy Statement and our fiscal 2018 Annual Report at http://www.envisionreports.com/LGND, which does not have cookies that identify visitors to the site. A copy of the Annual Report of the Company on Form 10-K for the 2018 fiscal year has been mailed concurrently with this proxy statement to all stockholders that received a copy of the proxy materials in the mail. The Annual Report is not incorporated into this proxy statement and is not considered proxy solicitation material. Written requests for copies of our Annual Report to stockholders may also be directed to our Corporate Secretary, Ligand Pharmaceuticals Incorporated, 3911 Sorrento Valley Boulevard Suite 110, San Diego, CA 92121.</font></div><div><br></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ligand Pharmaceuticals Incorporated 2019 Proxy Statement </font><font style="font-family:Wingdings;font-size:8pt;">l</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">63</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="s9A113BA2D2D65CBEA338225FC3ED185A"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:24px;text-align:center;font-size:18pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:top;background-color:#727272;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:5px;text-align:left;padding-left:9px;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;color:#ffffff;font-weight:bold;">Solicitation of Proxies</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company will bear the entire cost of solicitation, including the preparation, assembly, printing and mailing of this proxy statement, the proxy and any additional solicitation material furnished to stockholders. Copies of solicitation material will be furnished to brokerage houses, fiduciaries and custodians holding shares in their names that are beneficially owned by others so that they may forward this solicitation material to such beneficial owners. In addition, the Company may reimburse such persons for their costs of forwarding the solicitation materials to such beneficial owners. The original solicitation of proxies by mail may be supplemented by solicitation by telephone, telegram or other means by directors, officers, employees or agents of the Company. No additional compensation will be paid to directors, officers or employees of the Company for any such services. Except as described above, the Company does not presently intend to solicit proxies other than by internet.</font></div><div><a name="s690011C0DEA053CE9E88DD75AADACCF8"></a></div><div style="line-height:174%;padding-top:24px;text-align:center;font-size:18pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.63492063492063%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:top;background-color:#727272;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:5px;text-align:left;padding-left:9px;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;color:#ffffff;font-weight:bold;">Householding of Proxy Materials</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The SEC has adopted rules that permit companies and intermediaries (such as brokers) to satisfy the delivery requirements for proxy statements and annual reports with respect to two or more stockholders sharing the same address by delivering a single proxy statement addressed to those stockholders. This process, which is commonly referred to as &#8220;householding,&#8221; potentially results in a reduced usage of natural resources and cost savings for companies.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A number of brokers with account holders who are our stockholders will be &#8220;householding&#8221; our proxy materials. A single proxy statement and one annual report will be delivered to multiple stockholders sharing an address unless contrary instructions have been received from the affected stockholders. Once you have received notice from your broker that they will be &#8220;householding&#8221; communications to your address, &#8220;householding&#8221; will continue until you are notified otherwise or until you revoke your consent. Any stockholder at a shared address to which a single copy of the documents was delivered and who wishes to receive a separate copy of the documents can request a copy of the documents by sending a written request to our Corporate Secretary, Ligand Pharmaceuticals Incorporated, 3911 Sorrento Valley Boulevard, Suite 110, San Diego, CA 92121, or contact our Corporate Secretary at (858)&#160;550-7500. Also, if you no longer wish to participate in &#8220;householding&#8221; and would prefer to receive a separate proxy statement and annual report in the future, please notify your broker or direct your written request to Corporate Secretary, Ligand Pharmaceuticals Incorporated, 3911 Sorrento Valley Boulevard, Suite 110, San Diego, CA 92121, or contact our Corporate Secretary at (858)&#160;550-7500. Stockholders who currently receive multiple copies of the proxy statement at their address and would like to request &#8220;householding&#8221; of their communications should contact their broker.</font></div><div><a name="sA29B7E02171656789901370479754AFD"></a></div><div style="line-height:120%;padding-top:24px;text-align:center;font-size:18pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:top;background-color:#727272;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:5px;text-align:left;padding-left:9px;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;color:#ffffff;font-weight:bold;">Other Business</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of the date of this proxy statement, the board of directors knows of no other business that will be presented for consideration at the annual meeting. If other matters are properly brought before the annual meeting, however, it is the intention of the persons named in the accompanying proxy to vote the shares represented thereby on such matters in accordance with their best judgment.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:45.63492063492063%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By Order of the Board of Directors,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/&#160;&#160;&#160;&#160;C</font><font style="font-family:inherit;font-size:8pt;">HARLES</font><font style="font-family:inherit;font-size:10pt;">&#160;S. B</font><font style="font-family:inherit;font-size:8pt;">ERKMAN</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:4px;font-size:7.5pt;"><font style="font-family:inherit;font-size:7.5pt;font-weight:bold;">Charles S. Berkman</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:4px;font-size:7.5pt;"><font style="font-family:inherit;font-size:7.5pt;font-style:italic;font-weight:bold;">Senior Vice President, General Counsel&#160;&amp; Secretary</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:21px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">April 24, 2019</font></div><div><br></div><hr style="page-break-after:always"><div><a name="s28368a12ab9640cf90a65408e98ba370"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:18pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:top;background-color:#727272;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:5px;text-align:left;padding-left:9px;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;color:#ffffff;font-weight:bold;">Appendix A - Amendment and Restatement of the Ligand Pharmaceuticals Incorporated 2002 Stock Incentive Plan</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">LIGAND PHARMACEUTICALS INCORPORATED</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">2002 STOCK INCENTIVE PLAN</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">(AS AMENDED AND RESTATED EFFECTIVE JUNE 6, 2019)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">ARTICLE ONE</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">GENERAL PROVISIONS</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">I.    PURPOSE OF THE PLAN</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;This 2002 Stock Incentive Plan is intended to promote the interests of Ligand Pharmaceuticals Incorporated, a Delaware corporation, by providing eligible persons in the Corporation&#8217;s and its Subsidiaries&#8217; service with the opportunity to acquire a proprietary interest, or otherwise increase their proprietary interest, in the Corporation as an incentive for them to remain in such service. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">Capitalized terms shall have the meanings assigned to such terms in the attached Appendix.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">II.   </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">STRUCTURE OF THE PLAN</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;A. </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">The Plan shall be divided into three separate equity incentives programs:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">1.     </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">the Discretionary Option Grant Program under which eligible persons may, at the discretion of the Plan Administrator, be granted options to purchase shares of Common Stock,</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">2.     </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">the Stock Issuance Program under which eligible persons may, at the discretion of the Plan Administrator, be issued shares of Common Stock, and</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:11pt;">3.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">the Other Stock Award Program under which eligible persons may, at the discretion of the Plan Administrator, be granted restricted stock units, stock appreciation rights and dividend equivalents. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;B. </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">The provisions of Articles One, Five and Six shall apply to all equity programs under the Plan and shall govern the interests of all persons under the Plan.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">III.  </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">ADMINISTRATION OF THE PLAN</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;A. </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">The Primary Committee shall have sole and exclusive authority to administer the Plan with respect to Section 16 Insiders (other than non-employee Board members, whose Awards shall be administered by the full Board, as provided below). Administration of the Plan with respect to all other persons eligible to participate in those programs may, at the Board&#8217;s discretion, be vested in the Primary Committee or a Secondary Committee, or the Board may retain the power to administer those programs with respect to all such persons. However, any discretionary Awards for members of the Primary Committee must be authorized by a disinterested majority of the Board. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;B. </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">Members of the Primary Committee or any Secondary Committee shall serve for such period of time as the Board may determine and may be removed by the Board at any time. The Board may also at any time </font></div><div><br></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ligand Pharmaceuticals Incorporated 2019 Proxy Statement </font><font style="font-family:Wingdings;font-size:8pt;">l</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">65</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">terminate the functions of any Secondary Committee and reassume all powers and authority previously delegated to such committee.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;C. </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">Each Plan Administrator shall, within the scope of its administrative functions under the Plan, have full power and authority (subject to the provisions of the Plan) to establish such rules and regulations as it may deem appropriate for proper administration of the Plan and to make such determinations under, and issue such interpretations of, the provisions of those programs and any outstanding Awards thereunder as it may deem necessary or advisable. Decisions of the Plan Administrator within the scope of its administrative functions under the Plan shall be final and binding on all parties who have an interest in the equity incentive programs under its jurisdiction or any Award thereunder.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;D. </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">Service on the Primary Committee or the Secondary Committee shall constitute service as a Board member, and members of each such committee shall accordingly be entitled to full indemnification and reimbursement as Board members for their service on such committee. No member of the Primary Committee or the Secondary Committee shall be liable for any act or omission made in good faith with respect to the Plan or any Awards under the Plan.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;E. </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">Notwithstanding the foregoing, the full Board shall administer the Plan with respect to any Awards to the non-employee members of the Board.  In addition, in its sole discretion, the Board may at any time and from time to time exercise any and all rights and duties of the Primary Committee or any Secondary Committee under the Plan except with respect to matters which under Rule 16b&#8209;3 under the Exchange Act, or any regulations or rules issued thereunder, are required to be determined in the sole discretion of the Primary Committee.  Should any Awards made under the Plan prior to November 2, 2017, be intended to qualify as Qualified Performance-Based Compensation within the meaning of Section 162(m)(4)(C) of the Code prior to its repeal, then all such determinations regarding such Awards will be made solely by the Primary Committee comprised solely of two of more &#8220;outside directors&#8221; within the meaning of Section 162(m) of the Code.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">IV.   </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">ELIGIBILITY</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">A. </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">The persons eligible to participate in the Discretionary Option Grant, Stock Issuance and Other Stock Award Programs are as follows:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;(i) </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">Employees,</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;(ii) </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">non-employee members of the Board or the board of directors of any Parent or Subsidiary, and</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;(iii) </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">consultants and other independent advisors who provide services to the Corporation (or any Parent or Subsidiary). </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">B. </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">Each Plan Administrator shall, within the scope of its administrative jurisdiction under the Plan, have full authority to determine, (i) with respect to the option grants under the Discretionary Option Grant Program, which eligible persons are to receive such grants, the time or times when those grants are to be made, the number of shares to be covered by each such grant, the status of the granted option as either an Incentive Option or a Non-Statutory Option, the time or times when each option is to become exercisable, the vesting schedule (if any) applicable to the option shares, the maximum term for which the option is to remain outstanding and such other terms and conditions of such option as the Plan Administrator determines are appropriate, (ii) with respect to stock issuances under the Stock Issuance Program, which eligible persons are to receive such issuances, the time or times when the issuances are to be made, the number of shares to be issued to each Participant, the vesting schedule (if any) applicable to the issued shares, the purchase price, if any, and consideration for such shares and such other terms and conditions of such issued shares as the Plan Administrator determines are appropriate, and (iii) with respect to other Awards under the Other Stock Awards Program, which eligible persons </font></div><div><br></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ligand Pharmaceuticals Incorporated 2019 Proxy Statement </font><font style="font-family:Wingdings;font-size:8pt;">l</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">66</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">are to receive such Awards, the type of Award, the time or times when the issuances are to be made, the number of shares subject to such Award to be issued to each Participant, the vesting schedule (if any) applicable to the Awards, the consideration for such Awards and such other terms and conditions of such Awards as the Plan Administrator determines are appropriate.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">V.    </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">STOCK SUBJECT TO THE PLAN</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">A. </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">Subject to adjustment pursuant to this Section V, the number of shares of Common Stock which may be issued or transferred pursuant to Awards under the Plan is 6,299,254 shares, which number shall be reduced at any time by (i) one share for each share subject to any outstanding Award that is not a Full Value Award, and (ii) 1.5 shares for each share subject to any outstanding Award that is a Full Value Award.  Notwithstanding anything in this Section V.A. to the contrary, the number of shares of Common Stock that may be issued or transferred pursuant to Incentive Stock Options under the Plan shall not exceed an aggregate of 6,299,254 shares, subject to adjustment pursuant to this Section V.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;B. </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">No one person participating in the Plan may receive Awards for more than 1,000,000 shares of Common Stock in the aggregate per calendar year.  In addition, notwithstanding any provision to the contrary in the Plan,  the sum of any cash compensation, or other compensation, and the value (determined as of the grant date in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 718, or any successor thereto) of Awards granted to a non-employee member of the Board as compensation for services as a non-employee member of the Board during any calendar year of the Corporation may not exceed $550,000, increased to 850,000 in the calendar year of his or her initial service as a non-employee member of the Board.  The Plan Administrator may make exceptions to this limit for individual non-employee members of the Board in extraordinary circumstances, as the Plan Administrator may determine in its discretion, provided that the non-employee member of the Board receiving such additional compensation may not participate in the decision to award such compensation or in other contemporaneous compensation decisions involving non-employee members of the Board.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">C. </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">To the extent all or a portion of an Award is forfeited, expires or such Award or portion thereof is settled for cash (in whole or in part), the shares of Common Stock subject to such Award or portion thereof, shall, to the extent of such forfeiture, expiration or cash settlement, again be available for future grants of Awards under the Plan in an amount corresponding to the reduction in the share reserve previously made in accordance with Section V.A above.  Notwithstanding anything to the contrary contained herein, the following shares of Common Stock shall not be added to the shares of Common Stock authorized for grant under Section V.A and will not be available for future grants of Awards: (i) shares of Common Stock tendered by an Optionee or withheld by the Corporation in payment of the exercise price of an option; (ii) shares of Common Stock tendered by the Optionee or Participant or withheld by the Corporation to satisfy any tax withholding obligation with respect to an option or stock appreciation right; (iii) shares of Common Stock subject to a stock appreciation right that are not issued in connection with the stock settlement of the stock appreciation right on exercise thereof; and (iv) shares of Common Stock purchased on the open market with the cash proceeds from the exercise of options.  Shares of Common Stock tendered by the Participant or withheld by the Corporation to satisfy any tax withholding obligation with respect to a Full Value Award shall be available for future grants of Awards under the Plan in an amount corresponding to the reduction in the share reserve previously made in accordance with Section V.A. above; provided, however, that, notwithstanding the foregoing, in the event shares subject to a Full Value Award are delivered by a Participant or withheld by the Company to satisfy any Withholding Taxes at a tax withholding rate in excess of the minimum statutory withholding rates, such shares tendered or withheld to satisfy the Withholding Taxes at a rate in excess of the minimum statutory withholding rates shall not be available for future grants of Awards under the Plan and shall continue to be counted against the share reserve in an amount corresponding to the reduction in the share reserve previously made in accordance with Section V.A. above. Any shares of Common Stock forfeited by the Participant or repurchased by the Corporation under Article Three, Section I.C at a price not greater than the price originally paid by the Participant so that such shares are returned to the Corporation will again be available for Awards in an amount corresponding to the reduction in the share </font></div><div><br></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ligand Pharmaceuticals Incorporated 2019 Proxy Statement </font><font style="font-family:Wingdings;font-size:8pt;">l</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">67</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">reserve previously made in accordance with Section V.A. above.  The payment of Dividend Equivalents in cash in conjunction with any outstanding Awards shall not be counted against the shares available for issuance under the Plan.  Notwithstanding the provisions of this Section V.C, no shares of Common Stock may again be optioned, granted or awarded if such action would cause an Incentive Option to fail to qualify as an incentive stock option under Section 422 of the Code. </font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;D. </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">If any change is made to the Common Stock by reason of any stock split, stock or cash dividend (other than normal cash dividends), recapitalization, combination of shares, exchange of shares or other change affecting the outstanding Common Stock as a class without the Corporation&#8217;s receipt of consideration, equitable adjustments shall be made by the Plan Administrator to (i) the maximum number and/or class of securities issuable under the Plan or with respect to Incentive Stock Options under the Plan, (ii) the maximum number and/or class of securities for which any one person may be granted Awards under the Plan per calendar year, (iii) the number and/or class of securities for which grants are subsequently to be made under the Automatic Option Grant Program to new and continuing non-employee Board members, (iv) the number and/or class of securities and the exercise or purchase price per share in effect under each outstanding Award under the Plan, and (v) the terms and conditions of any outstanding Awards (including, without limitation, any applicable performance targets or criteria with respect thereto). Such adjustments to the outstanding Awards are to be effected in a manner which shall preclude the enlargement or dilution of rights and benefits under such Awards. The adjustments determined by the Plan Administrator shall be final, binding and conclusive.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;">E</font><font style="font-family:inherit;font-size:11pt;">.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">Subject to Article Two, Section III, Article Three, Section II and Article Four, Section V, in the event of any transaction or event described in Section V.D or any unusual or nonrecurring transactions or events affecting the Corporation, any affiliate of the Corporation, or the financial statements of the Corporation or any affiliate, or of changes in applicable laws, regulations or accounting principles, including, without limitation, a Change in Control or a Hostile Take-Over, the Plan Administrator, in its sole and absolute discretion, and on such terms and conditions as it deems appropriate, either by the terms of the Award or by action taken prior to the occurrence of such transaction or event and either automatically or upon the Optionee&#8217;s or Participant&#8217;s request, is hereby authorized to take any one or more of the following actions whenever the Plan Administrator determines that such action is appropriate in order to prevent dilution or enlargement of the benefits or potential benefits intended to be made available under the Plan or with respect to any Award under the Plan, to facilitate such transactions or events or to give effect to such changes in laws, regulations or principles:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:11pt;">1.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">To provide for either (A) termination of any such Award in exchange for an amount of cash, if any, equal to the amount that would have been attained upon the exercise of such Award or realization of the Optionee&#8217;s or Participant&#8217;s rights (and, for the avoidance of doubt, if as of the date of the occurrence of the transaction or event described in this Section V.E the Plan Administrator determines in good faith that no amount would have been attained upon the exercise of such Award or realization of the Optionee&#8217;s or Participant&#8217;s rights, then such Award may be terminated by the Corporation without payment) or (B) the replacement of such Award with other rights or property selected by the Plan Administrator in its sole discretion;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:11pt;">2.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">To provide that such Award be assumed by the successor or survivor corporation, or a parent or subsidiary thereof, or shall be substituted for by similar Awards covering the stock of the successor or survivor corporation, or a parent or subsidiary thereof, with appropriate adjustments as to the number and kind of shares and prices; </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:11pt;">3.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">To make adjustments in the number and type of shares of Common Stock (or other securities or property) subject to outstanding Awards, and in the number and/or in the terms and conditions of (including the grant or exercise price), and the criteria included in, outstanding Awards;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:11pt;">4.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">To provide that such Award shall be exercisable or payable or fully vested with respect to all shares covered thereby, notwithstanding anything to the contrary in the Plan or the applicable award agreement; and</font></div><div><br></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ligand Pharmaceuticals Incorporated 2019 Proxy Statement </font><font style="font-family:Wingdings;font-size:8pt;">l</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">68</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:11pt;">5.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">To provide that the Award cannot vest, be exercised or become payable after such event.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:11pt;">F.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">In the event of any pending stock dividend, stock split, combination or exchange of shares, merger, consolidation or other distribution (other than normal cash dividends) of Corporation assets to stockholders, or any other change affecting the shares of Common Stock or the share price of the Common Stock, for reasons of administrative convenience, the Corporation in its sole discretion may refuse to permit the exercise of any Award during a period of thirty (30) days prior to the consummation of any such transaction.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">ARTICLE TWO</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">DISCRETIONARY OPTION GRANT PROGRAM</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">I.   </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">OPTION TERMS</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;Each option shall be evidenced by one or more documents in the form approved by the Plan Administrator; provided, however, that each such document shall comply with the terms specified below. Each document evidencing an Incentive Option shall, in addition, be subject to the provisions of the Plan applicable to such options.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;A. </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">EXERCISE PRICE.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">1. </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">The exercise price per share shall be fixed by the Plan Administrator but shall not be less than one hundred percent (100%) of the Fair Market Value per share of Common Stock on the option grant date. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">2. </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">The exercise price shall become immediately due upon exercise of the option and shall, subject to the provisions of the documents evidencing the option, be payable in one or more of the forms specified below:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">(i) </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">cash or check made payable to the Corporation, </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">(ii) </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">shares of Common Stock held by the Optionee or otherwise issuable upon exercise of the option and valued at Fair Market Value on the Exercise Date, </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">(iii) </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">to the extent the option is exercised for vested shares, through a special sale and remittance procedure pursuant to which the Optionee shall concurrently provide irrevocable instructions to (a) a Corporation-designated brokerage firm to effect the immediate sale of the purchased shares and remit to the Corporation, out of the sale proceeds available on the settlement date, sufficient funds to cover the aggregate exercise price payable for the purchased shares plus all applicable income and employment taxes required to be withheld by the Corporation by reason of such exercise and (b) the Corporation to deliver the certificates for the purchased shares directly to such brokerage firm in order to complete the sale, or</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:144px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:11pt;">(iv)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">with the consent of the Plan Administrator, a promissory note bearing interest at no less than such rate as shall then preclude the imputation of interest under the Code.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;Except to the extent such sale and remittance procedure is utilized, payment of the exercise price for the purchased shares must be made on the Exercise Date.  Notwithstanding any other provision of the Plan to the contrary, no Optionee who is a member of the Board or an &#8220;executive officer&#8221; of the Corporation within the meaning of Section 13(k) of the Exchange Act shall be permitted to pay the exercise price of an option, or continue any extension of credit with respect to the exercise of an option, with a loan from the Corporation or a loan arranged by the Corporation in violation of Section 13(k) of the Exchange Act.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;B. </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">EXERCISE AND TERM OF OPTIONS. Each option shall be exercisable at such time or times, </font></div><div><br></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ligand Pharmaceuticals Incorporated 2019 Proxy Statement </font><font style="font-family:Wingdings;font-size:8pt;">l</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">69</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">during such period and for such number of shares as shall be determined by the Plan Administrator and set forth in the documents evidencing the option. However, no option shall have a term in excess of ten (10) years measured from the option grant date.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;C. </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">EFFECT OF TERMINATION OF SERVICE.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">1. </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">The following provisions shall govern the exercise of any options held by the Optionee at the time of cessation of Service or death: </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">(i) </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">Any option outstanding at the time of the Optionee&#8217;s cessation of Service for any reason shall remain exercisable for such period of time thereafter as shall be determined by the Plan Administrator and set forth in the documents evidencing the option, but no such option shall be exercisable after the expiration of the option term. </font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:144px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:11pt;">(ii) </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">Any option held by the Optionee at the time of death and exercisable in whole or in part at that time may be subsequently exercised by the personal representative of the Optionee&#8217;s estate or by the person or persons to whom the option is transferred pursuant to the Optionee&#8217;s will or the laws of inheritance or by the Optionee&#8217;s designated beneficiary or beneficiaries of that option. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">(iii) </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">During the applicable post-Service exercise period, the option may not be exercised in the aggregate for more than the number of vested shares for which the option is exercisable on the date of the Optionee&#8217;s cessation of Service. Upon the expiration of the applicable exercise period or (if earlier) upon the expiration of the option term, the option shall terminate and cease to be outstanding for any vested shares for which the option has not been exercised. However, the option shall, immediately upon the Optionee&#8217;s cessation of Service, terminate and cease to be outstanding to the extent the option is not otherwise at that time exercisable for vested shares.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">2. </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">The Plan Administrator shall have complete discretion, exercisable either at the time an option is granted or at any time while the option remains outstanding, to:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">(i) </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">extend the period of time for which the option is to remain exercisable following the Optionee&#8217;s cessation of Service from the limited exercise period otherwise in effect for that option to such greater period of time as the Plan Administrator shall deem appropriate, but in no event beyond the expiration of the option term, and/or </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;(ii) </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">permit the option to be exercised, during the applicable post-Service exercise period, not only with respect to the number of vested shares of Common Stock for which such option is exercisable at the time of the Optionee&#8217;s cessation of Service but also with respect to one or more additional installments in which the Optionee would have vested had the Optionee continued in Service. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">D. </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">STOCKHOLDER RIGHTS. The holder of an option shall have no stockholder rights with respect to the shares subject to the option until such person shall have exercised the option, paid the exercise price and become a holder of record of the purchased shares.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">E. </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">REPURCHASE RIGHTS. The Plan Administrator shall have the discretion to grant options which are exercisable for unvested shares of Common Stock. Should the Optionee cease Service while holding such unvested shares, the Corporation shall have the right to repurchase any or all of those unvested shares. The terms upon which such repurchase right shall be exercisable (including the period and procedure for exercise and the appropriate vesting schedule for the purchased shares) shall be established by the Plan Administrator and set forth in the document evidencing such repurchase right. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;F. </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">LIMITED TRANSFERABILITY OF OPTIONS. During the lifetime of the Optionee, Incentive Options shall be exercisable only by the Optionee and shall not be assignable or transferable other than by will or </font></div><div><br></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ligand Pharmaceuticals Incorporated 2019 Proxy Statement </font><font style="font-family:Wingdings;font-size:8pt;">l</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">70</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">the laws of inheritance following the Optionee&#8217;s death. Non-Statutory Options shall be subject to the same restriction, except that a Non-Statutory Option may be assigned in whole or in part during the Optionee&#8217;s lifetime to one or more members of the Optionee&#8217;s family or to a trust established exclusively for one or more such family members or to Optionee&#8217;s former spouse, to the extent such assignment is in connection with the Optionee&#8217;s estate plan or pursuant to a domestic relations order. The assigned portion may only be exercised by the person or persons who acquire a proprietary interest in the option pursuant to the assignment. The terms applicable to the assigned portion shall be the same as those in effect for the option immediately prior to such assignment and shall be set forth in such documents issued to the assignee as the Plan Administrator may deem appropriate. Notwithstanding the foregoing, the Optionee may also designate one or more persons as the beneficiary or beneficiaries of his or her outstanding options under this Article Two, and those options shall, in accordance with such designation, automatically be transferred to such beneficiary or beneficiaries upon the Optionee&#8217;s death while holding those options. Such beneficiary or beneficiaries shall take the transferred options subject to all the terms and conditions of the applicable agreement evidencing each such transferred option, including (without limitation) the limited time period during which the option may be exercised following the Optionee&#8217;s death.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">II.   </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">INCENTIVE OPTIONS</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;The terms specified below shall be applicable to all Incentive Options. Except as modified by the provisions of this Section II, all the provisions of Articles One, Five and Six shall be applicable to Incentive Options.  To the extent an option which is designated as an Incentive Option fails to meet the requirements of Section 422 of the Code, then such option shall be treated as a Non-Statutory Option.  Options which are specifically designated as Non-Statutory Options when issued under the Plan shall not be subject to the terms of this Section II.  </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;A. </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">ELIGIBILITY. Incentive Options may only be granted to Employees. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;B. </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">DOLLAR LIMITATION. The aggregate Fair Market Value of the shares of Common Stock (determined as of the respective date or dates of grant) for which one or more options granted to any Employee under the Plan (or any other option plan of the Corporation or any Parent or Subsidiary) may for the first time become exercisable as Incentive Options during any one calendar year shall not exceed the sum of One Hundred Thousand Dollars ($100,000). To the extent the Employee holds two (2) or more such options which become exercisable for the first time in the same calendar year, the foregoing limitation on the exercisability of such options as Incentive Options shall be applied on the basis of the order in which such options are granted.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">C. </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">10% STOCKHOLDER. If any Employee to whom an Incentive Option is granted is a 10% Stockholder, then the exercise price per share shall not be less than one hundred ten percent (110%) of the Fair Market Value per share of Common Stock on the option grant date, and the option term shall not exceed five (5) years measured from the option grant date.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">III.  </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">CHANGE IN CONTROL/HOSTILE TAKE-OVER</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">A. </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">In the event of a Change in Control, each outstanding option under the Discretionary Option Grant Program shall automatically accelerate so that each such option shall, immediately prior to the effective date of that Change in Control, become exercisable for all the shares of Common Stock at the time subject to such option and may be exercised for any or all of those shares as fully vested shares of Common Stock. However, an outstanding option shall NOT become exercisable on such an accelerated basis if and to the extent: (i) such option is to be assumed by the successor corporation (or parent thereof) or is otherwise to continue in full force and effect pursuant to the terms of the Change in Control transaction or (ii) such option is to be replaced with a cash incentive program of the successor corporation which preserves the spread existing at the time of the Change in Control on any shares for which the option is not otherwise at that time exercisable and provides for subsequent payout of that spread in accordance with the same exercise/vesting schedule applicable to those option shares or (iii) the acceleration of such option is subject to other limitations imposed by the Plan Administrator at the time of </font></div><div><br></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ligand Pharmaceuticals Incorporated 2019 Proxy Statement </font><font style="font-family:Wingdings;font-size:8pt;">l</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">71</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">the option grant. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">B. </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">All outstanding repurchase rights under the Discretionary Option Grant Program shall automatically terminate, and the shares of Common Stock subject to those terminated rights shall immediately vest in full, in the event of a Change in Control, except to the extent: (i) those repurchase rights are to be assigned to the successor corporation (or parent thereof) or are otherwise to continue in full force and effect pursuant to the terms of the Change in Control transaction or (ii) such accelerated vesting is precluded by other limitations imposed by the Plan Administrator at the time the repurchase right is issued. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">C. </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">Immediately following the consummation of the Change in Control, all outstanding options under the Discretionary Option Grant Program shall terminate and cease to be outstanding, except to the extent assumed by the successor corporation (or parent thereof) or otherwise continued in full force and effect pursuant to the terms of the Change in Control transaction. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">D. </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">Each option which is assumed in connection with a Change in Control or otherwise continued in effect shall be appropriately adjusted, immediately after such Change in Control, to apply to the number and class of securities which would have been issuable to the Optionee in consummation of such Change in Control had the option been exercised immediately prior to such Change in Control. Appropriate adjustments shall also be made to the exercise price payable per share under each outstanding option, provided the aggregate exercise price payable for such securities shall remain the same (subject only to reduction by reason of rounding). To the extent the actual holders of the Corporation&#8217;s outstanding Common Stock receive cash consideration for their Common Stock in consummation of the Change in Control, the successor corporation may, in connection with the assumption of the outstanding options under the Discretionary Option Grant Program, substitute one or more shares of its own common stock with a fair market value equivalent to the cash consideration paid per share of Common Stock in such Change in Control transaction.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">E. </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">The Plan Administrator shall have the discretionary authority to structure one or more outstanding options under the Discretionary Option Grant Program so that those options shall, immediately prior to the effective date of a Change in Control, become exercisable for all the shares of Common Stock at the time subject to those options and may be exercised for any or all of those shares as fully vested shares of Common Stock, whether or not those options are to be assumed in the Change in Control transaction or otherwise continued in effect. In addition, the Plan Administrator shall have the discretionary authority to structure one or more of the Corporation&#8217;s repurchase rights under the Discretionary Option Grant Program so that those rights shall immediately terminate upon the consummation of the Change in Control transaction, and the shares subject to those terminated rights shall thereupon vest in full. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">F. </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">The Plan Administrator shall have full power and authority to structure one or more outstanding options under the Discretionary Option Grant Program so that those options shall become exercisable for all the shares of Common Stock at the time subject to those options in the event the Optionee&#8217;s Service is subsequently terminated by reason of an Involuntary Termination within a designated period (not to exceed eighteen (18) months) following the effective date of any Change in Control transaction in which those options do not otherwise accelerate. In addition, the Plan Administrator may structure one or more of the Corporation&#8217;s repurchase rights so that those rights shall immediately terminate with respect to any shares held by the Optionee at the time of such Involuntary Termination, and the shares subject to those terminated repurchase rights shall accordingly vest in full at that time. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">G. </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">The Plan Administrator shall have the discretionary authority to structure one or more outstanding options under the Discretionary Option Grant Program so that those options shall, immediately prior to the effective date of a Hostile Take-Over, become exercisable for all the shares of Common Stock at the time subject to those options and may be exercised for any or all of those shares as fully vested shares of Common Stock. In addition, the Plan Administrator shall have the discretionary authority to structure one or more of the Corporation&#8217;s repurchase rights under the Discretionary Option Grant Program so that those rights shall terminate </font></div><div><br></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ligand Pharmaceuticals Incorporated 2019 Proxy Statement </font><font style="font-family:Wingdings;font-size:8pt;">l</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">72</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">automatically upon the consummation of such Hostile Take-Over, and the shares subject to those terminated rights shall thereupon vest in full. Alternatively, the Plan Administrator may condition the automatic acceleration of one or more outstanding options under the Discretionary Option Grant Program and the termination of one or more of the Corporation&#8217;s outstanding repurchase rights under such program upon the subsequent termination of the Optionee&#8217;s Service by reason of an Involuntary Termination within a designated period (not to exceed eighteen (18) months) following the effective date of such Hostile Take-Over.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">H. </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">The portion of any Incentive Option accelerated in connection with a Change in Control or Hostile Take-Over shall remain exercisable as an Incentive Option only to the extent the applicable One Hundred Thousand Dollar ($100,000) limitation is not exceeded. To the extent such dollar limitation is exceeded, the accelerated portion of such option shall be exercisable as a Nonstatutory Option under the Federal tax laws.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">I. </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">The outstanding options shall in no way affect the right of the Corporation to adjust, reclassify, reorganize or otherwise change its capital or business structure or to merge, consolidate, dissolve, liquidate or sell or transfer all or any part of its business or assets.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">ARTICLE THREE</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">STOCK ISSUANCE PROGRAM</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">I.    </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">STOCK ISSUANCE TERMS</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;Shares of Common Stock may be issued under the Stock Issuance Program through direct and immediate issuances without any intervening option grants. Each such stock issuance shall be evidenced by a Stock Issuance Agreement which complies with the terms specified below. Shares of Common Stock may also be issued under the Stock Issuance Program pursuant to share right awards which entitle the recipients to receive those shares upon the attainment of designated performance goals or the satisfaction of specified Service requirements.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">A. </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">PURCHASE PRICE.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">1. </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">The purchase price per share, if any, shall be fixed by the Plan Administrator. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">2. </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">Shares of Common Stock may be issued under the Stock Issuance Program for any form of consideration as the Plan Administrator may deem appropriate in each individual instance, including, without limitation:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">(i) </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">cash or check made payable to the Corporation, or </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">(ii) </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">past services rendered to the Corporation (or any Parent or Subsidiary), or</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">(iii) </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">future services to be rendered to the Corporation (or any Parent or Subsidiary). </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:11pt;">B.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">RESTRICTIONS.  Shares of Common Stock issued under this Stock Issuance Program shall be subject to such restrictions on transferability and other restrictions as the Plan Administrator may impose (including, without limitation, limitations on the right to vote such shares or the right to receive dividends on such shares).  These restrictions may lapse separately or in combination at such times, pursuant to such circumstances, in such installments, or otherwise, as the Plan Administrator determines at the time of the grant of the shares or thereafter.</font><font style="font-family:inherit;font-size:12pt;">&#32;</font><font style="font-family:inherit;font-size:11pt;">Notwithstanding the foregoing, with respect to shares of Common Stock issued under this Stock Issuance Program subject to vesting, dividends which are paid prior to vesting shall only be paid out to the Participant to the extent that the vesting conditions are subsequently satisfied and the share vests.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:11pt;">C.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">Forfeiture.  Except as otherwise determined by the Plan Administrator at the time of the grant of the shares or thereafter, upon termination of employment or service during the applicable restriction period, shares </font></div><div><br></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ligand Pharmaceuticals Incorporated 2019 Proxy Statement </font><font style="font-family:Wingdings;font-size:8pt;">l</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">73</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">of Common Stock issued under this Stock Issuance Program that are at that time subject to restrictions shall be forfeited; </font><font style="font-family:inherit;font-size:11pt;font-style:italic;">provided, however</font><font style="font-family:inherit;font-size:11pt;">, that, the Plan Administrator may (a) provide in any award agreement that restrictions or forfeiture conditions relating to such shares will be waived in whole or in part in the event of terminations resulting from specified causes, and (b) in other cases waive in whole or in part restrictions or forfeiture conditions relating to such shares.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">II.   CHANGE IN CONTROL/HOSTILE TAKE-OVER</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">A. </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">All of the Corporation&#8217;s outstanding forfeiture restrictions or repurchase rights on any shares of Common Stock issued under the Stock Issuance Program shall terminate automatically, and all the shares of Common Stock subject to those terminated rights shall immediately vest in full, in the event of any Change in Control, except to the extent (i) those forfeiture restrictions or repurchase rights are to be assigned to the successor corporation (or parent thereof) or are otherwise to continue in full force and effect pursuant to the terms of the Change in Control transaction or (ii) such accelerated vesting is precluded by other limitations imposed in the Stock Issuance Agreement.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">B. </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">The Plan Administrator shall have the discretionary authority to structure one or more of the Corporation&#8217;s forfeiture restrictions or repurchase rights under the Stock Issuance Program so that those rights shall automatically terminate in whole or in part, and the shares of Common Stock subject to those terminated rights shall immediately vest, in the event the Participant&#8217;s Service should subsequently terminate by reason of an Involuntary Termination within a designated period (not to exceed eighteen (18) months) following the effective date of any Change in Control transaction in which those forfeiture restrictions or repurchase rights are assigned to the successor corporation (or parent thereof) or are otherwise continued in effect. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">C. </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">The Plan Administrator shall also have the discretionary authority to structure one or more of the Corporation&#8217;s forfeiture restrictions or repurchase rights under the Stock Issuance Program so that those rights shall automatically terminate in whole or in part, and the shares of Common Stock subject to those terminated rights shall immediately vest, either upon the occurrence of a Hostile Take-Over or upon the subsequent termination of the Participant&#8217;s Service by reason of an Involuntary Termination within a designated period (not to exceed eighteen (18) months) following the effective date of that Hostile Take-Over.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">III.  </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">SHARE ESCROW/LEGENDS</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">Unvested shares may, in the Plan Administrator&#8217;s discretion, be held in escrow by the Corporation until the Participant&#8217;s interest in such shares vests or may be issued directly to the Participant with restrictive legends on the certificates evidencing those unvested shares. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">ARTICLE FOUR</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">OTHER STOCK AWARDS PROGRAM</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">I.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">STOCK APPRECIATION RIGHTS</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:11pt;">A.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">A stock appreciation right may be granted to any eligible person selected by the Plan Administrator.  A stock appreciation right shall be subject to such terms and conditions not inconsistent with the Plan as the Plan Administrator shall impose and shall be evidenced by a stock appreciation right agreement.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:11pt;">B.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">A stock appreciation right shall entitle the Participant (or other person entitled to exercise the stock appreciation right pursuant to the Plan) to exercise all or a specified portion of the stock appreciation right (to the extent then exercisable pursuant to its terms) and to receive from the Corporation an amount equal to the product of (i) the excess of (A) the Fair Market Value of the Common Stock on the date the stock appreciation right is exercised over (B) the Fair Market Value of the Common Stock on the date the stock appreciation right </font></div><div><br></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ligand Pharmaceuticals Incorporated 2019 Proxy Statement </font><font style="font-family:Wingdings;font-size:8pt;">l</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">74</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">was granted and (ii) the number of shares of Common Stock with respect to which the stock appreciation right is exercised, subject to any limitations the Plan Administrator may impose.  The exercise or base price per share of a stock appreciation right shall be fixed by the Plan Administrator but shall not be less than one hundred percent (100%) of the Fair Market Value per share of Common Stock on the date the stock appreciation right was granted. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:11pt;">C.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">Subject to Section I.B above, payment of the amounts determined under Sections I.B. above shall be in cash, in Common Stock (based on its Fair Market Value as of the date the stock appreciation right is exercised) or a combination of both, as determined by the Plan Administrator.  To the extent any payment is effected in Stock, it shall be made subject to satisfaction of all provisions of Article Two above pertaining to options.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">D.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">Each stock appreciation right shall be exercisable at such time or times, during such period and for such number of shares as shall be determined by the Plan Administrator and set forth in the documents evidencing the stock appreciation right. However, no stock appreciation right shall have a term in excess of ten (10) years measured from the date the stock appreciation right was granted.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">II.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Dividend Equivalents</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Any eligible person selected by the Plan Administrator may be granted dividend equivalents based on the dividends declared on the shares of Common Stock that are subject to any Award, to be credited as of dividend payment dates, during the period between the date the Award is granted and the date the Award is exercised, vests or expires, as determined by the Plan Administrator.  Such dividend equivalents shall be converted to cash or additional shares of Common Stock by such formula and at such time and subject to such limitations as may be determined by the Plan Administrator.  Notwithstanding anything to the contrary, dividends or dividend equivalents with respect to an Award that is subject to vesting that are based on dividends paid prior to the vesting of such Award shall only be paid out to the extent that the vesting conditions are subsequently satisfied and the Award vests. In addition, notwithstanding anything to the contrary, no dividend equivalents shall be payable with respect to options or stock appreciation rights. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">III.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Restricted Stock Units</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Plan Administrator is authorized to make Awards of restricted stock units (a right to shares of Common Stock deliverable in the future) to any eligible person selected by the Plan Administrator in such amounts and subject to such terms and conditions as determined by the Plan Administrator.  At the time of grant, the Plan Administrator shall specify the date or dates on which the restricted stock units shall become fully vested and nonforfeitable, and may specify such conditions to vesting as it deems appropriate.  At the time of grant, the Plan Administrator shall specify the maturity date applicable to each grant of restricted stock units which shall be no earlier than the vesting date or dates of the Award and may be determined at the election of the grantee.  On the maturity date, the Corporation shall, subject to Article Six, Section V,  transfer to the Participant one unrestricted, fully transferable share of Common Stock for each restricted stock unit scheduled to be paid out on such date and not previously forfeited.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">IV.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">OTHER TERMS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:11pt;">A.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">Except as otherwise provided herein, the term of any award of stock appreciation rights, dividend equivalents or restricted stock units shall be set by the Plan Administrator in its discretion.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:11pt;">B.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">Except as otherwise provided herein, the Plan Administrator may establish the exercise or purchase price, if any, of any award of stock appreciation rights, dividend equivalents or restricted stock units.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:11pt;">C.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">An award of stock appreciation rights, dividend equivalents or restricted stock units shall only be exercisable or payable prior to the Participant&#8217;s termination of Service; </font><font style="font-family:inherit;font-size:11pt;font-style:italic;">provided, however</font><font style="font-family:inherit;font-size:11pt;">, that the Plan Administrator in its sole and absolute discretion may provide that an award of stock appreciation rights, dividend </font></div><div><br></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ligand Pharmaceuticals Incorporated 2019 Proxy Statement </font><font style="font-family:Wingdings;font-size:8pt;">l</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">75</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">equivalents or restricted stock units may be exercised or paid subsequent to a termination of Service, as applicable, or following a Change in Control of the Corporation, or because of the Participant&#8217;s retirement, death or disability, or otherwise.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:11pt;">D.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">Payments with respect to any Awards granted under this Article Four shall be made in cash, in Stock or a combination of both, as determined by the Committee.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:11pt;">E.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">All Awards under this Article Four shall be subject to such additional terms and conditions as determined by the Plan Administrator and shall be evidenced by an award agreement.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">V.  </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">CHANGE IN CONTROL/HOSTILE TAKE-OVER</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">A. </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">In the event of a Change in Control, each outstanding Award under the Other Stock Award Program shall automatically accelerate so that each such Award shall, immediately prior to the effective date of that Change in Control, become vested and exercisable and/or payable with respect to all the shares of Common Stock at the time subject to such Award and may be exercised or paid for any or all of those shares as fully vested shares of Common Stock. However, an outstanding Award shall NOT become vested and exercisable and/or payable on such an accelerated basis if and to the extent: (i) such Award is to be assumed by the successor corporation (or parent thereof) or is otherwise to continue in full force and effect pursuant to the terms of the Change in Control transaction or (ii) such Award is to be replaced with a cash incentive program of the successor corporation which preserves the spread existing at the time of the Change in Control on any shares for which the Award is not otherwise at that time vested, exercisable or payable and provides for subsequent payout of that spread in accordance with the same exercise/vesting/payment schedule applicable to those Award shares or (iii) the acceleration of such Award is subject to other limitations imposed by the Plan Administrator at the time of the Award grant. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">B. </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">Immediately following the consummation of the Change in Control, all outstanding Awards under the Other Stock Award Program shall terminate and cease to be outstanding, except to the extent assumed by the successor corporation (or parent thereof) or otherwise continued in full force and effect pursuant to the terms of the Change in Control transaction. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">C. </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">Each Award which is assumed in connection with a Change in Control or otherwise continued in effect shall be appropriately adjusted, immediately after such Change in Control, to apply to the number and class of securities which would have been issuable to the Participant in consummation of such Change in Control had the Award been exercised or paid immediately prior to such Change in Control. Appropriate adjustments shall also be made to the exercise or purchase price payable per share under each outstanding Award, provided the aggregate exercise or purchase price payable for such securities shall remain the same. To the extent the actual holders of the Corporation&#8217;s outstanding Common Stock receive cash consideration for their Common Stock in consummation of the Change in Control, the successor corporation may, in connection with the assumption of the outstanding Awards under the Other Stock Award Program, substitute one or more shares of its own common stock with a fair market value equivalent to the cash consideration paid per share of Common Stock in such Change in Control transaction.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">D. </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">The Plan Administrator shall have the discretionary authority to structure one or more outstanding Awards under the Other Stock Award Program so that those Awards shall, immediately prior to the effective date of a Change in Control, become vested and exercisable and/or payable exercisable for all the shares of Common Stock at the time subject to those Awards and may be exercised or paid for any or all of those shares as fully vested shares of Common Stock, whether or not those Awards are to be assumed in the Change in Control transaction or otherwise continued in effect. In addition, the Plan Administrator shall have the discretionary authority to structure one or more of the Corporation&#8217;s repurchase rights under the Other Stock Award Program so that those rights shall immediately terminate upon the consummation of the Change in Control transaction, and the shares subject to those terminated rights shall thereupon vest in full. </font></div><div><br></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ligand Pharmaceuticals Incorporated 2019 Proxy Statement </font><font style="font-family:Wingdings;font-size:8pt;">l</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">76</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">E. </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">The Plan Administrator shall have full power and authority to structure one or more outstanding Awards under the Other Stock Award Program so that those Awards shall become vested and exercisable and/or payable for all the shares of Common Stock at the time subject to those Awards in the event the Participant&#8217;s Service is subsequently terminated by reason of an Involuntary Termination within a designated period (not to exceed eighteen (18) months) following the effective date of any Change in Control transaction in which those Awards do not otherwise accelerate. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">F. </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">The Plan Administrator shall have the discretionary authority to structure one or more outstanding Awards under the Other Stock Award Program so that those Awards shall, immediately prior to the effective date of a Hostile Take-Over, become vested and exercisable and/or payable for all the shares of Common Stock at the time subject to those Awards and may be exercised or paid for any or all of those shares as fully vested shares of Common Stock. Alternatively, the Plan Administrator may condition the automatic acceleration of one or more outstanding Awards under the Other Stock Award Program upon the subsequent termination of the Optionee&#8217;s Service by reason of an Involuntary Termination within a designated period (not to exceed eighteen (18) months) following the effective date of such Hostile Take-Over.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;G. </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">The outstanding Awards shall in no way affect the right of the Corporation to adjust, reclassify, reorganize or otherwise change its capital or business structure or to merge, consolidate, dissolve, liquidate or sell or transfer all or any part of its business or assets.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">ARTICLE FIVE</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">PERFORMANCE-BASED AWARDS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:11pt;">Notwithstanding any other provision of the Plan or any Award, with respect to any Award which is intended to continue to qualify as Qualified Performance-Based Compensation (as described in Section 162(m)(4)(C) of the Code prior to its repeal) pursuant to the transition relief rules in the Tax Cuts and Jobs Act of 2017, to the extent any of the provisions of the Plan or any Award (or any amendments hereto pursuant to this amendment and restatement of the Plan) would cause such Awards to fail to so qualify, any such provisions shall not apply to such Awards to the extent necessary to ensure the such Awards continue to so qualify.  In addition, any Award which is intended to continue to qualify as Qualified Performance-Based Compensation (as described in Section 162(m)(4)(C) of the Code prior to its repeal) pursuant to the transition relief rules in the Tax Cuts and Jobs Act of 2017 shall be subject to any additional limitations as the Primary Committee determines necessary for such Award to continue to so qualify. To the extent permitted by applicable law, and the Plan and any such Awards shall be deemed amended to the extent necessary to conform to such requirements.</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">ARTICLE SIX</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">MISCELLANEOUS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">I.   </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">TAX WITHHOLDING</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">A. </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">The Corporation&#8217;s obligation to deliver shares of Common Stock upon the exercise, vesting or payment of Awards under the Plan shall be subject to the satisfaction of all applicable income and employment tax withholding requirements.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">B. </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">The Plan Administrator may, in its discretion, provide any or all holders of Awards under the Plan with the right to use shares of Common Stock in satisfaction of all or part of the Withholding Taxes to which such holders may become subject in connection with the exercise, vesting or payment of their Awards. Such right may be provided to any such holder in either or both of the following formats:</font></div><div><br></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ligand Pharmaceuticals Incorporated 2019 Proxy Statement </font><font style="font-family:Wingdings;font-size:8pt;">l</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">77</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">Stock Withholding: The election to have the Corporation withhold, from the shares of Common Stock otherwise issuable upon the exercise, vesting or payment of such Award, a portion of those shares with an aggregate Fair Market Value equal to the minimum required percentage of the Withholding Taxes.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">Stock Delivery: The election to deliver to the Corporation, at the time the Award is exercised, vests or is paid, one or more shares of Common Stock previously acquired by such holder (other than in connection with the exercise, vesting or payment triggering the Withholding Taxes) and held for at least six (6) months (or such other period determined by the Plan Administrator) with an aggregate Fair Market Value equal to the percentage of the Withholding Taxes (not to exceed one hundred percent (100%)) designated by the holder.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:11pt;">C.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">Notwithstanding any other provision of the Plan, the number of shares of Common Stock which may be withheld or delivered by the Participant in order to satisfy the Withholding Taxes with respect to the exercise, vesting or payment of an Award shall be limited to the number of shares of Common Stock which have a Fair Market Value on the date of withholding or delivery equal to the aggregate amount of such Withholding Taxes based on the minimum statutory withholding rates for federal, state, local and foreign income tax and payroll tax purposes that are applicable to such supplemental taxable income or such higher rate as may approved by the Administrator (which rates shall in no event exceed the maximum individual statutory tax rate in the applicable jurisdiction at the time of such withholding (or such other rate as may be required to avoid the liability classification of the applicable award under generally accepted accounting principles in the United States of America)); provided, however, unless otherwise approved by the Administrator, to the extent such shares of Common Stock were acquired by the Participant from the Company as compensation, the shares of Common Stock must have been held for the minimum period required by applicable accounting rules to avoid a charge to the Company&#8217;s earnings for financial reporting purposes; provided, further, that the number of shares of Common Stock withheld or delivered shall be rounded up to the nearest whole share sufficient to cover the Withholding Taxes to the extent rounding up to the nearest whole share does not result in the liability classification of the applicable Award under generally accepted accounting principles in the United States of America.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">II.  </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">EFFECTIVE DATE AND TERM OF THE PLAN</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">A. </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">This Plan constitutes an amendment and restatement of the Ligand Pharmaceuticals Incorporated 2002 Stock Incentive Plan most recently adopted by the Board on April 5, 2016, and approved by the Corporation's stockholders on May 23, 2016 (the "</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Existing Plan</font><font style="font-family:inherit;font-size:11pt;">").  This amended and restated Plan was adopted by the Board on March 28, 2019, and will become effective on the Restatement Effective Date.  </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">B. </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">The Plan shall terminate upon the earliest to occur of (i) March 28, 2029, or (ii) the termination of all outstanding options in connection with a Change in Control. In the event of the termination of the Plan, then all option grants and unvested stock issuances outstanding at that time shall continue to have force and effect in accordance with the provisions of the documents evidencing such grants or issuances.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:11pt;">C.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">This amended and restated Plan shall be submitted for the approval of the Company&#8217;s stockholders within 12 months after the date of the Board&#8217;s adoption of this amended and restated Plan.  If this amended and restated Plan is not approved by the Company's stockholders, this amended and restated Plan shall not become effective and the Existing Plan shall continue in full force and effect in accordance with its terms.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">III.   </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">AMENDMENT OF THE PLAN</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">The Board shall have complete and exclusive power and authority to amend or modify the Plan in any or all respects. However, no such amendment or modification shall adversely affect the rights and obligations with respect to Awards at the time outstanding under the Plan unless the Optionee or the Participant consents to such amendment or modification. In addition, certain amendments may require stockholder approval pursuant to applicable laws or regulations.  Except as permitted by Article One, Section V, Article Two, Section III or Article </font></div><div><br></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ligand Pharmaceuticals Incorporated 2019 Proxy Statement </font><font style="font-family:Wingdings;font-size:8pt;">l</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">78</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Four, Section V in connection with a transaction specified in Article One, Section V.D or V.E (including, without limitation, any Change in Control, Hostile Take-Over, stock dividend, stock split, extraordinary cash dividend, recapitalization, combination of shares or exchange of shares), the terms of outstanding Awards may not be amended to reduce the exercise price of outstanding Options or stock appreciation rights or cancel, exchange, substitute, buyout or surrender outstanding Options or stock appreciation rights in exchange for cash, other Awards or Options or stock appreciation rights with an exercise price that is less than the exercise price of the original Options or stock appreciation rights without stockholder approval.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">IV.    </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">USE OF PROCEEDS</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">Any cash proceeds received by the Corporation from the sale of shares of Common Stock under the Plan shall be used for general corporate purposes.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">V.   </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">REGULATORY APPROVALS</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">A. </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">The implementation of the Plan, the granting of any Award under the Plan and the issuance of any shares of Common Stock under the Plan shall be subject to the Corporation&#8217;s procurement of all approvals and permits required by regulatory authorities having jurisdiction over the Plan, the Awards granted under it and the shares of Common Stock issued pursuant to it. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">B. </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">No shares of Common Stock or other assets shall be issued or delivered under the Plan unless and until there shall have been compliance with all applicable requirements of applicable securities laws, including the filing and effectiveness of the Form S-8 registration statement for the shares of Common Stock issuable under the Plan, and all applicable listing requirements of any stock exchange (or the Nasdaq Global Market, if applicable) on which Common Stock is then listed for trading.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:11pt;">C.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">All stock certificates delivered pursuant to the Plan are subject to any stop-transfer orders and other restrictions as the Plan Administrator deems necessary or advisable to comply with federal, state, or foreign jurisdiction, securities or other laws, rules and regulations and the rules of any national securities exchange or automated quotation system on which the Stock is listed, quoted, or traded.  The Plan Administrator may place legends on any stock certificate to reference restrictions applicable to the Common Stock.  In addition to the terms and conditions provided herein, the Board may require that an Optionee or Participant make such reasonable covenants, agreements, and representations as the Board, in its discretion, deems advisable in order to comply with any such laws, regulations, or requirements. The Plan Administrator shall have the right to require any Optionee or Participant to comply with any timing or other restrictions with respect to the settlement or exercise of any Award, including a window-period limitation, as may be imposed in the discretion of the Plan Administrator.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:11pt;">D.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">Notwithstanding any other provision of the Plan, unless otherwise determined by the Plan Administrator or required by any applicable law, rule or regulation, the Corporation shall not deliver to any Optionee or Participant certificates evidencing shares of Common Stock issued in connection with any award and instead such shares of Common Stock shall be recorded in the books of the Corporation (or, as applicable, its transfer agent or stock plan administrator).</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">E.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">In the event that the Corporation establishes, for itself or using the services of a third party, an automated system for the documentation, granting or exercise of Awards, such as a system using an internet website or interactive voice response, then the paperless documentation, granting or exercise of Awards by an Optionee or a Participant may be permitted through the use of such an automated system.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">VI.  </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">NO EMPLOYMENT/SERVICE RIGHTS</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">Nothing in the Plan shall confer upon the Optionee or the Participant any right to continue in Service for any period of specific duration or interfere with or otherwise restrict in any way the rights of the Corporation (or </font></div><div><br></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ligand Pharmaceuticals Incorporated 2019 Proxy Statement </font><font style="font-family:Wingdings;font-size:8pt;">l</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">79</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">any Parent or Subsidiary employing or retaining such person) or of the Optionee or the Participant, which rights are hereby expressly reserved by each, to terminate such person&#8217;s Service at any time for any reason, with or without cause.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">VII.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">COMPLIANCE WITH SECTION 409A OF THE CODE</font><font style="font-family:inherit;font-size:11pt;">&#32;&#32;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:11pt;">To the extent that the Plan Administrator determines that any Award granted under the Plan is subject to Section 409A of the Code, the agreement evidencing such Award shall incorporate the terms and conditions required by Section 409A of the Code.  To the extent applicable, the Plan and Award agreements shall be interpreted in accordance with Section 409A of the Code and Department of Treasury regulations and other interpretive guidance issued thereunder, including without limitation any such regulations or other guidance that may be issued after the adoption of the Plan.  Notwithstanding any provision of the Plan to the contrary, in the event that following the adoption of the Plan the Plan Administrator determines that any Award may be subject to Section 409A of the Code and related Department of Treasury guidance (including such Department of Treasury guidance as may be issued after the adoption of the Plan), the Plan Administrator may adopt such amendments to the Plan and the applicable Award agreement or adopt other policies and procedures (including amendments, policies and procedures with retroactive effect), or take any other actions, that the Plan Administrator determines are necessary or appropriate to (a) exempt the Award from Section 409A of the Code and/or preserve the intended tax treatment of the benefits provided with respect to the Award, or (b) comply with the requirements of Section 409A of the Code and related Department of Treasury guidance.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">VIII.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">FORFEITURE AND CLAW-BACK PROVISIONS</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">A. </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">Pursuant to its general authority to determine the terms and conditions applicable to Awards under the Plan, the Plan Administrator shall have the right to provide, in the terms of Awards made under the Plan, or to require a participant to agree by separate written or electronic instrument, that: (1) any proceeds, gains or other economic benefit actually or constructively received by the participant upon any receipt or exercise of the Award, or upon the receipt or resale of any shares underlying the Award, must be paid to the Corporation, and (2) the Award shall terminate and any unexercised portion of the Award (whether or not vested) shall be forfeited, if (i) a termination of Service occurs prior to a specified date, or within a specified time period following receipt or exercise of the Award, (ii) the participant at any time, or during a specified time period, engages in any activity in competition with the Corporation, or which is inimical, contrary or harmful to the interests of the Corporation, as further defined by the Plan Administrator or (iii) the participant incurs a termination of Service for Misconduct; and</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">B. </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">All Awards (including any proceeds, gains or other economic benefit actually or constructively received by a participant upon any receipt or exercise of any Award or upon the receipt or resale of any shares underlying the Award) shall be subject to the applicable provisions of any claw-back policy implemented by the Corporation, whether implemented prior to or after the grant of such Award, including without limitation, any claw-back policy adopted to comply with the requirements of applicable law, including without limitation, the Dodd-Frank Wall Street Reform and Consumer Protection Act and any rules or regulations promulgated thereunder, to the extent set forth in such claw-back policy and/or in the applicable Award agreement.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ligand Pharmaceuticals Incorporated 2019 Proxy Statement </font><font style="font-family:Wingdings;font-size:8pt;">l</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">80</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">APPENDIX</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:11pt;">The following definitions shall be in effect under the Plan: </font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:11pt;">A. </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">AWARD shall mean an option, stock issuance award, stock appreciation right award, restricted stock unit award or dividend equivalent award granted pursuant to the Plan.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">B. </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">BOARD shall mean the Corporation&#8217;s Board of Directors. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">C. </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">CHANGE IN CONTROL shall mean a change in ownership or control of the Corporation effected through any of the following transactions: </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">(i) </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">a merger, consolidation or other reorganization approved by the Corporation&#8217;s stockholders, unless securities representing more than fifty percent (50%) of the total combined voting power of the voting securities of the successor corporation are immediately thereafter beneficially owned, directly or indirectly and in substantially the same proportion, by the persons who beneficially owned the Corporation&#8217;s outstanding voting securities immediately prior to such transaction, or </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">(ii) </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">the sale, transfer or other disposition of all or substantially all of the Corporation&#8217;s assets in complete liquidation or dissolution of the Corporation, or</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">(iii) </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">the acquisition, directly or indirectly by any person or related group of persons (other than the Corporation or a person that directly or indirectly controls, is controlled by, or is under common control with, the Corporation), of beneficial ownership (within the meaning of Rule 13d-3 of the 1934 Act) of securities possessing more than fifty percent (50%) of the total combined voting power of the Corporation&#8217;s outstanding securities pursuant to a tender or exchange offer made directly to the Corporation&#8217;s stockholders. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:11pt;">D. </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">CODE shall mean the Internal Revenue Code of 1986, as amended. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">E. </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">COMMON STOCK shall mean the Corporation&#8217;s common stock. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">F. </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">CORPORATION shall mean Ligand Pharmaceuticals Incorporated, a Delaware corporation, and any corporate successor to all or substantially all of the assets or voting stock of Ligand Pharmaceuticals Incorporated which shall by appropriate action adopt the Plan.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">G. </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">DISCRETIONARY OPTION GRANT PROGRAM shall mean the discretionary option grant program in effect under Article Two of the Plan. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;H. </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">EMPLOYEE shall mean an individual who is in the employ of the Corporation (or any Parent or Subsidiary), subject to the control and direction of the employer entity as to both the work to be performed and the manner and method of performance.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">I. </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">EXERCISE DATE shall mean the date on which the Corporation shall have received written notice of the option exercise.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">J. </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">FAIR MARKET VALUE per share of Common Stock on any relevant date shall be determined in accordance with the following provisions: </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">(i) </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">If the Common Stock is at the time traded on the Nasdaq Global Market, then the Fair Market Value shall be the closing selling price per share of Common Stock on the date in question, as such price is       reported by the National Association of Securities Dealers on the Nasdaq Global Market and published in The Wall Street Journal. If there is no closing selling price for the Common Stock on the date in question, then the Fair Market Value shall be the closing selling price on the last preceding date for which such quotation exists.</font></div><div><br></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ligand Pharmaceuticals Incorporated 2019 Proxy Statement </font><font style="font-family:Wingdings;font-size:8pt;">l</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">81</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">(ii) </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">If the Common Stock is at the time listed on any Stock Exchange, then the Fair Market Value shall be the closing selling price per share of Common Stock on the date in question on the Stock Exchange     determined by the Plan Administrator to be the primary market for the Common Stock, as such price is officially quoted in the composite tape of transactions on such exchange and published in The Wall Street Journal. If there is no closing selling price for the Common Stock on the date in question, then the Fair Market Value shall be the closing selling price on the last preceding date for which such quotation exists. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">K. </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">Full Value Award shall mean any Award other than an option or a stock appreciation right and that is settled by the issuance of shares of Common Stock.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">L.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">HOSTILE TAKE-OVER shall mean a change in ownership or control of the Corporation effected through either of the following transactions: </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">(i) </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">a change in the composition of the Board over a period of thirty-six (36) consecutive months or less such that a majority of the Board members ceases, by reason of one or more contested elections for Board membership, to be comprised of individuals who either (A) have been Board members continuously since the beginning of such period or (B) have been elected or nominated for election as Board members during such period by at least a majority of the Board members described in clause (A) who were still in office at the time the Board approved such election or nomination, or</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">(ii)  </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">a Hostile Tender-Offer.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">M. </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">HOSTILE TENDER-OFFER shall mean the acquisition, directly or indirectly, by any person or related group of persons (other than the Corporation or a person that directly or indirectly controls, is controlled by, or is under common control with, the Corporation) of beneficial ownership (within the meaning of Rule 13d-3 of the 1934 Act) of securities possessing more than fifty percent (50%) of the total combined voting power of the Corporation&#8217;s outstanding securities pursuant to a tender or exchange offer made directly to the Corporation&#8217;s stockholders which the Board does not recommend such stockholders to accept.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">N. </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">INCENTIVE OPTION shall mean an option which satisfies the requirements of Code Section 422.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">O. </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">INVOLUNTARY TERMINATION shall mean the termination of the Service of any individual which occurs by reason of:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">(i) </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">such individual&#8217;s involuntary dismissal or discharge by the Corporation for reasons other than Misconduct, or</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">(ii) </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">such individual&#8217;s voluntary resignation following (A) a change in his or her position with the Corporation which materially reduces his or her duties and responsibilities or the level of management to which he or she reports, (B) a reduction in his or her level of compensation (including base salary, fringe benefits and target bonus under any corporate-performance based bonus or incentive programs) by more than fifteen percent (15%) or (C) a relocation of such individual&#8217;s place of employment by more than fifty (50) miles, provided and only if such change, reduction or relocation is effected by the Corporation without the individual&#8217;s consent.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">P. </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">MISCONDUCT shall mean the commission of any act of fraud, embezzlement or dishonesty by the Optionee or Participant, any unauthorized use or disclosure by such person of confidential information or trade secrets of the Corporation (or any Parent or Subsidiary), or any other intentional misconduct by such person adversely affecting the business or affairs of the Corporation (or any Parent or Subsidiary) in a material manner. The foregoing definition shall not in any way preclude or restrict the right of the Corporation (or any Parent or Subsidiary) to discharge or dismiss any Optionee, Participant or other person in the Service of the Corporation (or </font></div><div><br></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ligand Pharmaceuticals Incorporated 2019 Proxy Statement </font><font style="font-family:Wingdings;font-size:8pt;">l</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">82</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">any Parent or Subsidiary) for any other acts or omissions, but such other acts or omissions shall not be deemed, for purposes of the Plan, to constitute grounds for termination for Misconduct. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">Q. </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">1934 ACT shall mean the Securities Exchange Act of 1934, as amended.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">R. </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">NON-STATUTORY OPTION shall mean an option not intended to satisfy the requirements of Code Section 422.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">S. </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">OPTIONEE shall mean any person to whom an option is granted under the Discretionary Option Grant Program.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:11pt;">T.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">OTHER STOCK AWARD PROGRAM shall mean the discretionary stock award grant program in effect under Article Four of the Plan</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">U. </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">PARENT shall mean any corporation (other than the Corporation) in an unbroken chain of corporations ending with the Corporation, provided each corporation in the unbroken chain (other than the Corporation) owns, at the time of the determination, stock possessing fifty percent (50%) or more of the total combined voting power of all classes of stock in one of the other corporations in such chain.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">V. </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">PARTICIPANT shall mean any person who is issued an Award under the Plan other than an option.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:11pt;">W.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">Performance Criteria shall mean the criteria that the Primary Committee selects for purposes of establishing the Performance Goal or Performance Goals for a Participant for a Performance Period, determined as follows:  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:11pt;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">The Performance Criteria that will be used to establish Performance Goals shall be determined by the Plan Administrator.  Such criteria may include, but are not limited to, one or more of the following: net earnings (either before or after interest, taxes, depreciation and amortization), gross or net sales or revenue, adjusted net income, operating earnings or profit, cash flow (including, but not limited to, operating cash flow and free cash flow), return on assets, return on capital, return on stockholders&#8217; equity, total stockholder return, return on sales, gross or net profit or operating margin, expenses, working capital, earnings per share, adjusted earnings per share, price per share of Stock, regulatory body approval for commercialization of a product, implementation or completion of critical projects, and market share, any of which may be measured either in absolute terms or as compared to any incremental increase or decrease or as compared to results of a peer group or to market performance indicators or indices.    </font></div><div style="line-height:120%;text-align:left;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:11pt;">(ii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">The Plan Administrator may, in its sole discretion, provide that one or more adjustments shall be made to one or more of the Performance Goals.  Such adjustments may include, but are not limited to, one or more of the following: items related to a change in accounting principle, items relating to financing activities, expenses for restructuring or productivity initiatives, other non-operating items, items related to acquisitions, items attributable to the business operations of any entity acquired by us during the performance period, items related to the disposal of a business or segment of a business, items related to discontinued operations that do not qualify as a segment of a business under applicable accounting standards, items attributable to any stock dividend, stock split, combination or exchange of stock occurring during the performance period, other items of significant income or expense which are determined to be appropriate adjustments, items relating to unusual or extraordinary corporate transactions, events or developments, items related to amortization of acquired intangible assets, items that are outside the scope of our core, on-going business activities, items related to acquired in-process research and development, items relating to changes in tax laws, items relating to major licensing or partnership arrangements, items relating to asset impairment charges, items relating to gains or losses for litigation, arbitration and contractual settlements, or items relating to any other unusual or nonrecurring events or changes in applicable laws, accounting principles or business conditions.  </font></div><div><br></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ligand Pharmaceuticals Incorporated 2019 Proxy Statement </font><font style="font-family:Wingdings;font-size:8pt;">l</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">83</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:11pt;">X.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">Performance Goals shall mean, for a Performance Period, the goals established in writing by the Plan Administrator for the Performance Period. Performance Goals may be expressed in terms of overall Corporation performance or the performance of a division, business unit, or an individual.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:11pt;">Y.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">Performance Period shall mean the one or more periods of time, which may be of varying and overlapping durations, as the Plan Administrator may select, over which the attainment of one or more Performance Goals will be measured for the purpose of determining a Participant&#8217;s right to, and the payment of, an Award.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">Z. </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">PERMANENT DISABILITY OR PERMANENTLY DISABLED shall mean the inability of the Optionee or the Participant to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment expected to result in death or to be of continuous duration of twelve (12) months or more. However, solely for purposes of the Awards granted to non-employee Board members, Permanent Disability or Permanently Disabled shall mean the inability of the non-employee Board member to perform his or her usual duties as a Board member by reason of any medically determinable physical or mental impairment expected to result in death or to be of continuous duration of twelve (12) months or more. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">AA. </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">PLAN shall mean the Corporation&#8217;s 2002 Stock Incentive Plan, as amended and restated and set forth in this document.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:11pt;">BB. </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">PLAN ADMINISTRATOR shall mean the particular entity, whether the Primary Committee, the Board or the Secondary Committee, which is authorized to administer the Plan with respect to one or more classes of eligible persons, to the extent such entity is carrying out its administrative functions under those programs with respect to the persons under its jurisdiction.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;CC. </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">PRIMARY COMMITTEE shall mean the committee of two (2) or more non-employee Board members appointed by the Board to administer the Discretionary Option Grant and Stock Issuance Programs with respect to Section 16 Insiders.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:11pt;">DD.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">Qualified Performance-Based Compensation means any compensation granted under the Plan prior to November 2, 2017 that is intended to qualify as &#8220;qualified performance-based compensation&#8221; as described in Section&#160;162(m)(4)(C) of the Code prior to its repeal. </font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">EE. </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">RESTATEMENT EFFECTIVE DATE shall mean the date the Plan shall become effective and shall be coincident with the approval of the Plan at the 2019 Annual Meeting of Stockholders scheduled to take place on June 6, 2019.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:11pt;">FF.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">SECONDARY COMMITTEE shall mean a committee of one or more Board members appointed by the Board to administer the Discretionary Option Grant, Stock Issuance and Other Stock Award Programs with respect to eligible persons other than Section 16 Insiders.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">GG. </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">SECTION 16 INSIDER shall mean an officer or director of the Corporation subject to the short-swing profit liabilities of Section 16 of the 1934 Act.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:11pt;">HH. </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">SERVICE shall mean the performance of services for the Corporation (or any Parent or Subsidiary) by a person in the capacity of an Employee, a non-employee member of the board of directors or a consultant or independent advisor, except to the extent otherwise specifically provided in the documents evidencing the option grant or stock issuance.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">II. </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">STOCK EXCHANGE shall mean either the American Stock Exchange or the New York Stock Exchange.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ligand Pharmaceuticals Incorporated 2019 Proxy Statement </font><font style="font-family:Wingdings;font-size:8pt;">l</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">84</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">JJ. </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">STOCK ISSUANCE AGREEMENT shall mean the agreement entered into by the Corporation and the Participant at the time of issuance of shares of Common Stock under the Stock Issuance Program.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">KK. </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">STOCK ISSUANCE PROGRAM shall mean the stock issuance program in effect under Article Three of the Plan.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">LL. </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">SUBSIDIARY shall mean any corporation (other than the Corporation) in an unbroken chain of corporations beginning with the Corporation, provided each corporation (other than the last corporation) in the unbroken chain owns, at the time of the determination, stock possessing fifty percent (50%) or more of the total combined voting power of all classes of stock in one of the other corporations in such chain.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">MM. </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">10% STOCKHOLDER shall mean the owner of stock (as determined under Code Section 424(d)) possessing more than ten percent (10%) of the total combined voting power of all classes of stock of the Corporation (or any Parent or Subsidiary).</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">NN. </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">WITHHOLDING TAXES shall mean the applicable income and employment withholding taxes to which the holder of Non-Statutory Options or unvested shares of Common Stock may become subject in connection with the exercise of those options or the vesting of those shares.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ligand Pharmaceuticals Incorporated 2019 Proxy Statement </font><font style="font-family:Wingdings;font-size:8pt;">l</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">85</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="sb6e62536bc644ccb9ea4178e9b4c6808"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:18pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:top;background-color:#727272;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:5px;text-align:left;padding-left:9px;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;color:#ffffff;font-weight:bold;">Appendix B - Amendment and Restatement of the Ligand Pharmaceuticals Incorporated Employee Stock Purchase Plan</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">LIGAND PHARMACEUTICALS INCORPORATED </font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EMPLOYEE STOCK PURCHASE PLAN </font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(AS AMENDED AND RESTATED EFFECTIVE JUNE 6, 2019) </font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">I. </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PURPOSE OF THE PLAN </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This Employee Stock Purchase Plan is intended to promote the interests of Ligand Pharmaceuticals Incorporated, a Delaware corporation, by providing eligible employees with the opportunity to acquire a proprietary interest in the Corporation through participation in a payroll deduction-based employee stock purchase plan designed to qualify under Section&#160;423 of the Code. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Capitalized terms herein shall have the meanings assigned to such terms in the attached Appendix. </font></div><div style="line-height:120%;padding-top:18px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">II. </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ADMINISTRATION OF THE PLAN </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Plan Administrator shall have full authority to interpret and construe any provision of the Plan and to adopt such rules and regulations for administering the Plan as it may deem necessary in order to comply with the requirements of Code Section&#160;423. Decisions of the Plan Administrator shall be final and binding on all parties having an interest in the Plan. </font></div><div style="line-height:120%;padding-top:18px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">III. </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">STOCK SUBJECT TO PLAN </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A. &#160;&#160;&#160;&#160;The stock purchasable under the Plan shall be shares of authorized but unissued or reacquired Common Stock, including shares of Common Stock purchased on the open market. The aggregate number of shares of Common Stock reserved for issuance over the term of the Plan shall be 218,374 shares. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">B. &#160;&#160;&#160;&#160;Should any change be made to the Common Stock by reason of any stock split, stock dividend, recapitalization, combination of shares, exchange of shares or other change affecting the outstanding Common Stock as a class without the Corporation&#8217;s receipt of consideration, appropriate adjustments shall be made to (i)&#160;the maximum number and class of securities issuable under the Plan, (ii)&#160;the maximum number and class of securities purchasable per Participant on any one Purchase Date and (iii)&#160;the number and class of securities and the price per share in effect under each outstanding purchase right in order to prevent the dilution or enlargement of benefits thereunder. </font></div><div style="line-height:120%;padding-top:18px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">IV. </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">OFFERING PERIODS </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A. &#160;&#160;&#160;&#160;Shares of Common Stock shall be offered for purchase under the Plan through a series of successive Offering Periods, which shall continue until such time as (i)&#160;the maximum number of shares of Common Stock available for issuance under the Plan shall have been purchased (ii)&#160;the Plan Administrator shall have terminated the Offering Period as provided below or (iii)&#160;the Plan shall have been sooner terminated. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">B. &#160;&#160;&#160;&#160;Each Offering Period shall be six (6)&#160;months in duration, commencing on each January&#160;1 and July&#160;1 during the term of the Plan. The Plan Administrator shall have the power to change the duration of Offering Periods (including the commencement dates thereof) with respect to future offerings (but in no event may the duration of any Offering Period under the Plan exceed twenty-four (24)&#160;months), or to provide that purchases shall be made more frequently under the Plan during each Offering Period, without stockholder approval pursuant to an action taken prior to the commencement of the first Offering Period to be affected thereafter. </font></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">C. &#160;&#160;&#160;&#160;The Plan Administrator may in its discretion terminate any ongoing Offering Period when, in the sole discretion of the Plan Administrator, such termination would be in the best interests of the Corporation or its stockholders, including, without limitation, to assure that the Corporation will not recognize, for financial reporting purposes, any compensation expense in connection with the shares of Common Stock offered for purchase under the Plan. Upon such early termination, a new Offering Period will begin at the time designated by the Plan Administrator. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ligand Pharmaceuticals Incorporated 2019 Proxy Statement </font><font style="font-family:Wingdings;font-size:8pt;">l</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">86</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:18px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">V. </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ELIGIBILITY </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A. &#160;&#160;&#160;&#160;Each individual who is an Eligible Employee on the Entry Date of any Offering Period under the Plan may enter that Offering Period on such Entry Date, provided he or she remains an Eligible Employee. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">B. &#160;&#160;&#160;&#160;Each Eligible Employee must complete the enrollment forms prescribed by the Plan Administrator (including a stock purchase agreement and a payroll deduction authorization or such other forms as the Plan Administrator may determine) and file such forms with the Plan Administrator (or its designate) on or before his or her scheduled Entry Date. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">C. &#160;&#160;&#160;&#160;A Participant&#8217;s completion of the enrollment forms will enroll such Participant in the Plan for each successive Offering Period on the terms contained therein until the Participant either submits new enrollment forms, withdraws from participation under the Plan or otherwise becomes ineligible to participate in the Plan. </font></div><div style="line-height:120%;padding-top:18px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">VI. </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PAYROLL DEDUCTIONS </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A. &#160;&#160;&#160;&#160;The payroll deduction authorized by the Participant for purposes of acquiring shares of Common Stock during an Offering Period may be any multiple of one percent (1%)&#160;of the Cash Earnings paid to the Participant during each Offering Period, up to a maximum of ten percent (10%). The deduction rate so authorized shall continue in effect throughout the Offering Period, except to the extent such rate is changed in accordance with the following guidelines: </font></div><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:32px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(i) &#160;&#160;&#160;&#160;The Participant may, at any time during an Offering Period, reduce his or her rate of payroll deduction (including to zero (0%)) to become effective as soon as possible after filing the appropriate form with the Plan Administrator. The Participant may not, however, effect more than one (1)&#160;such reduction per Offering Period. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:32px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(ii) &#160;&#160;&#160;&#160;The Participant may, prior to the commencement of any new Offering Period, increase the rate of his or her payroll deduction by filing the appropriate form with the Plan Administrator. The new rate (which may not exceed the ten percent (10%)&#160;maximum) shall become effective on the start date of the first Offering Period following the filing of such form. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">B. &#160;&#160;&#160;&#160;Payroll deductions shall begin on the first pay day administratively feasible following the Participant&#8217;s Entry Date into the Offering Period and shall (unless sooner terminated by the Participant) continue through the pay day ending with or immediately prior to the last day of that Offering Period. The amounts so collected shall be credited to the Participant&#8217;s book account under the Plan, but no interest shall be paid on the balance from time to time outstanding in such account. The amounts collected from the Participant shall not be required to be held in any segregated account or trust fund and may be commingled with the general assets of the Corporation and used by the Corporation for general corporate purposes. </font></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">C. &#160;&#160;&#160;&#160;Payroll deductions shall automatically cease upon the termination of the Participant&#8217;s purchase right in accordance with the provisions of the Plan. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">D. &#160;&#160;&#160;&#160;Subject to the terms and conditions contained herein, the Participant&#8217;s acquisition of Common Stock under the Plan on any Purchase Date shall neither limit nor require the Participant&#8217;s acquisition of Common Stock on any subsequent Purchase Date, whether within the same or a different Offering Period. </font></div><div style="line-height:120%;padding-top:18px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">VII. </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PURCHASE RIGHTS </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A. &#160;&#160;&#160;&#160;GRANT OF PURCHASE RIGHTS. A Participant shall be granted a separate purchase right for each Offering Period in which he or she participates. The purchase right shall be granted on the Participant&#8217;s Entry Date into the Offering Period and shall provide the Participant with the right to purchase shares of Common Stock, in a series of one or more installments over the remainder of such Offering Period, upon the terms set forth below. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under no circumstances shall purchase rights be granted under the Plan to any Eligible Employee if such individual would, immediately after the grant, own (within the meaning of Code Section&#160;424(d)) or hold outstanding options or other rights to purchase, stock possessing five percent (5%)&#160;or more of the total combined voting power or value of all classes of stock of the Corporation or any Corporate Affiliate. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">B. &#160;&#160;&#160;&#160;EXERCISE OF THE PURCHASE RIGHT. Each purchase right shall be automatically exercised in one or more installments on each successive Purchase Date, and shares of Common Stock shall accordingly be purchased on behalf of each Participant on each such Purchase Date. The purchase shall be effected by applying the Participant&#8217;s payroll </font></div><div><br></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ligand Pharmaceuticals Incorporated 2019 Proxy Statement </font><font style="font-family:Wingdings;font-size:8pt;">l</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">87</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">deductions for the Offering Period ending on such Purchase Date to the purchase of whole shares of Common Stock at the purchase price in effect for the Participant for that Purchase Date. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">C. &#160;&#160;&#160;&#160;PURCHASE PRICE. The purchase price per share at which Common Stock will be purchased on the Participant&#8217;s behalf on each Purchase Date within the Offering Period shall be equal to eighty-five percent (85%)&#160;of the lower of (i)&#160;the Fair Market Value per share of Common Stock on the Entry Date for that Offering Period or (ii)&#160;the Fair Market Value per share of Common Stock on that Purchase Date. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">D. &#160;&#160;&#160;&#160;NUMBER OF PURCHASABLE SHARES. The number of shares of Common Stock purchasable by a Participant on each Purchase Date during the Offering Period shall be the number of whole shares obtained by dividing the amount collected from the Participant through payroll deductions during the Offering Period by the purchase price in effect for the Participant for that Purchase Date. However, the maximum number of shares of Common Stock purchasable per Participant during any Offering Period shall not exceed 1,250 shares, subject to periodic adjustments in the event of certain changes in the Corporation&#8217;s capitalization as contemplated in Section III.B. above. However, the Plan Administrator shall have the discretionary authority, exercisable prior to the start of any Offering Period under the Plan, to increase or decrease the limitations to be in effect for the number of shares purchasable per Participant and to establish limitations on the maximum number of shares that may be purchased in total by all Participants on each Purchase Date during that Offering Period. </font></div><div style="line-height:120%;text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">E. &#160;&#160;&#160;&#160;EXCESS PAYROLL DEDUCTIONS. Any payroll deductions not applied to the purchase of shares of Common Stock on any Purchase Date because they are not sufficient to purchase a whole share of Common Stock shall be held for the purchase of Common Stock on the next Purchase Date. However, any payroll deductions not applied to the purchase of Common Stock by reason of the limitation on the maximum number of shares purchasable per Participant or in total by all Participants on the Purchase Date shall be promptly refunded. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F. &#160;&#160;&#160;&#160;SUSPENSION OF PAYROLL DEDUCTIONS. In the event that a Participant is, by reason of the accrual limitations in Article VIII, precluded from purchasing additional shares of Common Stock on one or more Purchase Dates during the Offering Period in which he or she is enrolled, then no further payroll deductions shall be collected from such Participant with respect to those Purchase Dates. The suspension of such deductions shall not terminate the Participant&#8217;s purchase right for the Offering Period in which he or she is enrolled, and payroll deductions shall automatically resume on behalf of such Participant once he or she is again able to purchase shares during that Offering Period in compliance with the accrual limitations of Article VIII. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">G. &#160;&#160;&#160;&#160;TERMINATION OF PURCHASE RIGHT. The following provisions shall govern the termination of outstanding purchase rights: </font></div><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:32px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(i) &#160;&#160;&#160;&#160;A Participant may, at any time prior to the next scheduled Purchase Date in the Offering Period, terminate his or her outstanding purchase right by filing the appropriate form with the Plan Administrator (or its designate), and no further payroll deductions shall be collected from the Participant with respect to the terminated purchase right. Any payroll deductions collected during the Offering Period in which such termination occurs shall be refunded as soon as possible. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:32px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(ii) &#160;&#160;&#160;&#160;The termination of such purchase right shall be irrevocable, and the Participant may not subsequently rejoin the Offering Period for which the terminated purchase right was granted. In order to resume participation in any subsequent Offering Period, such Participant must re-enroll in the Plan (by making a timely filing of the prescribed enrollment forms) on or before his or her scheduled Entry Date into that Offering Period. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:32px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(iii) &#160;&#160;&#160;&#160;Should the Participant cease to remain an Eligible Employee for any reason (including death, disability or change in status) while his or her purchase right remains outstanding, then that purchase right shall immediately terminate, and all of the Participant&#8217;s payroll deductions for the Offering Period in which the purchase right so terminates shall be immediately refunded. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:32px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(iv)&#160;&#160;&#160;&#160;If a leave of absence is unapproved or fails to meet the requirements of Treasury Regulation Section&#160;1.421-7(h)(2), the Participant will cease automatically to participate in the Plan. In such event, the Corporation will automatically cease to deduct the Participant&#8217;s payroll under the Plan and will pay to the Participant his or her total payroll deductions for the Offering Period, in cash in one lump sum (without interest), as soon as practicable after the participant ceases to participate in the Plan. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:32px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During a leave of absence approved by the Corporation or a Corporate Affiliate and meeting the requirements of Treasury Regulation Section&#160;1.421-7(h)(2), a Participant may continue to participate in the Plan by making cash payments to the Corporation on each pay day equal to the amount of the Participant&#8217;s payroll deductions </font></div><div><br></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ligand Pharmaceuticals Incorporated 2019 Proxy Statement </font><font style="font-family:Wingdings;font-size:8pt;">l</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">88</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">under the Plan for the pay day immediately preceding the first day of such Participant&#8217;s leave of absence. The payroll deductions of an individual who returns to active employment following an approved leave of absence or a leave of absence meeting the requirements of Treasury Regulation Section&#160;1.421-7(h)(2) shall automatically resume at the rate in effect at the time such leave began, unless the Participant withdrew from the Plan during his or her leave of absence. If a leave of absence is unapproved or fails to meet the requirements of Treasury Regulation Section&#160;1.421-7(h)(2), the Participant will cease automatically to participate in the Plan and all of the Participant&#8217;s payroll deductions for the Offering Period in which the purchase right so terminates shall be immediately refunded. An individual who returns to active employment following a leave of absence that was unapproved or fails to meet the requirements of Treasury Regulation Section&#160;1.421-7(h)(2) will be treated as a new employee for purposes of subsequent participation in the Plan and must accordingly re-enroll in the Plan (by making a timely filing of the prescribed enrollment forms). </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">H. &#160;&#160;&#160;&#160;CHANGE IN CONTROL. Each outstanding purchase right shall automatically be exercised, immediately prior to the effective date of any Change in Control (or such other date prior to the occurrence of the Change in Control as is determined by the Plan Administrator), by applying the payroll deductions of each Participant for the Offering Period in which such Change in Control occurs to the purchase of whole shares of Common Stock at a purchase price per share equal to eighty-five percent (85%)&#160;of the lower of (i)&#160;the Fair Market Value per share of Common Stock on the Participant&#8217;s Entry Date into the Offering Period in which such Change in Control occurs or (ii)&#160;the Fair Market Value per share of Common Stock on such date. However, the applicable limitation on the number of shares of Common Stock purchasable per Participant shall continue to apply to any such purchase, but not the limitation applicable to the maximum number of shares of Common Stock purchasable in total by all Participants on any one Purchase Date, as may have been established by the Plan Administrator pursuant to Section VII.D. above. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Corporation shall use its best efforts to provide at least ten (10)&#160;days&#8217; prior written notice of the occurrence of any Change in Control, and Participants shall, following the receipt of such notice, have the right to terminate their outstanding purchase rights prior to the effective date of the Change in Control. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I. &#160;&#160;&#160;&#160;PRORATION OF PURCHASE RIGHTS. Should the total number of shares of Common Stock to be purchased pursuant to outstanding purchase rights on any particular date exceed the number of shares then available for issuance under the Plan, the Plan Administrator shall make a pro-rata allocation of the available shares on a uniform and nondiscriminatory basis, and the payroll deductions of each Participant, to the extent in excess of the aggregate purchase price payable for the Common Stock pro-rated to such individual, shall be refunded. In addition, the Plan Administrator may limit the total number of shares to be issued on any Purchase Date when, in the sole discretion of the Plan Administrator, such limitation would be in the best interests of the Corporation or its stockholders, including without limitation to limit or eliminate any compensation expense to the Corporation in connection&#160;with&#160;the shares of Common Stock to be issued under the Plan. In the event of such a limitation, the Plan Administrator shall make&#160;a&#160;pro-rata allocation of the available shares and any appropriate refund as provided above. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">J. &#160;&#160;&#160;&#160;ASSIGNABILITY. The purchase right shall be exercisable only by the Participant and shall not be assignable or transferable by the Participant. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">K. &#160;&#160;&#160;&#160;STOCKHOLDER RIGHTS. A Participant shall have no stockholder rights with respect to the shares subject to his or her outstanding purchase right until the shares are purchased on the Participant&#8217;s behalf in accordance with the provisions of the Plan and the Participant has become a holder of record of the purchased shares. </font></div><div style="line-height:120%;text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">VIII. </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ACCRUAL LIMITATIONS </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A. &#160;&#160;&#160;&#160;No Participant shall be entitled to accrue rights to acquire Common Stock pursuant to any purchase right outstanding under this Plan if and to the extent such accrual, when aggregated with (i)&#160;rights to purchase Common Stock accrued under any other purchase right granted under this Plan and (ii)&#160;similar rights accrued under other employee stock purchase plans (within the meaning of Code Section&#160;423)) of the Corporation or any Corporate Affiliate, would permit such Participant's rights to purchase stock of the Corporation or any Corporate Affiliate to accrue at a rate which exceeds $25,000 of the fair market value of such stock (determined as of the first day of the Offering Period during which such rights are granted) for each calendar year in which such rights are outstanding at any time.  This limitation shall be applied in accordance with Section&#160;423(b)(8) of the Code and the Treasury Regulations thereunder. </font></div><div><br></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ligand Pharmaceuticals Incorporated 2019 Proxy Statement </font><font style="font-family:Wingdings;font-size:8pt;">l</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">89</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">B. &#160;&#160;&#160;&#160;If by reason of such accrual limitations, any purchase right of a Participant does not accrue for a particular Offering Period, then the payroll deductions that the Participant made during that Offering Period with respect to such purchase right shall be promptly refunded. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">C. &#160;&#160;&#160;&#160;In the event there is any conflict between the provisions of this Article and one or more provisions of the Plan or any instrument issued thereunder, the provisions of this Article shall be controlling. </font></div><div style="line-height:120%;padding-top:18px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">IX. </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EFFECTIVE DATE AND TERM OF THE PLAN </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A. &#160;&#160;&#160;&#160;This Plan constitutes an amendment and restatement of the Ligand Pharmaceuticals Incorporated Employee Stock Purchase Plan most recently adopted by the Board on April 16, 2009, and approved by the Corporation's stockholders on May 29, 2009 (the "Existing Plan").  This amended and restated Plan was adopted by the Board on April&#160;16, 2019, and will become effective on the Restatement Effective Date. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">B. &#160;&#160;&#160;&#160;The Plan shall terminate upon such date as is determined by the Board in its sole discretion.  The Plan shall automatically be suspended on the date on which all shares available for issuance under the Plan shall have been sold pursuant to purchase rights exercised under the Plan pending approval of an increase in the number of shares available for issuance under the Plan. No further purchase rights shall be granted or exercised, and no further payroll deductions shall be collected, under the Plan following such termination. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">C.&#160;&#160;&#160;&#160;This amended and restated Plan shall be submitted for the approval of the Corporation's stockholders within 12 months after the date of the Board&#8217;s adoption of this amended and restated Plan.  If this amended and restated Plan is not approved by the Corporation's stockholders, this amended and restated Plan shall not become effective and the Existing Plan shall continue in full force and effect in accordance with its terms.</font></div><div style="line-height:120%;padding-top:18px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">X. </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">AMENDMENT OF THE PLAN </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A. &#160;&#160;&#160;&#160;The Board may alter, amend, suspend or terminate the Plan at any time. However, no such amendment, modification or termination may adversely affect any purchase rights outstanding under the Plan without the consent of the affected Plan participant if such Board action shall become effective prior to the close of the current Offering Period. However, the Plan may be amended or terminated immediately upon Board action, if and to the extent necessary to assure that the Corporation will not recognize, for financial reporting purposes, any compensation expense in connection with the shares of Common Stock offered for purchase under the Plan. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">B. &#160;&#160;&#160;&#160;In no event may the Board effect any of the following amendments or revisions to the Plan without the approval of the Corporation&#8217;s stockholders: (i)&#160;increase the number of shares of Common Stock issuable under the Plan, except for permissible adjustments in the event of certain changes in the Corporation&#8217;s capitalization, (ii)&#160;alter the purchase price formula so as to reduce the purchase price payable for the shares of Common Stock purchasable under the Plan to an amount less than 85% of the lower of (A)&#160;the Fair Market Value per share of Common Stock on the Entry Date for an Offering Period or (B)&#160;the Fair Market Value per share of Common Stock on the Purchase Date, whichever is lower, or (iii)&#160;modify the eligibility requirements for participation in the Plan. </font></div><div style="line-height:120%;padding-top:18px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">XI. </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">GENERAL PROVISIONS </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A. &#160;&#160;&#160;&#160;All costs and expenses incurred in the administration of the Plan shall be paid by the Corporation; however, each Plan Participant shall bear all costs and expenses incurred by such individual in the sale or other disposition of any shares purchased under the Plan. </font></div><div style="line-height:120%;text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">B. &#160;&#160;&#160;&#160;Nothing in the Plan shall confer upon the Participant any right to continue in the employ of the Corporation or any Corporate Affiliate for any period of specific duration or interfere with or otherwise restrict in any way the rights of the Corporation (or any Corporate Affiliate employing such person) or of the Participant, which rights are hereby expressly reserved by each, to terminate such person&#8217;s employment at any time for any reason, with or without cause. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">C. &#160;&#160;&#160;&#160;The provisions of the Plan shall be governed by the laws of the State of California without resort to that State&#8217;s conflict-of-laws rules. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">D. &#160;&#160;&#160;&#160;All Eligible Employees of the Corporation (or of any Corporate Affiliate) will have equal rights and privileges under this Plan so that this Plan qualifies as an &#8220;employee stock purchase plan&#8221; within the meaning of Section&#160;423 of the Code or applicable Treasury regulations thereunder. Any provision of this Plan that is inconsistent with Section&#160;423 or applicable Treasury regulations will, without further act or amendment by the Corporation, the Board or the Plan </font></div><div><br></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ligand Pharmaceuticals Incorporated 2019 Proxy Statement </font><font style="font-family:Wingdings;font-size:8pt;">l</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">90</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Administrator, be reformed to comply with the equal rights and privileges requirement of Section&#160;423 or applicable Treasury regulations. </font></div><div style="line-height:120%;text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ligand Pharmaceuticals Incorporated 2019 Proxy Statement </font><font style="font-family:Wingdings;font-size:8pt;">l</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">91</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">APPENDIX </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following definitions shall be in effect under the Plan: </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A. &#160;&#160;&#160;&#160;BOARD shall mean the Corporation&#8217;s Board of Directors. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">B. &#160;&#160;&#160;&#160;CASH EARNINGS shall mean (i)&#160;the regular base salary paid to a Participant by one or more Participating Companies during such individual&#8217;s period of participation in one or more Offering Periods under the Plan plus (ii)&#160;all overtime payments, bonuses, commissions, profit-sharing distributions and other incentive-type payments received during such period. Such Cash Earnings shall be calculated before deduction of (A)&#160;any income or employment tax withholdings or (B)&#160;any contributions made by the Participant to any Code Section&#160;401(k) salary deferral plan or any Code Section&#160;125 cafeteria benefit program now or hereafter established by the Corporation or any Corporate Affiliate. However, Cash Earnings shall NOT include any contributions made by the Corporation or any Corporate Affiliate on the Participant&#8217;s behalf to any employee benefit or welfare plan now or hereafter established (other than Code Section&#160;401(k) or Code Section&#160;125 contributions deducted from such Cash Earnings). </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">C. &#160;&#160;&#160;&#160;CHANGE IN CONTROL shall mean a change in ownership of the Corporation pursuant to any of the following transactions: </font></div><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:32px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(i) &#160;&#160;&#160;&#160;a merger, consolidation or other reorganization approved by the Corporation&#8217;s stockholders, UNLESS securities representing more than fifty percent (50%)&#160;of the total combined voting power of the voting securities of the successor corporation are immediately thereafter beneficially owned, directly or indirectly and in substantially the same proportion, by the persons who beneficially owned the Corporation&#8217;s outstanding voting securities immediately prior to such transaction, or </font></div><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:32px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(ii) &#160;&#160;&#160;&#160;the sale, transfer or other disposition of all or substantially all of the assets of the Corporation in complete liquidation or dissolution of the Corporation, or </font></div><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:32px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(iii) &#160;&#160;&#160;&#160;the acquisition, directly or indirectly, by a person or related group of persons (other than the Corporation or a person that directly or indirectly controls, is controlled by or is under common control with the Corporation) of beneficial ownership (within the meaning of Rule 13d-3 of the 1934 Act) of securities possessing more than fifty percent (50%)&#160;of the total combined voting power of the Corporation&#8217;s outstanding securities pursuant to a tender or exchange offer made directly to the Corporation&#8217;s stockholders. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">D. &#160;&#160;&#160;&#160;CODE shall mean the Internal Revenue Code of 1986, as amended. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">E. &#160;&#160;&#160;&#160;COMMON STOCK shall mean the Corporation&#8217;s common stock. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F. &#160;&#160;&#160;&#160;CORPORATE AFFILIATE shall mean any parent or subsidiary corporation of the Corporation (as determined in accordance with Code Section&#160;423), whether now existing or subsequently established. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">G. &#160;&#160;&#160;&#160;CORPORATION shall mean Ligand Pharmaceuticals Incorporated, a Delaware corporation, and any corporate successor to all or substantially all of the assets or voting stock of Ligand Pharmaceuticals Incorporated that shall by appropriate action adopt the Plan. </font></div><div style="line-height:120%;text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">H. &#160;&#160;&#160;&#160;ELIGIBLE EMPLOYEE shall mean any person who is employed by a Participating Corporation on a basis under which he or she is regularly expected to render more than twenty (20)&#160;hours of service per week for more than five (5)&#160;months per calendar year for earnings considered wages under Code Section&#160;3401(a). For purposes of the Plan, the employment relationship shall be treated as continuing intact while the individual is on sick leave or other leave of absence approved by the Corporation or Corporate Affiliate and meeting the requirements of Treasury Regulation Section&#160;1.421-7(h)(2). Where the period of leave exceeds ninety (90)&#160;days and the individual&#8217;s right to reemployment is not provided either by statute or by contract, the employment relationship shall be deemed to have terminated on the ninety-first (91</font><font style="font-family:inherit;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">st</sup></font><font style="font-family:inherit;font-size:10pt;">)&#160;day of such leave. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I. &#160;&#160;&#160;&#160;ENTRY DATE shall mean the first day of each Offering Period. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">J. &#160;&#160;&#160;&#160;FAIR MARKET VALUE per share of Common Stock on any relevant date shall be determined as follows: If the Common Stock is at the time listed on any Stock Exchange, then the Fair Market Value shall be the closing selling price per share of Common Stock on the date in question on the Stock Exchange determined by the Plan Administrator to be the primary market for the Common Stock, as such price is officially quoted in the composite tape of transactions on such exchange and published in THE WALL STREET JOURNAL. If there is no closing selling price for the Common Stock on </font></div><div><br></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ligand Pharmaceuticals Incorporated 2019 Proxy Statement </font><font style="font-family:Wingdings;font-size:8pt;">l</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">92</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the date in question, then the Fair Market Value shall be the closing selling price on the last preceding date for which such quotation exists. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">K. &#160;&#160;&#160;&#160;1933 ACT shall mean the Securities Act of 1933, as amended. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">L. &#160;&#160;&#160;&#160;OFFERING PERIOD shall mean each six (6)&#160;month period commencing on any January&#160;1 or July&#160;1. The duration and timing of Offering Periods may be changed pursuant to Section IV.B of the Plan. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">M. &#160;&#160;&#160;&#160;PARTICIPANT shall mean any Eligible Employee of a Participating Corporation who is actively participating in the Plan. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">N. &#160;&#160;&#160;&#160;PARTICIPATING CORPORATION shall mean the Corporation and such Corporate Affiliate or Affiliates as may be authorized from time to time by the Board to extend the benefits of the Plan to their Eligible Employees. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">O. &#160;&#160;&#160;&#160;PLAN shall mean the Corporation&#8217;s Employee Stock Purchase Plan, as amended and restated and set forth in this document. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">P. &#160;&#160;&#160;&#160;PLAN ADMINISTRATOR shall mean the committee of two (2)&#160;or more Board members appointed by the Board to administer the Plan. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Q. &#160;&#160;&#160;&#160;PURCHASE DATE shall mean the last Trading Day of each Offering Period. </font></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">R. &#160;&#160;&#160;&#160;RESTATEMENT EFFECTIVE DATE shall mean the date the Plan shall become effective and shall be coincident with the approval of the Plan at the 2019 Annual Meeting of Stockholders scheduled to take place on June 6, 2019.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">S. &#160;&#160;&#160;&#160;STOCK EXCHANGE shall mean any established national securities exchange, including, without limitation, the American Stock Exchange, the Nasdaq Stock Market or the New York Stock Exchange. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">T. &#160;&#160;&#160;&#160;TRADING DAY shall mean any day on which the Common Stock is actually traded. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ligand Pharmaceuticals Incorporated 2019 Proxy Statement </font><font style="font-family:Wingdings;font-size:8pt;">l</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">93</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="sC3899CB815DD5C26846CC6C578A1F778"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;"><img src="proxycard1of2.jpg" alt="proxycard1of2.jpg" style="height:886px;width:672px;"></div><div><br></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;"><img src="proxycard2of2.jpg" alt="proxycard2of2.jpg" style="height:866px;width:671px;"></div><div><br></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>graph.jpg
<TEXT>
begin 644 graph.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" +_!C # 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MLIC!$DUI:&9IA$8_G\S;@C* $D@8^6N?^*'[9 ^&T/QVD/A'^T!\+XM*E/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_!/Q=X&^U"PGU>S*6UT>D-PC"2%SP>!(B$XYP#CFO XOVO\ XM:'X:3PM?\
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M5#!E)W*P'5ZQKFG>';$WNJZA:Z99"2.(W%Y,L,8>1U2-=S$#+.RJ!W+ #DT
M?EGIO@&Z\0?&OX)^(_#/P8^-D,6C>*K)M;\6_$N2ZGO55B?E6W+N!".'>X"J
MJ[ #C//VO^R7X9UCPWK7QT?5M)OM+34?B+J-]9->VSPBZMV@M@LT18#?&2K
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** ,7Q=XU\/?#_19-8\4:]IGAO2(V5'O]7O([6!68X4&21@
MH)/ &>:Y[PC\>OAG\0-632O"_P 1?"?B35'!9;+2-<M;J9@ 22$C<MP 3T[&
MO(/^"A%C;:I\#=%LKVWBN[.X\8Z##-;SH'CE1K^(,C*>"I!((/!!JK^TK^Q]
M\)9O@KXJU3P_X%T#P3XDT*QFUK2M>\,Z7!87=I=6R&6)P\2J6&Y!E3QSV(!
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M!XI^%'@OQ]X6T[X)^)+RZE>XO[2=]>TJUNI&DN;2V"CR70EW 9R& D;!! H
M^C_V9]<O/$O[.GPOU;49FN;^]\,Z;<7$SDEI)&MHRS$GDDDDY->0?LI>%=(\
M;WO[1VI:]86NKW>N>/=5T34&NXO,\ZQMTCAAMGW#F-4+87D?.?I7M]GX;\1^
M#;SP%H'A--%B\ Z79R6.JIJ)F.H+''"B6@M2OR'YE/F>9VQMYKP?QA^SY\<?
M!/Q \=W_ ,$_&7A/2_#/CVY_M#5+;Q1;3O<Z1>M&L4MU8F(%79PJMME^4,@'
M3)H \+^ JCQ?I_[&WAC6IAJNB6.I^*IXK>Z+2)(^G/+%9,0PY,2G*Y QM&,=
M*^B[/3[;PU_P46NO[,2.T'B3X=&]U6*$%1<W%O?I%#,X'#.(Y&3<<G: .!UJ
M^)/V-]1\._!WX5:-\,_$T.D^.?AE,;O1M6UB$R6U])(C+=QW*KEECG\Q\E<L
MN>,]:Z+X!_!'X@:3\3?$?Q4^+VNZ%JWCO5-.AT2TT_PM%,FF:981N9"D1F_>
M.TDAWL6Z'(!(Q@ ^@Z\T\0?M-?"#PGJ5_IVL_%3P7I>I6#O%=6-UK]I'<0NO
MWD:(R;@PQC;C.>,5Z77E7[6/_)K/QD_[$S6?_2&:@# TG]N+X$Z]?)9:9\2M
M(U&\<$K;V@EED8 9)"JA)P*W_P#AJ+X8_P#0S?\ DA=?_&JZKX3_ /)+/!O_
M &!K/_T0E=70!Y5_PU%\,?\ H9O_ "0NO_C5'_#47PQ_Z&;_ ,D+K_XU7JM%
M 'E7_#47PQ_Z&;_R0NO_ (U1_P -1?#'_H9O_)"Z_P#C5>JT4 >5?\-1?#'_
M *&;_P D+K_XU1_PU%\,?^AF_P#)"Z_^-5ZK10!Y5_PU%\,?^AF_\D+K_P"-
M4?\ #47PQ_Z&;_R0NO\ XU7JM% 'E7_#47PQ_P"AF_\ )"Z_^-4?\-1?#'_H
M9O\ R0NO_C5>JT4 >5?\-1?#'_H9O_)"Z_\ C5'_  U%\,?^AF_\D+K_ .-5
MZK10!Y5_PU%\,?\ H9O_ "0NO_C5'_#47PQ_Z&;_ ,D+K_XU7JM% 'E7_#47
MPQ_Z&;_R0NO_ (U1_P -1?#'_H9O_)"Z_P#C5>JT4 >5?\-1?#'_ *&;_P D
M+K_XU1_PU%\,?^AF_P#)"Z_^-5ZK10!Y5_PU%\,?^AF_\D+K_P"-4?\ #47P
MQ_Z&;_R0NO\ XU7JM% 'E7_#47PQ_P"AF_\ )"Z_^-4?\-1?#'_H9O\ R0NO
M_C5>JT4 >5?\-1?#'_H9O_)"Z_\ C5'_  U%\,?^AF_\D+K_ .-5ZK10!Y5_
MPU%\,?\ H9O_ "0NO_C5'_#47PQ_Z&;_ ,D+K_XU7JM% 'E7_#47PQ_Z&;_R
M0NO_ (U1_P -1?#'_H9O_)"Z_P#C5>JT4 >5?\-1?#'_ *&;_P D+K_XU1_P
MU%\,?^AF_P#)"Z_^-5ZK10!Y5_PU%\,?^AF_\D+K_P"-4?\ #47PQ_Z&;_R0
MNO\ XU7JM% 'E7_#47PQ_P"AF_\ )"Z_^-4?\-1?#'_H9O\ R0NO_C5>JT4
M>5?\-1?#'_H9O_)"Z_\ C5'_  U%\,?^AF_\D+K_ .-5ZK10!Y5_PU%\,?\
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M_P D+K_XU1_PU%\,?^AF_P#)"Z_^-5ZK10!Y5_PU%\,?^AF_\D+K_P"-4?\
M#47PQ_Z&;_R0NO\ XU7JM% 'E7_#47PQ_P"AF_\ )"Z_^-4?\-1?#'_H9O\
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M?^AF_P#)"Z_^-5ZK10!Y5_PU%\,?^AF_\D+K_P"-4?\ #47PQ_Z&;_R0NO\
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M_P"AF_\ )"Z_^-4?\-1?#'_H9O\ R0NO_C5>JT4 >5?\-1?#'_H9O_)"Z_\
MC5'_  U%\,?^AF_\D+K_ .-5ZK10!Y5_PU%\,?\ H9O_ "0NO_C5'_#47PQ_
MZ&;_ ,D+K_XU7JM% 'E7_#47PQ_Z&;_R0NO_ (U1_P -1?#'_H9O_)"Z_P#C
M5>JT4 >5?\-1?#'_ *&;_P D+K_XU1_PU%\,?^AF_P#)"Z_^-5ZK10!Y5_PU
M%\,?^AF_\D+K_P"-4?\ #47PQ_Z&;_R0NO\ XU7JM% 'E7_#47PQ_P"AF_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 5Y5\?/^:<_]CGIO_M2O5:\J^/G_-.?^QSTW_VI0!ZK1110 4444 %%%% !
M1110 4444 %%%% !7E7[6/\ R:S\9/\ L3-9_P#2&:O5:\J_:Q_Y-9^,G_8F
M:S_Z0S4 =5\)_P#DEG@W_L#6?_HA*ZNN4^$__)+/!O\ V!K/_P!$)75T %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>5
M?'S_ )IS_P!CGIO_ +4KU6O*OCY_S3G_ +'/3?\ VI0!ZK1110 4444 %%%%
M !1110 4444 %%%% !7E7[6/_)K/QD_[$S6?_2&:O5:\J_:Q_P"36?C)_P!B
M9K/_ *0S4 =5\)_^26>#?^P-9_\ HA*ZNN4^$_\ R2SP;_V!K/\ ]$)75T %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M>5?'S_FG/_8YZ;_[4KU6O*OCY_S3G_L<]-_]J4 >JT444 %%%% !1110 444
M4 %%%% !1110 5Y5^UC_ ,FL_&3_ +$S6?\ TAFKU6O*OVL?^36?C)_V)FL_
M^D,U '5?"?\ Y)9X-_[ UG_Z(2NKKE/A/_R2SP;_ -@:S_\ 1"5U= !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M,CE5QF/RM@)D+#E0@)/8&L_X,?M ?#[]H70+C6?A[XGM?$EC;2^3<>5')#+
MQS@212JLB9P<%E .#C-?#?P%4>+]/_8V\,:U,-5T2QU/Q5/%;W1:1)'TYY8K
M)B&')B4Y7(&-HQCI7T79Z?;>&O\ @HM=?V8D=H/$GPZ-[JL4(*BYN+>_2*&9
MP.&<1R,FXY.T <#J ?3=>5?M8_\ )K/QD_[$S6?_ $AFKU6OFW]K;XV>'H?@
M)\8_#K:=XN.H'POK%EYR^#-8:R\PVDJAOM8M?(\O)_UOF; .2V.: /9_A/\
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M(?\ Y!H_X:6\(_\ 0(^('_AN/$/_ ,@T >JT5Y5_PTMX1_Z!'Q _\-QXA_\
MD&C_ (:6\(_] CX@?^&X\0__ "#0!ZK17E7_  TMX1_Z!'Q _P##<>(?_D&C
M_AI;PC_T"/B!_P"&X\0__(- 'JM%>5?\-+>$?^@1\0/_  W'B'_Y!H_X:6\(
M_P#0(^('_AN/$/\ \@T >JT5Y5_PTMX1_P"@1\0/_#<>(?\ Y!H_X:6\(_\
M0(^('_AN/$/_ ,@T >JT5Y5_PTMX1_Z!'Q _\-QXA_\ D&C_ (:6\(_] CX@
M?^&X\0__ "#0!ZK17E7_  TMX1_Z!'Q _P##<>(?_D&C_AI;PC_T"/B!_P"&
MX\0__(- 'JM%>5?\-+>$?^@1\0/_  W'B'_Y!H_X:6\(_P#0(^('_AN/$/\
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M'Q _\-QXA_\ D&C_ (:6\(_] CX@?^&X\0__ "#0!ZK17E7_  TMX1_Z!'Q
M_P##<>(?_D&C_AI;PC_T"/B!_P"&X\0__(- 'JM%>5?\-+>$?^@1\0/_  W'
MB'_Y!H_X:6\(_P#0(^('_AN/$/\ \@T >JT5Y5_PTMX1_P"@1\0/_#<>(?\
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M_(- 'JM%>5?\-+>$?^@1\0/_  W'B'_Y!H_X:6\(_P#0(^('_AN/$/\ \@T
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M "#0!ZK17E7_  TMX1_Z!'Q _P##<>(?_D&C_AI;PC_T"/B!_P"&X\0__(-
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M\-+>$?\ H$?$#_PW'B'_ .0:/^&EO"/_ $"/B!_X;CQ#_P#(-5SR[CNSLO\
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M?UBM_._O8<TNXY_V7OA=(C*?"5N PP=MQ.#^8?BJG_#)?PI_Z%7_ ,J-W_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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ME.4MV%%%%<Q 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !7E7Q\_P":<_\ 8YZ;_P"U*]5KRKX^?\TY_P"QSTW_ -J4
M >JT444 %%%% !1110 4444 %%%% !1110 5Y5^UC_R:S\9/^Q,UG_TAFKU6
MO*OVL?\ DUGXR?\ 8F:S_P"D,U '5?"?_DEG@W_L#6?_ *(2NKKE/A/_ ,DL
M\&_]@:S_ /1"5U= !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MI6=ZCN8RDY;A1116!(4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %>5?'S_FG/_8YZ;_[4KU6O*OCY_S3
MG_L<]-_]J4 >JT444 %%%% !1110 4444 %%%% !1110 5Y5^UC_ ,FL_&3_
M +$S6?\ TAFKU6O*OVL?^36?C)_V)FL_^D,U '5?"?\ Y)9X-_[ UG_Z(2NK
MKE/A/_R2SP;_ -@:S_\ 1"5U= !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M1110 4444 %>5?'S_FG/_8YZ;_[4KU6O*OCY_P TY_['/3?_ &I0!ZK1110
M4444 %%%% !1110 4444 %%%% !7E7[6/_)K/QD_[$S6?_2&:O5:\J_:Q_Y-
M9^,G_8F:S_Z0S4 =5\)_^26>#?\ L#6?_HA*ZNN4^$__ "2SP;_V!K/_ -$)
M75T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M3\0/_ [P]_\ +6O5:* /*O\ A<GB[_HA/Q _\#O#W_RUH_X7)XN_Z(3\0/\
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MK_A<GB[_ *(3\0/_  .\/?\ RUH_X7)XN_Z(3\0/_ [P]_\ +6O5:* /*O\
MA<GB[_HA/Q _\#O#W_RUH_X7)XN_Z(3\0/\ P.\/?_+6O5:* /*O^%R>+O\
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MQ _\#O#W_P M:]5HH \J_P"%R>+O^B$_$#_P.\/?_+6C_A<GB[_HA/Q _P#
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ML6NH;,8/7RY .CC\F R.X'%^ _ >L_$CQ+;:'H=L;B[F.68\1PH.LCGLH_P
MR2!7ZA>(_#FF^+M$N](U>TCOM/NDV2PR#@CU'H0>01R" 17-?"WX/^'?A#I,
M]EH4$A>X??/>73!YY>3M#, .%!P  !U/4DGUH9JU2M)7F;JO[NNY>^&/@>/X
M;^!=)\.1W37OV&(JUPZA3(Q8L3@=!DX'4X Y-=3117@2DY-R>[.5N[NPHHHJ
M1!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **Y+XK?$"/X7?#_ %;Q/)9-J*V"QXM5D\LR%Y$C
M W8.!EP2<'@=*^;O^'@7_4A_^5C_ .T5SU,12I/EF[,]?!Y3C<?!U,-3YDG;
M=+7YM=SZ^HKY;\%?MP)XN\8:)H;^#&LEU.]AL_M"ZIYAC,CA VWR5R 2.XKZ
MDJJ=:%97@[F&,R_$Y?)0Q,>5O;5/\FPHHHK8\\**** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ KRKX^?\TY_['/3?_:E>JUY5\?/^:<_]CGIO
M_M2@#U6BBB@ HHHH **** "BBB@ HHHH **** "O*OVL?^36?C)_V)FL_P#I
M#-7JM>5?M8_\FL_&3_L3-9_](9J .J^$_P#R2SP;_P!@:S_]$)75URGPG_Y)
M9X-_[ UG_P"B$KJZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M//PZ901XTT7!YYO$']:\6;]@CP_N.WQ3J07/ ,$9-4S^P'I_;QG<X_Z\%_\
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MN/$05L?4S#^='UJIUI,/[#PK^'&P_+]3[MHKX2_X5W^TKIO[S[7XD?=\N/\
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M](9J]5KRK]K'_DUGXR?]B9K/_I#-0!U7PG_Y)9X-_P"P-9_^B$KJZY3X3_\
M)+/!O_8&L_\ T0E=70 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P IJ/\ A)/C?_T3SX?_ /A>7W_RFH ]5HKRK_A)/C?_ -$\^'__ (7E]_\
M*:C_ (23XW_]$\^'_P#X7E]_\IJ /5:*\J_X23XW_P#1//A__P"%Y??_ "FH
M_P"$D^-__1//A_\ ^%Y??_*:@#U6BO*O^$D^-_\ T3SX?_\ A>7W_P IJ/\
MA)/C?_T3SX?_ /A>7W_RFH ]5HKRK_A)/C?_ -$\^'__ (7E]_\ *:C_ (23
MXW_]$\^'_P#X7E]_\IJ /5:*\J_X23XW_P#1//A__P"%Y??_ "FH_P"$D^-_
M_1//A_\ ^%Y??_*:@#U6BO*O^$D^-_\ T3SX?_\ A>7W_P IJ/\ A)/C?_T3
MSX?_ /A>7W_RFH ]5HKRK_A)/C?_ -$\^'__ (7E]_\ *:C_ (23XW_]$\^'
M_P#X7E]_\IJ /5:*\J_X23XW_P#1//A__P"%Y??_ "FH_P"$D^-__1//A_\
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M_P#1//A__P"%Y??_ "FH_P"$D^-__1//A_\ ^%Y??_*:@#U6BO*O^$D^-_\
MT3SX?_\ A>7W_P IJ/\ A)/C?_T3SX?_ /A>7W_RFH ]5HKRK_A)/C?_ -$\
M^'__ (7E]_\ *:C_ (23XW_]$\^'_P#X7E]_\IJ /5:*\J_X23XW_P#1//A_
M_P"%Y??_ "FH_P"$D^-__1//A_\ ^%Y??_*:@#U6BO*O^$D^-_\ T3SX?_\
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M /1//A__ .%Y??\ RFH_X23XW_\ 1//A_P#^%Y??_*:NLH]5HKRK_A)/C?\
M]$\^'_\ X7E]_P#*:C_A)/C?_P!$\^'_ /X7E]_\IJ /5:*\J_X23XW_ /1/
M/A__ .%Y??\ RFH_X23XW_\ 1//A_P#^%Y??_*:@#U6BO*O^$D^-_P#T3SX?
M_P#A>7W_ ,IJ/^$D^-__ $3SX?\ _A>7W_RFH ]5HKRK_A)/C?\ ]$\^'_\
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M_P!$\^'_ /X7E]_\IJ /5:*\J_X23XW_ /1//A__ .%Y??\ RFH_X23XW_\
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M_P#PO+[_ .4U=B2BK)'STZDZLN:;;?F>JT5Y5_PDGQO_ .B>?#__ ,+R^_\
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MN>-]4\42:[XO\(WFN0QVWB"U\)ZR;&UUZ)!M5+V/:WF#9E.-I(8\YYKZ)HH
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M.GX^RV=O;8Z>3$J?R%6Z/[-QL_XF*?R5OU#DEUD?-?F?%[6^<:M'N_V5MO\
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M?4&3^>*/[#^+VE_\M-6?_M]6?K_P,T?VM6C_ !,+->BO^@>T?6)]*45\U_\
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M% !1110 4444 %%%% !1110 4444 %%%% !1110 5Y5\?/\ FG/_ &.>F_\
MM2O5:\J^/G_-.?\ L<]-_P#:E 'JM%%% !1110 4444 %%%% !1110 4444
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M*2>RL@HHHK(@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M<?XF.A\M?U.+^+7Q<\;VWQ2\7V]KXQURVM(-7NH88;74IHXTC29E5556
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M?A71E69?VA"7,K23_#I_D53GSDU%%%>Z:A1110 4444 %%%% !1110 4444
M%>5?'S_FG/\ V.>F_P#M2O5:\J^/G_-.?^QSTW_VI0!ZK1110 4444 %%%%
M!1110 4444 %%%% !7E7[6/_ ":S\9/^Q,UG_P!(9J]5KRK]K'_DUGXR?]B9
MK/\ Z0S4 =5\)_\ DEG@W_L#6?\ Z(2NKKE/A/\ \DL\&_\ 8&L__1"5U= !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !139)$AC9Y&5$49+,< 5RFL_%?PGH>X7&M6\DB_\
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MJZY3X3_\DL\&_P#8&L__ $0E=70 4444 %%%% !1110 4444 %%%% !1110
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MTN09FSZ_/G'X5U4<:PHJ(JHBC 51@"CZCF%?_>,1RKM%?KH')-[R/FR/X/\
MC_QA()-8N6B4G.[4;LR$?15W8^G%=5HW[,MA%M;5=8N+D]3':QB,?3+;L_D*
M]KHK6GD>#@^::<WYO_AAJE'J<=H_PB\):'M,.C03R#_EI=YF)/KAL@?@*ZZ&
M&.WC6.*-8HUX"(H 'T I]%>U3HTJ*M2BH^BL:I);!139)%C1G=@B*,EF. !Z
MUA:C\0?"VCY^W^)=(LMO7[1?Q1XYQW;UK5M+<TC"<W:"N;]%>;ZA^T=\--+S
MYWC'3GQ_S[LT_P#Z #Z5R^I?ME?#&QSY.IWNH8_Y]K&09_[^!?\ (K)UJ4=Y
M+[SOIY;C:GP49/\ [=9[A17S/J/[>/@^$D66@ZU=8[S+%$#^3M7+:E^W[(P*
MV'@M4/:2YU$MV_NB,=_>L7C*"^T>A3X>S.IM1MZM+\V?8-%?#-Y^W/XZU"3R
MM.T/18"WW1Y,TTGKQ^\ Z>U0?\+W^/\ XFXTRPU)%;_H'Z#O&.G5HVQU'/TK
M/Z]2^RF_D=BX8QRUJ2C'UE_DF?9GQ$UJY\-_#_Q-J]D56\L-+NKJ!G7<HD2)
MF7([C(%? G_#6WQ7_P"AK_\ *=:?_&JW?$MO^T'K7AS5;G6CK\>CQVDLEZLT
MB6R& (3(&3*Y&T'(QSZ<\^!UYV*Q,Y-<MX_@?89'DN&HTYJMR57?I:5O+4]A
MC_:X^*T<B,WBA9%4@E&TZUPWL<1 X^AK] +KQMX>L=WVG7M,M]IVMYMY&N#Z
M'+5^3U?5-M^P-K3'_2/%EA$,?\L[5WY].2.*>%KU_>LN;Y[&.>9;EB]FZDU1
MWVCOMV[?J?4=U\8O =CO$_C3P^C)]Y/[3A+#_@(;-9-U^T1\-K/=YGC+2VVC
M<?*E,G_H(.3[5\U^*/V-]#^'VAR:QXG^(Z6-E&,$+I?S.V.$3]]EC[ 5X%I/
M@VY\:>*AH_A*SOM5>5R(5D15D90?ON =J#&,Y8@>M>S2I8^NG*%-675O_@GS
M,<#DG_03)^D6OS1]2_&W]L^T@M7TGX?R_:;B1<2:U)$56+/:)& );_:88'8'
MJ/GWX<OX*U+Q!)K/Q&UR^N8VE,CV=O%)+-=/G):64]%/L2QYY7O]%^#?V$="
M31;=_%.M:C+JS'=+'I<D<<"=/D!>-F;O\W'T[UUEO^Q/\-X00ZZM/GO)> 8_
M[Y45K#&8^C%TZ<8KSUO]]QK^P*2LIU']W^2,NT_;0^&/AS3;>QTS2=8BLK<>
M7%;V=C$B(H] 9  /\:IW7[>GA-=WV;P[K4O/R^;Y*9'OASBNVM_V0?A7"27\
M.RSY[2:A<#'_ 'S(*UK7]F/X86A!3PA:-@;?WLLLG_H3GGWKAY<9+5R1G[;(
M([4JC^:_S/'KK]OS3DW_ &;P;=2\?+YM^J9^N(VQ^M95U^W]=L3]G\%0Q#''
MFZD7Y]>(AQ[5]%VOP)^'=GL\OP5HC;1@>;9))^>X'/XUK6OPS\'V.W[-X4T.
MWVG*^5IT*X/MA:7L\4]ZB^X7UW)(_#A&_63_ ,SY(N/V]?$[$>1X:TF,=_,>
M5_Y,*S_^&VOB3J2_Z+I&B#:?F-O93M^>937VY:^']+LABWTVS@&=W[J!%Y]>
M!UK0H^KUWO5_ /[6RR/P8%?.7_ /A1OVD_CEJ6Y;72YE(.X_9M$9R!Z<J>*/
M^%F?M)ZME8[+Q!'&XW#9X?2-<>S&'/ZU]UT4_JL^M5A_;F&C\&"I_-7_ $/A
M3=^TMK!_YF*/S!CI';XX_P" [?TH'PU_:4U;:TE[X@B1AL.[Q D0Q[J)@?TK
M[KHI?4T]YO[P_P!8YQ_AX>FO^W?^"?"B_LW?'/4MINM4G4J<#[1K;,0/7ACQ
M_A2?\,3_ !*U)2+K5]% 4Y N+V=OQ&(C7W911]1I=6W\P_UHQR^",5Z1_P""
M?$=O^P5XH8GS_$FD1C''EI*_\U%:MK^P#>-C[3XU@B&.?*TUGY].91Q[U]CT
M52P-#M^)E+B;,Y;5$ODO\CY.M?V ]/39]I\974O][RK!4S],R-C]:U;7]@OP
MFNW[3XBUF7GYO*\E,CVRC8KZ<HJU@Z"^R<\N(,SEO6?W+_(^>;;]AOX>P##W
MFO7'.<R7<0_#Y8A6K;_L:?#&'=OTV]GST\R^D&/^^2*]QHJUAJ*^RCFEG&82
MWKR^\\EM_P!E'X56I)3PI&Q(P?,O;E_YR&M6U_9W^&UGM\OP;I;;1M'FQ&3_
M -")R?>O1:*M4::VBON.>688R7Q5I/\ [>?^9R%K\'O =CL,'@OP^C)]U_[,
MA+#_ ($5S6K:^"?#UCM^S:#IEOM.Y?*LXUP?486MJBK4(K9'-+$5I?%-OYLB
MM[6&U4K!#'"I.2(U"@_E7A_[4'P'UWXV+X:_L.]TZT;3#<^:-0DD0,)/*QM*
M(W3RSUQUKW6BE4IQJ1<);&N%Q=7!UXXBD_>7ZJQ\)?\ #"/C[_H+^&__  )N
M/_C%>M?LU?LU>)O@WXXO]:UJ_P!)NK:?3GLTCL)97?<TL3Y.Z-1C$9[]Q7TG
M17+#!TJ<E*.Z/:Q/$6.Q5&5"HURRWT"BBBNX^9"BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MQ_JWQ*\2?"WXO:)H.D^/-*T^'6K2]\+2S/INJ6$CM&9(A-^\1HY!L8.<DG(
M'4 ^@:\J_:Q_Y-9^,G_8F:S_ .D,U>JUY5^UC_R:S\9/^Q,UG_TAFH ZKX3_
M /)+/!O_ &!K/_T0E=77*?"?_DEG@W_L#6?_ *(2NKH **** "BBB@ HHHH
M**** "BBB@ HHHH **^=?BU^UX/AC\0[_P *0^$GU>6T\D&X_M#R=[21K( %
M\INS@=>N>*QM>_;*U+PK;QS7O@^"]2=SM\C4#%Y/&0C$QMO/7YAMSC[HKSZF
M/PU*:ISEJ_7H>K_9>+YJ4>36JKQUCJK7[Z:=SZCHKS#X-_'73_BIX)N?$5Y;
M0^&T@O7LVBN;Q74E41]P<JO:0=NU7]9^.GA#2,A;^34)!_!9Q%O_ !XX7]:T
MGC,/3CS3FDO-GGXBE/"U)4:RM);H] HKP76?VG)&W+I.BJOI+>2D_P#CBX_]
M"KS?Q%^T-KUXSI<>)+?35_YXVSI"P^A^_P#K7D5,^PD7RTKS?DO\[&$'*K+E
MI1<GY*Y]=7VH6NFPF:\N8;6(=9)Y B_F37&:S\;O"&C[E_M/[=(/X+-#)G_@
M7W?UKY!D^(7AK4)O/U3Q4TLA^]MM[B>7_P >4*?^^N]6K?XM_"O2^9+3Q/KL
MJ]C'!:PMQ[2,WZ_G7(\TQM;^%24%WD_T7^1ZE/*,TK?!AY+U5OSL>\ZQ^TXO
MS+I.BD^DMY+C\T7_ .*KGO\ A8'Q+\<<:;%<QP-WT^UV(/\ MH<D?]]5YU;_
M +77A7P^0-"^&-NKK]VXO+T-(.?4QL?_ !ZH;[]N[QC<$)I_A_1;<MP/-6:5
MOPPZ\].U8N%>M_O&*?I%6_'3\CT(<+YM4^.-OFOT9ZA:_ GQGXEF6XUJ^C@8
M]6O+EIY?TR/UKL=&_9JT:UVMJ6I75^PZK$!"A_F?UKYS_P"&C/CKXF_Y!6G7
M2;NG]FZ&9?RW(_H?UH\S]I7Q1SCQ'#N_V4LO?_8QU_SBM:6!P$'?V4ION]?Z
M^XW7"TZ>M:M3CZR_X!]C:-\,_"^@[3::):AUZ23+YK_F^2*W+S4['28P;J[M
M[.,#CSI%08Z=S7P[_P ,[_'CQ-_R%=1O%W<'^T==,OMSM=^U6K']A/QI>-YF
MH:_HMNS_ #,8WFF;)]<HO.?>O9IU)4URT:%E]WZ&JR;+Z?\ $QL?DK_DSZRU
M+XR> ])S]J\8Z'&PZH-0B9_^^0Q/Z5R^I?M5?"W3,A_%4<[]EMK6>7/XJF._
MK7CFG?L J"&O_&K,.\=OIV/_ !XR?TKJ--_81\%V^#>ZUK=VP[1R11*>O4>6
M3Z=ZU]IBY;02']5R&G\6(G+T5OS1IZC^V]\.K(D01:SJ'H;>T50?^^W7_)KE
MM1_;YT6/=]@\)7]R>WVBZ2'/'L'[UWVG?L=?"^QQYVCW5^?6XOYA_P"@,O\
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M3=-M-'L(+&PMHK.S@0)%! @1$4=  .!5FL\1BY5O<BK170\Z=1RT6B"BBBN
MR"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\J^/G_-.?\
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M#]C3Q/K0CTO1-0U/Q7!#<71,:1R:@\LEFI+'@R 87).2PQGK7T=::I:>)/\
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MJT4 >5?\))\;_P#HGGP__P#"\OO_ )34?\))\;_^B>?#_P#\+R^_^4U>JT4
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\J^/G_-
M.?\ L<]-_P#:E>JUY5\?/^:<_P#8YZ;_ .U* /5:*** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MQH?X;^$VM?'_ (#AMCI-H8HYO ][(ZIY*8#,-84,0,9(49]!TKI?^$<^-_\
MT4/X?_\ A!WW_P N: /5:*\J_P"$<^-__10_A_\ ^$'??_+FC_A'/C?_ -%#
M^'__ (0=]_\ +F@#U6BO*O\ A'/C?_T4/X?_ /A!WW_RYH_X1SXW_P#10_A_
M_P"$'??_ "YH ]5HKRK_ (1SXW_]%#^'_P#X0=]_\N:/^$<^-_\ T4/X?_\
MA!WW_P N: /5:*\J_P"$<^-__10_A_\ ^$'??_+FC_A'/C?_ -%#^'__ (0=
M]_\ +F@#U6BO*O\ A'/C?_T4/X?_ /A!WW_RYH_X1SXW_P#10_A__P"$'??_
M "YH ]5HKRK_ (1SXW_]%#^'_P#X0=]_\N:/^$<^-_\ T4/X?_\ A!WW_P N
M: /5:*\J_P"$<^-__10_A_\ ^$'??_+FC_A'/C?_ -%#^'__ (0=]_\ +F@#
MU6BO*O\ A'/C?_T4/X?_ /A!WW_RYH_X1SXW_P#10_A__P"$'??_ "YH ]5H
MKRK_ (1SXW_]%#^'_P#X0=]_\N:/^$<^-_\ T4/X?_\ A!WW_P N: /5:*\J
M_P"$<^-__10_A_\ ^$'??_+FC_A'/C?_ -%#^'__ (0=]_\ +F@#U6BO*O\
MA'/C?_T4/X?_ /A!WW_RYH_X1SXW_P#10_A__P"$'??_ "YH ]5HKRK_ (1S
MXW_]%#^'_P#X0=]_\N:/^$<^-_\ T4/X?_\ A!WW_P N: /5:*\J_P"$<^-_
M_10_A_\ ^$'??_+FC_A'/C?_ -%#^'__ (0=]_\ +F@#U6BO*O\ A'/C?_T4
M/X?_ /A!WW_RYH_X1SXW_P#10_A__P"$'??_ "YH ]5HKRK_ (1SXW_]%#^'
M_P#X0=]_\N:/^$<^-_\ T4/X?_\ A!WW_P N: /5:*\J_P"$<^-__10_A_\
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M_P N: /5:*\J_P"$<^-__10_A_\ ^$'??_+FC_A'/C?_ -%#^'__ (0=]_\
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M_P#10_A__P"$'??_ "YH ]5HKRK_ (1SXW_]%#^'_P#X0=]_\N:/^$<^-_\
MT4/X?_\ A!WW_P N: /5:*\J_P"$<^-__10_A_\ ^$'??_+FC_A'/C?_ -%#
M^'__ (0=]_\ +F@#U6BO*O\ A'/C?_T4/X?_ /A!WW_RYH_X1SXW_P#10_A_
M_P"$'??_ "YH ]5HKRK_ (1SXW_]%#^'_P#X0=]_\N:/^$<^-_\ T4/X?_\
MA!WW_P N: /5:*\J_P"$<^-__10_A_\ ^$'??_+FC_A'/C?_ -%#^'__ (0=
M]_\ +F@#U6BO*O\ A'/C?_T4/X?_ /A!WW_RYH_X1SXW_P#10_A__P"$'??_
M "YH ]5HKRK_ (1SXW_]%#^'_P#X0=]_\N:/^$<^-_\ T4/X?_\ A!WW_P N
M: /5:*\J_P"$<^-__10_A_\ ^$'??_+FC_A'/C?_ -%#^'__ (0=]_\ +F@#
MU6BO*O\ A'/C?_T4/X?_ /A!WW_RYH_X1SXW_P#10_A__P"$'??_ "YH ]5H
MKRK_ (1SXW_]%#^'_P#X0=]_\N:/^$<^-_\ T4/X?_\ A!WW_P N: /5:*\J
M_P"$<^-__10_A_\ ^$'??_+FC_A'/C?_ -%#^'__ (0=]_\ +F@#U6BO*O\
MA'/C?_T4/X?_ /A!WW_RYH_X1SXW_P#10_A__P"$'??_ "YH ]5HKRK_ (1S
MXW_]%#^'_P#X0=]_\N:/^$<^-_\ T4/X?_\ A!WW_P N: /5:*\J_P"$<^-_
M_10_A_\ ^$'??_+FC_A'/C?_ -%#^'__ (0=]_\ +F@#U6BO*O\ A'/C?_T4
M/X?_ /A!WW_RYH_X1SXW_P#10_A__P"$'??_ "YH ]5HKRK_ (1SXW_]%#^'
M_P#X0=]_\N:/^$<^-_\ T4/X?_\ A!WW_P N: /5:*\J_P"$<^-__10_A_\
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M_P N: /5:*\J_P"$<^-__10_A_\ ^$'??_+FC_A'/C?_ -%#^'__ (0=]_\
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M_P#10_A__P"$'??_ "YH ]5HKRK_ (1SXW_]%#^'_P#X0=]_\N:/^$<^-_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M\J^/G_-.?^QSTW_VI7JM>5?'S_FG/_8YZ;_[4H ]5HHHH **** "BBB@ HHH
MH **** "BBB@ KRK]K'_ )-9^,G_ &)FL_\ I#-7JM>5?M8_\FL_&3_L3-9_
M](9J .J^$_\ R2SP;_V!K/\ ]$)75URGPG_Y)9X-_P"P-9_^B$KJZ "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O*OCY
M_P TY_['/3?_ &I7JM>5?'S_ )IS_P!CGIO_ +4H ]5HHHH **** "BBB@ H
MI&;:I)Z#FOSVL=)^*?QH^"?BK]I'2_C#XK\.:[ ^I:KX;\)V-THT&.PM)9%C
MM[FU*XF>1(7S(Q&"ZD@[: /T*HKEOA7XW3XF?#+PEXNCA^S)KVDVNIB$$GR_
M.B63;D]<;L?A7RE'X,\>?M<>/OBOKEC\7?%WPXTSP?KL_AGPSIGAB\%O;&YM
M8T,MS?)MS<HTK#]V2N%5AG!H ^UJ*^%$^/'CO]H+X2?L^>$;#Q!<^"_$_P 1
M+F_M?$7B#1RJ7,$.F*ZWAMFVXCDF=%VLOW-W (KT7X#?\)3\$_VD-=^#&L^-
M]>^(7AN]\-Q^*-"U/Q3<BZU*TVW'V>YMY9]H,JEF1U) VCY0.IH ^IJ\J_:Q
M_P"36?C)_P!B9K/_ *0S5ZK7E7[6/_)K/QD_[$S6?_2&:@#JOA/_ ,DL\&_]
M@:S_ /1"5U=<I\)_^26>#?\ L#6?_HA*ZN@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHK#\/>,-/\ $VK>)]-LO-^T^'=133+WS$VKYS6EO=C8<\CRKJ+G
MUW#M0!N4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !116'XZ\8:?\._!/B'Q5JWFC2M#TZXU.[\A-\GD
MPQ-(^U<C)VJ<#N: -RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BL.\\8:?8^-M)\*R>;_:NI
MZ=>:G;X3,?DVLMK'+EL\'=>0X'<;O2MR@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBL/P=XPT_Q
MSI-QJ6F>;]F@U&^TQ_.3:WG6EW-:3<9Z>; ^#W&#WH W**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHK#\8^,-/\#:3;ZEJ?F_9I]1L=,3R4W-YUW=PVD/&>GFSID]AD]J -RBBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BL.S\8:??>-M6\*Q^;_:NF:=9ZG<93$?DW4MU'%AL\G=9
MS9'8;?6MR@ HHHH **** "BBB@ HHHH **** "BBB@ KRKX^?\TY_P"QSTW_
M -J5ZK7CG[1NL6^F7GPEMIMWF:CX[T^U@VC(WB&XE.?0;8G_ !Q0!['1110
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MU:[LOCO\7+:YU:Z6]OI$U73\W$PAB@#M_H/4101)]$%?2%% 'S__ ,,H:O\
M]'!?&#_P:Z=_\@T?\,H:O_T<%\8/_!KIW_R#7T!10!\__P##*&K_ /1P7Q@_
M\&NG?_(-'_#*&K_]'!?&#_P:Z=_\@U] 44 ?/_\ PRAJ_P#T<%\8/_!KIW_R
M#1_PRAJ__1P7Q@_\&NG?_(-?0%% 'S__ ,,H:O\ ]'!?&#_P:Z=_\@T?\,H:
MO_T<%\8/_!KIW_R#7T!10!\__P##*&K_ /1P7Q@_\&NG?_(-'_#*&K_]'!?&
M#_P:Z=_\@U] 44 ?/_\ PRAJ_P#T<%\8/_!KIW_R#1_PRAJ__1P7Q@_\&NG?
M_(-?0%% 'S__ ,,H:O\ ]'!?&#_P:Z=_\@T?\,H:O_T<%\8/_!KIW_R#7T!1
M0!\__P##*&K_ /1P7Q@_\&NG?_(-'_#*&K_]'!?&#_P:Z=_\@U] 44 ?/_\
MPRAJ_P#T<%\8/_!KIW_R#1_PRAJ__1P7Q@_\&NG?_(-?0%% 'S__ ,,H:O\
M]'!?&#_P:Z=_\@T?\,H:O_T<%\8/_!KIW_R#7T!10!\__P##*&K_ /1P7Q@_
M\&NG?_(-'_#*&K_]'!?&#_P:Z=_\@U] 44 ?/_\ PRAJ_P#T<%\8/_!KIW_R
M#1_PRAJ__1P7Q@_\&NG?_(-?0%% 'S__ ,,H:O\ ]'!?&#_P:Z=_\@T?\,H:
MO_T<%\8/_!KIW_R#7T!10!\__P##*&K_ /1P7Q@_\&NG?_(-'_#*&K_]'!?&
M#_P:Z=_\@U] 44 ?/_\ PRAJ_P#T<%\8/_!KIW_R#6?XA_8QF\6>']3T35_C
MO\7+_2=2M9;*\M)M5T\I-#(A21&_T'HRL0?K7TA10!\__P##*&K_ /1P7Q@_
M\&NG?_(-'_#*&K_]'!?&#_P:Z=_\@U] 44 ?/_\ PRAJ_P#T<%\8/_!KIW_R
M#1_PRAJ__1P7Q@_\&NG?_(-?0%% 'S__ ,,H:O\ ]'!?&#_P:Z=_\@T?\,H:
MO_T<%\8/_!KIW_R#7T!10!\__P##*&K_ /1P7Q@_\&NG?_(-'_#*&K_]'!?&
M#_P:Z=_\@U] 44 ?/_\ PRAJ_P#T<%\8/_!KIW_R#1_PRAJ__1P7Q@_\&NG?
M_(-?0%% 'S__ ,,H:O\ ]'!?&#_P:Z=_\@T?\,H:O_T<%\8/_!KIW_R#7T!1
M0!\__P##*&K_ /1P7Q@_\&NG?_(-'_#*&K_]'!?&#_P:Z=_\@U] 44 ?/_\
MPRAJ_P#T<%\8/_!KIW_R#1_PRAJ__1P7Q@_\&NG?_(-?0%% 'S__ ,,H:O\
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M5_\ HX+XP?\ @UT[_P"0:^@** /G_P#X90U?_HX+XP?^#73O_D&C_AE#5_\
MHX+XP?\ @UT[_P"0:^@** /G_P#X90U?_HX+XP?^#73O_D&C_AE#5_\ HX+X
MP?\ @UT[_P"0:^@** /G_P#X90U?_HX+XP?^#73O_D&C_AE#5_\ HX+XP?\
M@UT[_P"0:^@** /G_P#X90U?_HX+XP?^#73O_D&C_AE#5_\ HX+XP?\ @UT[
M_P"0:^@** /G_P#X90U?_HX+XP?^#73O_D&C_AE#5_\ HX+XP?\ @UT[_P"0
M:^@** /G_P#X90U?_HX+XP?^#73O_D&C_AE#5_\ HX+XP?\ @UT[_P"0:^@*
M* /G_P#X90U?_HX+XP?^#73O_D&C_AE#5_\ HX+XP?\ @UT[_P"0:^@** /G
M_P#X90U?_HX+XP?^#73O_D&C_AE#5_\ HX+XP?\ @UT[_P"0:^@** /G_P#X
M90U?_HX+XP?^#73O_D&C_AE#5_\ HX+XP?\ @UT[_P"0:^@** /G_P#X90U?
M_HX+XP?^#73O_D&C_AE#5_\ HX+XP?\ @UT[_P"0:^@** /G_P#X90U?_HX+
MXP?^#73O_D&C_AE#5_\ HX+XP?\ @UT[_P"0:^@** /G_P#X90U?_HX+XP?^
M#73O_D&C_AE#5_\ HX+XP?\ @UT[_P"0:^@** /G_P#X90U?_HX+XP?^#73O
M_D&C_AE#5_\ HX+XP?\ @UT[_P"0:^@** /G_P#X90U?_HX+XP?^#73O_D&L
M_0_V,9O#5E)::7\=_BY96TEU<7KQQ:KI^#-/,\\S_P#'CU>661S[L:^D** /
MG_\ X90U?_HX+XP?^#73O_D&C_AE#5_^C@OC!_X-=._^0:^@** /G_\ X90U
M?_HX+XP?^#73O_D&C_AE#5_^C@OC!_X-=._^0:^@** /G_\ X90U?_HX+XP?
M^#73O_D&C_AE#5_^C@OC!_X-=._^0:^@** /G_\ X90U?_HX+XP?^#73O_D&
MC_AE#5_^C@OC!_X-=._^0:^@** /G_\ X90U?_HX+XP?^#73O_D&C_AE#5_^
MC@OC!_X-=._^0:^@** /G_\ X90U?_HX+XP?^#73O_D&C_AE#5_^C@OC!_X-
M=._^0:^@** /G_\ X90U?_HX+XP?^#73O_D&C_AE#5_^C@OC!_X-=._^0:^@
M** /G_\ X90U?_HX+XP?^#73O_D&C_AE#5_^C@OC!_X-=._^0:^@** /G_\
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MOH"B@#Y__P"&4-7_ .C@OC!_X-=._P#D&C_AE#5_^C@OC!_X-=._^0:^@**
M/G__ (90U?\ Z."^,'_@UT[_ .0:/^&4-7_Z."^,'_@UT[_Y!KZ HH ^?_\
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MK'BKX>P>"_AB?B9X,T^Z;5]8TM/$-II/VB[A939I(\Y):)'S*4"D,R)D@#!
M+'[&7QL\>?&B^^*\_CJS.BRZ7XACM].T)XHUDTRT>UBECAD91EI,."Y8DARP
M&  !]+5\2_L+^./B#XA^.GQYA\3_  S_ .$2M;S71>ZA<_V_;WO]GWPMK9%L
MML:@R[H\R><ORC&W&:^VJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MC\(Q%3J5O?)+#%,);;&^-$\J0[V55.%P<L*^]O'D9A^&_B*,G)32;A<_2%J
M/"?#W[2.N^&_V#_#_P 6]:B7Q+XMNM"M9DAV)"M[?W#K%"I5 JJIED3.T# S
MBN0^%GBSXYZ9\6]%L[OXO^"?C1!-<^1XO\&Z+#865WX41@?WT3),))4CDVHP
ME!<CHI8[EX'QIX.U#QK_ ,$A_"MMIUO=74MEH.DZG+%8C-P8()XI9FC_ -I8
MU=A_NU1\26_[/=]XM_9W_P"&=QX:B\=KXHL)$_X1/9]O72!&YOA?[,MCR>&\
M_P"?)(_O4 ?HM1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*X?XT>*/ OPS\=?LP_$/1+_2D^$.AW.I>'O[8TF5+C3K&.YM5AMV,R%E6,/
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MHW@G27U/7=1ATRP5E0S3' +'H !R3[#T/I32<G9 <%_PCGQO_P"BA_#_ /\
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M_P!%#^'_ /X0=]_\N:/^$<^-_P#T4/X?_P#A!WW_ ,N:]5HH \J_X1SXW_\
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MOVA;C[),R@O%YJ_*^UB5W#@XR*TJ /*O^$<^-_\ T4/X?_\ A!WW_P N:/\
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M_P#X0=]_\N:]5HH \J_X1SXW_P#10_A__P"$'??_ "YH_P"$<^-__10_A_\
M^$'??_+FO5:X[QA\4M)\%^-O _A>]BNI-2\77=S:6#0HIC1H+9[AVD)(P-J8
M& 3DCMS0!S?_  CGQO\ ^BA_#_\ \(.^_P#ES1_PCGQO_P"BA_#_ /\ "#OO
M_ES7JM% 'E7_  CGQO\ ^BA_#_\ \(.^_P#ES1_PCGQO_P"BA_#_ /\ "#OO
M_ES5JT^,OVK]HS4/A7_8^W[)X9B\1?VM]ISNWW+0>3Y6SC&W=NW]\;>]>ET
M>5?\(Y\;_P#HH?P__P#"#OO_ )<T?\(Y\;_^BA_#_P#\(.^_^7->JT4 >5?\
M(Y\;_P#HH?P__P#"#OO_ )<T?\(Y\;_^BA_#_P#\(.^_^7->JT4 >5?\(Y\;
M_P#HH?P__P#"#OO_ )<T?\(Y\;_^BA_#_P#\(.^_^7->JT4 >5?\(Y\;_P#H
MH?P__P#"#OO_ )<T?\(Y\;_^BA_#_P#\(.^_^7->JT4 >5?\(Y\;_P#HH?P_
M_P#"#OO_ )<T?\(Y\;_^BA_#_P#\(.^_^7->JT4 >5?\(Y\;_P#HH?P__P#"
M#OO_ )<T?\(Y\;_^BA_#_P#\(.^_^7->JUY'-^UC\*8)GC;Q6I9&*DI873+D
M'L1%@CW'%1*I"'Q.QTT<-7Q-_84W*V]DW^1/_P (Y\;_ /HH?P__ /"#OO\
MY<T?\(Y\;_\ HH?P_P#_  @[[_Y<UU'P_P#BOX5^*4=Z_AC5EU1;(HMQ^XEB
M,>[.WB15.#M;D>AKK:<9*2O%W1E4IU*,W"I%Q:Z-69Y5_P (Y\;_ /HH?P__
M /"#OO\ Y<T?\(Y\;_\ HH?P_P#_  @[[_Y<UZ)XBU;^P/#^IZGY7G_8K66Y
M\K=MW[$+;<X.,XZXKR;]EW]J#1_VGOA /&FG:;+HM_;LT6HZ'<2^9)9RA!(H
MW[5WH\;(ZOM&0_3((JC,U?\ A'/C?_T4/X?_ /A!WW_RYH_X1SXW_P#10_A_
M_P"$'??_ "YK0_9Y^+W_  OCX,^&?'QTG^PAK4,DW]G_ &G[1Y.V5X\>9L3=
M]S/W1UKD/V<?VJ])_:*USQGIUEI$NCC1+K=I\TTWF#5M.:26**^C&Q=J/)!,
MNWYL;0<_,* -_P#X1SXW_P#10_A__P"$'??_ "YH_P"$<^-__10_A_\ ^$'?
M?_+FN9^,W[3&O>#?B)'\/?AS\,M1^*GC=-/75;VS@U*#3+.QM7=D0RW4V55V
M*MM3&2 3FN>M_P!L^\TSP/\ $F;Q?\-]0\&?$/P/H3>(+KPC?:C%-'>6N&VR
M6][$K(Z%D*%@GRGC!H ]'_X1SXW_ /10_A__ .$'??\ RYH_X1SXW_\ 10_A
M_P#^$'??_+FO&S^UU\<=#T'_ (2;Q-^RQJECX2AMQ>W5_H_C*PU.YCM]H8R)
M:JJN^%R<9'3G%?16C_%CPOKWPKA^(MEJD<WA"72SK U#!4"V$9D9F!&5(4'*
MD9!!!&10!S/_  CGQO\ ^BA_#_\ \(.^_P#ES1_PCGQO_P"BA_#_ /\ "#OO
M_ES5']EW]HR#]I3P#=ZZV@3^%-5LKPVMYHMU/YLL :-)H'+;$R)()8I!QQN*
MY.TU@_%7]J+6M"\?WO@+X7?#/4_BWXQTN*.?5[>VU"'3+'3%D7=&DUW,"@E9
M?F$8!)'<4 =9_P (Y\;_ /HH?P__ /"#OO\ Y<T?\(Y\;_\ HH?P_P#_  @[
M[_Y<U@_!7]IR;X@^-+OP#XW\#:I\+_B/;6?]HC0M2GCNX+RVW;6EM;N+Y)E5
ML!N 1GC.&QZ+\6/BGX>^"WP_U?QCXHNFM='TV,/)Y:[Y97)"I%&O\4CL555[
MDCH.: .8_P"$<^-__10_A_\ ^$'??_+FC_A'/C?_ -%#^'__ (0=]_\ +FO(
M-0_;,^)?A&Q?Q7XS_9N\2>&_AC&HGN/$"ZY9W5_:6YQB:?34_>1A<Y<;LH 2
M<XQ7U5I>IVFM:;::C87$=W8W<*7%O<1-N26-U#*RGN"""/K0!YI_PCGQO_Z*
M'\/_ /P@[[_Y<T?\(Y\;_P#HH?P__P#"#OO_ )<UZK10!Y5_PCGQO_Z*'\/_
M /P@[[_Y<T?\(Y\;_P#HH?P__P#"#OO_ )<UZK10!Y5_PCGQO_Z*'\/_ /P@
M[[_Y<T?\(Y\;_P#HH?P__P#"#OO_ )<UZK10!Y5_PCGQO_Z*'\/_ /P@[[_Y
M<T?\(Y\;_P#HH?P__P#"#OO_ )<UVGC+6M?T5-&.@^&_^$D:ZU*"UOE^W1VO
MV*T<GS;KYP?,\L 'RU^9L\5G_#[XI:3\2=2\8V>EQ74;^%]:DT*\:X155[A(
M8I6,>"<KB91DX.0>,8H YO\ X1SXW_\ 10_A_P#^$'??_+FC_A'/C?\ ]%#^
M'_\ X0=]_P#+FO5:Q/&NJZQH?A'6-0\/:%_PDVN6MK)+9:-]K2T^VS!25B\Y
MP5CW'C<PP,T <+_PCGQO_P"BA_#_ /\ "#OO_ES1_P (Y\;_ /HH?P__ /"#
MOO\ Y<UX2W[8_P ?E^("^"3^RK_Q4[::=8%C_P +$T__ (]!*(C)O\G9]\@;
M=V[OC'-?5W@;5]:U[P?I&H^(] _X1;7;FW62]T7[8EY]CE(^:+SD 63']Y1@
MT </_P (Y\;_ /HH?P__ /"#OO\ Y<T?\(Y\;_\ HH?P_P#_  @[[_Y<UTWQ
M<^)VE?!GX;>(/&VMQ7,^E:+;&YGBLT#S.,@ *"0,DD=2*ZR&031)(N0&4,,^
M] 'EO_".?&__ **'\/\ _P (.^_^7-'_  CGQO\ ^BA_#_\ \(.^_P#ES6I\
M?/BQ_P */^$NO^-_[*_MK^REB;[#]H^S^;OF2/\ UFQMN-^?NGIBNUU+4/[/
MTBZOO+\SR(&F\O.,[5)QG\* /-O^$<^-_P#T4/X?_P#A!WW_ ,N:/^$<^-__
M $4/X?\ _A!WW_RYKPSP1^V%\?\ XB>#=)\6:#^RH^H>'=4MEO+6[C^(-@&E
MA89#")XE?./X2 :^B?@7\8M.^.WPUT[Q=IVGWVC^?)-;76EZE'Y=S97,,C13
M0R+V971A^73I0!D_\(Y\;_\ HH?P_P#_  @[[_Y<T?\ ".?&_P#Z*'\/_P#P
M@[[_ .7->JUQWPE^*6D_&3P3#XHT.*ZATV:[N[1%O$5)"UO<R6[M@$\%HF(Y
MS@C.#Q0!S?\ PCGQO_Z*'\/_ /P@[[_Y<T?\(Y\;_P#HH?P__P#"#OO_ )<U
MZK10!Y5_PCGQO_Z*'\/_ /P@[[_Y<T?\(Y\;_P#HH?P__P#"#OO_ )<UZK10
M!Y5_PCGQO_Z*'\/_ /P@[[_Y<T?\(Y\;_P#HH?P__P#"#OO_ )<UZK10!Y5_
MPCGQO_Z*'\/_ /P@[[_Y<T?\(Y\;_P#HH?P__P#"#OO_ )<UZK10!Y5_PCGQ
MO_Z*'\/_ /P@[[_Y<T?\(Y\;_P#HH?P__P#"#OO_ )<UZK10!Y5_PCGQO_Z*
M'\/_ /P@[[_Y<T?\(Y\;_P#HH?P__P#"#OO_ )<UZK10!Y5_PCGQO_Z*'\/_
M /P@[[_Y<T?\(Y\;_P#HH?P__P#"#OO_ )<UZK10!Y5_PCGQO_Z*'\/_ /P@
M[[_Y<T?\(Y\;_P#HH?P__P#"#OO_ )<UZK4%[>0:=9S75S*L-O"ADDD8X"J!
MDDTFTE=@>8_\(Y\;_P#HH?P__P#"#OO_ )<T?\(Y\;_^BA_#_P#\(.^_^7->
MFZ??V^J64-W:3+/;3*'CD0Y#*>]6*$U)70'E7_".?&__ **'\/\ _P (.^_^
M7-'_  CGQO\ ^BA_#_\ \(.^_P#ES7JM>%77[5VCZ5^U</@CJFDRV%S<Z7#>
MZ?KAGW0W-PXD;[*R;!Y;[(I&4[CNV,, @98'0?\ ".?&_P#Z*'\/_P#P@[[_
M .7-'_".?&__ **'\/\ _P (.^_^7-6K3XR_:OVC-0^%?]C[?LGAF+Q%_:WV
MG.[?<M!Y/E;.,;=V[?WQM[URWQG_ &K-)^#?Q>\">!KK2)=1&OLK:EJ<<^R/
M1899TMK661=AW"6X<1CYEQAFY H W_\ A'/C?_T4/X?_ /A!WW_RYH_X1SXW
M_P#10_A__P"$'??_ "YK:^-WQ@TCX$_#G4?%^LVUYJ$%L\4$&GZ;%YMU>7$L
MBQQ01)D;G9V 'XFO$[7]K_X@^$+_ $^\^+7P$U7X;^"KZ[ALD\2Q>(;/54M9
M)G"1-=0Q /"A9E!8YVEL4 >I?\(Y\;_^BA_#_P#\(.^_^7-'_".?&_\ Z*'\
M/_\ P@[[_P"7->7>)/VJOBW<?%+QSX4^'?[/W_"P-.\*7T6GW.L?\)I::;OE
M>WCGQY,T61A91T+#CKV'H/P$_:.3XPZMXB\,:[X5U+X??$'PX8FU3PSJLB3,
ML4H)BGAF3Y)HFP1N7H1R,%20#0_X1SXW_P#10_A__P"$'??_ "YH_P"$<^-_
M_10_A_\ ^$'??_+FL#5/VK-)TS]J*Q^#S:1*Z3VR++XA\_$,&HR127$-B4V<
MN]O$\F[?_=&,M79_&[XUZ'\"?!\>N:Q;WVIW-W=1Z=IFCZ5 9[W4KR3/EV\*
M=V;!ZD  $T 9?_".?&__ **'\/\ _P (.^_^7-'_  CGQO\ ^BA_#_\ \(.^
M_P#ES7DLW[9?Q ^'XBUGXN_L_:Y\// DDB1R>)K/7;7619*[!5DNK>$!X8QN
M&X_,03C!-?5=O<17EO%/!(LT$JAXY(SE64C((/<$4 >7?\(Y\;_^BA_#_P#\
M(.^_^7-'_".?&_\ Z*'\/_\ P@[[_P"7->,Z/^UY\;/&EYKMQX+_ &:&\4>&
M]-UB^TA-73QW8VK3M;3O"[""6(.IRA.W\B>M>M_#_P"/EY\6OAQX:\5^#_!U
MW?27FL_V3K6DZA>Q6=QH?ERO%=O)NR)&A9/]6OS.&!&.E %O_A'/C?\ ]%#^
M'_\ X0=]_P#+FC_A'/C?_P!%#^'_ /X0=]_\N:]5KCO&'Q2TGP7XV\#^%[V*
MZDU+Q==W-I8-"BF-&@MGN':0DC VI@8!.2.W- '-_P#".?&__HH?P_\ _"#O
MO_ES1_PCGQO_ .BA_#__ ,(.^_\ ES7JM% 'E7_".?&__HH?P_\ _"#OO_ES
M1_PCGQO_ .BA_#__ ,(.^_\ ES6I\?/BQ_PH_P"$NO\ C?\ LK^VO[*6)OL/
MVC[/YN^9(_\ 6;&VXWY^Z>F*[^-M\:MC&1F@#RS_ (1SXW_]%#^'_P#X0=]_
M\N:/^$<^-_\ T4/X?_\ A!WW_P N:]5HH \J_P"$<^-__10_A_\ ^$'??_+F
MC_A'/C?_ -%#^'__ (0=]_\ +FM/XQ_%K_A4L/@Y_P"RO[5_X2+Q+8^'L?:/
M)^S_ &AF'G?<;=MV_=XSGJ*]"H \J_X1SXW_ /10_A__ .$'??\ RYH_X1SX
MW_\ 10_A_P#^$'??_+FO5:* /*O^$<^-_P#T4/X?_P#A!WW_ ,N:/^$<^-__
M $4/X?\ _A!WW_RYKU6N8^*'C7_A6WPU\6>+?L?]H_V#I-UJGV/S?*\_R86D
M\O?M;;NVXS@XSG!H Y'_ (1SXW_]%#^'_P#X0=]_\N:/^$<^-_\ T4/X?_\
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M %%%% 'E7[2W_).M(_['/PG_ .I#IU>JUY5^TM_R3K2/^QS\)_\ J0Z=7JM
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M'P<_93^$W[/^KZIJO@#P58^'M3U(%;B\1Y9Y=A8,8T:5V,<9(!V)M7*KQP,
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M#!@;1[5KVY62S,*;(]LRR"4X7CESG SG% 'Y[^(/"OBOX^_%CXKZ_K?P*O\
MXO7VA^);W3M/UF/XGQ:!_P (]! VR%8;,L#"0$67S'!#D[@,9SZIYFK_ !V\
M*?LR> /B[K<B>&O$EOJO]N+I^NPS1:[<6F$LX);^TD*2[UW.RHX+NIZ,,#Z9
M^*G[$_P2^-GC!/%/C+P!8ZOKZ[=]\EQ<6S3[0 OG"&1!-@*H_>!N!CIQ77>.
MOV?_ (<_$KX=6O@/Q'X/TS4/"-HB)::6L7DQV@12J& QE6B(4E04*D D9YH
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M>*X_V%_A+\*_#/AJYU[Q1\1[RZGA\-+=I83-H(N9KV:/SW(2(-;M#%N;M,<
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MW2_V?_#7[-?[6GP<N_!%SK-O-XQMM7M/$SZAJUS>-K#PVBS1W$YE=LR!]QX
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M"/Q \:V%K%H_A^ZN)8X]SI:P6B3L 3DD90G&3^M=)_PFGQ>_Y]]6_P#!,O\
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M?P*O_B]?:'XEO=.T_68_B?%H'_"/00-LA6&S+ PD!%E\QP0Y.X#&<_<G@O\
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M >5?\+D\7?\ 1"?B!_X'>'O_ ):T?\+D\7?]$)^('_@=X>_^6M>JT4 >5?\
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M'>'O_EK7JM% 'E7_  N3Q=_T0GX@?^!WA[_Y:T?\+D\7?]$)^('_ ('>'O\
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MA[_Y:T?\+D\7?]$)^('_ ('>'O\ Y:UZK10!Y5_PN3Q=_P!$)^('_@=X>_\
MEK1_PN3Q=_T0GX@?^!WA[_Y:UZK10!Y5_P +D\7?]$)^('_@=X>_^6M'_"Y/
M%W_1"?B!_P"!WA[_ .6M>JT4 >5?\+D\7?\ 1"?B!_X'>'O_ ):T?\+D\7?]
M$)^('_@=X>_^6M>JT4 >5?\ "Y/%W_1"?B!_X'>'O_EK1_PN3Q=_T0GX@?\
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MD\7?]$)^('_@=X>_^6M'_"Y/%W_1"?B!_P"!WA[_ .6M>JT4 >5?\+D\7?\
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MK7JM% 'E7_"Y/%W_ $0GX@?^!WA[_P"6M'_"Y/%W_1"?B!_X'>'O_EK7JM%
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*BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image1a01.gif
<TEXT>
begin 644 image1a01.gif
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9A0 PH-MNL_UD0@,'O+?0  Q\H-@& 0$ .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image2.gif
<TEXT>
begin 644 image2.gif
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$! 0 .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>image3.gif
<TEXT>
begin 644 image3.gif
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MB0]"3O# M:O7KUP16 R00J)&@08K/%"@@(*)LP)_#KP DFC(!64AUI1@MR\
M!"OB7I"9H82'#D)U,EBA@45=  PD(AUI40*+$1D.F$ A(D'(JB$I;.! N 0(
M#78%G"#A.&0 LRQ(^R5:(#!L@B8X]FU@VV=&%7R)$L"@42X)L;,M"B#NF\4*
MW<E=OXW+ G7TH98EIB ,E ';[^#90HD@0<*S1:,;H"<E$$(%])"6*\"4*4 R
M8<H )K 8#("G^\\X6;#!9!8YP((#"JC  @D#<* "<J!9)%I6(24%6 9#"4#"
M"?7A=-4*CV&T0@44E&CBB118\,$'YD%FE@F/72=3!=0)))^,(7$PD%PK3!!
;= @\U%Q$&A PE %N%;?!DDPVZ>234"X9$  [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image4.gif
<TEXT>
begin 644 image4.gif
M1TE&.#EA'@ = /0  )F9F:"@H*BHJ*^OK["PL+:VMK>WM[V]O;Z^OL3$Q,O+
MR\_/S]'1T=34U-?7U]W=W=[>WN#@X./CX^;FYNGIZ>SL[.WM[>_O[_3T]/KZ
M^OW]_?___YF9F9F9F9F9F9F9F2P     '@ = $0(_P W"!Q(, ,%!@@9.+A
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:&7K@A0'Z3>150YL-U-H!^0$@0 *0:180 #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>ligandlogo41719.jpg
<TEXT>
begin 644 ligandlogo41719.jpg
M_]C_X  02D9)1@ ! 0$ V #8  #_X1#H17AI9@  34T *@    @ ! $[  (
M   *   (2H=I  0    !   (5)R=  $    4   0S.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $QI+"!*96YN
M>0  !9 #  (    4   0HI $  (    4   0MI*1  (    #.34  )*2  (
M   #.34  .H<  <   @,   (E@     <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0        $" P0%!@<("0H+_\0
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MNQI-NR)**I6VM:;>S"&TOH)I",A$<$FKM*,HR5XNXY1E!VDK!1115$A1110
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MCV->L_"+_D5[G_KZ/_H*UQGQ2_Y'B;_KE'_Z#79_"+_D5[G_ *^C_P"@K3Z
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MC5XV#(PRK \$4K,%4LQ 4#))/2@#P?Q]X;LO#&LV]KIS3-') )&\U@QSN([
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DB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>ligandlogo41719a01.jpg
<TEXT>
begin 644 ligandlogo41719a01.jpg
M_]C_X  02D9)1@ ! 0$ V #8  #_X1#H17AI9@  34T *@    @ ! $[  (
M   *   (2H=I  0    !   (5)R=  $    4   0S.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $QI+"!*96YN
M>0  !9 #  (    4   0HI $  (    4   0MI*1  (    #.34  )*2  (
M   #.34  .H<  <   @,   (E@     <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0        $" P0%!@<("0H+_\0
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MNQI-NR)**I6VM:;>S"&TOH)I",A$<$FKM*,HR5XNXY1E!VDK!1115$A1110
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MCV->L_"+_D5[G_KZ/_H*UQGQ2_Y'B;_KE'_Z#79_"+_D5[G_ *^C_P"@K3Z
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MC5XV#(PRK \$4K,%4LQ 4#))/2@#P?Q]X;LO#&LV]KIS3-') )&\U@QSN([
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DB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>proxycard1of2.jpg
<TEXT>
begin 644 proxycard1of2.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_X1#H17AI9@  34T *@    @ ! $[  (
M   *   (2H=I  0    !   (5)R=  $    4   0S.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $QI+"!*96YN
M>0  !9 #  (    4   0HI $  (    4   0MI*1  (    #,S0  )*2  (
M   #,S0  .H<  <   @,   (E@     <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0        $" P0%!@<("0H+_\0
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MUYV-*>45JDG%27Q.'7=)OMMH>ST5PTNM:BMYXA07;A;718[B$<?)(48EA[Y
MI?#FM:C>>)M(M[FZ>2&?P_'=2(0,-*7 +?6E[-_U\_\ (YW@*B@YW6BO^"?Z
MG<45Y?IOB76)OB)XAT^6_D:UM8+AH8L#"%<8(X[51\.^+-<O/!SW=SJ,LDXU
M:W@#D#.QL97IWS35)M?=^)T/**R5^9?9[_:VZ'KU%%%9'CA1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 >>>+/\ D==4_P"Q6G_]#-9GC/\
MY(CHG^Y;?^BS6GXL_P"1UU3_ +%:?_T,UF>,_P#DB.B?[EM_Z+-=,?ACZK\V
M?68;XL-ZQ_(PM>_UG@+_ *]8/_0UK;U'_D+W/_8VVW_H%8FO?ZSP%_UZP?\
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M*TSQ=_KO'_\ N:?_ $I_QJ_Y!6B?[[_^@K4PWA_7V4<F$_WG#?U_RZID%_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%<UXG^(?A;P=,D'B#5H[>X<!E@5&DDP>Y502!P>3B@#I:
M*X*R^-O@"^NE@CUY8F8X#3V\D:_BS* /Q-=Z"" 0<@]"* "BBN4U3XB:38:I
M-IEA:ZCKE_;_ .OM])M3.8?9VR%4^Q;- '5T5@>'/&FD>)YI[:Q>>"^ML&>Q
MO(6AGB!Z$HW./<9%;] !1110 4444 %%%% !1110 4444 %%%><^/_C5X>^'
MOB33]'U))KF:X.ZZ-O@_9(S]UF'<D\X'. 3Z @'HU%5-+U6PUO3(-1TB[BO+
M.==T<T+;E8?Y[=JMT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110!YYXL_Y'75/^Q6G_ /0S69XS_P"2(Z)_N6W_ *+->BW>
M@Z;?7LMW=6WF3S6K6;OYC#,+')7 ./QZ^]1WOAG2-0T.#1[RT\RPMPHCA\UQ
MMVC Y!R>/>ME-))=K?FSVZ.84H.DVG[C3?R734\AU[_6> O^O6#_ -#6MO4?
M^0O<_P#8VVW_ *!7=S^"] N38&>PW'3D5+7]](/+ .0.&YZ=\U/)X7T>69I9
M+/+M=K>D^:_,RC ;K^G3VJ_:QNOG^:9T/-:#459Z)]NLK]SE]!_Y /CC_L(W
MG_H KSNQ_P"2-:G_ -A2/_T$5[G!H>G6MO?0P6^V/4)'EN5WL?,9QACR>,CT
MQ6<G@7PY'HTNDIIV+*643/%Y\G+@8!SNSV]:F-1*_P#V[^ J&:4:<I-IZRB^
MFRWZG*^%?^0SX4_[ 4G_ *$*SO"GWO 7_774/ZUZ3:>'M+L9K26UM=CV<!MX
M#YC'9&>2O)Y^IYJ*T\+:/8_8/LMGL_LXR-:_O7/EF3[_ %/.??/M3]HKO^OY
MO\S*68TFI:/6_;M47?\ O+\3SW4/^3AK3Z+_ .B37/:)_P @SQU_UR_]J&O9
M)/"^CR^(4UR2SSJ28VS^:_'&W[N=O3VJO!X(\/6T5]'#I^U-0&VY'G2'S!G/
M][CGTQ251<J7E;\3HAFU",(Q:>D8+I]F5WU^X\\U[_CS\:_]>VF_R6K?QJ_Y
M!6B?[[_^@K7?7'A/1;I+U)[+<M^L27(\UQY@CQLZ'C&!TQGO3]:\,:1XBB@C
MUBT^TI 28QYKIMSU^Z1GI3557B^W^21E2S.C"O2J-.T=]OY(Q[]T_D>;W_\
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MSL\47GR#:S=3G=D_B:I58W;\[FU#-J%.;DT_XCGTV::[[Z_\$Y>?_C_\5?\
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M'%Q+;:#>.]U#'YCP31%'"YQD9X(R1T/<5U=?+?[-_P#R4ZX_[!DO_H<=?4E
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MU^QL+K8'\FXF"MM/0X/;@T =!17'_P#"VO '_0W:3_X$BC_A;7@#_H;M)_\
M D4 =A15#1M=TOQ%IXOM#OX+^U+E!- ^Y2PZC-7Z &NZQ1L\C*B*"69C@ #N
M37QM\</BO+\0/$7]E:,[?V#8R[8 N?\ 2Y.AD(].RCTY[X'>_M&?%ORUF\#^
M'9OF88U2X0] ?^6 ]_[WX#UK,_9V^$9U*ZB\:>)+;_0X&SIMO(/]=(#_ *TC
M^ZI^[ZGGL,@'?_ 7X2_\(3HW]NZ["O\ ;M^G",.;2(\[/]X]6_ =CGV*BB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MV9_&@#[D^UV__/>+_OL4[SXO+W^8FS.-VX8_.OF7_ADO4O\ H:[7_P  V_\
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M?^ABODNOK3X__P#)([W_ *^(/_0Q7R70")K2UGOKR&ULXGFN)W$<<:#+.Q.
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M\;7_ -*I: /J6O*_VD/^2*:C_P!?%O\ ^C!7JE>5_M(?\D4U'_KXM_\ T8*
M/$O '[0E[X#\%V?AZ#P_;WB6K2,)GN60MO<OT"G^]BND_P"&M-2_Z%2U_P#
MQO\ XFO2_P!GFWAD^".C,\4;-YEQR5!_Y;O7IOV2W_YX1?\ ? H EHHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#E/B;_R3K4_I'_Z-6H?#
M?_)1/%/_ %RL_P#T4:F^)O\ R3K4_I'_ .C5J'PW_P E$\4_]<K/_P!%&MH_
MPW\__;3VJ/\ R+I_]O?^E4CS7PW_ ,BYXX_ZXK_Z&U;?A'_D"^#?^PE<?^@M
M6)X;_P"1<\<?]<5_]#:MOPC_ ,@7P;_V$KC_ -!:MY[/Y?D?1XWX:O\ B_\
M<3)?"GWO 7_774/ZT[4/^3AK3Z+_ .B33?"GWO 7_774/ZT[4/\ DX:T^B_^
MB30_C^4OS9RR_P!XJ_\ 7NI_Z7(Y[1/^09XZ_P"N7_M0UU^N?\C%=?\ 8H2?
MS-<AHG_(,\=?]<O_ &H:Z_7/^1BNO^Q0D_F:F6_R_0UQ/^\O^OLTRIXS_P"2
M(Z)_N6W_ *+-86O?ZSP%_P!>L'_H:UN^,_\ DB.B?[EM_P"BS6%KW^L\!?\
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M.N/^P9+_ .AQU]25\M_LW_\ )3KC_L&2_P#H<=?4E ,****!!1110 5\F_M
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MZ"R5?Q&0?Y5UM!(4444 %?)O[0'_ "5N[_Z]H?\ T"OK*ODW]H#_ )*W=_\
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M_7O'_P"@B@&6Z***!!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% '*?%'_DE?B+_KQD_E7Q77VO
M\2X9+CX8>(HX4+N;"4A0.3A<G]!7Q10-'H'P:\6Z3X,\;S:EKTLD5L]D\(:.
M,N=Q9".![*:]T_X7_P" O^?^Z_\  1_\*^2Z*!GUI_PO_P !?\_]U_X"/_A1
M_P +_P# 7_/_ '7_ ("/_A7R710%CZT_X7_X"_Y_[K_P$?\ PK5\.?%WP?XI
MUJ+2M*U"0WDP/E)+ R;\#) )&,X!KXVKJ?AFMPWQ1\."T.)/[0A)X_@# O\
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M^T7XTMI%-U'IMXF?F$EN5)'L588KT7PI^T7H&K3QVOB*TDT:9S@3;O-@S[D
M%?Q&!W->$>)?AWXJ\(QF77=(F@MPVW[2A$D77 ^920,^^#7,T ??D,T5S DU
MO(DL4BAD=&RK ]"".M?/?[3.@.FHZ/XAC3,<D1LI6'9E)=/S#/\ ]\UC? KX
MD7&A>((/#6J3M)I6H2".#><_9YC]W'HK'@CU(/'.?HKQ1X;L?%OAN[T;5%)@
MN4QO7[T;#E77W!YH%L?"U?07P-^*^G6FC1^%O$UVEHT#$6-S,V$9"<^6S'@$
M$G&>,8';GR+QKX#UKP+JS6FKVY,#,1!=H/W4X]0>Q]5/(_6N:H&??RLKJ&1@
MRD9!!R#5>_U&RTNS>ZU*[AM+>,9:6>0(H_$U\-6/B#6=,B\K3=6OK./GY+>Y
M>,?D#5>]U*^U*42:C>7%VXZ-/*SD?B30*Q[E\3OCV+F&;1O LKHK92;4\;21
MW$0ZC_>//IZUX*26)).2>23WK<\*^#=<\9:D+/0;)YSG]Y,PQ%$/5FZ#Z=3V
M!KT/XI?#73?A[\.M(2$BYU*XO?\ 2KPK@M^[/RKZ*/UZGV!GC]?=GAK_ )%/
M2?\ KRA_] %?"=?=GAK_ )%/2?\ KRA_] % F</\?_\ DD=[_P!?$'_H8KY+
MKZT^/_\ R2.]_P"OB#_T,5\ET CZ-_9B_P"0#KW_ %\Q?^@FO<J\-_9B_P"0
M#KW_ %\Q?^@FO<J 84444""OAOQI_P C[K__ &$[G_T:U?<E?#?C3_D?=?\
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M&K5_J-GI=FUWJ-S';VZ=9)&P*Y+0-/M]7T7Q)/?Q)+)>WMS&[,H)"K\B@'V
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MQGKC/K7844 %<CXK^&'A7QI>K>ZY8,]VJ>6)XIF1BHZ X.#CW%==10!YM8_
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MZY&<,.QJ:BDY71SU\1[:-N6VK?WVO^*N%%%%0<@4444 %%%% !1110 4444
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M.CC2&-8XD5$0855& H] *4HJ*\[_ .1SXJC2I4THWO>2?RL.HHHK,\\****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH *BFM;>X&+B".7_?0-_.I:* *G]DZ=
M_P! ^U_[\K_A5B*&*!=L,:1KTPB@"GT4 %%%% !1110 4444 %%%% !1110
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M8VNFWUK=/-?MJ.?M<]RV7EXP.1C  Z8Z5'I'A&#3-1CO9]0O=1EMXS%;?:Y
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M %%%% !1110 4444 %%%-D8I$[JI<JI(4=3[4 .HKE?^$OU/_H3]7_\ '/\
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M;76O$FG0_+!;WPDC0=$\Q Q ]!G-2:YK>I?V_%HF@M:13^1]HN+F\R4C3.%
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MK'+I\UK(DBKAB25#9/ON.:?/:R^.-6N;B.UN;.QBTV6UBDNHC&SRR]2%/.
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M1_8+?]%(LO\ P+?_ !K=_P"$-^&G_0P1_P#@QC_PH_X0WX:?]#!'_P"#&/\
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M.F,8IG]EZM_T,$__ ("Q?_$UH7MS]CT^XN=N_P F)I-N<;L#.,_A5'PSK?\
MPD7ARTU7[/\ 9OM 8^5OW[<,5ZX&>GI3UM<V4JOLW4LK7MM'=_+R&_V7JW_0
MP3_^ L7_ ,30-+U;_H8)_P#P%B_^)J'0_$O]LZ]K6F_9/)_LJ5(_,\S=YN[=
MSC Q]WU/6GW_ (A^P^+=)T3[+O\ [125O.\S'E[%+?=QSG'J*=I7L:.-=3=-
MQ5TK[1VMS?EJ._LO5O\ H89__ 6+_P")J2;3M3DE+1:Y-$N!A!;Q'''J1^-:
ME8LGB'R_&\7A[[+GS++[7]H\SI\Y7;MQ[9SG\*2N]C.$JM1OE2T5]H[?</\
M[+U;_H8)_P#P%B_^)H_LO5O^A@G_ / 6+_XFM>BE<S]M+LON7^1EIIVIK%(K
M:Y,S,!M<V\0V<^F.?3FF?V7JW_0P3_\ @+%_\36O11</;2[+[E_D9 TO5O\
MH8)__ 6+_P")I/[+U;_H89__  %B_P#B:V**+A[>79?<O\C(.EZM_P!#!/\
M^ L7_P 33Y=.U-PGEZY-'M3#8MXCN/KR.*U**+A[:79?<O\ (JV%M=6R.+R_
M>\+'*L\:IM]OE JU112,I-R=V%%%% @HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?0?#\VJ:7X)U..9$CTRW9I$8'+[T4#'Y46A:_P#6W^8E1PGL_:=-NN_L[_\
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MKO3S90XSDXX Q0!]<45P'CKXNZ1X(L;,RV\E[J%[ )XK.-PI5"."[<[02".
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M4ZG\3W\<>*M,_LI5$DBQM%Y)DE=60@1GD !F))[XZ\X][H%U/GK_ (9?N/\
MH:HO_  __'*]0^&'@!_AWH%UILFHK?FXNC/YBP^7M^55QC)_NUVM% 'E?[1'
M_)+?^WZ+_P!!>O/?'6FV5I^S7X3N+6TAAFEO(S)(B ,Y:.4L2>^2J_D*]3^-
MF@:IXD^'WV#0[.2\NOM<;^5&0#M ;)Y/N*Y+QIX*\1:E\ O#.AV.E33:E:7$
M3SVRE=T8$<H)/..K#\Z%LQ]CS3QQ=W#7G@2$0?;UAT*Q,=D5+"8EF^7 Y.[
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M? _Q1=B_T6WU72+S]R7GB#17,?4 /@[&QU!S[@C!KZ)\!ZWHNO\ @RQO/#,
MMK +Y:VVT*8"O5"!Z?KG/>O#];O?C))I=UX7UK0I=3AO&(^T"S$P4;LC$B?*
M!GD;N1[8KU?X/>#;WP3X"2QU4!+VYN&NIXE8,(BRJH7(X)P@SC(SGDT=!LQO
MVB/^26_]OT7_ *"]>>^.M-LK3]FOPG<6MI##-+>1F21$ 9RT<I8D]\E5_(5Z
MG\;- U3Q)\/OL&AV<EY=?:XW\J,@': V3R?<5R7C3P5XBU+X!>&=#L=*FFU*
MTN(GGME*[HP(Y02><=6'YT+9AV."UY1JOBSX::5?MOLI-+TV)XV^[M>0JWYC
MC\*Z+]HJTM]%\4^']5TN*.WNVC8EHU"\Q,I0X'?YL9_V1Z5=\:?"[Q!>>"_"
M6L:);.-<T?3X+>XME(\T;/F4KS@E6+<=3D8Z50TWPMX[^*?CK3M4\;Z9)IVG
M6.T2"> P JISM6-N26/4].OH!0MPZ$7Q:NW\$_'2+Q#:0L9;BQ\U2#@%VB>#
MK[8!/UKS?0=1O/"EXFHHK1IJ6GW,<14<,KK)"#S_ '9!G_@->\_'SP/K'BN#
M1KKP]927D]LTL<L<9 .UMI!Y(Z8/YUS?C_X5ZW<^ /!MOH>F//>V-HT=[#&5
MRK/M<\D]G,GYT=!Z'8_L\:6;+X8F\;EM0O))@?\ 97$>/S1OSK1^.L4;_!W6
M9'C5GC\C8Q4$KFXCS@]JZ7P-H[Z!X#T;3)XQ'/;VB"9!_#(1EQ_WT35+XG^'
M[OQ1\-=7TG31NNIHT>)./G*2*^T9P,G;C\:'N2CS_P "!;3]F"]OK>-([M;&
M^VSA!O'S2#KUJA\"?#^EZM\+/$CZA;Q2O=W$EM*[J"0BQ*R\]L%V.?7Z4_X2
MZ7XRN=/F\)^(](N=-\-Q6ES#(9K<QM,\IQC+<G[[$%>/TKEH=!^)_P /AJ_A
MC1-*N+RQU0E!=6UNTB8QMWJP_P!62#@[N>/;- SI_P!F*ZE>U\2VK$B&*2WD
M1/[K-Y@/Z(OY5V_QPT7^V?A3J!1%>6Q9+N/=VVG#'_OAFI/@WX#NO _A.4:N
M%74[^037"*P;RP!A4)'!(R2<<9..<9/<ZG81:KI-WI]R-T-W \$@/=64J?T-
M##K<^2[_ %I_&NA^ _"L4Q-S;EK:0)T4R3!$R/4(J_F?6NQGLX-1_:SM].O4
M62SM9$6&)QE5$=IO08_WE!J/X3_"SQ+I7Q+L[_Q#I4EK9V/F2AV*E7?:54#!
MSU(/_ :Z#XK>!O$EAX^MO'G@FV>[N$*-/#"F^171=N=O5E90%('/7UIAY&-X
MYMX=#_:<\/RZ4BP->7%H\WEC )>3RWX'JHY^M)<VEN/VOUM_(B\CS$_=;!M_
MX\@>G3K5_P !^#?%_B[XG1^-O'=D]C%;D2QPS1F-F=1A%6,\JJX!R?0=221!
M\1O#GC#0_C8/%_AC1Y]3$XC:%HH&E6-A"(B'"\CIG)P.1Z&D!E?'N:2/XK:-
M:P6BW<4%I 8K (2LI,K_ ";1UW<# YK$\27OB_Q-XMT[7O\ A!KS3KNR:/'V
M2PF4.4;<I.1U' SZ >E>@?$3X>>+/$&@>'?$UJC2^)[&W3[;$NU9-V[>"N/E
MRC,W ]L=*L^#/$'Q?\0>+;&75M*&GZ5 2EVES;&W61>,MAOF+^FWC/H,T(.A
MEG39/^&PPV#L(^T9R/N_8\?^A<5[]7D!N?B;_P +V$(CN?\ A&_._P">8^S?
M9\?WL??_ !SGVKU^CH(**** "BBB@ HHHH **** "HKEMEI,Q<H%1CN R5XZ
MU+4-XP6QG9DW@1L2I_BXZ4GL5'XD>3?\)?IW_0^:Q_X K_A1_P )?IW_ $/F
ML?\ @"O^%8?_  DFD?\ 1/K?_OX__P 31_PDFD?]$^M_^_C_ /Q-=_(NWY'W
M?U./_/N7_E+_ "-S_A+]._Z'S6/_  !7_"E7Q?IY8 >.]8//3["O/Z5A?\))
MI'_1/K?_ +^/_P#$TY/$FD&1?^+?VXYZ^8_'_CM-4U?;\@^IQ_Y]R_\ *7^1
M[R.@HH'045P'P04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M&-;G(_\ "2^,?^A+C_\ !M#1_P )+XQ_Z$N/_P &T-<U_P ([H7_ $3C5_\
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M;&,LTD+1KPS @#[P!X)S[5?\'V/Q$L[RWMO%-WHC:9:0^4#:)(TUP0 %8EL
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MQ%;R6ZZ9;Z.-.2+<WFA@V0<8QC'OGVK6\=Z!=>*/ VJ:-I\D,=S>1!(VG8A
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M8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/7D5/10 BJJ(%10JJ,  8 %+110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% &=!H&D6VLSZO;Z;;1ZC<#$MT(AYCC &-W7
MH!6C110 4444 %%%% !1110 4444 %%%% !1110 4444 %17)Q:3'Y/N-_K!
M\O3O[5+45UO%I-Y:[GV-M4C.3C@8I/8J/Q(\?^UQ^OPY_P# =O\ XFC[7'Z_
M#G_P';_XFG?;/'__ $*EE_X +_C1]L\?_P#0J67_ ( +_C7=]WWGVW+YQ_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% '.^.O%L?@KPG<:LULUW/N6&UM4.#
M/,YVHF>V3^F:Y-?#WQ=U:%+NZ\<:;H$L@RUC9Z3'<+'GL7D))(]N*/C?_P >
M?@G_ +&^P_E)7IU 'F/_  A?Q7_Z*O%_X3UO1_PA?Q7_ .BKQ?\ A/6]>G5Y
M9JOB#XFZGX^\0Z5X)7PV+#2)((\ZDLPD)D@20\J<'ECZ4 2_\(7\5_\ HJ\7
M_A/6]'_"%_%?_HJ\7_A/6]0_\7V_ZDG_ ,F*/^+[?]23_P"3% $W_"%_%?\
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M,(QE%WO?I;;KZ=O1A1114G.%%%% !1110 4444 %%%% !1110 4444 %%%%
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M/+C';IG]*/V=?^07XD_["/\ 0T+77R_R!Z:'>?#SQI!XZ\*1:DB"&ZC8PWD
M_P"6<HZX]CG(^N.H-=37C?PD)M_BS\0;.VYM!>%N.BL)7 '' ZL/P]J]DH#K
M8****0!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !396987:-=[!257.,GTS3JCN &M90R&0%""@ZMQTH8UN<C_P )
M+XQ_Z$N/_P &T-'_  DOC'_H2X__  ;0US7_  CNA?\ 1.-7_P# EO\ XY1_
MPCNA?]$XU?\ \"6_^.5TVAV_K_P(^F]CA/Y%_7_<8Z7_ (27QC_T)<?_ (-H
M:4>)?&!89\&1@9Y/]K0US/\ PCNA?]$XU?\ \"6_^.4J^'M"# CX<ZL.>OVE
MN/\ R)32AV_K_P "%['"?R+^O^XQZM10.E%<I\R%%%% !1110 4444 %%%%
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M]$M/^/.'_KFO\J\A^+/BW1?''A@>!/!^HV^M:MKD\*#[!()TMXTE61I793@
M!?7/->PQ)Y4*1YSM4+GUQ0 ZBBB@#BOBAX#G^(/AVWTRVOH[)HKD3&22,N"
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MCINP>E>L^#M-N-'\%Z38WKR2745JGGM*Y9C(1E\D\GYB:VJ* "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J
M*[&ZRG&\1YC8;R?N\=:EJ.X5'M95F;;&R$,<XP,<TGL5'XD>(?V"W_12++_P
M+?\ QH_L%O\ HI%E_P"!;_XUN_\ "&_#3_H8(_\ P8Q_X4?\(;\-/^A@C_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M00B0298=000 .N3Z>N*3V!;GA'PO;X87NN:%;SV6I6NOQR1/'<S2X@DN5((
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M:I:BNMXM)O+7<^QMJD9R<<#%)[%1^)'C_P!KC]?AS_X#M_\ $T?:X_7X<_\
M@.W_ ,33OMGC_P#Z%2R_\ %_QH^V>/\ _H5++_P 7_&N[[OO/MN7SC_X&O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% ",JNA1U#*PP5(R"*@M+"ST^
M$PV%I!;1$DE(8PBD^N!5BB@"O_9]F(#"+2#RBVXQ^4-N?7&.M3@!5 4  #
M[4M% %5-,L(KY[V*RMDNW&&G6)1(WU;&32W6FV-[+')>V5O<21<QO+$KE/H2
M.*LT4 5UT^S7R]MI /+.Y,1#Y#ZCCBI([:"*5Y8H8TDD^^ZH 6^I[U)10!6M
M=-L;&626RLK>WDE.9'BB5"Y]R!S5@@,I# $$8(/>EHH JV>F6&GLYL+&VM3(
M<N8(53<?? YK+\-^#M-\+WNKW=@]Q)/J]T;FY>=@QW$DX& .!N/7)YZUO44
M0SV=K=,#<VT,Q48!DC#8_.DAL;2VDWV]K#$^,;HXPIQ^%3T4 5ETZR6_-ZMG
M;B[8;3<")?,(]-V,U*UO"\ZS/#&TJ#"N5!9?H:DHH A@M+:U:5K:WBA,SEY#
M&@7>QZDXZGWH>TMI;J.YDMXGN(@1'*R N@/4 ]1FIJ* "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ J.XC:6UECC;:[H55L]"1UJ2H[G_CUE^_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M1SCGG@G.<5].Z-J2:SH5AJ<*E8[VVCN$4]@ZA@/UKY[TCP=XO\*7,N@+\/\
M2]?+7GF1ZG=PJR&+@$;L_*#C(R<C)X-?1=G;QVEC!;001V\4,:QI#%]R, 8"
MKP.!T'%'0;W)J***!!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %-E9EA=HUWL%)5<XR?3-.ILD:RQ-'(,HX*L/4&@:
MWU./_P"$E\8_]"7'_P"#:&C_ (27QC_T)<?_ (-H:E_X5=X._P"@/_Y-3?\
MQ='_  J[P=_T!_\ R:F_^+K?FI]OZ^\]KVV7?R?^2O\ ^6D7_"2^,?\ H2X_
M_!M#2CQ+XP+#/@R,#/)_M:&I/^%7>#O^@/\ ^34W_P 72CX7^#U8$:1R.G^D
MS?\ Q='-2[?A_P $/;9=_)_Y*_\ Y:=91116!X@4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M)F(-NZ@*" <D@<\BCK872YUU%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M1O?2RM?1Z>=]V]DU9ZF=XE\.7WPZU;^W_#"HEDD8BS._F-N;(/!_"I_$DWQ
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MI4J,+@CVXJG-\.?#5QK.EZG)9,;C2K9;2U'F-M6-00H*]#@,>:=];BZ6./\
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MX@MM9UFUE>[MU"_NY2BR '(W =<?A3CHQ/8\;\21M\-O$]]K^BW>C>(=!O\
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M>BN^UWZ:?YE6N[+O;YZ_Y'M]8.E>++;5_%VM:!;V\J2Z.(O.E<C:YD!("CV
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MG'/IQWHV6N__  $RFM=/ZUL>N>*?%EMX573/M-O+.VI7\=C$(R %9S]YB>P
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M=Q113;ON2E;8****0SSF7X97&H?\)S!J5S;K;^(Y8Y+5HBS-$4'!8$ ?>P<
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%?#]UK"ZM<Z+82Z@I!%T]LADR.AW8SD>M:U% &9J?AO1-:N(9]8TFROI8/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M)!;*K10L6(5@""<'(Z D'/:OKBJ)"BBBD 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M<W3S@2QN/NA4SR/P/X8YU7N[:-L/<1*=VW!<#GT^M'0":BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MK5] :.816(@Q*K>8W)?OSD_C7I7B6>:U\)ZM<6N?/BLIGCQ_>"$C]:X'P_\
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MK;9^,8/[4S_PD[NV[[/_ ,>VY2O][Y^O^S5U-6VNTK?.5U^!,-&K]X_@K/\
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M_P -'PWX='VS5Y&@T[2([D[0=[;B9&YP.I)[G\:O0_%@V?A_Q#-XCT9[#5]
M"?:+%)@ZR;^(RKXZ$D>N*J6C?D*-Y)>9Z/17)>"_$?B;7'D/B/PRFDP-"DUO
M<17BS+*&_AP.AQ6YKU[J&G:+/<Z-IAU6]0#RK03"+S"2!]X\#&<_A2>FX+78
MT:*\]T3XB:M-J&N:3XE\/IIFJ:78&^6..Z$J2ICIN X.<>OZ5DZ1\7]:NI-
MO-7\)BQT77+@6L%XMX)&\PG .S&<9'?'0FFE=V7]?U8-E_7]=3U@D $DX ZD
MTR*6.>%98)%DC<95T;(8>H(KR/Q_X^U;5-,\6Z3X>\/?;=+TVWDM;_4#=*AC
M<H=Q5#]X+W^G:N[^'?\ R33P[_V#8/\ T 4EJF_3\;_Y ]';U_0WYKJ"VV_:
M)XXMYPN]PNX^@S4M>+VGA33_ (J^._&-SXE\V>#39AIVG(LK*MN5!W. I&3D
M9YXYKMTM_$7@KP)IVFZ/;-XKU" B#S)9EMOEY(9BQ/ &!C.>E"^&[\OQ&U[U
ME_5CL:*\UMOBI>KX2\37VJ:$MIJOAQU2XLQ<[D?<>"' ^OK3_#WQ+UF]\5Z3
MI7B3PQ_9$.MV[3V$RW:REMJ[L, .,CGU&1^#2N[+^M+_ )"V5_ZT/1Z*\W\1
M?$7Q-X8U W&J^#Q%H O%M?M@OE:1@3@2! ,X/H?SJ?Q3X^U:'Q+=>'O"?A[^
MV;BSM!<7SM=+"(E8<*N>K8YJ6_=NOZTN.VMOZ['?1313H6@D210Q4E&! (."
M..X-/KROX4WVHZ?\!;*ZT?3#JMZCS>7:"81>83,P^\>!C.?PK=\'^.-5U?Q1
M?^'/$VA+I.IVD"W($5R)D>-CCJ.AY%6XVDXDWTN=O1114C"BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^H([5TB_!GX>*P(\)V&0<\JQ_K7865C:Z;8PV>GVT5K:P*$BAA0(B*.P X%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'+J^DR$&9% \Q0Q5@=O&5; R.H/MD@CU.BJ.MG41H-Z=#,(U$0L;;SQE"^.
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M=0?3YG34444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%>6_%GQMJL5[9>!/ P\SQ+K2D-
M*&P+* \&0G^$XS@]@">N,@$GCCXNG3-</A7P)IK>(_%#@@P1\PVI]9&R.F>1
MD8[D5C6_P:\1>,Y!??%SQ9=78<AAH^FR>7;1<D@'C![<A0>/O'K7=?#WX=Z/
M\/-"%GIL8EO)@#>7SK^\N']2>R@DX';ZY)Y>Z_:'\&Z9XMU'0M76_L_L-S);
M->FWWPLZ-M8#;EN#G^'M]* -W3?@S\/=*A$=OX5L)0/XKI3.Q_%R:L77PE\
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M*3T^[&H^IHZH+V(O%&DZ5X6_9LLM%UZYGL/.2 %H;<32>>S^<RA2R@]''+#
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MWC;X:Z5K$[9NS'Y-U_UU0[6/XXW?1A785X]\$%_L?Q9\0_"X0)%8ZS]IA5>
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M\,Z/-/-I=M))+)81,SL8E)8DKDDGG-<Y^TK_ ,DVT_\ ["T?_HF:N_\  /\
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M8#_<'_U^I&/5[>WAM+:.WM8DA@B4)''&NU44<  #H* ,/_A ?!__ $*>A_\
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ML=,MX-0N@PGN43#R!B"<GW(!_"O#?B)\/M7USQE=:3X4\#6=E \B.VKJ2JR
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M,I"@ 8\O'USR17N>F:9%K7PMLM,N/]5>:/' Q] T(&?UJ]?^%M"U32(-*O\
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MR7C7_M__ /2M*]_KP#X4?\G)>-?^W_\ ]*TH&>_T444""BBB@ HHHH ****
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MTZ66]^U0NY.+=I2IPX&TC:N,=S0] .^\(^,='\;:0^HZ#-))#'*87$D91E8
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M?>GR'_O@)7TAK^I2Z/X!U#4K89GM=.>6(?[:QDK^N*5[7\@:V\S*UGXL^"M
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M:T27]?U_5BV[LYOX9V%_IT&JPS_9X].^T*UE:P:F;[[-\@WH9& /7# '^]7
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M 4444 %%%% !1110 4444 %%%% !1110!Y!^TK_R3;3_ /L+1_\ HF:N_P#
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M?*W;O+WW,3;<X&<9QG H ^CZ***!!1110 4444 %%%% !1110 4444 %%%%
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M^'NG^%]5^!=Y8>,=0738)]?9;6Z/_+*;R(\'IC&-P.<#!ZC@U>^&6M:OX/\
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MI?"Z0L1<6=QE1<*00>-Z[O0K@GD>M?4GA;PII7@[1SIFA1/%:F4RE9)"YW$
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %<_XY\4?\(7X+OM?^Q_;?LGE_N/-\
MO?OD5/O8.,;L].U=!61XJT>QU_PS=:9JT'VBSGV>9'O9=V'5ARI!Z@=Z /%_
M^&HO^I0_\J?_ -JH_P"&HO\ J4/_ "I__:JZ+_A3W@7_ * ?_DW/_P#%T?\
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M ,J?_P!JH_X:B_ZE#_RI_P#VJNB_X4]X%_Z ?_DW/_\ %T?\*>\"_P#0#_\
M)N?_ .+H"Z.=_P"&HO\ J4/_ "I__:J/^&HO^I0_\J?_ -JKHO\ A3W@7_H!
M_P#DW/\ _%T?\*>\"_\ 0#_\FY__ (N@+HYW_AJ+_J4/_*G_ /:J/^&HO^I0
M_P#*G_\ :JZ+_A3W@7_H!_\ DW/_ /%T?\*>\"_] /\ \FY__BZ NCG?^&HO
M^I0_\J?_ -JH_P"&HO\ J4/_ "I__:JZ+_A3W@7_ * ?_DW/_P#%T?\ "GO
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M_P#)N?\ ^+H"Z.=_X:B_ZE#_ ,J?_P!JH_X:B_ZE#_RI_P#VJNB_X4]X%_Z
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M"Z.=_P"&HO\ J4/_ "I__:J/^&HO^I0_\J?_ -JKHO\ A3W@7_H!_P#DW/\
M_%T?\*>\"_\ 0#_\FY__ (N@+HYW_AJ+_J4/_*G_ /:J/^&HO^I0_P#*G_\
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M_P"&HO\ J4/_ "I__:JZ+_A3W@7_ * ?_DW/_P#%T?\ "GO O_0#_P#)N?\
M^+H"Z.=_X:B_ZE#_ ,J?_P!JH_X:B_ZE#_RI_P#VJNB_X4]X%_Z ?_DW/_\
M%T?\*>\"_P#0#_\ )N?_ .+H"Z.=_P"&HO\ J4/_ "I__:J/^&HO^I0_\J?_
M -JKHO\ A3W@7_H!_P#DW/\ _%T?\*>\"_\ 0#_\FY__ (N@+HYW_AJ+_J4/
M_*G_ /:J/^&HO^I0_P#*G_\ :JZ+_A3W@7_H!_\ DW/_ /%T?\*>\"_] /\
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M_P#VJNB_X4]X%_Z ?_DW/_\ %T?\*>\"_P#0#_\ )N?_ .+H"Z.=_P"&HO\
MJ4/_ "I__:J/^&HO^I0_\J?_ -JKHO\ A3W@7_H!_P#DW/\ _%T?\*>\"_\
M0#_\FY__ (N@+HYW_AJ+_J4/_*G_ /:J/^&HO^I0_P#*G_\ :JZ+_A3W@7_H
M!_\ DW/_ /%T?\*>\"_] /\ \FY__BZ NCG?^&HO^I0_\J?_ -JH_P"&HO\
MJ4/_ "I__:JZ+_A3W@7_ * ?_DW/_P#%T?\ "GO O_0#_P#)N?\ ^+H"Z.=_
MX:B_ZE#_ ,J?_P!JH_X:B_ZE#_RI_P#VJNB_X4]X%_Z ?_DW/_\ %T?\*>\"
M_P#0#_\ )N?_ .+H"Z.=_P"&HO\ J4/_ "I__:J/^&HO^I0_\J?_ -JKHO\
MA3W@7_H!_P#DW/\ _%T?\*>\"_\ 0#_\FY__ (N@+HYW_AJ+_J4/_*G_ /:J
M/^&HO^I0_P#*G_\ :JZ+_A3W@7_H!_\ DW/_ /%T?\*>\"_] /\ \FY__BZ
MNCG?^&HO^I0_\J?_ -JH_P"&HO\ J4/_ "I__:JZ+_A3W@7_ * ?_DW/_P#%
MT?\ "GO O_0#_P#)N?\ ^+H"Z.=_X:B_ZE#_ ,J?_P!JH_X:B_ZE#_RI_P#V
MJNB_X4]X%_Z ?_DW/_\ %T?\*>\"_P#0#_\ )N?_ .+H"Z.=_P"&HO\ J4/_
M "I__:J/^&HO^I0_\J?_ -JKHO\ A3W@7_H!_P#DW/\ _%T?\*>\"_\ 0#_\
MFY__ (N@+HYW_AJ+_J4/_*G_ /:J/^&HO^I0_P#*G_\ :JZ+_A3W@7_H!_\
MDW/_ /%T?\*>\"_] /\ \FY__BZ NCG?^&HO^I0_\J?_ -JH_P"&HO\ J4/_
M "I__:JZ+_A3W@7_ * ?_DW/_P#%T?\ "GO O_0#_P#)N?\ ^+H"Z.=_X:B_
MZE#_ ,J?_P!JH_X:B_ZE#_RI_P#VJMZX^$_P^M(&FNM)C@B49:22^F51]27K
MG9]&^"EN^V26R)_Z9W\[C\U<T#T)/^&HO^I0_P#*G_\ :J/^&HO^I0_\J?\
M]JJM_9OP1_OVW_@5<_\ Q5']F_!'^_;?^!5S_P#%4!H6?^&HO^I0_P#*G_\
M:J/^&HO^I0_\J?\ ]JJM_9OP1_OVW_@5<_\ Q5']F_!'^_;?^!5S_P#%4!H6
M?^&HO^I0_P#*G_\ :J/^&HO^I0_\J?\ ]JJM_9OP1_OVW_@5<_\ Q5']F_!'
M^_;?^!5S_P#%4!H6?^&HO^I0_P#*G_\ :J/^&HO^I0_\J?\ ]JJM_9OP1_OV
MW_@5<_\ Q5']F_!'^_;?^!5S_P#%4!H6?^&HO^I0_P#*G_\ :J/^&HO^I0_\
MJ?\ ]JJM_9OP1_OVW_@5<_\ Q5']F_!'^_;?^!5S_P#%4!H6?^&HO^I0_P#*
MG_\ :J/^&HO^I0_\J?\ ]JJM_9OP1_OVW_@5<_\ Q5']F_!'^_;?^!5S_P#%
M4!H6?^&HO^I0_P#*G_\ :J/^&HO^I0_\J?\ ]JJM_9OP1_OVW_@5<_\ Q5']
MF_!'^_;?^!5S_P#%4!H6?^&HO^I0_P#*G_\ :J/^&HO^I0_\J?\ ]JJM_9OP
M1_OVW_@5<_\ Q5']F_!'^_;?^!5S_P#%4!H6?^&HO^I0_P#*G_\ :J/^&HO^
MI0_\J?\ ]JJM_9OP1_OVW_@5<_\ Q5']F_!'^_;?^!5S_P#%4!H6?^&HO^I0
M_P#*G_\ :J/^&HO^I0_\J?\ ]JJM_9OP1_OVW_@5<_\ Q5']F_!'^_;?^!5S
M_P#%4!H6?^&HO^I0_P#*G_\ :J/^&HO^I0_\J?\ ]JJM_9OP1_OVW_@5<_\
MQ5']F_!'^_;?^!5S_P#%4!H6?^&HO^I0_P#*G_\ :J/^&HO^I0_\J?\ ]JJM
M_9OP1_OVW_@5<_\ Q5']F_!'^_;?^!5S_P#%4!H6?^&HO^I0_P#*G_\ :J/^
M&HO^I0_\J?\ ]JJM_9OP1_OVW_@5<_\ Q5']F_!'^_;?^!5S_P#%4!H6?^&H
MO^I0_P#*G_\ :J/^&HO^I0_\J?\ ]JJM_9OP1_OVW_@5<_\ Q5']F_!'^_;?
M^!5S_P#%4!H6?^&HO^I0_P#*G_\ :J/^&HO^I0_\J?\ ]JJM_9OP1_OVW_@5
M<_\ Q5']F_!'^_;?^!5S_P#%4!H6?^&HO^I0_P#*G_\ :J/^&HO^I0_\J?\
M]JJM_9OP1_OVW_@5<_\ Q5']F_!'^_;?^!5S_P#%4!H6?^&HO^I0_P#*G_\
M:J/^&HO^I0_\J?\ ]JJM_9OP1_OVW_@5<_\ Q5.32_@D[!5DM 3_ 'KRX _,
MM0&A/_PU%_U*'_E3_P#M5'_#47_4H?\ E3_^U5KZ?\,_AKJT'G:78V]Y%T+V
M^H2N!^4E6_\ A3W@7_H!_P#DW/\ _%T"NCG?^&HO^I0_\J?_ -JH_P"&HO\
MJ4/_ "I__:JZ+_A3W@7_ * ?_DW/_P#%T?\ "GO O_0#_P#)N?\ ^+H"Z.=_
MX:B_ZE#_ ,J?_P!JH_X:B_ZE#_RI_P#VJNB_X4]X%_Z ?_DW/_\ %T?\*>\"
M_P#0#_\ )N?_ .+H"Z.=_P"&HO\ J4/_ "I__:J/^&HO^I0_\J?_ -JKHO\
MA3W@7_H!_P#DW/\ _%T?\*>\"_\ 0#_\FY__ (N@+HYW_AJ+_J4/_*G_ /:J
M/^&HO^I0_P#*G_\ :JZ+_A3W@7_H!_\ DW/_ /%T?\*>\"_] /\ \FY__BZ
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M^T%IK7\:'1+I;1L;YC,N]?\ @&,'_OJNP\7?$33O"6EZ=J$EO->V^H M"T!
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MM\&6VE() /<'N.W;Z<BN?\6?&K3/#NLR:98:?)JDT#[)W641HC=" <')!X/
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M;)'T!;UK(\T]#HJ.VG2ZM8KB(YCE0.I]01D5)0(**** "BBB@ HHHH ****
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M,M5_MG]GG1KLMO?S(8I&/4L@=&/XE<_C74R>!E/P7_L06"?VB+ /L"KO,_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?_RH?_:J/^&B?^I7_P#*A_\ :J LSVRBO$_^&B?^I7_\J'_VJC_AHG_J5_\
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M]2O_ .5#_P"U4?\ #1/_ %*__E0_^U4!9GME%>)_\-$_]2O_ .5#_P"U4?\
M#1/_ %*__E0_^U4!9GME%>)_\-$_]2O_ .5#_P"U4?\ #1/_ %*__E0_^U4!
M9GME%>)_\-$_]2O_ .5#_P"U4?\ #1/_ %*__E0_^U4!9GME%>)_\-$_]2O_
M .5#_P"U4?\ #1/_ %*__E0_^U4!9GME%>)_\-$_]2O_ .5#_P"U4?\ #1/_
M %*__E0_^U4!9GME%>)_\-$_]2O_ .5#_P"U4?\ #1/_ %*__E0_^U4!9GME
M%>)_\-$_]2O_ .5#_P"U4?\ #1/_ %*__E0_^U4!9GME%>)_\-$_]2O_ .5#
M_P"U4?\ #1/_ %*__E0_^U4!9GME%>)_\-$_]2O_ .5#_P"U4?\ #1/_ %*_
M_E0_^U4!9GME%>)_\-$_]2O_ .5#_P"U4?\ #1/_ %*__E0_^U4!9GME%>)_
M\-$_]2O_ .5#_P"U4?\ #1/_ %*__E0_^U4!9GME%>)_\-$_]2O_ .5#_P"U
M4?\ #1/_ %*__E0_^U4!9GME%>)_\-$_]2O_ .5#_P"U4?\ #1/_ %*__E0_
M^U4!9GME%>)_\-$_]2O_ .5#_P"U4?\ #1/_ %*__E0_^U4!9GME%>)_\-$_
M]2O_ .5#_P"U4?\ #1/_ %*__E0_^U4!9GME%>)_\-$_]2O_ .5#_P"U4?\
M#1/_ %*__E0_^U4!9GME%>)_\-$_]2O_ .5#_P"U4?\ #1/_ %*__E0_^U4!
M9GME%>)_\-$_]2O_ .5#_P"U4?\ #1/_ %*__E0_^U4!9GME%>)_\-$_]2O_
M .5#_P"U4?\ #1/_ %*__E0_^U4!9GME%>)_\-$_]2O_ .5#_P"U4?\ #1/_
M %*__E0_^U4!9GME%>)_\-$_]2O_ .5#_P"U4?\ #1/_ %*__E0_^U4!9GME
M%>)_\-$_]2O_ .5#_P"U4?\ #1/_ %*__E0_^U4!9GME%>)_\-$_]2O_ .5#
M_P"U4?\ #1/_ %*__E0_^U4!9GME%>)_\-$_]2O_ .5#_P"U4?\ #1/_ %*_
M_E0_^U4!9GME%>)_\-$_]2O_ .5#_P"U4?\ #1/_ %*__E0_^U4!9GME%>)_
M\-$_]2O_ .5#_P"U4?\ #1/_ %*__E0_^U4!9GME%>)_\-$_]2O_ .5#_P"U
M4?\ #1/_ %*__E0_^U4!9GME%>)_\-$_]2O_ .5#_P"U4?\ #1/_ %*__E0_
M^U4!9GME%>)_\-$_]2O_ .5#_P"U4?\ #1/_ %*__E0_^U4!9GME%>)_\-$_
M]2O_ .5#_P"U4?\ #1/_ %*__E0_^U4!9GME%>)_\-$_]2O_ .5#_P"U4?\
M#1/_ %*__E0_^U4!9GME4]7TFRUW2I].U2!;BUG7:Z-^A![$=0>U>/\ _#1/
M_4K_ /E0_P#M5'_#1/\ U*__ )4/_M5 69OPZ9XW^'Q,.A(OB?05_P!5:RR;
M+BW7T![CITS]!5Q?BU#&-M[X2\2P2CJ@L0<?FP_E7*?\-$_]2O\ ^5#_ .U4
M?\-$_P#4K_\ E0_^U4!8ZS_A;MA_T+'B?_P7K_\ %T?\+=L/^A8\3_\ @O7_
M .+KD_\ AHG_ *E?_P J'_VJC_AHG_J5_P#RH?\ VJ@+'6?\+=L/^A8\3_\
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M+^)B/0Z>O_Q=<I_PT3_U*_\ Y4/_ +51_P -$_\ 4K_^5#_[50/4ZP?%S3U
M"^%_$P Z :>O_P 71_PMVP_Z%CQ/_P""]?\ XNN3_P"&B?\ J5__ "H?_:J/
M^&B?^I7_ /*A_P#:J!6.L_X6[8?]"QXG_P#!>O\ \72?\+:TTOO/A;Q+N]?[
M.7/_ *'7*?\ #1/_ %*__E0_^U4?\-$_]2O_ .5#_P"U4#U.L_X6[8?]"QXG
M_P#!>O\ \71_PMVP_P"A8\3_ /@O7_XNN3_X:)_ZE?\ \J'_ -JH_P"&B?\
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M_P#!>O\ \71_PMVP_P"A8\3_ /@O7_XNN3_X:)_ZE?\ \J'_ -JH_P"&B?\
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M'_#1/_4K_P#E0_\ M5 69[917B?_  T3_P!2O_Y4/_M5'_#1/_4K_P#E0_\
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M_P"3MQ_\<KT"B@#S_P#X4;\.O^A>_P#)VX_^.4?\*-^'7_0O?^3MQ_\ '*]
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M?]"]_P"3MQ_\<KT"B@#S_P#X4;\.O^A>_P#)VX_^.4?\*-^'7_0O?^3MQ_\
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MO^A>_P#)VX_^.4?\*-^'7_0O?^3MQ_\ '*] HH \_P#^%&_#K_H7O_)VX_\
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M_P"3MQ_\<KT"B@#S_P#X4;\.O^A>_P#)VX_^.4?\*-^'7_0O?^3MQ_\ '*]
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M7SJ97CRBHR6_X&!CZ\]ZA)\Z\RKKE?D=!\%)?%.K>&Y->\6ZK<7:WAQ9PR@
M+&.K\ =3T]A[UZ;45K;0V5I%:VL:Q00H(XT48"J!@ 5+6DFF]"(IVU"BBBI&
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444      P!T HHHH *IS:387&K6^IS6L;WMJC)!.P^:-6^\
M!]:N44 %%%% !1110!3FTFPN-6M]3FM8WO;5&2"=A\T:M]X#ZU<HHH ****
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MR::][?2/^6GR.,U[P5K6KZW<7UEXPO\ 38)=NVUA#[8\* <8D Y()Z=ZT?\
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M?7K7144>TE=/L4\=7<HRNKQVTCUT[:_,YWPIX<U'P_\ :_[3\076L^?LV?:
MW[K;NSC+MUR/3I7._P#"N/$7_10-4_*3_P".UZ)13522=QQS#$1G*HFKRM?W
M8]/E9?(Y7Q1X3U77M3CNM.\47FD1)"(S! 'VLP8G=PZ\\@=.U6-(\.:CIWAB
M^TRZ\075]=7/F>7?2!M\&Y HQER>"-W4=>U=%12YY6L0\96=-4KJR\E^=KG"
M:?X!UZSU.UNI_'&HW44,R2/ XDVRJ&!*G,IX.,=#5C7O!6M:OK=Q?67C"_TV
M"7;MM80^V/"@'&) .2">G>NSHI^TE>YK_:.)Y_:75[6^&/Y6L<[_ ,(YJ/\
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M,'_/>/\ [[%<M97UKJ-JMS87$5S Q8++$X96()!P1UY!%3T =%]I@_Y[Q_\
M?8H^TP?\]X_^^Q7.T4 =%]I@_P">\?\ WV*/M,'_ #WC_P"^Q7*WFHV6GJK7
M]Y;VJN<*9I53=],FJZ>(-&D#F/5[!A&I=RMRAVJ.I// ]Z .R^TP?\]X_P#O
ML4?:8/\ GO'_ -]BN9M[B&[M8KFUD66&9!)'(AR'4C((/H14E '1?:8/^>\?
M_?8H^TP?\]X_^^Q7.U1?7-*CNC;2:G9K.&VF)KA P/IC.<T =A]I@_Y[Q_\
M?8H^TP?\]X_^^Q7.T4 =%]I@_P">\?\ WV*/M,'_ #WC_P"^Q7.T4 =%]I@_
MY[Q_]]BC[3!_SWC_ .^Q7,75W;V-J]S>SQ6\$8R\LKA54>Y/ I\<B31))$P9
M'4,K#H0>AH Z3[3!_P ]X_\ OL4?:8/^>\?_ 'V*YVL_4=?TC1Y(X]6U2SLG
MD&46XG6,L/7D]/>@#LOM,'_/>/\ [[%'VF#_ )[Q_P#?8KG'=8XV>1@B*"69
MC@ >IJI:ZOIM]+Y=CJ%K<R 9VPSJY_(&@#KOM,'_ #WC_P"^Q1]I@_Y[Q_\
M?8KEEOK1[Y[)+F%KJ- [P"0%U4]"5Z@>]3T =%]I@_Y[Q_\ ?8H^TP?\]X_^
M^Q7.T4 =%]I@_P">\?\ WV*/M,'_ #WC_P"^Q7*W%_:6DT$-U<PPRW#[(4=P
M&D;T4=_PJQ0!T7VF#_GO'_WV*/M,'_/>/_OL5SM% '1?:8/^>\?_ 'V*/M,'
M_/>/_OL5SM% '1?:8/\ GO'_ -]BC[3!_P ]X_\ OL5SM% '1?:8/^>\?_?8
MH^TP?\]X_P#OL5SM% '1?:8/^>\?_?8H^TP?\]X_^^Q7.T4 =%]I@_Y[Q_\
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MV*YVB@#HOM,'_/>/_OL4?:8/^>\?_?8KG:KS7]I;WEO:3W,4=S<DB&%G >3
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MUCXHN-#\)Z,FIW%C!Y]VSD_*H )  (Z CGU.,50O/C,\^A:1)H&F)-JFHS-
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M_(HZQ_UXS?\ HLUX!%X2M[7X16?C+3)IK;5;:YR[K(<,HD*C [$'!R/>O?\
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MP#X^&FF4V>^U\@S8W^7]I&W=CC=C&<=Z2U&]+'9Z5_R5GP!_V+47_HJ:NO\
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M+7BUW:Z)H^G^%=1\'7Y?Q%*R&:"*;?A^."/X<DXQW%>T_%;_ ))=K7_7)/\
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M$94Y!P0#^% 'P15J]U*^U)D;4;VXNV084SRLY4>V3Q7VK_P@/@__ *%/0_\
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MT36%G<W$<]Q:02S1?ZN1XPS)]">175?9H/\ GA'_ -\"C[-!_P \(_\ O@4
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MC_[X% ',RV\,Z!)X8Y5!R Z@@?G1]GA,S2F&/S&&TOM&2/3-=-]F@_YX1_\
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MW,UE)'8RP13L %>XA,J#GG*!E)XR.H_I74_9H/\ GA'_ -\"C[-!_P \(_\
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M9H/^>$?_ 'P*/LT'_/"/_O@4 <[171?9H/\ GA'_ -\"C[-!_P \(_\ O@4
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MA5(^=,'.3G/YU=TWQQXIT-4O?$.IV^KV]]X<?6(H5M%@^SN@4[,K]X'=R3^
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M NT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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ME64C!!'<8IMM:6]G:1VMI!%!;Q+LCAB0*B+Z #@#VJ;;VZ_\'_,=]%?^MO\
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M*=PSFA?PTNO_  %^OWCE;GO_ %O_ %Z&=H'B72/%%@][H%ZE[;I(8FD12 &
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M3.*9X9\%Z_I^A^ [>\L/+ETF_N9KU?.C/E(XDVGAOFSN'3/6G97^[\W^EO\
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MF)!88)&W&#U/\ZH:1IOBZ^U__A)];\/Q6$VD:6]KINF?;DE:XE/)8R+\J@X
MJ8Z-O^MG^MA25XI+^M8_I<],HJEH]S?7FBVEQJUD+&]DB#36PD#^4W==PZU=
MJGH["W"BBBD 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M-+\,MJTD-A]NDE6[$8CC&=Q(*G@ >O>J%_\ &IWMK ^&O#DVK7$VG'4;N(7
M06L8SN&<'<00>P[=S@)XQ\+ZUJ'Q U^^LM/DEMKGPI<64,JD8>=@V$Z]3FN-
MT?P=XT\&V]MJ6F^'7U"?4M%DTVYM_-"M:R%SAB.A& I_,<=:G[/G_P /_P
M-+_UY?\ !.KU#XZ2'[,?#OAB35$FTW^T)'-V(_)1699 1L/W2A&<\^E7O"OQ
M>D\3>((M*U#P]+I:7]B]Y8RF[#M,B[AG 4%<['P?]G\:Y30_AQXDT-Y;>:P>
M7_BDKFU\R-E*FXD9W$0YY(W8STJUX;\%>(K/QOX0O;G2YH[>Q\.O:W,A*XCE
M/G_(>>OSK^=.RL_Z[_Y(3\OZV_X([PW\3)]#\)>'K#0/#E]K%QJDETL,5SJ>
M^0,DG.7,8!')/08 _&M=/C:;W0=(DT?P])>ZUJ4LL7]GBY"B(Q_>)<CH001P
M._/'.'X-\%>(]/U+P+)>Z3-"FGS7S718K^Y#D[,\]ZY.Q^%'B"T\.Z1J&I>%
MY=3:UN9H[K2C.(W>-@NQ@RGUST]!QBA[#=KZ?UN>E'XVQWNB:2^@:#+?ZSJ,
MLD3:<9PGD-& 6RY'(Y!' XSG'2H)/CHMUIND?V#X?DO=4U!Y(WLI+E8A"Z8R
MNXCYB<C'3/'<XKE-6^%ES'INAZQ:^"&=$:47^A)?EF(;A'#Y)' !('3 ]35C
M6O!E\O@>STVV^&;A9O-N/W&H[YK*X;"J1DDX*HI*].G(-(#W'1+ZYU/0[.]O
M["33KBXB622TD;<T)/\ "3@<_@/I5ZN>\!6&L:9X#TJS\2RF74X8<3LS[B/F
M)52>Y"X&?:NAIO<2V"BBBD 4444 %%%% !1110 4444 %%%% !7/^/O^2;>)
M?^P3=?\ HEJZ"N?\??\ )-O$O_8)NO\ T2U ' ?LU?\ )-M0_P"PM)_Z)AKU
M^O(/V:O^2;:A_P!A:3_T3#7K] !7@'[47_,K?]O?_M&O?Z\ _:B_YE;_ +>_
M_:- T>O^ ?\ DFWAK_L$VO\ Z)6N@KG_  #_ ,DV\-?]@FU_]$K704" ]*^6
M]'^*&I6GPI\1Z7/J=Y)JKW<:V<[SLTJH^=^"3D ",].A>OJ0]*^8+7X-ZW+:
M6UQ=:1,EQ]COGD@.,F5?]3SG&277 ]$-+N4K'I5AXXUGP[\(_#6HP:1-KTUS
M;GSII;T1[",D%F;)8GG'KC'7%1M\;+FYTO09-%\+2:A?:QYR"T%X%,4D9P1G
M8=PP<YXXKE=<\ ^(Y='\%&Z\.S:S:6&GO;W.EK<B(QS$MAB<].5/'79@D9JU
MX%\#^)-,U/P3)?:/-;I87%Z]SN93Y(<#;GGO5NSD_7_,E:1"P^(VH:+\2M<-
MWI5Q>:OJ9L;>VTDW)'DDQEF7>5( 4MSP.3GUKN/C7=75K\)-0DAD>"9FA1_)
MD(X+@,N>,@\CWK@O%_P]\37/Q"U[Q5HVGS&[L[VTN-.^9=MP  'P,]00O7'&
M:]#^*NEZGXE^%MQ:Z782RWLY@D%KD;U^=20><9']*G=+Y?H5HIF?X:^*IEMM
M9M_$NB2Z-<:)8I=M"9Q*TL17([##'*\?[7.,50T_XWR2)<_VQX:DT^5M.?4=
M/0W0874:@G!.WY#A2>AZ=.F:-[\/M:UGQMXV\VT>"TU31X(+6Y=AM>5(X?EZ
MY'S1D'CM7/Z#\/+_ /L748G\ 2Z=J5OI4T*7WV\L;B<H4^6/."&!/L#WZ"B7
M6W8F-M+_ -;'8+\9=43PXFJ7W@V:W:^EABTF'[8&-X7W9.=HP!M';G<OUKJ_
M 7CD>,[:_CN;!M-U/3)_(O+1I!($/."&'4'!_(_6N&\7> -5U?X4^$8TTPW=
M]HB1&YTUI-AE3: Z9!Z_*.A]<5T_PG\.IHNEW]S_ ,(LWAJ2[E4?9WO#.SHH
M.TG)^4Y9AVSZ=*;M=BZ(Y >-=7T/XU>*KS4-'N9;"TME65?MJD6T"XVRJIX^
M? .T8P7Y]:Z?P=\5KCQ!XDL](UKP]+HS:G;&[TZ1IQ*+B,9//RC'"D_A[BN=
M\8>$/$VI_$/Q/#8Z/YVG^(-/B@2^,P5(3&JG+=\[DQCT.?:G^"= \6ZCXX\-
MWWB#0_['L_#&F-9!WE#FY;84!7!ST(/<?*>>10OZ_$;_ *_ G^,.NWWA+Q=H
M>KP7]S%;7%E=VS0)*PC:01G8Q4'&=T@Y]O:N6^%'BG6?%'B[PO82ZC>2Q:7:
M74M[OG<^<2S;=_/S8W)C.:[_ .-WA'4?%OA*RAT6T-U>07R-M#!<1E2&//OM
MJC\-OAW<^%/B9XHOWMFAL&00V#G&'1VW$#_=VJ*E=?Z_K<;M;0\YG_M>X^"Z
M^*/^$GUR.\MKY[41I?.$=2_5N<DC/K78>*KH_#B[\!F[\1:M/8&ZGFO)KFX>
M1I%(C.U@OW@,\#!ZFJ@\$>)/^&?IM$_LB;^TVU,S"URN[9N!SUQ79^,_#FHZ
MKXM\!30:>US:Z?/(UZQVE8E*QXW ]>A_*KZ_/]!/_,\Y_P"$ON]6\(_%'5=,
MUB^:W6[M7L)1/(IAC:8_<!.4!'88K3TSXC6^N?%+PPVD:K>7-G9Z-+]N@+2(
MKS)#(QW*V QX'/-2W_@?7SH_Q/M[;1Y?^)K>V[Z>B;0)D68DE>>,#GG%;4G@
MJ_;XG>$[I=*,>G0:(]K>S1A0(Y&BD4@X[\@9]ZGI_78/Z_%'")>^)=/\)V'Q
M2DUZ^GN;K52DEEYA$)M]S+LVYQC*D8Z $8Y%>G_#"_O+WQ+XYCN[N>XCM]:=
M(5EE9Q$N6^503P/85Y_#X&\=W>E6?P\O=*2/1;34C<MJJR *T.2<#G_:8XQG
MD=,&M[1)?&_@_P 9>)S8^"IM2L]5U9YTN3<K& F\X('.1@Y[4U;^OD$OZ_$Y
M?5F\0"3QUXFT[Q/JUO-X?UHK#:BY9H6C,I&-A..,CCI@$8KVB_\ %L]E\,D\
M5P:=]KD-C%>&T$GEY5@K-\V#C )/3M7DNI>%?'=Y?>+_  _IWA[;I_B#5S.V
MI33JJI$)"00,YYX/KC(P<U[:F@VJ>$5\/'+6BV(L>1U3R]G\J7V=/ZT'UU//
M]5^.-CIK0%-*-Q%)I$>HN4N@&C>0@+%C;SRRY;/<\<8/.>,_BGK&J>"=>T:Y
M\/76BZQ#%#+*$O.8K9BI\S< ,\E$*_\ 33V(K"T?X.>);KP3X@74; PZHDD"
MV$<D@_>I&6+ '/0@C'3D5LZGX4\:>,E\6>(+_0/[-N;S3(;*UL&E4O*5EC=R
M#V_U9QG&=P'.,T/^OZ_ $=./B7JNB>&/#ME_PBLLVN:A'LM['[8F#$B#]Z7Q
M@;ASCM@Y/KV7@;QC;>./#$>K6L#6SB1H9[=SDQ2+C*Y[]0<^]>3^*?!_B#Q#
MI_AC7M2\(/>-80&RNM&%UMD:-1A'W#H2<G Z<=>:]-^&NA+H/@Y(?[#_ +"D
MGF:>6R^TF;:3A0<DG&55>.U-]25LCQ;0/&6IZ5XP\7>,M:T2[N;C3[@PM"=1
M"I:EY-@@/RG=@ X8 #Y/<8]$G^+&NP6MA;R^"9UUS4IF%IIIO!EH54-YA;:,
M=2,8_A.<8Q7*:AX%\32Z)\1HH](F:35-:2XLE!7,\8G=BPYZ8(/-=;XXT/7K
M#Q9X9\8^']);5YM+MWMKBR64(Q5E(R/^^V]>W%+^OP_S*_X(DWQI4^"-/US3
M] EN[NZU Z=)IYN-C13!<X#;3NZKV'6LR'X[WT=P@U7PA)9VT-^MA?7'VY6$
M,K$_*!M^8@*Q_#KWK-L_A_XGM?".@"ZT\M?2>)QJEW!&RG[-&<#DYQ_#GCUJ
MIXG\!^)[[3]>2UT>>1KGQ<+V$ K\\&R4>8.>F67\ZJ*5]?ZV_P V*6VG];_\
M ]C\8^(+WPUH!U#3M(;59!(J&$7"PA ?XV9N  <?G7E&N_$6?QGX:T69;:;2
M;B#Q);VMW;)<%@P^\,D 9&>Q[BNI^-/AK5_$.G:*^F:?)JUI97OFWNG13>6U
MPG'?_OH9'(W9%<!I'P_\2P:5'$/#DUD/^$F@NUMO,5O*@4')W;N0.E*.^OE^
M:&[6^_\ )GHOPFNKBZOO&3W4\DS+KDJ@R.6(4  #GL!QBJ/B?XR7V@^(-9L+
M3PH]]:Z*T9N[P7H0*KXP=NS@Y;'4UL?#'0]2T:X\4MJEH]L+S6)9[?>1^\C/
M1A@]*XWQ=X+\0ZA)\2/L>E32C538_8L%?W^R1"^.>P!ZT+=>B_0';7U_4VM=
M^-1L=0NO[$\.S:KING10S7]ZLXC\D2XQA<'/7^?89J3Q/\8;C2=4BM= \./K
M$<FEIJGG_:O*VPD$DE2AZ#'?O7%3^"_&FA6.M:-I'A\W\/B>SM0UQYRK]D=%
M^=6!..I8=?0Y[5T-WX'URT\07"063W,$7@MM,2XCP%EG";0H!.<FI?\ 7W/]
M; K?U\O^"-;XQ'Q!I^H:=JGAZZTR&]T>>\LY([\"29%# D$+\F=KX.#]WH0:
M(?BS=Z'I&DZ9HGA>YU3;HD=^TDVHY>.( [BY*?-@+UXSGH*YZ?P!XI:ZT1UT
M:<K;^%);*7E?EF(N,)UZ_.OYUHV?@CQ)'Y@?29AGP1)IXY7_ (^"K 1]>O/T
MJY))M+^OB_X EM=_UM_P3H-1^-I^RZ>WAWP])JD\^G?VC=Q_:1&+6,9##.#N
M((/8=NYP-#5OBY$FCZ!/X9TB75[[7D9[>T,PB\M4X?<QST((].#SZ^6CX6ZU
MIT&CW^H>$)==66P,$]B+GRGMI@YVL2IY&W'MR>G!KH_&'PRN!IWA6_L?"AO;
M>PMWAO=#2])9-[,_RR9R<.[=,XXZBI?Z@C9D^.BW6FZ1_8/A^2]U34'DC>RD
MN5B$+IC*[B/F)R,=,\=SBO3M$OKG4]#L[V_L)-.N+B)9)+21MS0D_P ).!S^
M ^E>':UX,OE\#V>FVWPS<+-YMQ^XU'?-97#852,DG!5%)7ITY!KU[P%8:QIG
M@/2K/Q+*9=3AAQ.S/N(^8E5)[D+@9]J .AHHHH **** "BBB@ HHHH ****
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M +57K_\ P@/@_P#Z%/0__!;#_P#$T?\ " ^#_P#H4]#_ /!;#_\ $T#/(/\
MAJ+_ *E#_P J?_VJO/\ XH_%'_A9/]E_\2?^S?[/\[_EZ\[S/,V?["XQL]^M
M?3__  @/@_\ Z%/0_P#P6P__ !-'_" ^#_\ H4]#_P#!;#_\30 > ?\ DFWA
MK_L$VO\ Z)6N@J.WMX;2VBM[6*.&"%!''%&H544# 4 <  <8J2@04444 %%%
M% !1110 4444 %%%% !1110!EZGX8T'6KE;C6-$T[4)U01K+=6D<K!02=H+
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MBBB@ HHI"P52S$  9)/:@!:*YO0OB#X8\2ZO-IFBZHEQ=1 ML\ME$@!P2A(
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MLO\ PDNH_8OM>_R/W$DF_9MW?<4XQN7KZUT%> ?M1?\ ,K?]O?\ [1H [_\
MX7E\.O\ H8?_ "2N/_C='_"\OAU_T,/_ ))7'_QNN,\,?L^>%=:\(Z1JEUJ&
ML)/?6,-Q(L<T04,\88@ QDXR?4UJ?\,U>#_^@EKG_?\ A_\ C5 ]#?\ ^%Y?
M#K_H8?\ R2N/_C=:&A?%;P9XEUJ#2=%UG[3?7&[RHOLLR;MJECRR #A2>37(
M?\,U>#_^@EKG_?\ A_\ C5</X4\-6?@_]JBTT+3))Y;6UW['N&#.=UDSG)
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MJ1R*\(^(_P #_#?@_P"'^I:[IE[JLMU:^5L2XEC9#NE1#D",'HQ[UZ/\#?\
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MZ^^WZK[M#Q6[M/#_ (>\*Z/J=EXU:#4DENKW2]1FL&6*<.1YD31XP QZ=.O
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M6V5,<I]T $@9'3(KTJFHB1KMC55'7"C%3'W5;R_2PY:_UYW.!\(*I^,'CTD
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M ,=K'\5_'#Q)XP\,7>A:G8Z5%:W6S>]O%(KC:ZN,$R$=5':OK>B@#S_X&_\
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M@_%6M:)?:7=:?HZ07UO);R-'#*&"NI4D$R$9P?0U]5T4 > ?LN_\S3_VZ?\
MM:O?Z**!!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MAOX"UWPKXVTI]1M#]G@T)H99U8%%F:9I#'UY(#8STXKV2J_K\1=?Z[!1112
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M9RW3&VBD65@'6+IN[Y]:YNYU>RL1J_AZZF\K59?&R7*6S(=QB,J$/TQ@CO\
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M001FTBN'65&SN3YN0Y.,'IZUI-\2O"*ZM<:8=:C-Y;"4S1"*0^6(@2^2%P,
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MXC66ZG6)2Q!.T%B!G )Q[&KE>0?M*_\ )-M/_P"PM'_Z)FI#._\ ^$^\'_\
M0V:'_P"#*'_XJC_A/O!__0V:'_X,H?\ XJO / WP&_X33P78Z_\ \)']B^U^
M9^X^P^9LV2,GWO,&<[<].]=!_P ,N_\ 4W_^4S_[;0/0]?\ ^$^\'_\ 0V:'
M_P"#*'_XJI+?QMX5N[F*WM?$VCS3S.(XXH[^)F=B<!0 V22>,5XY_P ,N_\
M4W_^4S_[;7'WO@+_ (5W\;?"6D_VE_:/G7=G<^;Y'E8S<[=N-S?W,YSWH ^K
MZ***!!6;K.M:'I4*Q>(-3L+&.Z5E5;VX2(2@8# ;B,]1GZBM*O /VHO^96_[
M>_\ VC0!Z1X=U3X9^$[%K3P]K?AZRB<Y?9J43,Y[;F9RQZ]S6O\ \)]X/_Z&
MS0__  90_P#Q5>(:!^SE_;GAO3-6_P"$I\C[?:17/E?V=N\O>@;;GS1G&<9P
M*T/^&7?^IO\ _*9_]MH'H>O_ /"?>#_^ALT/_P &4/\ \55BQ\7>&]4O8[/3
M/$.E7EU)G9!;WL<CM@$G"AB3@ G\*\8_X9=_ZF__ ,IG_P!MKG_ WA?_ (0O
M]IJQT#[9]M^R>9^_\KR]^^S9_NY.,;L=>U 'T_1110(*S]4U_1]#\K^VM6L=
M.\[/E?:[E(O,QC.-Q&<9&<>HK0KP#]J+_F5O^WO_ -HT >O_ /"?>#_^ALT/
M_P &4/\ \51_PGW@_P#Z&S0__!E#_P#%5Y!_PR[_ -3?_P"4S_[;1_PR[_U-
M_P#Y3/\ [;0/0]?_ .$^\'_]#9H?_@RA_P#BJN:9XGT'6KEK?1];T[4)U0R-
M%:W<<K!00-Q"DG&2!GW%>*?\,N_]3?\ ^4S_ .VUG_ G2_[#^-OB+2?.\_[!
M:7-MYNW;YFRYB7=C)QG&<9- 'T?1110(**** "BBB@ HHHH *0* Q8  GJ<=
M:6B@ I&17 #J& .1D9P:6B@!&17&'4,,YP1FEHHH *0(H<N% 9NI Y-+10 B
MHJ+A%"CT Q0J*@PBA1G. ,4M% ";%\S?M&_&-V.<>E+110 4B(L:[8U"KZ*,
M4M% !1110 C*'4JX#*1@@C(-*  , 8 [444 8OB?PQ9^*?#<^B7;O;VT[HSF
M  -\KAN,C'.*V(XTB3;&H4>PQFG44=+ -1$C7;&JJ.N%&*=110 BHJ A%"@G
M)P,<TBHB%BBJI8Y.!C)IU% !2*BJ6*J 6.20.M+10 4UT20 .JL <C(S@TZB
M@"CK6GSZII,UI:W\FGRR8VW,4:.R8()P&!'3C..*A\.>'[/PQH-OI.F^888<
MG?*VYY&))9F/<DDFM2B@!JQHC,415+'+$#&?K0(T52JHH4YR .#FG44 (JJB
MA44*HX  P!2.B2 !U5@#D9&<&G44 (R*Q!902IR,CH:6BB@ I BARX4;B,%L
M<D4M% "%%+ARH+#@''(I:** $V+YF_:-^,;L<X]*6BB@ I$18UVHH5?0#%+1
M0 U8T6/8J*$_N@<4H550*J@*!@ #C%+10 BJJ*%10JCH , 4I&1@]*** $55
M10J*%4<  8 I:** .=D\'PW/C2+Q#?W]Q<FU!^QV9"+%;LRA6;@99B,\L3C/
MTKHJ**.E@ZW"BBB@ I-HW;L#=C&<<XI:* "BBB@ KY@_:5_Y*3I__8)C_P#1
MTU?3]?,'[2O_ "4G3_\ L$Q_^CIJ!H^GZ***!!7@'PH_Y.2\:_\ ;_\ ^E:5
M[_7@'PH_Y.2\:_\ ;_\ ^E:4#/?Z***!!7S!XT_Y.PMO^PMIO_H,%?3]?,'C
M3_D["V_["VF_^@P4#1]/T444""O /V7?^9I_[=/_ &M7O]> ?LN_\S3_ -NG
M_M:@9[_1110(*\ _YO._S_T#Z]_KP#_F\[_/_0/H&>_T444".?\ 'W_)-O$O
M_8)NO_1+5P'[-7_)-M0_["TG_HF&N_\ 'W_)-O$O_8)NO_1+5P'[-7_)-M0_
M["TG_HF&@9Z_1110(**** &NB2(5D574]0PR*4JI()4$KT..E+10 5C^*O#=
MMXM\.SZ-?2RQ6\[(7:'&["N&P,@CG&*V** V,7Q-X7L_%'AJ?1+MY(+:=D9V
M@P&^5PW<8YV]:V(XTB3;&H4>PQ3J* $=%D4JZAE/4$9!I:** $9%< .H8 Y&
M1G!I:**  @,"&&0>"#WI%4(H50%4#  '2EHH *145!A%"C.< 8I:*  @,"&&
M0>"#WI%544*BA5'  & *6B@!K1HY4NBL5.5R,X-*45F5F4%E^Z2.E+10 52U
MK3(];T*^TN:1HX[RW>!G3JH92"1[\U=HI-75F--IW12TC2K?1=(M-.L]QBM8
M4A5GQN8*H4$D 9.!5M41"Q154L<G QDTZBJ;;=V2E96"FK&B,Q1%4L<L0,9^
MM.HI#$5%1<(H4>@&*%14&$4*,YP!BEHH 38OF;]HWXQNQSCTI:** "D1%C7;
M&H5?11BEHH *1452Q50"QR2!UI:* "FHB1KMC55'7"C%.HH *1E5U*NH93U!
M&0:6B@ HHHH ;L0R!RJ[P,!L<XI2BEPY4%AP#CD4M% !1110 4U41"Q154L<
MG QDTZB@!HC1=VU%&XY; ZGWI5544*BA5'0 8 I:* $5%0810HSG &*6BB@!
MH1 Y<*H9NK <FG=:** $1%C0+&H51T"C %+110 $!@0PR#P0>]-,49B\LHI3
M&-N.,?2G44  &!@4UHT<J716*G*DC.#3J* $"@,6  )ZG'6EHHH *\@_:5_Y
M)MI__86C_P#1,U>OUY!^TK_R3;3_ /L+1_\ HF:@#?\ @;_R1C0O^WC_ -*)
M*] KS_X&_P#)&-"_[>/_ $HDKT"@ KP#XK_\G)>"O^W#_P!*WKW^O /BO_R<
MEX*_[</_ $K>@:/?Z***!!7@'[47_,K?]O?_ +1KW^O /VHO^96_[>__ &C0
M-'K_ (!_Y)MX:_[!-K_Z)6N@KG_ /_)-O#7_ &";7_T2M=!0(*\ _P";SO\
M/_0/KW^O /\ F\[_ #_T#Z!GO]%%% @KP#]J+_F5O^WO_P!HU[_7@'[47_,K
M?]O?_M&@:/?Z***!!7@'PH_Y.2\:_P#;_P#^E:5[_7@'PH_Y.2\:_P#;_P#^
ME:4#/?Z***!!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %?,'[2O_)2=/\ ^P3'_P"CIJ^GZR]3\,:#K5RMQK&B:=J$ZH(UENK2.5@H
M).T%@3C))Q[F@#S3_AI7P?\ ] W7/^_$/_QVC_AI7P?_ - W7/\ OQ#_ /':
M[_\ X0'P?_T*>A_^"V'_ .)H_P"$!\'_ /0IZ'_X+8?_ (F@9P'_  TKX/\
M^@;KG_?B'_X[7)_!#4X=:^.WB?5+59$@OK>[N(UD #!7N8V (!(S@^IKVO\
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MZ_\ \(#X/_Z%/0__  6P_P#Q-:&EZ!H^A^;_ &+I-CIWG8\W[);)%YF,XSM
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MZ+X<V=KKFH:9#JUG<+>2:?-Y<C/%&,\D'!W*><=Z(^\M._\ G_DQM6:]/Z_
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MA1KRTLYT6*9TP%8AE// _*NATSPO9:5XCU/6K>6X:YU*.&.9)&4HHB7:NT
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M_P!> ?LN_P#,T_\ ;I_[6H&>_P!%%% @KP#_ )O._P _] ^O?Z\ _P";SO\
M/_0/H&>_T444".?\??\ )-O$O_8)NO\ T2U<!^S5_P DVU#_ +"TG_HF&N_\
M??\ )-O$O_8)NO\ T2U<!^S5_P DVU#_ +"TG_HF&@9Z_1110(**** ,'Q-X
M7/B/[,\6M:II$]L6*2Z?<>7N!ZAE((8<>G%4-,^'>G:.VE'3]1U2(:?-+<2#
M[3G[;)(/F:;CYS^5=;10M-@>ICZ]X:L_$4VF/?R3J--O%O(HXV 5Y%!V[L@Y
M SVQ7'_$GP ^J:-K][H*7$VJZO':P26X=%C;RY5(?D @A<\DXQVK<^(GB35/
M#/A^VN-!CLY+VYOH;1!>JQC'F$C)VD'KC_"N3U7XE^)O#^A^([;7;+2UUS1X
M[>5);,NUM(DSA0<-\P(ST)YH6K^?^7Z6*5TU_77_ #)/%?PQFC\!ZW!I5SJ.
MMZUJ9MHS->SJT@CCD4A0<   9.:Z33?AS86>G:O#>:EJ6HW&L6WV6XO+N97E
M6(*5"*=N!C).<')ZU<TGX@^%]:TF^U'3]9@FMM.&;N3:R^5[D$ D<'!'!J*Q
M^)7A'4M"N]8L]:B>PLF5;B4QNOE%CA<J5#<GOC%-[-,E-V5B74? VF:EX0L?
M#\LUU'%IZQ?9+J.0+/"\8PCAL8W?ACGI56#X;Z1'X4U70[FYO;O^V&+WM[/(
M&GE<XPV<8&,# Q@4U_BOX)CTU+^37HEM9))(TD,,GSLF-P4;<G&X=.N>,U8T
MGXD^$-=UB'2M)URWN;V>/S(XE5QN&,XR1C=C^'.?:AWE?S#:WD4Y_ACIAT[1
M;;3M1U+3)=&A:"WN[255E:-OOACMP<XSG YJ32/AIH^BKH MKJ_D_L&2>2V,
MLB$R&;.[?A1GKQC'XU=TWX@^%M8\1RZ#IVL0SZE$6#0!'&2OW@&(VL1Z GI3
M].\=^&-7\13Z%IVL03ZE!D/ N[J.H#$88CN 3BA-WNNNH;*W8L>)_#-EXKTD
M65\\T)CE6>"XMWV2P2K]UU/8BL2+X8Z0NAR:?/>:A<23W\>H7-[+*IFGE0@K
MN)7&W@#  XK2L/'GAC5/$-QH=AK%O-J-OGS(%W=NH#$88CN 3BI%\:^'GTVS
MOUU.,VM\9!;R;6Q(8P2^..P5ORI;*_\ 7]:?@-IO1E_6M*BUS0[S2[B6:&&\
MA:&1X" X5A@X)!&<>U94_@C2YAX?VR7$)\/\6AC90679L*ME3D$=<8KD](^*
M*>(/ >K:A;:OIMEJ5E,VYYH)&AAB,VV,L!R=R^G<]JZS5/'OAG0M4M-+UG6;
M>VOKI5,<9#8.>A) (0'MN(HM^-A?\'_@E;2OAWI.D6^@0VUQ>LN@RS2VQD="
M7,N[=OPHR/F.,8_&JLGPNTD:9;V]E?ZE9W-I>37EM?0RJ)HGE.74';@J>F"*
MT]:^(/A;P[K,&E:UK$-I>S@%(F1SP> 2P!"CW)%9\7CA;;QCXIM-:FMK32=#
M@MI%G((/[Q226/?G   _.B]]1ZO^N_\ PY>N/!%G>Z7H]E?:AJ5T=(O4O8KB
M:8/++(A)&]BO(Y/ Q^%5=2^&^DZE!J -U?03WNH+J2W$4BA[:=5"@QG;P,#H
M<]36SX<\4:-XLTXW_AZ^6]ME<HSJC+M;K@A@"#R.U84GCR/3?&/B&RUV6VM-
M)TFVMI5N-C;LRY!W$$Y&<8P!0]'9_P!;?Y(%JM/ZZ?J1VGPLTFWCC$NIZK=R
MIJL>K--<3(SR3HN!D[/NGTZ^A%7+KX=Z3=VM_!)<7H6^U1-4D*NF1*NW"CY?
MN_*..3[U?\/^-/#OBF&ZFT'5(;N.S;$Y 9/+Z\G<!QP>>G%5M+^(OA+6H[]]
M-UVVE33U+W+'<@11U;Y@,K[C(IWM_7I_DON%NOZ\_P#-D$?P_M;;Q/+J^GZO
MJUC%/<BZN-/MK@+;S2]V88SSW .#3[[X?Z5J$GB-YKB\4^(HXH[O8ZC8(UVC
M9\O''7.:6R^)'A'4-"NM9M-;A>PLV5;B4HZF(L<#*D!L$]#C%"_$GPBVA?VS
M_;40TXW)M1<-&ZJ90,[1E>>._3WI;*W]=/\ @#N[W_K34DC\%6T'C&+Q#;:A
M?PRK;);RVR2*(IU0$*7&,G&>Q':E\3>#+;Q+?6-^-1O]+OK(.D=S82A'*/C<
MAR",' ^E+!X_\+7/A>7Q%#K,!TJ%MDEP0PVM_=*D;L\CC&3FHQ\1O"7_  CL
M6N_VW --FF\A9RK#]YC.TC&5.!GD"A^?3]?\Q+R_JQ5T7X::/H;:"UK=7\AT
M(W!MC-(AWF;._?A1GKQC'OFEN/AOI,WA==$2ZOHA%>M?V]VDBB:"8N7W*=N.
M"Q'3I^=.O/BEX-T_2K#4;S6TBM=1!-JY@ES( <$[=N0,]R!6?J/Q/TNR^(FE
MZ&=0M197=IYID"LS-(Y7R5!'&&#$_P!13U;M_7?] OI?^OZU-[PIX1MO"<5Z
M+:^OKZ6_N/M$\U](KNS[0"<A1QQ5&\^'&C7VE:[83S7ACUN[%Y.PD4-%(-N#
M&=O&-HZYJ[+X[\,P^*E\.2ZQ NK,0!;'/4]%W8VAO]G.?:L'QA\4-*T;48M$
MTG4+:;6VO;>"6V9&;8CN QR/EW 'IGCN*6[5NNGY?\ >U_+4U=>\!VVMWUI?
MQ:MJ>F:C;0?9C>V,RI)-$>JOE2#SSD 8-0:]\.X=?2.&X\0ZY#:_9EMKBVCN
MP4N47^^"I^8]V&":T/'>O77ACP/J>LZ?'#)<VD0>-9U)0G<!R 0>_K67I.O>
M)-(TJXU?XD7/A^TTQ8HVBETT3[E+$#Y]^>.1THW#56_KM_P"Z/ MA'XJ36[:
M\O;<?9%M);**0"">- 0H88R<!O7L*S-&^%.FZ-K.F7\>L:Q<)I+2&PM)YT:&
M!7!!4#9G'/KV%2#XQ> 2$(\26_SR^2/W<F=WJ1MX7_:/R^]7M4^)/A#1=7_L
MO5-<@M[P.J&)E<[2PR,D# &".2<4U>^G]?U?\1=/Z]#.'PJTO^S;VQ.IZH89
M[O[;;#SU!L)MQ;?%A>#ECUSQ5ZX\ VVH>#;GP[JVL:M?Q74HEENIYU:;(96
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M /86C_\ 1,U>OUY!^TK_ ,DVT_\ ["T?_HF:@#?^!O\ R1C0O^WC_P!*)*]
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M(BHA#HJ")B1UW!N/QKVRFJBINV*JECDD#J?6FW>]_/\ 'F_^2%T5NEOPY?\
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MI/\ :7]G>3=K<^;Y'FYPCKMQN7^_G.>U &?\#?\ DC&A?]O'_I1)7H%> ?\
M#+O_ %-__E,_^VT?\,N_]3?_ .4S_P"VT#/?Z\ ^*_\ R<EX*_[</_2MZ/\
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M"BO /^&7?^IO_P#*9_\ ;:/^&7?^IO\ _*9_]MH&>_UX!\*/^3DO&O\ V_\
M_I6E'_#+O_4W_P#E,_\ MM=A\-/@U_PKOQ)<:M_;O]H^=:-;>5]C\K&71MV=
M[?W,8QWH ]/HHHH$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M>-/&D?A$:<AM&NIM0N!#&-^U4Y&23S_>Z=_:@#N_[9_Z8?\ C_\ ]:C^V?\
MIA_X_P#_ %JRZYCPOXS3Q/X@U[3X;-H(](E2+S'?)E)+@G Z#Y/4]:0'=_VS
M_P!,/_'_ /ZU']L_],/_ !__ .M6713 U/[9_P"F'_C_ /\ 6H_MG_IA_P"/
M_P#UJRZ* -3^V?\ IA_X_P#_ %J/[9_Z8?\ C_\ ]:LNB@#4_MG_ *8?^/\
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M\?\ _K5R_AO5KC7/#]KJ-YITVF33*2UK/]Y.2/0'!QD9 ZUJ4 :G]L_],/\
MQ_\ ^M1_;/\ TP_\?_\ K5EUC^+/$4?A7PS=:O-;O<+;@8B1@I8D@#D]!S2
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MW[%).6P2,DLW Z<=>M<=4H#[8KPOXXZA;7OBW3M*NK@0P6EG),7P3^\8$JI
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M^#['^T[J%K[49;9IEE8D!I$7/7G&>E=_XK\#^+!XZU'6?";6C1:M:?99_/8
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MO'8GKDDUZ?39/4\XL-8^+#ZC;)J'AO2([1I4$[I(-RID;B/WQY SV->CT44
M>2?!/_D!^)/^OL_^@FO,[32IK3P'/XIL]1N;>YMM8^S1Q1MM4?(&+\=^0/P_
M+VKX;^#M4\+:9K$&J>3OO)S)%Y3[AC!'/'%<PGPP\0CX6W6@D6OVZ75_MBCS
MOE\ORU7KCKD4=5\BE;4;!J.M7OQ,\6?V;-,UVV@));Q*YPLAB@/RCH#DG'N:
MS_A$MA/XI@DN-=U&WUF,2BYTZX)"7+<]#GG .2I&<C/0&NIM_!'B:R\8:WJ^
MFSVEN]WI,=I:S.Y.R58X5)(QQ]QL'GMQ5/1/ _C#4?B'8^(/%YL8?L  ,EMM
M#7) ."0H]^2<<# %/2Y"O8Z_XE?VL/ &H_V!YOVO:N?)SOV9&[;CV_3->8^
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MYFD'R\\?A6V_PSU]O _AO2A]E^TZ;?O//^]^7:6R,'')JIK7PY\91:OXBMM
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MW_PEGA*\TE9%BEE :*1APKJ<C/L<8/L:3V!6NKGG>E>%-3\$^')?%UIXAN9
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M:W:* ,+^SKK_ )Y?^/#_ !JKJ?AL:QIL^GZE9B>UG7;)&SXW#KU!R/PKIZ*
M.4TGPI!H5B+/2-.BM( <[(L#)]2<Y)]S5[^SKK_GE_X\/\:W:*8&%_9UU_SR
M_P#'A_C1_9UU_P \O_'A_C6[12 PO[.NO^>7_CP_QH_LZZ_YY?\ CP_QK=HH
M PO[.NO^>7_CP_QH_LZZ_P">7_CP_P :W:* ,+^SKK_GE_X\/\:/[.NO^>7_
M (\/\:W:* ,+^SKK_GE_X\/\:/[.NO\ GE_X\/\ &MVB@#"_LZZ_YY?^/#_&
MC^SKK_GE_P"/#_&MVB@#"_LZZ_YY?^/#_&C^SKK_ )Y?^/#_ !K=HH PO[.N
MO^>7_CP_QH_LZZ_YY?\ CP_QK=HH PO[.NO^>7_CP_QH_LZZ_P">7_CP_P :
MW:* ,+^SKK_GE_X\/\:/[.NO^>7_ (\/\:W:* ,+^SKK_GE_X\/\:/[.NO\
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M7_CP_P :/[.NO^>7_CP_QK=HH PO[.NO^>7_ (\/\:/[.NO^>7_CP_QK=HH
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M9LXW*57<4+#(SQC-<WX7^(]WK^K16-_X:N-,-YI_]H6#M=)+]ICXST^X?F&
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M+^)M&TGP]<P:(U[<Z;KEW=2VB7,:L8I3(%8,3C^('U]J>EU_74J=KNWG^O\
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M)E0XN \DD9.#\QW2$97(XK1'@KQ!_86JV_V#][<>+EU*)?.C^:W\Q&WYW<<
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M7YSYF <-NQC"\C'-8ECX(\16/@/58[?PY]DG/B*/4[72TNHF/D*R':&#;<@
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M#R"BL>P\2VNH>*M5T&"*47&EQPO-(P&UO,!("\YZ#GI6Q0&SL%%%% !1110
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MKJVDN5< ;%1" 0><YRWI1UL!JT444 %%%% !14%]</::?<7,=O)<O#&SK!$
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M3''S@YRIX'W<56;X;^&&\/#16L':U6X^TAC<R&42_P!\2;MP/XT+:WI^%O\
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MQT_RFTIIFLSY\C>49?\ 6=6YSGOG';%)6TOV2_#_ #*<OBMU;_7_ #/'=/\
M#VG:Q:>"+?5$FN475[VP!:YD4^0AD*+E6&,8'(Y[=.*]*^+%S-IGPRNUL99+
M8.\%N\J,0T<;2*K<]?NDC/O6C>?#SPS?:3!IL^GL+:WNGNX@EQ(K+*Y)8A@V
M>=QXSBMK4M)L=7TB;2]1MUGLIX_+DB;."OUZCZTNEGW^_;\]1?:NO^&U?_ ^
MX\MTBRT3X=^+/&GV"VF33++1[><P),SM_P M"0K,21GZ\9KF]!T58O%6I:=<
M:+_8]CJGAJ2\DM(]4EN?..\%9&<D$-VX_J:]<T?X>>&-#M[Z&PTT[=0A$%WY
MT\DOG(,C!W,>Q/2F:'\-_"_AV\>[TO3W6X>W-LTDMU++F(X^3#,1C@=J35[^
MC7Y_YH$[?>OPM_DSQY=&4>&_ >BZ;I$FI6NLVLE[>V#:F]LMW,L:XRY)V@9)
MVK@<5Z_\.+#7-+\'I8^)(S%/!-(L*-<"<K#G**7'WL XS[4Q?A=X270ETA=.
MD%K'/]HB/VF7S(GQC*/NW*,#& <5T.D:19:%I4.FZ7#Y%K ,(F\MCG)Y8DGD
M]S5N6_G_ %^&WH3;1>7]?CN>"MI-M:VNO^*K4S1ZU9>,6AMY4F<91I4#)L!V
MG(8YXR<58M-.\3^(O%6IZ]I6DO-JEGKKPKJ;:MY?DP1N ;?[.>"I7WYS7J<?
MPQ\)1^(/[:32S]M-R;MBUQ*R-,3G>4+%<@DXXXJQ-\/_  W/XF&OOIY%_P"8
MLI9)G5&D7H[(#M+#U(I1TY?+_P"U_P GVW]2I^\Y6Z_\'_-?<>8^,+^ZT[Q%
M\1Y+*=[9Y$TN%YT.&C1_E8@]N">:K^(-'C\+7OB71?"SS1:=9:7;:PL/GO((
MIHYLL0221N0$D=Z]BF\):'<W6JW%QIZ2R:Q$D5]O=F$RH,*,$X& >H JKHW@
M+PYH.FWUCIVG[8=03R[HR2O(\J8*[2S$G !( !XI*Z6FZ_R_)/4<FI/7;3]+
M_?L>*Z=K.HZWXG%G-),;7Q?JL%_:@Y&VWAFD##VRL:\>]?14<B2INB=77IE3
MD5B6_@KP]:S:5+!IJH^CPO!8GS'/DHPPPY/S9'=LFK7A_P /:9X7TE=-T2W^
MSVBNSA-[/RQR>6)-5I:R_KHOP2(U;O\ UY_B:=%%%2,**** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH X+QOHEU'K7_"4>%-4@M=?T^R/GVDY
M#1W=L"6VNO5>0<-_^L8NI^)9->UWX;ZU:QO#]MCO)C!NXW>1T]^179>)/A]X
M:\6WD5WKFG>=<1IY8ECE>)F3^ZQ4C(]C6@WAC1FN=)G^PHKZ.K+8;&95@#+M
M("@X/ QR#26UOZZ_\ JZO?R?Y'B_AC2[5#X$\2++/)JVM7EPVH3M<.WG,$DP
M"I.T;<8X%0^![&UTFW\">)8GN%OK^YO(;V4SNWFQ*)2%VDXP-HZ <UV]O\+X
MX/B=;:O8:=;:;I=C)).&2[DD>YDD3! C/RQ*"Q)QUP/PZ^T\%>'[&TTRVM=/
M"0Z5(\MFAFD;RF?.X\M\V=QX;/6JOI=:?IY"?9Z_T_\ -'CFBQ1WWQ'\-:O:
MZ&^DV/B4W@DD_M22>2]B\L\2*3A,=0%/&?:F+HMCH_P"U_4--22"ZEOVA>03
MR'Y$O,*,%B!QW')[YKU?2_ACX3T;68-5T[3&BN[9W>!C=2E8=P(8*A;:!R>,
M=ZFA^'GAF"UU:U33LV^L$F[B:9V5B23\H)^3DD_+CGZ"A.UK=/\ .]AWUN_Z
MW_X'W'F7Q+N)5N?&XCGD4+IVF8V.1MS-SCTJQXU\,V^E:EX:\)Z#HLE_IFH/
M<W=SISZF\ NY51?O2L2W'+8[FN\MOA9X0M=/O+)-+=H;Y8UNO,NYF:4(VY,D
MOD8/ICTZ5K^(?"NC^*;&*UUJU,R0.)(721HWB;U5E((_.EHE;S_K_,7]?@D9
MGPXL-<TOP>ECXDC,4\$TBPHUP)RL.<HI<?>P#C/M5#PO_P E>\<_[EA_Z*:N
MMTC2++0M*ATW2X?(M8!A$WEL<Y/+$D\GN:2UT73[+6+[5+:WV7FH",7,N]CY
MFP87@G P#V JKZW$M(M?UO<YW5]$\=7.K7$VC^+K.QLG;,5O)IBR-&,#@L3S
MSFMSP]::Q9:7Y7B'4XM3O-Y/GQ6XA&WL-H)Z>M:E%2M%8'J>*V'AW7_%6J^.
M-'L;^QLM%NM:9+UWA9[DC:I(0YV@$ #D9JCXMNKK0M3^(HTAY(G6WTJV#H^U
ME1@$/S=N#C/;->TZ;HFGZ1<7TVGV_DR:A.;BY;>S>9(0 6Y)QP!P,"JTWA/0
M[BZU6XN-/2635XDBOM[LPF5!A1M)P, ]@*2T27DOT_ OFU;[_P"=SRBSL]2\
M#Z'KK:CX:EL= OH(8+?2X=:,Y:Y=]F1+PR!MV2?;\*I:#X9U>:+QYX2TF%-!
MD$=F\-BE^\T2LP)91(?F&\#!^N*]2M/AKX6L]#O=)CTYI+2^"BX6:XDD9MOW
M<,S$KCMC&*CM_A=X1MM/OK./39#'J C^U,]W,SRE#E#N+Y!!YR,57<E:?U_7
M]=3RR^O+>#P1:^&]"T&[TR5]>BLM5TB346 )*%O+6<EMJ/M'(]_6O1_AAHVM
MZ#8ZG9:MI_\ 9MA]H#Z=9F^^U?9XROS('ZX!&1GUK3A^'7A>'PY<:&-,#V5U
M)YTWF2NTCR=G\PG=N&.#GBM/0/#NF^&-.-EH\+Q0LYD?S)6D9V/4EF))/%.^
M_G_P/\B6MO+_ (/^9XEXBNIX_C=J]M=QR#P_<:GIPU*6-L8/E8B1C_<+')^E
M6O%6FZ]XK^(OB6/3=*DO;S2?(CTVY&J_9?[.)0-O6/H^XYSGTQ7K-]X(\/:D
MVJM>Z<)3J_E&])FD'FF/[AX;Y<?[.*@UGX?>&M?U.+4-3L&DN8T6,ND\B>8J
MG(#[6&\ ^N:E:)+M_DO\BY.[;1Y+K6G>)_%GC/7$32'N]6TJ&U2TN!JWV;^S
M9#$&+J@X?<V<G/08I->TA=4U'Q_J>M--'JNBV5G<VSQW+J+>?R,L0%."<C'?
MKQ7KFM?#_P -^(-5CU'5-/,ETBA"\<SQ^8H.0'"D!@#ZUSQ^%5AJWC[7=;\2
M6T=S:W3VYLXEG<<1H PD4$ @L!P<]*:[;?IMJO/^KB6GX'42Q7VM?#\QQ71L
M[^\TT 7'(,4C1_>]L$UXM<0VWASX8^*]"?2KC1O$%M;VTEWB\>:*Y'G*!/&2
MQQN.<CCM7OM]I]KJ6FSZ?>PK+:W$9BDBR0&4C!''M7.6GPP\)VFE7VG)IC/;
MZ@$6Y\VYE=W5#E5WEMP (Z BB_OM]PA[JC?H>8>+=.M]=;Q[JFJ/.U]H-O;Q
MZ;MN'06Z-$"2 I .XDYSFM/Q1H=EXE^(;66KB:6WA\)"Y2-)W0"57.UOE(SC
MWR*W_B-\-$\57,)TK3;9+FY18;K4);N1/)C4C:?*7B5L9 )Z<?AV7_"+Z2=2
M_M"2VWWAL?[/:8R,-T&<[< XZ]\9]Z3UC_79J_WNX1]VU_ZU6GX,\3UJY'BK
MP3I=G)HKZQ?Z9X<6_FO)]2> 6^5(5PJ_ZQQMSS].]:^A:#I^N^-O!-[JT<MQ
M<W'AU;J64W$@+RQ^6%8X8?B.A[YKOK_X7>$=2AM(KK2V\NSMA:1B.YE3,(Z(
MQ5@6 ]R:MS> O#L\FCNUBRG14$=D4GD'EH,84_-\P^4?>STJKKFOYW_]*_S7
MW$_9MY?Y?Y/[SS 7,W_"-ZUF9]P\>*@^<Y"^:G'T]JDT?38(=*\?>+HTFDUS
M2]0U%+*<S.1"NSLF=O<GIVKT*Y^&7A.\U]]8N-++7CSK<DBXE5/-4@A]@8+N
MX].?Q-;6G>'M+TF&^BL+18X]0N'N;I69G$LC_>)W$XSCH./:H^Q;K:WX17Z/
M[S1R3E?I>_XR?ZGEWPMT#7M/US3M4@T=K#2KZPW7TS:O]K^VRD!EG*G&UB<]
M/6F?%:2^M/&1TW3I9(Y/%6G16$)4G"RK<+N;CI^[<_E7HGA[P'X>\+7TMWHE
MDT$LJE/FGD<(F<[55F(49["M'4- TS5=2T_4+^U6:ZTUVDM)"S#RF88)P#@\
M>N:J5I-=O^'_ ,R(W5^_ZJW^1Y!X/U&ZU_PKXMUFY:026.A)I?S$@B6.%S(?
MKN(IFA>&]+U7Q1X+N-0ADEEE\,BY=OM$B[I(_+"'AAT].A[YKUNS\)Z)I^EZ
MCIUG8K%:ZG)++=QB1_WK2##G.<C(],8[8JI<> /#ERVD&2P8?V,@CLMEQ(NQ
M!C"DAOF'RC[V:3=W?^MI7_%W'HHV7];6_!'D'P\T:TTN/X?ZW8^=%?:E>7=M
M=N)G*RQCS,+M)P "H/ '/-.U)#J!O+*YEF,%Q\0!;R!)64F-EP5!!R!]*]CL
MO!>@:?;:7;V=AY<6DRO-9+YTA\IWSN/+?-G<>N>M-/@;PZ9"YT_YCJ0U4GSY
M/^/H?\M/O?\ COW?:KNN>[V_X,7^C'??S_RE_FCG_A=91:1/XIT:Q,BV&GZL
MT=K"\A?RD,:-M!))QDFN1\3>&=);QIX_O#;O]HM]#%S&WGR8$CQRACC=@YQT
M(P.P%>OZ?HUAI=S?7%C!Y4M_-Y]RV]F\Q\!<\DXX X&!67JW@/P[K>M/JNI6
M+2W<EL;61EGD0/&01@A6 /#'GJ,^PK*2;2[VM^%OS"+2;];_ (W_ "/./ 6D
MVWAOQ/X>DT99HSJOA<W5W&TSNLTJ^7M;#$XZX & !6;\.-,\2ZAJ6A^*K32G
M1[JYD;5-4;5O,^V1$L"I@. NTXP!TVU[-:>&-(L;NPNK6TV3:?:?8K9O-<^7
M#Q\N"<'[HY.3QUJAIWP_\-Z5XA;6M/T\PWC,SC;,_EHS?>*QYV@GV%:\RYK^
MOYM_D[&=O=M_6UCE?B1HMCXA^)?@G2]6B::SN%O1+&LC1[@(E.,J0>WK7,6\
MT]QX!T;P]<7<_P#94_BF32I)/,8,]JKMMCWYS@X"_08KU?Q+X*T'Q:]K)KMF
M\\EGN^SR1W$D31EL9(*,/0=:'\$>'I/":>&FTV/^RHP-D 9@5(.=P;.[=GG=
MG-0M%K_P^M_^!\RY.]K?UH_\[_(\GOH(=%\.>-M,L+J:WM/#>HVT^C$R-(8I
MBJGR5)))!;C&?XJ[KX2RQ2^"!JEW<[]0U*\EEOC+\I2<N08L'IMQ@#_&M>U^
M'WAFSTVVL8=-_<6UV+U0T\A+SCI(YW9<_P"]D>U+<_#_ ,-7?F>=IW$E^NI.
MHGD -P/X\;L#/<#@TT^_E^E_OM^"\R7_ )_K_7S?D=)1112&%%%% !1110 4
M444 %%%% &)XOT;3?$'A:[TS6K@6UK.%'G^8$,;[@48$\9# ?6O*O%FOZ]:^
M!?%OA3Q%=1W=_I5O;30ZE;@H9XGE4#>!]UQW]?U/L>L:-I^OZ5-INL6J7=G.
M,21/G!]#D<@^XYK!LOAEX3L=#OM)ATO-IJ!7[5OGD9Y=IRH+[MV!C@ BA;E)
MI-/L>7^+=.M]=;Q[JFJ/.U]H-O;QZ;MN'06Z-$"2 I .XDYSFJWB/2+;4KSQ
M[J=TUP;O1K2PGL)$N'7R)#""6 !P3QW!KN_B-\-$\57,)TK3;9+FY18;K4);
MN1/)C4C:?*7B5L9 )Z<?AU3>"= EAU-)K'S/[6BCAOB9G'GK&NU>C?+@?W<4
MULW_ %?N):63_K;3\#S?XG/#XBW:<N@G5+S2]&.H2W4NHO;K;;@<,J+Q(X*D
M\\=N]5](T'3]=\7>#;W5DFN+FX\-"ZEE-Q("\L?EA6.&'XCH>^:])UWX>>&?
M$ES#/J^GM+)%!]G#1W$D6^+LC;&&X?6GS^ O#D\FCN]BP.BH([+;/(-B#&%/
MS?,/E'#9Z4M/Q_\ DO\ -?<+HEY?Y?Y/[SS/P=<S/X=^&1>9V:34[P/ER2P
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M&EP";4O$H>X75;3QK]EAG%P^$B:50R;<[<'<<\5)K]PNH>-M/\4Z1HKV:_\
M"21:>=5;4G:2;:VUT\C[JH<'\O>O8O\ A"O#_P!EGM_L'[JXU :E*OG2?-<9
M#;\[N.0..GM6?)\,/"4NN'5Y-+;[5]I%V-MS*J+,#G>$#!<DCGCFE"T7&_2W
MY1O^3^\J3NY/O?\ 7_-' 6'AO2]-L/B=?V4$D5U:FY@A?[1(=J&!6(P6P3GG
M)Y]ZAU&YF_LG1RLSY/@.X<X<\ML3GZ^]>J1^"M!BUW4-76RS=ZE&8KK=*Y21
M2 #E"=N2 !G']:S=.^%?@_2O/^R:6X,]L]HY>[F;]R_WD&7X'TY':IM[MO)+
M\&OUN/F7-?SO^*?Z'F^J:)#HOPP\+KHEG--+XFN+)=35KYXS>9B+>69&)V!C
MQQVXKOOAAHVMZ#8ZG9:MI_\ 9MA]H#Z=9F^^U?9XROS('ZX!&1GUKHKWPIHN
MH^&8_#]Y8K)ID4:1QPEVR@087#9W C'7.:DT#P[IOAC3C9:/"\4+.9'\R5I&
M=CU)9B23Q6CDN:377_@?Y&5M(KM_P3Q7XCS:K;^+M=\.:1+*DU_)#K,)4GA(
M8)"X'IEXU_.I/[2EUK0;/Q,DDBKK'C*U\OYB/W2#8!],AN*]GN/#FDW>O)K-
MQ9J^H);-:K,6;B)CDKC..YYQFJ<7@?P[#HFGZ1%IP6PTVY6ZM81-)^[E5BP;
M.[)Y8\$D5,/=M?R_!K]$OQ+DT_Q_%/\ 5L\QL_#.DV&F_%"\M;=TN+8W5O$Q
MGD8+&T 8C!8@\GJ1GWK-TS2+7P[:VSZ09X#JO@J>YO 9W82RK&N&P2<$9P,8
M [5ZZ_@3P])JNJ:B]BQGU:%H+S$\@616 5OE#8!( &1@U,W@S07C@1K#*V]@
MVFQ#SI/EMV !3[W/ ')Y]ZFWNV\DOP:_-IE*2YKOO?\ %/\ 1H\9MM%L_%%_
MI=IK7GSPQ>!X[I%$[I^]5N'.TC)&>^17K7@4MJWPMT4:B[W!N=-C69F<[G!3
M!R1SG'?K5RU\&:!93QS6UALDCT\:8A\Z0XM@<[.6_7K[UI:9IMIH^EVVG:=%
MY-I:QB.&/<6VJ.@R22?QJY-.Z[_YR_1HC6Z?;_)?Y,\#D\/Z;IW[/OB"\LX7
M2>>_,,C&9VRB7F%&"2!@=P,GOFK/B&!O \7C73?"SW%M:O:V$FS[2Q*-+(4D
M<.Q)4D=3[^U>J+\-_"PM-3M3IK&WU642W41N9=K,&WC'S?+\W/RXK2N?"NBW
MEQ?SW5@DSZE;K;76]F(EC7.U<9P,9/(P:GHOZZ+3[RKK\?U_R.,^&7A[6_#V
MM:@DNB_V+H<\"-#9_P!I_; LP/S,&/(W Y/;(K+\9>'-,\3_ !EN;36D=X(O
M#)G3;,\>UUF.&^4C.,YP<CVKT/PWX/T;PG%,FB6\D7GE?,:6=Y6;:,*,N3@
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MZ_\ /UKG_@_7_P"/4?\ "%_'7_GZUS_P?K_\>KZ?HH"Y\P?\(7\=?^?K7/\
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MGS!_PA?QU_Y^M<_\'Z__ !ZC_A"_CK_S]:Y_X/U_^/5]/T4!<^8/^$+^.O\
MS]:Y_P"#]?\ X]1_PA?QU_Y^M<_\'Z__ !ZOI^B@+GS!_P (7\=?^?K7/_!^
MO_QZC_A"_CK_ ,_6N?\ @_7_ ./5]/T4!<^0/%$OQ3\%_9?^$EUO7++[7O\
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M/H_XR)_S_9]>_P!% '@'_&1/^?[/H_XR)_S_ &?7O]% '@'_ !D3_G^SZ/\
MC(G_ #_9]>_T4 > ?\9$_P"?[/H_XR)_S_9]>_T4 > ?\9$_Y_L^C_C(G_/]
MGU[_ $4 > ?\9$_Y_L^C_C(G_/\ 9]>_T4 > ?\ &1/^?[/H_P",B?\ /]GU
M[_10!X!_QD3_ )_L^C_C(G_/]GU[_10!X!_QD3_G^SZ/^,B?\_V?7O\ 10!X
M!_QD3_G^SZ/^,B?\_P!GU[_10!X!_P 9$_Y_L^C_ (R)_P _V?7O]% '@'_&
M1/\ G^SZ/^,B?\_V?7O]% '@'_&1/^?[/H_XR)_S_9]>_P!% '@'_&1/^?[/
MH_XR)_S_ &?7O]% '@'_ !D3_G^SZZ#X#>.?$7C3^WO^$EU'[;]D^S^1^XCC
MV;_-W?<49SM7KZ5Z_7@'[+O_ #-/_;I_[6H ]_HHHH$?/'Q&^(_CS3OC!>>&
MO"VJ^7&TUO#:6WV> Y>2*,XW.O=FZD\9]*L?\9$_Y_L^N?\ &G_)V%M_V%M-
M_P#08*^GZ!G@'_&1/^?[/H_XR)_S_9]>_P!% '@'_&1/^?[/H_XR)_S_ &?7
MO]% '@'_ !D3_G^SZ/\ C(G_ #_9]>_T4 > ?\9$_P"?[/H_XR)_S_9]>_T4
M > ?\9$_Y_L^C_C(G_/]GU[_ $4 > ?\9$_Y_L^C_C(G_/\ 9]>_T4 > ?\
M&1/^?[/H_P",B?\ /]GU[_10!X!_QD3_ )_L^C_C(G_/]GU[_10!X!_QD3_G
M^SZ/^,B?\_V?7O\ 10!X!_QD3_G^SZ/^,B?\_P!GU[_10!X!_P 9$_Y_L^C_
M (R)_P _V?7O]% '@'_&1/\ G^SZ/^,B?\_V?7O]% '@'_&1/^?[/H_XR)_S
M_9]>_P!% '@'_&1/^?[/H_XR)_S_ &?7O]% '@'_ !D3_G^SZ/\ C(G_ #_9
M]>_T4 > ?\9$_P"?[/H_XR)_S_9]>_T4 > ?\9$_Y_L^C_C(G_/]GU[_ $4
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P"*^^.BQX\S1O!Z;F[I)>-T_P"^<?@8SZUVOCKQ/%X/\%ZCK,N"\$6($/\
M'*W"#\R,^V:R_A3X8E\,^!K?^T-S:IJ+&]OG?[QDDYP?<# /OGUH [2BBB@
MHHHH **** "BBB@ HHHH **** "BBB@!&8(I9R%51DDG  KRSX;JWC+QYKWC
M^X!-KN.G:2&7&(4^\X^I_4L*T_C%KUQ8>$H]#TG+:MXAF%A;*.H5N';Z8.,]
MMPKK/#&@6WA?PQ8:+9 >59PB/=C&]NK,?<L23]: -6BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** / /VHO^96_[>_\
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M_P!A;3?_ $&"OI^OF#QI_P G86W_ &%M-_\ 08*^GZ!A1110(**** "BBB@
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M 4444 %%%% !1110 4444 %%%<=\4O%3^$_ =W<6A)U"[(M+)$&6:5^ 0!W
MR?J .] '-^&\^//C3J?B-_GTKPVIT^P]'G/^L<?3+?@4]*]5KF_A_P"%D\&^
M!].T< >=''ON6!SNE;ES],\#V KI* "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** / /VHO^96_[>__ &C7K_@'_DFW
MAK_L$VO_ *)6O(/VHO\ F5O^WO\ ]HUZ_P" ?^2;>&O^P3:_^B5H'T.@HHHH
M$> ?LN_\S3_VZ?\ M:O?Z\ _9=_YFG_MT_\ :U>_T#84444""BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\ _9=_YF
MG_MT_P#:U>_UX!^R[_S-/_;I_P"UJ!GO]%%% CY@\:?\G86W_86TW_T&"OI^
MOF#QI_R=A;?]A;3?_08*^GZ!A1110(**** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ KP#_F\[_/\ T#Z]_KP#_F\[_/\
MT#Z!GO\ 1110(**** "O/_CE_P D8UW_ +=__2B.O0*\_P#CE_R1C7?^W?\
M]*(Z ,#]FK_DFVH?]A:3_P!$PUZ_7S)\(OB[H/@'PC=:7K%IJ,T\U\]PK6L4
M;*%,<:X)9U.<H>WI7>?\-*^#_P#H&ZY_WXA_^.T#/7Z*\@_X:5\'_P#0-US_
M +\0_P#QVC_AI7P?_P! W7/^_$/_ ,=H$>OT5Y!_PTKX/_Z!NN?]^(?_ ([1
M_P -*^#_ /H&ZY_WXA_^.T >OT5Y!_PTKX/_ .@;KG_?B'_X[1_PTKX/_P"@
M;KG_ 'XA_P#CM 'K]%>0?\-*^#_^@;KG_?B'_P".T?\ #2O@_P#Z!NN?]^(?
M_CM 'K]%>0?\-*^#_P#H&ZY_WXA_^.T?\-*^#_\ H&ZY_P!^(?\ X[0!Z_7
M?$_P_K'BZ?0?#]I;-_8MQ>>;JMR' VQIR$QG/S<\CH0M<_\ \-*^#_\ H&ZY
M_P!^(?\ X[1_PTKX/_Z!NN?]^(?_ ([0,]=CC2&)(XE"(BA551@ #H!3J\@_
MX:5\'_\ 0-US_OQ#_P#':/\ AI7P?_T#=<_[\0__ !V@1Z_17D'_  TKX/\
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M&ZY_WXA_^.T >OT5Y!_PTKX/_P"@;KG_ 'XA_P#CM'_#2O@__H&ZY_WXA_\
MCM 'K]%>0?\ #2O@_P#Z!NN?]^(?_CM'_#2O@_\ Z!NN?]^(?_CM 'K]%>0?
M\-*^#_\ H&ZY_P!^(?\ X[1_PTKX/_Z!NN?]^(?_ ([0!Z_17D'_  TKX/\
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M&ZY_WXA_^.T >OT5Y!_PTKX/_P"@;KG_ 'XA_P#CM'_#2O@__H&ZY_WXA_\
MCM 'K]%>0?\ #2O@_P#Z!NN?]^(?_CM'_#2O@_\ Z!NN?]^(?_CM 'K]%>0?
M\-*^#_\ H&ZY_P!^(?\ X[1_PTKX/_Z!NN?]^(?_ ([0!Z_17D'_  TKX/\
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MX/\ ^@;KG_?B'_X[1_PTKX/_ .@;KG_?B'_X[0!Z_17D'_#2O@__ *!NN?\
M?B'_ ..T?\-*^#_^@;KG_?B'_P".T >OT5Y!_P -*^#_ /H&ZY_WXA_^.T?\
M-*^#_P#H&ZY_WXA_^.T >OT5Y!_PTKX/_P"@;KG_ 'XA_P#CM'_#2O@__H&Z
MY_WXA_\ CM 'K]%>0?\ #2O@_P#Z!NN?]^(?_CM'_#2O@_\ Z!NN?]^(?_CM
M 'K]%>0?\-*^#_\ H&ZY_P!^(?\ X[1_PTKX/_Z!NN?]^(?_ ([0!Z_17D'_
M  TKX/\ ^@;KG_?B'_X[1_PTKX/_ .@;KG_?B'_X[0!Z_17D'_#2O@__ *!N
MN?\ ?B'_ ..T?\-*^#_^@;KG_?B'_P".T >OT5Y!_P -*^#_ /H&ZY_WXA_^
M.T?\-*^#_P#H&ZY_WXA_^.T >OT5Y!_PTKX/_P"@;KG_ 'XA_P#CM'_#2O@_
M_H&ZY_WXA_\ CM 'K]%>0?\ #2O@_P#Z!NN?]^(?_CM'_#2O@_\ Z!NN?]^(
M?_CM 'K]> ?LN_\ ,T_]NG_M:N@_X:5\'_\ 0-US_OQ#_P#':Y_]EW_F:?\
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M&E?!_P#T#=<_[\0__': /7Z*\@_X:5\'_P#0-US_ +\0_P#QVC_AI7P?_P!
MW7/^_$/_ ,=H ]?HKR#_ (:5\'_] W7/^_$/_P =H_X:5\'_ /0-US_OQ#_\
M=H ]?HKR#_AI7P?_ - W7/\ OQ#_ /':/^&E?!__ $#=<_[\0_\ QV@#U^BO
M(/\ AI7P?_T#=<_[\0__ !VC_AI7P?\ ] W7/^_$/_QV@#U^BO(/^&E?!_\
MT#=<_P"_$/\ \=H_X:5\'_\ 0-US_OQ#_P#': /7Z*\@_P"&E?!__0-US_OQ
M#_\ ':/^&E?!_P#T#=<_[\0__': /7Z*\@_X:5\'_P#0-US_ +\0_P#QVC_A
MI7P?_P! W7/^_$/_ ,=H ]?HKR#_ (:5\'_] W7/^_$/_P =H_X:5\'_ /0-
MUS_OQ#_\=H ]?HKR#_AI7P?_ - W7/\ OQ#_ /':/^&E?!__ $#=<_[\0_\
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M -"GH?\ X+8?_B:Z"B@#G_\ A ?!_P#T*>A_^"V'_P")H_X0'P?_ -"GH?\
MX+8?_B:Z"B@#G_\ A ?!_P#T*>A_^"V'_P")H_X0'P?_ -"GH?\ X+8?_B:Z
M"B@#G_\ A ?!_P#T*>A_^"V'_P")H_X0'P?_ -"GH?\ X+8?_B:Z"B@#G_\
MA ?!_P#T*>A_^"V'_P")H_X0'P?_ -"GH?\ X+8?_B:Z"B@#G_\ A ?!_P#T
M*>A_^"V'_P")H_X0'P?_ -"GH?\ X+8?_B:Z"B@#G_\ A ?!_P#T*>A_^"V'
M_P")H_X0'P?_ -"GH?\ X+8?_B:Z"B@#G_\ A ?!_P#T*>A_^"V'_P")H_X0
M'P?_ -"GH?\ X+8?_B:Z"B@#G_\ A ?!_P#T*>A_^"V'_P")H_X0'P?_ -"G
MH?\ X+8?_B:Z"B@#G_\ A ?!_P#T*>A_^"V'_P")H_X0'P?_ -"GH?\ X+8?
M_B:Z"B@#G_\ A ?!_P#T*>A_^"V'_P")H_X0'P?_ -"GH?\ X+8?_B:Z"B@#
MG_\ A ?!_P#T*>A_^"V'_P")H_X0'P?_ -"GH?\ X+8?_B:Z"B@#G_\ A ?!
M_P#T*>A_^"V'_P")H_X0'P?_ -"GH?\ X+8?_B:Z"B@#G_\ A ?!_P#T*>A_
M^"V'_P")H_X0'P?_ -"GH?\ X+8?_B:Z"B@#G_\ A ?!_P#T*>A_^"V'_P")
MH_X0'P?_ -"GH?\ X+8?_B:Z"B@#G_\ A ?!_P#T*>A_^"V'_P")H_X0'P?_
M -"GH?\ X+8?_B:Z"B@#G_\ A ?!_P#T*>A_^"V'_P")H_X0'P?_ -"GH?\
MX+8?_B:Z"B@#G_\ A ?!_P#T*>A_^"V'_P")H_X0'P?_ -"GH?\ X+8?_B:Z
M"B@#G_\ A ?!_P#T*>A_^"V'_P")H_X0'P?_ -"GH?\ X+8?_B:Z"B@#G_\
MA ?!_P#T*>A_^"V'_P")K<M[>&TMHK>UBCA@A01QQ1J%5% P% '  '&*DHH
M**** .?_ .$!\'_]"GH?_@MA_P#B:/\ A ?!_P#T*>A_^"V'_P")KH** .?_
M .$!\'_]"GH?_@MA_P#B:/\ A ?!_P#T*>A_^"V'_P")KH** .?_ .$!\'_]
M"GH?_@MA_P#B:/\ A ?!_P#T*>A_^"V'_P")KH** .?_ .$!\'_]"GH?_@MA
M_P#B:/\ A ?!_P#T*>A_^"V'_P")KH** .?_ .$!\'_]"GH?_@MA_P#B:/\
MA ?!_P#T*>A_^"V'_P")KH** .?_ .$!\'_]"GH?_@MA_P#B:/\ A ?!_P#T
M*>A_^"V'_P")KH** .?_ .$!\'_]"GH?_@MA_P#B:/\ A ?!_P#T*>A_^"V'
M_P")KH** .?_ .$!\'_]"GH?_@MA_P#B:/\ A ?!_P#T*>A_^"V'_P")KH**
M .?_ .$!\'_]"GH?_@MA_P#B:/\ A ?!_P#T*>A_^"V'_P")KH** .?_ .$!
M\'_]"GH?_@MA_P#B:/\ A ?!_P#T*>A_^"V'_P")KH** .?_ .$!\'_]"GH?
M_@MA_P#B:/\ A ?!_P#T*>A_^"V'_P")KH** .?_ .$!\'_]"GH?_@MA_P#B
M:/\ A ?!_P#T*>A_^"V'_P")KH** .?_ .$!\'_]"GH?_@MA_P#B:/\ A ?!
M_P#T*>A_^"V'_P")KH** .?_ .$!\'_]"GH?_@MA_P#B:/\ A ?!_P#T*>A_
M^"V'_P")KH** .?_ .$!\'_]"GH?_@MA_P#B:/\ A ?!_P#T*>A_^"V'_P")
MKH** .?_ .$!\'_]"GH?_@MA_P#B:/\ A ?!_P#T*>A_^"V'_P")KH** .?_
M .$!\'_]"GH?_@MA_P#B:/\ A ?!_P#T*>A_^"V'_P")KH** .?_ .$!\'_]
M"GH?_@MA_P#B:/\ A ?!_P#T*>A_^"V'_P")KH** .?_ .$!\'_]"GH?_@MA
M_P#B:/\ A ?!_P#T*>A_^"V'_P")KH** .?_ .$!\'_]"GH?_@MA_P#B:/\
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M/_Q-'_" ^#_^A3T/_P %L/\ \37044 <_P#\(#X/_P"A3T/_ ,%L/_Q-'_"
M^#_^A3T/_P %L/\ \37044 <_P#\(#X/_P"A3T/_ ,%L/_Q-'_" ^#_^A3T/
M_P %L/\ \37044 <_P#\(#X/_P"A3T/_ ,%L/_Q-'_" ^#_^A3T/_P %L/\
M\37044 <_P#\(#X/_P"A3T/_ ,%L/_Q-'_" ^#_^A3T/_P %L/\ \37044 <
M_P#\(#X/_P"A3T/_ ,%L/_Q-'_" ^#_^A3T/_P %L/\ \37044 <_P#\(#X/
M_P"A3T/_ ,%L/_Q-'_" ^#_^A3T/_P %L/\ \37044 <_P#\(#X/_P"A3T/_
M ,%L/_Q-'_" ^#_^A3T/_P %L/\ \37044 <_P#\(#X/_P"A3T/_ ,%L/_Q-
M'_" ^#_^A3T/_P %L/\ \37044 <_P#\(#X/_P"A3T/_ ,%L/_Q-'_" ^#_^
MA3T/_P %L/\ \37044 <_P#\(#X/_P"A3T/_ ,%L/_Q-'_" ^#_^A3T/_P %
ML/\ \37044 <_P#\(#X/_P"A3T/_ ,%L/_Q-'_" ^#_^A3T/_P %L/\ \370
M44 <_P#\(#X/_P"A3T/_ ,%L/_Q-'_" ^#_^A3T/_P %L/\ \37044 <_P#\
M(#X/_P"A3T/_ ,%L/_Q-'_" ^#_^A3T/_P %L/\ \37044 <_P#\(#X/_P"A
M3T/_ ,%L/_Q-'_" ^#_^A3T/_P %L/\ \37044 <_P#\(#X/_P"A3T/_ ,%L
M/_Q-'_" ^#_^A3T/_P %L/\ \37044 <_P#\(#X/_P"A3T/_ ,%L/_Q-'_"
M^#_^A3T/_P %L/\ \37044 <_P#\(#X/_P"A3T/_ ,%L/_Q-'_" ^#_^A3T/
M_P %L/\ \37044 <_P#\(#X/_P"A3T/_ ,%L/_Q-'_" ^#_^A3T/_P %L/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'W_)&/#/_;K_ .D[59L/^3=6_P"N,O\ Z4-6/V%ZGC_\PE+_ *_?JRU\%/\
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M^-/^2'Z-_P!<;3_T770?"K_DG5A_OR_^C&K&7\+YGE8K_D6/_KZ_R9QWQO\
M^0EI/_7&3^8K,^#/_([S?]>3_P#H25I_&_\ Y"6D_P#7&3^8K,^#/_([S?\
M7D__ *$E;1_W<]BC_P B'_MU_FS)^)?_ "475?\ ?3_T6M=_\$O^1>U'_KZ'
M_H K@/B7_P E%U7_ 'T_]%K7?_!+_D7M1_Z^A_Z **G\!?(,Q_Y$L/2'Z'-?
M!7_D=+O_ +![_P#HR.CPU_R7R;_L(7O_ *#+1\%?^1TN_P#L'O\ ^C(Z/#7_
M "7R;_L(7O\ Z#+3E\4_0O%?[QBO^O?Z,E\;_P#):['_ *[VG_H2U[97B?C?
M_DM=C_UWM/\ T):]LKFJ_#'T/G<U_P!WPW^#_(^6=<_Y&'4?^OJ7_P!#->M^
M'/\ D@=W_P!>MU_Z$]>2:Y_R,.H_]?4O_H9KUOPY_P D#N_^O6Z_]">NJM\$
M?5'TV;_[M0_Q1_)GBU>T?%K_ ))SI7_7U#_Z)>O%Z]H^+7_).=*_Z^H?_1+T
MZOQP-<R_WS"^K_0YK6?^2!Z!_P!A!_\ T*>N@L/^3=6_ZXR_^E#5S^L_\D#T
M#_L(/_Z%/706'_)NK?\ 7&7_ -*&K.7P_P#;QYN(_A1_Z_O\V6O@I_R*E]_U
M^G_T!*B^-O\ R+VG?]?1_P#0#4OP4_Y%2^_Z_3_Z E1?&W_D7M._Z^C_ .@&
ML_\ E^<2_P"1]_V]^AP'PT_Y*+I7^^__ *+:M;XS?\CO#_UY)_Z$]9/PT_Y*
M+I7^^_\ Z+:M;XS?\CO#_P!>2?\ H3UT/^.O0]^I_P CF'^#]6>D?"[_ ))M
MI?\ VV_]'/76UR7PN_Y)MI?_ &V_]'/76UP5/C?J?!YA_OE7_%+\V5-5U&+2
M-)NM0N<^5;1-(P'4X'2N1L/#NL>)K"+5M9\0:E82W*^;#:V$OE1P*>5!X^8X
MQ6I\1(WE^'VK+&"2(@QQZ!@3^@-;>F2)-I%G+"08W@1E(]"HQ1'2-T73FZ&&
M52'Q.35]]$E^=_P,CPI/K(6]T[7U>66RFV17ICVK<QD9#>F1WQ70U5@U*SN=
M0N+&"X1[FUV^=$.J;AD9^HJU2D[NYRUI.51R<>6_3^N^YP'C/Q3J!N4LM%AN
M(K>WO88[R^Y09+C]VAZGW/IQWKIO%-UJ=KHNW0XF>]GE2%'6,N(0QP9"/0#\
M*SOB%QX=ML?]!"W_ /1@KJ))$AB:25U1$!9F8X"@=233NN5.W7_([9S@J5&<
M8+1O3OMN<1?V^J>#[G3KY==O=2@N;N.VNH+Q@P(?C<F!\N#VK8U^WUG4M6L]
M.T^>:PT]D:2ZO8,;\CA8U)Z$]<XK,M?-\;Z_;ZDR-'H.FR[[4,,&[F''F8_N
MCMZUUMTOGP2VT=P8)I(R%="-Z=MP!]*<G:U]RJU1TYPYDN=)WTVOM=+2Z_#;
MH<YX=N;VP\4ZAX>O+Z748H(([F">?!D4,<%6(Z\\@U3^)'B*\TS2'L]%=DO6
MC,\LJ'!@A4@%L]B20!^-0Z2K^$/&%]97LK7Z7UJUZ+Z49G/E\%&/0@#IC%<M
M>^+M"OO!^N37%^&UK5A_J?)D_=(&^2(-MQP.3SU)JU'FDFM?Z_K[COH87VF*
MC54.:/N[+1M[MKHM&WY^IZI>7ILO#$U\[',-H92Q]0F:Y71/#NN:EHME>W'B
M[4HI;B!)FB"K\NX9Q6S'+8>+_ TD5C?;;:XA\AI]A&TXPW#8^E<]XA\%V/AO
MP[)K>B37,.JZ>BR"Z>=F,P7&58$XP1V %)63:>AQX7E@G1;Y9N5M8I^E[[:[
MVN_(W/$%W?7FO6'AW2[QK-IHFN+JYC ,B1*0 %ST))QGM4FAV&MZ1KDUE<W=
MQJ6DM )(;JZ=6ECDS@H3P6!'.<5S=Y;3:_\ $RUB:XFM;:ZT5)9Q"VUG3>3L
M##D<D9QV%:FDVK>&/'2Z-9W$TFF7UHT\<,TA<PR(0#@GG!!Z>M%K*WK^I<Z:
MA05.+5^6]K?-N_=?=8EU7P]J$7VS4)?&&H6ELN^8HJKMB7DX'L!5/0-0U?2_
MA[J&NZG=37LC(]Q:)<?>6,#Y-V/7J:N^/7:\ATO0(VP=6NUCEP<'R5^9_P"0
MK2\5ZE%H'@^\NOLT<T<40C6!Q\K;B% (].?RJ=>6W<F,YSITZ<DFYM:62T3M
MO;J[_<<K=G6?#_AZR\3OK]W>RR-"US:2;3#(LA *HH'RD;N#[5O>+=3OEN]*
MT72)_LMUJDK W&W)BC0;G(![XKF=2\*7GASPW:ZK)J,FH+I;+<OILY)MP,\A
M!G(VYXSGITKI?$FGWNIQZ3KN@*DM[8-YT4,K;1-&ZX9,]B1BK?+=>K_X!M/V
M+G"=TU[RO:RO;W4UV3L[[6?D06[7_A?Q-IVG7.J7.IV&IAT1KLAI(95&[[P
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M#9R-(=T<;2.G!Z_+Y3GCIQ7H]87_  B&G&6&0O.6A6X"Y8?\MB2Q/'4;F ]
M3UJDTD=V$K4J:?M%U3^Z[_'1'$0ZC/):WCRW.N/?%X8K.6*ZD6!9&@C*ALML
MY<Y.1SGOFN_US4GT?PO<WLSQK-%#@,S;5\P\#GL-Q%16_A6P@TF]T[=-)!>X
M\S>PW#$:H"" ,'" _6KMQI<=W!9Q7,LL@M94E!)&9&3INX]<'C'(%7.49&U?
M$4:LXNVB?X67^3_,R/!^H?:M%N+4:DFHRV$K0_:_,$@E&-RL6!YX8 GU!JAX
M>DGM=5M(=4GU.VOI$83+=2&:WO&QDM$VXJN,9  !QQCBNF&EVXU*YO<N6NH5
MAEC)&Q@I;!QCK\Q'7I69#X2BC58Y-3OIH((VCM(G9#]FW*5RIVY)"D@%LXI<
MRU9*K46Y].;\[?=OY>:LT8WA[Q&+[6M14:I'<K?123V\"3AS;"-BF, _+N78
MV/7=61_;FJ'X=6ML+Z<ZBLJ--<>8PD\K:LN=W4Y#HOXUWTNA6DD&GQ(9(5T_
MB'RR!QL*;3QTP?T%4/\ A"M,\LKON.;*.RW;UR$0@@]/O':N3[#BJ4HI_=^!
MT0Q6%YN9QZI_==?E^)SFE3W=S/')9RZW+J U.19&D:9K3R1.P89;]WP@P,<Y
MK5GO;H?#/5KH7,PN(Q>;)A(=Z[99 N#U&  !Z8KI-,TV'2K,VUNSLAEDERY!
M.7<N>@'&6-9#>#XGM+JS.KZE]CN?-WVVZ+8/,)+8_=YZL2.:7,GH0\31J5+O
M1*2?>Z5]/\D'AN*(7#ND.N1MY6"=2N)'0Y(^Z&=AFG>2=:N=7\^>ZABMYE@B
M^SW#Q'Y4#$Y4@\ER/^ BKVG:3-83EY-8O[U=FT17)BVCW^5%.>/6BRL9+74]
M3^4_9[QUG5LCARH1EQ_P!3^)J9.]SFE57/*2EK96W[KOJ<C:7%SI>C>%;Z.7
M5+^6^=7N(1=-*TI-NYP [8QGG&0./:IH-8OKO7W)-Y9*=6CC%O<O@HOV1C@A
M6(P6&[&??K730^'[6"WTB%))BNDX\@EAEL1F/YN.>&/3'-,E\-V4VH27<C3,
MTERMRR9&TL(C%CITVG\_RJY2BV_ZZG2\51DY-K=/7YNWX&'X>>XMM6M(=3GU
M.WOI$83+=2&:WO&QG=$VXJN.H  ..,<4OC37_P"S=2LTCU*.S-FGVV6-I@AN
M%#!?*P3\V5\PX]0*U[#PS'8W5O(]_>74-F"+2WG92L&05X(4,V%) W$X!J_'
MI<"7E[<MND>]55D#XP%48"CCIR3SGDFI<ES7(EB*/M_:-7TV^?GY>O9.UCCM
M>U&!/$U])>S:RUG%8P2Q_P!G3R(B;C)EFVL ,X')XXJ&-[Z36!;ZT=;N9H]-
MMF9--NG4*Y,FXML902<#GVKK--\-V>F[PDDTXDM8[1A.P8&--V.@'.'(/X54
MB\'I:RK)9:SJELRP);DQO$=R(6*@[HSTW$57-'9&T<5147%/9))Z^7;;9W[F
M5XJUP:5-IL,6I&S%E +R2*>XQ)<*"%$1R<N2OF'ORHK=UNZD$VB-:3E$GO<$
MJQ"NODR$9]1D _A5JTT>&VDN9))9KJ6ZC2.62?:2RJN . !W)^K&HE\/VHT_
M3K-Y)I8M/8&+>P)<!&3#<<C:Q].U0VK'*ZU&T5VOKWNOT9@^'GN+;5K2'4Y]
M3M[Z1&$RW4AFM[QL9W1-N*KCJ  #CC'%7_%"7;7=FRQW\]@J/Y\6FSF.8-\N
MU^&4LH^;@'J1P:LV'AF.QNK>1[^\NH;,$6EO.RE8,@KP0H9L*2!N)P#5C4]%
M&H7,5U;WMQ87<2F-9[<J24)!*D,"",@'ID4W)<R9<J]-XA33Z>=NOS_.W2Z1
MQEO=_;M8=)+K7M3@CLH2C6$LD)5M\@;S%#KAOE .><J>E;.LZ6IU#0Q'>ZK"
MMU.(9474)DRH@=AD!OO949/4U:B\&PVMP9M/U74K)WC"2F%HSYI#,VYMR'DE
MV)QCK6K)I4<QT]IYYI9+"3S$D8KF1MC)EL#'1B>,<TW)7T-*N*ASJ5.6EFOP
M^[?L4-6DEM=5\.P033+&]TT<@\PGS%$$A 8_Q<@'GN,UA:]?7,8UT&ZO%CCU
M.RC MY'#JC"+<J;>1G)X'4FNLU72H]5MXU::6WEAD$L,\)&^-P",C((/!(((
MZ&J:>&;;["8)[FXGDDNH[N6X<KOED0J1G P!\BC  X'XTHR5TW_6J9E0KTH<
MLI;K3_R:]_NT*WAC[1]MOO+_ +2_LW;'Y']I^9YGF?-OQYGS;<;.O?.*Q]2M
MY-*U369K:_U%C96$5S DU_,T8D9I02REL%?E7@\<5W=4)='M)[R\N)U:7[9;
MK;31-C844OVZ\[SGGTI<VMR*>*2J2G+9VT]&OS5_O,=[27P_J>DO#?WER+VX
M^S7*W,[2"0F-F#@$X4@K_#@8/3I53QIK_P#9NI6:1ZE'9FS3[;+&TP0W"A@O
ME8)^;*^8<>H%;5EX=2UO8;BYU"\OOLP(MDN64K"",9&U06..,MDX_&KD>EP)
M>7MRVZ1[U560/C 51@*..G)/.>2:?,KWW*5>E&HIS]ZR^_7_ "9D21G7_$%W
M;R7MU#:6MO$T2VL[0EVDW'>2I!(  P.G6H+>TN-5U.;3[_5;J2/3[:("2UE:
M!II'W9D8H><;0,=,YXJY_P (K'##;K8:E?6<L-NML9XV0O+$OW5;<I&1DX(
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MQW_MW_\ :E9OPK_Y*9J'_7";_P!&+6E\#/\ F._]N_\ [4K-^%?_ "4S4/\
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MV@O6N;@WZ7< N925.W'#$+P2,@D ]O2KL>@RW/A_4;2_=(KC4GDDD,)W")F
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M?0_] %%3^ OD&8_\B6'I#]#FO@K_ ,CI=_\ 8/?_ -&1T>&O^2^3?]A"]_\
M09:/@K_R.EW_ -@]_P#T9'1X:_Y+Y-_V$+W_ -!EIR^*?H7BO]XQ7_7O]&2^
M-_\ DM=C_P!=[3_T):]LKQ/QO_R6NQ_Z[VG_ *$M>V5S5?ACZ'SN:_[OAO\
M!_D?+.N?\C#J/_7U+_Z&:];\.?\ ) [O_KUNO_0GKR37/^1AU'_KZE_]#->M
M^'/^2!W?_7K=?^A/756^"/JCZ;-_]VH?XH_DSQ:O:/BU_P DYTK_ *^H?_1+
MUXO7M'Q:_P"2<Z5_U]0_^B7IU?C@:YE_OF%]7^AS6L_\D#T#_L(/_P"A3UT%
MA_R;JW_7&7_TH:N?UG_D@>@?]A!__0IZZ"P_Y-U;_KC+_P"E#5G+X?\ MX\W
M$?PH_P#7]_FRU\%/^14OO^OT_P#H"5%\;?\ D7M._P"OH_\ H!J7X*?\BI??
M]?I_] 2HOC;_ ,B]IW_7T?\ T UG_P OSB7_ "/O^WOT. ^&G_)1=*_WW_\
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MXC_Y(':?]>MK_P"A)756WCZGU&;?Q<-_C1Y)H?\ R,.G?]?47_H8KTSXY_\
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MS[5;IVOJ;U, J:=Y>FF^_GIM_5CO:*X[Q.[6WC;1;\,P6TAD:0#NC21QL3[
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M')&79E\S#DD\XQW]*WJ5HRBDCVLPS;#5Z-.$&[QE%O3L?,]>T?%K_DG.E?\
M7U#_ .B7JQ_PI7P[_P _NJ?]_8__ (BNH\1>$['Q-HMOI=_+<1P6\BR*T+*&
M)52HSD$=&/:G.M"4HM="\9G&%K8BA4@W:#;>GH>5:S_R0/0/^P@__H4]=!8?
M\FZM_P!<9?\ TH:NGN?A[I5UX0L_#DEQ>"SLYC-&ZNGF%B7/)VXQ\Y[>E7(?
M!]A#X+/AE9KDV15E\PLOF89RYYVXZGTK.52+5O.YQU<RP\X**OI5Y]NEW_F<
MM\%/^14OO^OT_P#H"5%\;?\ D7M._P"OH_\ H!KL?"_A6Q\):?+9Z;+<2QRR
M^:QG920< =@..*3Q3X3L?%UG!;:E+<1)#)YBFW902<8YR#4\Z]KS=#F6.H_V
MI]:^S>_X'B'PT_Y*+I7^^_\ Z+:M;XS?\CO#_P!>2?\ H3UZ#H?PMT70-:M]
M3L[J_>:W)*K+(A4Y4CG" ]_6K'B;X=Z3XKU5;_4;B]CE6(1 0.@7 )/=3SS6
MSK0]JI=+'JSSC"O,8XA-\JC;;K=B?"[_ ))MI?\ VV_]'/76UG:#HMOX=T2W
MTNR>62"WW;6F(+'<Q8Y( '4GM6C7)-WDVCY;%U(U<14J1V;;^]A7,^-O!W_"
M8V^EQ?;OL?\ 9^H1WN?)\SS-F?E^\,9SUY^E=-14];G,%%%% 'GVK?#.]B\1
M7>N^!_$L_AV\OCNNXA L\,S?WMC< ^_/?UHTKX:7T_B"TUKQUXEF\1W-BV^T
MA^SK!!"W][8O!/'7C\:]!HH6FP/7<*Y?X@>#/^$Z\/1:7]O^P>7=)<>;Y/FY
MVYXQN'7/7-=110 BC:H'H*6BB@!'#%&$9"MCY21D _2N4\'>!5\,ZAJ>K:CJ
M!U;6=3EWSWKP^7A.T:KN;"CZ]AZ5UE%"T=PW5CE/'7@6'QE;6<D%ZVEZKI\P
MFL]0CCWM$<\C&1D''3/4"NFMDFCM8DNI5FG5 ))$38';')"Y.,^F34M%"T5@
MWU"BBB@ HHHH **** "L7P]X>_L&;5)/M7G_ -H7CW6/+V^7N_AZG/UXK:HI
MIM&D:DHQ<$]'O\@HHHI&92UG3O[7T.]T[S?)^U0M%YFW=MW#&<9&:31--_L;
M0K/3O-\[[+"L7F;=N[ ZXR<?G5ZBG=VL:>TG[/V=]+W^84444C,Q+;PYY'C2
M[\0/=>8UQ;K;I#Y>/+ P3\V><D>@K;HHIMMFE2I.HTY/9)?)!6;X@TR?6=!N
MM.MKPV3W"[#.$WE5SR,9'49'7O6E12%"<J<E..Z.$L/ OB/2[&.ST_QH\%O$
M,)&NFI@?^/5U&A:?J.FV+Q:MJS:K,TA99F@$6U<#Y< GT)S[UIT5<IREN=%;
M&5:Z:G;7^[%/[TDPK)\1>'K7Q'IRVUR[Q212"6">(X>)QT85K45&VJ.>G4E3
MDIP=FCCY_!^L:PD=KXE\1&\T]""]O!:B$SX.1O8$\>PKKHXTAB6.)0B( JJ!
MP .@IU%4Y-Z&E7$5*J2ELNB22^Y6"L/Q%X9CUU[:ZANI+#4;-BUM=Q $IGJ"
M#U!]*W**2;3NB*=2=*7/!V9R1\(:CJMW;OXJUO\ M&VMG$D=I#;B%'<=&?!)
M/TKK:**;DV55KSJVYNFR227W(****DQ"BBB@ HHHH **** "LS_A'=*WQM]D
M&Z)9E0[VX$IS)W[D_AVQ6G107&<X?"[&?!H.FV]C<V<5J!;W0Q-&S,P<; G<
M_P!U0/PJ9=.M5EM9/+8O:(4A+.QV@@ ]3R< <G)_,U:HIW8W4F]V_P"M/R*\
M-C;6\]S-#%M>Z8/-R2'(4+G'0< #CTK+3P=HB-_Q[2,@_P!7$]Q(4BY!PBEL
M*..@[<=.*W**+M#C6JQ^&37S*.H:-8:HVZ^@\T^4\.0[+\CXW+P1UP/RJ-_#
M^ER333/:CS)YDGD8.PW.@PIZ]AVZ5I4478E5J)64G]Y!;65O9Z?%8V\>RVBC
M$2)N)PH& ,GGI60O@O1$M3;""Y,.% 0WTY"[2"NW+_+@@8(Q6]11S.][CC6J
MPNXR:OYF;;>'["TMKF"(7+1W*;)1+=RR9&"."S$KU/3%3S:597$=M'+ "MHP
M: !B-AVE>Q_NDBK=%%VQ.K4;NY._J9SZ#IDD-C&]J"NGC%K\S9C&W;C.<GCC
MG-0Z;X7TC29HY;*WD#PKLB\VXDE$8QC"AV(7CCBM>BCF?<?MZO+R\SMZ_P!=
MRE?:18ZDSF]@\TO;O;-EB,QO@LO![[1SUXJ-- TR.]BNTM0LT)4QL';Y=J%!
MQG'"L1^-:-%%V)5:B7*I.WJ4SI-D3>GR2#?C%QM=AO\ EVYX/!QQD8/3TITF
MFVDHM \(Q9N'M\$CRR%*]O8D8-6J*+L7M)]W_6GY:&3=>&=+O+]KN>&3>Y#2
MHDSK',1T+H#M;&!U%6CI-B;&ZLV@W07A<SH6)WE_O<YS_AVJY11=E.M4:2<G
MIYF5%X9TB%8%2T_X]TECC+2.Q593E^2<G)[G\*M6FEV=C.9K6'9(88X"=Q/R
M)G:.3VW'GK5NBB[%*M4DK2DW\_G^>IEGPYIIU1M0"7"7#R"5BEW*JLP  )0-
MM/ ';G%10^%-)M[K[1!'=1OYIFVK?3A-Y;<3LW[>3SC&*V:*.9]ROK%:UN=_
M>R"*RMX;BXG2/]Y<D&5BQ.[ P.O08["JUIH6FV,+Q6UL%CD@6W96=F!C7=M7
MDG@;C^=:%%*Y'M)VM=_\-M]QA'P7H1$8%K*BQPK %2[F4&-<X4@-AAR>N>M:
MDNG6LUK#;R0KY,#H\:*2H4H05QCT('%6:*?,WU*E6JSLY2;MYF=#X?TRW=6A
MM0A66688=OOR??/7OG\.V*>NBV"VEE;+;XBL"IM@';,948'.<GCCGKWJ]11=
MB=6H]Y/[_P"N[((K*WAN+B=(_P!Y<D&5BQ.[ P.O08["J<OA[39M*M].,#+;
MVN/(V2NKPD# *N#N'!QUZ<5IT478*I-.Z;,[3M!T_2I3+9PLLK)L>1Y6=G&<
MY)8G))[]>GH*8WAK2729&M 5G2:.1?,;!65@T@Z\9(!XZ=L5J4478_;5;\W,
M[^IG)H&F1WL5VEJ%FA*F-@[?+M0H.,XX5B/QI^IZ/9:PD2WZ2-Y+[XVCF>)E
M;!&<H0>A(J]11=B]K4YE+F=UYF&W@_1VD$ACNQ($$>];^<,R@D@$A\G!8]?6
MM(Z;:M#:Q.C.EHRO#OD9B&48!))RW7OGUZU:HHYF^HY5JLOBDW\RC+HNGS:S
M%JLD&;V%=J2AV&!AARH.#P[=1WJK<>%-&NI)))+5E>6?[2SQ3R1GS-NW=E6&
M...*V**+L%7JQU4GVWZ=BKI^FVFE6OV>QB\N,L6.6+,S'J2Q))/N35JBBEN9
MRDY.\G=A1110(**** *&N_\ (NZC_P!>LO\ Z :^:_V;_P#DI=S_ -@V3_T-
M*^GKNV2\LYK:4L$FC:-BO4 C!Q7#^"?@_H'@/7'U72+S4IIW@: K=2QLNTD'
M.%13GY1WHA[LW)]O\QRU@EY_Y'>T444""BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
L !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>proxycard2of2.jpg
<TEXT>
begin 644 proxycard2of2.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_X1#H17AI9@  34T *@    @ ! $[  (
M   *   (2H=I  0    !   (5)R=  $    4   0S.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $QI+"!*96YN
M>0  !9 #  (    4   0HI $  (    4   0MI*1  (    #,3,  )*2  (
M   #,3,  .H<  <   @,   (E@     <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0        $" P0%!@<("0H+_\0
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M3QOJL,)>[E0S2 (.ORHJJ.>.P!/%=5;^.O#%UX>EURWUJU?386"2W 8XC8G
M##&0>1U%-JP&_17-:?\ $3PEJHO#8:]:2K91>=<-N*K&F0-V2 ",D#CUJ;P]
MXY\,^*IY(- UBWO)HUW-$N5<#UVL 2.1R/6D!OT444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% 'C7Q\_Y"G@G_ +"+?SCKGM;T:PUKXU^/8]2MDG%OX?GN(=PS
MY<@CC <>X#'%>N>-/ 5GXVN-)FO;N>V.ESF>,0@'>25X.?\ =JLWPVL6\8:[
MXA-]<>?K5@]A+%A=L:,$!9>,Y^0=?6D[VT\_R0TU?^NYX!%I%C9?#?P/K%I;
M+%J%QK$@EN%)W. X 'X;1^OJ:V;+0=)U?_A;5UJEM')/8OOM96X:)B\IX/N4
M4?IW->J-\&]+;PKHFAG4[SR='NVNHI,+ND+-NP>,8^E><>'?A8_CKQ?XON-0
MN]1TVQ74BB/"F([M?,?S%R>#M*)ZX/;I1+5V7G^@1TU?];F<C/KNG?"?3=<W
M/832.CQN?ED N-@4_554>P-4_&5E::%XK^(&D:(%ATW[%%*8(Q\BOYT)P/3!
M=P![U[GXH^%FA^)/"^FZ,C36']E*%L;B Y>+@ YSUS@$]#D9S619?!#1[7PK
MJFERZE>7%YJS(UWJ,F#(VUMV #G )Y.<DGOTP/4:=K'-ZSX+\.6?[."ZI;:1
M;I?2Z5:7+S[26,I"DOD]_P!X_P"!QTK+N[K1_#/P-\/6UIX=L;_4/$1C#),"
MJR.C9#L5().2 .1U.>,@^SR^$;&Y\ )X2N7DDLUL4LO,X#X10JMZ9^4'TS7#
M1? +2!X5ETFXUF_FG,J2P7;8S!M#855_N_,21GKZ55^_D(\ST>UU&P\;>-K;
M6--L]*O8_#TRRVEB (D&R,C&">HVL>3R?P%1=*L;'P%\.-7L[9(=0NM2G\^X
M3AI-MQM7)]@HQ_\ 7->O:'\$+#1YM2GDU[4+RXU*RDM)Y9@I/SXRXZG.1W)Z
MU<D^#NER>&_#NC'4KL1:#<23PR;5W2EY-Y#<=,\<4+22?I^8NC7];'&-X;T6
M[_:BO;.[TVWEM7M3=/$Z94RE Q<CU+$FO5O'_P#R3O7_ /KPF_\ 036!XM^$
M>F^*_%\.OOJ5Y83",17$=M@>>H]^W'!ZY%=EK>EIKF@WNES2-%'>0-"SH!E0
MPQD9J9:QL-?%<^7UTJQL? 7PXU>SMDAU"ZU*?S[A.&DVW&U<GV"C'_US6UHN
MB:5XCTWXH:GXBB2;4+61WBDE^] P,C#;Z990/H,=,UZA)\'=+D\-^'=&.I78
MBT&XDGADVKNE+R;R&XZ9XXJGXE^!>D>(/$5UJ<&K7VFQ:@^^^M;<C9.<Y)YZ
M9//(;GFF]5;U_3_(::3_ *\SR/P]I5CJOB+X<C4K2*Y%_;NMT)$_UP2:6- W
MKA$51[**] \5J-._:,\.KIT:QK;>'I! B#A=J7.T ?@*ZGQ1\'-&\06^BQ6-
MY<Z.='C\F%[7!8Q]<9/.<Y.[U)SFM-?AQI\?C31/$27ESYNC:>MA%"=I61 K
MJ"QQG/[P]/2JOI]Y#/,O@]X%\*>*/ K7_B2TBN;P:LP\R20JQ(5=L9.>0=Q.
M.^:XRWTC7O%.M>-(K'PY:ZQ/+=E9KFXE"2V1WN04RPQG'TPN.E>LO^S_ *$?
M$!NXM4U"'3#/]H.F1OM3=G. PY [=,X[]ZF\2_ O2-?\076I6FJWVEI?MOO;
M:WQLF.<D^V3R<YY.:G<N^YU'PTL=6TSX<:18>(HC#J%M&T3QE@VU5=@G()'W
M M>4^ O#NE:SXT^(M[J6G17EUIUT)+-I 3Y;EIFR!ZY1?R]S7NNEZ?%I.DVN
MGV[RR16L2Q(\SEW8*, DGJ:P/"?@2S\):UKVI6MW/<2:W.LTJ2@ 1D%SA<?]
M=#U]*3NW<2VL?-7A_P +^(O%?@RZ32/#-K?EK\LVJM.%N$< ?N\EAQ\V<$<[
MOI7H+Z<VN_'3PQIGC2V6>1=!C$UO-A@91"S..#@X?<<CN*Z2Y_9^T676FN+3
M6=2LM.>83MI\# *K@Y&T]L=N"1ZTSXV^%]&_L^S\37DVK6]W:%;-9=- D=U;
M. VYACG(W9S\W0\4^W]=!WO<\LT'7;71/ .KZ0-&M]4EU+6EAMK>Y+"-=@SD
MX(.<E1C(ZG/&0;FCVNHV'C;QM;:QIMGI5['X>F66TL0!$@V1D8P3U&UCR>3^
M Z7X>_"!_$'PSN8?$JW>EW%Q??:;-RN)8P%V[B#V.3QP> :Z[0_@A8:/-J4\
MFO:A>7&I64EI/+,%)^?&7'4YR.Y/6G+]/T%?^OF<GX2\/:79?LWW/B.ST^)=
M9FL+M)+L [V4RO&1]-B@?GZFN2O=%TNS\"_#?4K&VC2[N[R07$ZCYI")AP?7
M'2OH;P_X*T_0? 2>$S))>6 BEA=I<!G61F9AQT^^1Q7!6?[/&F6M];S'Q%J<
ML-I.);>!@NU,-G'ISZ@"B+M*_H#VMZG 7_\ R!OC#_V&8_\ TIEJ8Z=:Z!XN
M^'5UHENMK<7.A1W$K1#!EE:-B6/J23_2O5I_@_ID]KXI@.IW:KXDNUNIR%7]
MR1(SX7CIER.?2K9^%^G-K7AG43?7)?P[9QVD,95=LRH, MQU/M2Z_P!=A=&C
MP Z-IC_ "36?LT;:F-=\IK@CYU79G9GT[_C7U'IEK!?>$+2TO(EFMY[%(I8W
M&0ZM& 0?8@U\U^/?A_#9>,Y?#'@Z/6[JXEF2?[(\8-M&KC[P<') X&6 Q@Y)
MQ7U!86QLM-MK4MO,$*1E@.N !G]*J_N@]SQ#X#Z+IC6OB/4'LH3>6ET\5O.5
M^:-2C J#]*\Z31]/?X&:AK#6L9U%/$7D+<X^81B(';],L3_^H5[SX?\ A!IO
MAWQC=:[9:G>&.9Y'CL3@11EU93]<!B!Z>]0)\%=*3P%/X6_M2\-O/J/]H-/M
M3>'V!=O3&.*GJGZ%)K4\DNK?6O$/Q1UB*VT*V\0W)TY(_(O)-OE1F.-?,7+#
M##(Y'][->R?!;1==\/> 6TWQ);&VDAO)#;1F17_<LJL""I/\1>JWBKX*Z7XB
MOX;^SU6\TJ]6W2VGEM\?Z0BJ%^8<<[0!UQ@#BNS\+>'+7PGX;M=&L)KB:"V4
MA7N)-[')S] .> .!02>5G_DZ?4_^P5_[16O+DT?3W^!FH:PUK&=13Q%Y"W./
MF$8B!V_3+$__ *A7T>?A]9'XC7'C#[9<?:I[;[.8,+L V!<],YP*PD^"NE)X
M"G\+?VI>&WGU'^T&GVIO#[ NWIC'%'5?UUN4FM?ZZ'":/X=T>_\ V@TMK_3[
M>>WFTN.[DCD7(:9HE=G/N6).?4URD&DZ]XJUOQI'8^'+769YKLB:YN)=DMF=
M[D%,L,9Q^2XZ5[5XA^#6F:_XAL=6_M2]LI+>V2VF6# ^T*@P,GMD<'J"*J^)
MO@9I&O\ B&ZU.UU:^TM;]]][;6^-DQ)R3[9/)SGDYH>OX_F):+[CSG2?#5Q<
M_%'P+X?\<V"R21Z9+'/:RL&&V/SS$"5.",*AZ^Q[BNA\1>&]'D_:*\*Z#)I\
M+:6NG,HM&&4PJ3,H_, UZ#!\--/MO&>B^(8[^\:71[/[)#%*P<.NQTRS'DG#
M_I5N]\"6E[\2=/\ &3W<ZW5A T*6X V,"KKD]_XS^53K^([H^?\ 3)Y[/X&^
M,K>S9TA_M:*,JI/RH2,_GM45H>'/!'B;4=;\*:A'X0LK335CBBN9K>92+RU<
M!9'=2W)*.V<#OCT%>OZ+\)]%TKPWK>AW$]Q?6FLR^9-YH4%#U!7 Z@X(SW%9
M_A#X,67A3Q+#K!UW4KYK162UAD?:L:'/RG'4<].!GM5=?N_(73[SE_V?-%TQ
MI-<U![*$WEI?&*WG*_-&I4@J#]*ZCXV^(8-)\+6>FOI%OJUQJMTL<$%R6$8*
MD'<=I!SD@8R.ISQP;7AOX1Z;X8\;S^(+'4KPI)))+'8G BC9P0?K@,0/3WK8
M\>^!+#Q]HD=C?S2VLL$GFV]S#C=&V,=#U'MQT'-#UM\@ZL\0\(>']0O_ (G^
M*]!UG3+'2[ZXT22!K2R4"&-BL90C!(Y^5^IY].@R/!^K?V[K'@[2[Z.1K7PN
MMU>3-C)PC-,1]/D1?R%>V^"/A):>"_$<NMKK-]J-Y- T4IN<?,202V>N<CN3
MUJ?PY\*-%\.>*]7UR"::=M426-[>0+Y<:2,&8# SVQ]*!'SWXJNKW7/#/]OQ
M>%M)TK1[W5B$NK?YIVDPQ*$EB=I&3PH&5XQTKN]0);XJ_$PL22?",A)/?_18
M*WY?V<])DD=!XBU1;(2F2"U^4K$3UZ\$G YP.E=9-\+]/F\2:_K#7]R)=<TM
MM-FC 7;&AC2/<O'7" \^M-60I7;_ *[GC]IK9D^&O@3PO8:!8ZSJ=V\T\ OR
M?+C_ '\BC@,N<\YR<<#@\8Q+)+F'P;\2H;ZVAL[E+FW6>VMP!'$XG<%%P2,*
M<@<GZFO9=0^"&EW7AC1M,M=7O;2[T8O]FOXP/,P\A<@@8Z$\$$8J/3_@7I6G
M^'M8TE-8OY(]6\KS97"%D\MMPQQWSWI2UN-:6."?2;#0/$GPDOM#MDM[O4(+
M4W?E'!DW[-['W/F/^ QVJAJ'_(N_&?\ [#$'_I:]>J>$?@II/A;Q)!K$FJ7N
MIR6:;;.*Y(VP9SD\=>6) X )SR>:L3_"#3)['Q9:MJ5V%\3W27,Y 7,++,9<
M+QTR<<]J?0'J<!8VL%]\7?AW:7D2S6\_A".*6-QD.K03@@^Q!IGP?\':3X@\
M-^+HIK*#[699;2VN"@+0AD8?+_.O4+3X:6%IXL\/Z\M]<M-H>FIIT49"[945
M'7<W&<_.>GI5/PW\(]-\,>-Y_$%CJ5X4DDDECL3@11LX(/UP&('I[TY-._S_
M #)BFE]QXIX'FN/%_B+P7X0NX7$.@W4\TN[^)0_F$,/^ [>>F>*^A?B/<3VO
MPUU^6T++*+*0 KU (P3^1->>_!S2(KWXB>,O%,=N\=O)=/!:%@<,KR%V(S[!
M/^^L5[%>6D&H6,]G>1B6WN(VBEC;HRL,$?D:F6L2UI(^7=:T32=*^!WA'Q%I
M:I#K;7Q)NH_]8YWN3GUVE% ]/Q-=O\//#^DK\>_%BC3X NGD26HV?ZABPR5]
M.IK;TGX!Z'INOV]Y<:K?WUC9S>=:Z?.1Y:-D'GU' R !G SGI77:'X%L]#\:
MZSXD@NYY;C5@!)$X&Q.0>,#/:FOBOZ_H)[6.&_:2./ %C_V$%_\ 0&K+.D6'
MA?\ :1LK#PY;K:VESI4@N(8C\HQ"^./JB'W)S6Y^T+97>I>#=+L]-MIKJZFU
M%1%#"A9V.QSP!ST%;/@KX1Z9X.U.[U+^T+O4[V>$V\<UT1F&+ &T>IP ,^@P
M *A;O^NA3V_KN>4^!- TV3X+>*_$)L(Y-8M+FXCM[KG?$OE)]WT_UCG/^ QF
MZUHFDZ5\#O"/B+2U2'6VOB3=1_ZQSO<G/KM**!Z?B:][\'_#S3?"/A6_T%9I
M=0M-0FDEG%P -P=%1EX[87]:Y;2?@'H>FZ_;WEQJM_?6-G-YUKI\Y'EHV0>?
M4<#( &<#.>E-7_+\ ;7YGEOQB@TNR^+MS;6EY+;6E^(7U981Q&Q8%OE'WCC#
M\]R:Z_XH&'X>>._"GBS1(0;1+)K-(X\;"%0JO/?Y9!C/]VNP_P"%*:+/:Z^-
M2O[J]N]<=7DO)%0/"0^_Y,#C)QGV&*YKXPZ$VG?#/PUX2MI+C4[S[<D5K*ZX
M<HJLH!VC'&]%_ >E'1(74Z#X!Z(=-^&RW\P/GZK</<L6^]M!V*,]_ND_\"K!
M\9:78ZU^TUX<L-5MH[JTEL7+PR#*MMCF89_%0:]@T?38M&T2RTRV_P!59P)
MGN%4#/Z5A7O@2TO?B3I_C)[N=;JP@:%+< ;&!5UR>_\ &?RIRU>@+;4^;+?0
M=-7X+Z[J9ME:_M];CMX[@_>5 .GI_$?KQZ"NC\4:S=^*KS54T3POI=XVCZ*L
M=_J-YEIE58_FD4%@N5)., GY>_ KU%?@OI2^"[_PV-3O/(OKX7K2[4W*P ^4
M<8QQ5/7/@/I6K:J;RUUK4-/6:!(;J*'&)]J@ ^W*@D'//I1TL_ZT#^OQ/([O
M3;*;X<_#RXEMHWEFO9K:1R.6B$^=A]LNQ_X$:Z/Q_ILUO\:M)T?P_H%GJ,%I
M88L]*G.V!@0[-QD#@ECUZBO1+_X+:5?> =.\,C4KJ/\ LV=IK>\"J7&XDL".
M!CGMCH*36?@II6J:1I<$.JW]KJ.F1M''J2L#+(&<N=_3/S,Q&".IZTV[_?\
MH):'F1\-^(O#/P:\9VVO:;_9UI-<6TUI"LRR*&+D. 02> J#FI?'_AC1M'^
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MCM($PN)508!;CK]*M_&V2OAL?/'A_P +^(O%?@RZ32/#-K?EK\LVJM.%N$<
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M[D0C$*F2$Y.3Z*W3TKTNBB^WD*VECYU\?Z'X[\<:L+"\\"6T%XMV3#J\#?\
M+#)VH[YP<#!R>>.@R:]YN--FN/"\NF/<$SR69MS/WW%-N[\^:T:*72P^MSY3
MN/ ?C;_A&X_#2^!QYMG?FX?5$5?,F!& @?/*]S@GD+TQSW'QJ^'6N^(M8T6_
M\/:?)=NUI]ENE5E 3:<J6R?]H^OW:]THH#K<\(\8^"=<\/?$"QU;0O#$7B;3
METZ.QBMIT#QPLL?EC<IZ#@'/3DC(KGE^'/B[_A38TDZ'<_;QX@2Z\@LN[RA
MR[LYQU(%?3%%-.W]?,'J>)Z_X!\0ZS\2O'-Q;V<D5KJFCI#:7190LLBK;G9U
MXR8V'/%<AI?A#QA=:KX2AE\$?V=#H=TJW%Y&BJ]Q^\4EW/&X #CKU;GG ^FZ
M*+V%;2Q\XW.A_$'2-2\:6FD^%I;FT\2W!B%PQ'R+O?##GH5=LD],@\=#T6H?
M#K6M-'PNLK&S:[31+II=0EB(VPEY8I&/.,C._P#*O;**4?=V'+4^=]1\%^)_
M"?B[7$TWP58^)K75;@RV5S<PB1;?+$X//'WL') )4'I7NOANS.G^&[&W?3K7
M2Y%B#26=ICRHG;YF"X_VB3^/?K6G11TL#U=SY@U7P#XQT^+Q%X>M_""ZH;^Z
M$\6L;5+HBOGY'/0MQD9S@L,<\=-X@\+>+=+N/ &N:/H<FH7.E6$=O/: @&.1
M><,<\ [CST&/I7O-%"T!ZLX'0];^(%Q\0Q8:WH=O;Z']C1WN8QTE\M2<-N.3
MOW+MQP.?<W/BQX=NO$_PVU+3]-A\^]^26WC'4LK@D#WV[A7944;@M&?,6H?!
M?7W\.>$EMM*D6^D,L>IE67,"F7*%N?[K'IGH:[GXY^ -6\4-H$OANP-RUOO@
MF52!L0[2IY/08;\Z]DHIW \0\._"V^T7X_OJ4.GO'H-L&FAGR-KNT6,8SG(9
MB?PJ/6_A3?ZS\>;J^GT\MX?NXFD>?(VAV@*D8ZD[^>G2O<Z*0'SGX,\.?$/X
M>>%]4OM&\/>9J=W>0P>3,HD9(%#DL K<Y9E!YXQT[B]XH\)>)](\>W'B:#P?
M:>(XM6M4\VTD02K:W!5=W&<\,IYZ$-C/>O?J*!W/#?&_@SQ#J_P>TNRLO"MK
M8ZL]]]HN['30JH#L*[SS@$@+QD]N:Z*/PQJQ_:*N==DT]SI$EAY7VDD;2WEJ
M,8SGKGM7J%%"T=_Z["Z6/!_A9\+]8\/?%>\O]6L9(].T]9UL+F1@?,+-M!'.
M<%&<_C[TSPCI'CKP=\*WL8/"$.I23:I(][8WA5M]N8D'"YYRP/KC'0YKWNBC
MI8'J[GS9IGPY\5R> O&DJ: ^G'5FMQ9Z2K_-A;A7/#'("KD<\GFNK\7>#/$B
M>'? FNZ%IYN=5\.VT"W%B2-QVJAQUYP5(('//'2O:**=PZW/G6^\#>,_%&G^
M+/%.JZ/);:EJT<5O:::K OL$B$DY/&!&HYP3SP.,[MSX,\0OXH^'=RNES&'2
M]&@@O'RN(9%0@J>>N?2O;:*E*ST'>ZL>8_!?PMJ>B> M5TWQ%8R64EWJ,SB-
MR,F-HHUSP3Z'\J\\TCP=XO\ "ES+H"_#_2]?+7GF1ZG=PJR&+@$;L_*#C(R<
MC)X-?2-%"T!NY\W:A=Z[X?\ CAXAC\&:%'>SC2EMOLD(^6"(I$ 5 QD*P08Q
MTSP.HL+\*?%'ACPMX;US2K);K6].OGO;NQ5@3\Q3:HYYP$ ('/S<=,U[9I_@
M[2=-\6ZCXEACD?5-041R2NY(2/"_(J] ,H#SDY[XXK=H2L@;/#]%\)>*]:?Q
MIXN\0:8UE?ZOILEG9Z=NRY! QG/3&Q0,XSSP!BNP^'OAK4K+X'P>']3@-G?O
M;74+1R$'89))-I./9@:] HHL@NSP;P.GQ,\+^![W1;'PA"_V61F3[8X_?EG7
M< -P##:&Z'G/!XP8/!'AKQA:>,-<\6Z?X3CT'%A*MKIA;:DTQ PH4D'!8;NP
MZ 8KZ HJKN]Q'A&NZ3\0?$&C^&O&5SHB#7]&NW:2P1=C2Q!@R-M)XY# @<D$
M$5+XDT/XA?$7P++>:OH\%A?V5^MSIUF&VRM'M(=2"< @[2,\G#<=,^Y44AW/
M&/#&B^,/%_Q,7QEXLT@Z-%I]B]O;6['YI'*,IP#SC+LV3[ 9Y-<RGP]\5_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?_T$M<_[_P /_P :H_X9J\'_ /02US_O_#_\:H ]?HKR#_AFKP?_ -!+7/\
MO_#_ /&J/^&:O!__ $$M<_[_ ,/_ ,:H ]?HKR#_ (9J\'_]!+7/^_\ #_\
M&J/^&:O!_P#T$M<_[_P__&J /7Z*\@_X9J\'_P#02US_ +_P_P#QJC_AFKP?
M_P!!+7/^_P##_P#&J /7Z*\@_P"&:O!__02US_O_  __ !JC_AFKP?\ ]!+7
M/^_\/_QJ@#U^BO(/^&:O!_\ T$M<_P"_\/\ \:H_X9J\'_\ 02US_O\ P_\
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MBO(/^&:O!_\ T$M<_P"_\/\ \:H_X9J\'_\ 02US_O\ P_\ QJ@#U^BO(/\
MAFKP?_T$M<_[_P /_P :H_X9J\'_ /02US_O_#_\:H ]?HKR#_AFKP?_ -!+
M7/\ O_#_ /&J/^&:O!__ $$M<_[_ ,/_ ,:H ]?HKR#_ (9J\'_]!+7/^_\
M#_\ &J/^&:O!_P#T$M<_[_P__&J /7Z*\@_X9J\'_P#02US_ +_P_P#QJC_A
MFKP?_P!!+7/^_P##_P#&J /7Z*\@_P"&:O!__02US_O_  __ !JC_AFKP?\
M]!+7/^_\/_QJ@#U^BO(/^&:O!_\ T$M<_P"_\/\ \:H_X9J\'_\ 02US_O\
MP_\ QJ@#U^BO(/\ AFKP?_T$M<_[_P /_P :H_X9J\'_ /02US_O_#_\:H ]
M?HKR#_AFKP?_ -!+7/\ O_#_ /&J/^&:O!__ $$M<_[_ ,/_ ,:H ]?HKR#_
M (9J\'_]!+7/^_\ #_\ &J/^&:O!_P#T$M<_[_P__&J /7Z*\@_X9J\'_P#0
M2US_ +_P_P#QJC_AFKP?_P!!+7/^_P##_P#&J /7Z*\@_P"&:O!__02US_O_
M  __ !JC_AFKP?\ ]!+7/^_\/_QJ@#U^BO(/^&:O!_\ T$M<_P"_\/\ \:H_
MX9J\'_\ 02US_O\ P_\ QJ@#U^BO(/\ AFKP?_T$M<_[_P /_P :H_X9J\'_
M /02US_O_#_\:H ]?HKR#_AFKP?_ -!+7/\ O_#_ /&J/^&:O!__ $$M<_[_
M ,/_ ,:H ]?HKR#_ (9J\'_]!+7/^_\ #_\ &J/^&:O!_P#T$M<_[_P__&J
M/7Z*\@_X9J\'_P#02US_ +_P_P#QJC_AFKP?_P!!+7/^_P##_P#&J /7Z*\@
M_P"&:O!__02US_O_  __ !JC_AFKP?\ ]!+7/^_\/_QJ@#U^BO(/^&:O!_\
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MSCM5[Q3\:%\-:[?6/_"*ZI<V^GNJ75WPJ)G&".",$$$9(SD4 >G%@I ) +'
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MH&!D8LS(P?<3\P^0C(R.>M-^-&O:G#XM\.Z"FNS>'M)O07N;^%BN#NQR00<
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MH9!_$K#(H M4444 > ?\WG?Y_P"@?7O]> ?\WG?Y_P"@?7O] PHHHH$%%%%
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MU)/]3 5Z*WN?ZC&><;%'2X!1110 4444 %%%% !1110 4444 %%%% !1110
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MI+CX/B-'+&WU":-@<_*2%? _!@?QKTOPOHS^'O"NG:1->2WLEG L3W$QRTC
M<G\_TKS+]F<!OASJMS%!Y%O=:Y<36Z<<)Y<0 P.F""/PH ]:O[&VU/3KBQOX
M5GM;F)HIHG&0Z,,$'\#7DWP+GG\.ZAXH^'5_*TC:!>F6S9\9:WD.1T]\-]9*
M]AKQ^_\ ^)/^UQIDBKL76]!>$L!]]T+,1^"Q+^E 'L%%%% '@'_-YW^?^@?7
MO]> ?\WG?Y_Z!]>_T#"BBB@04444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'D
M'P;_ .2D_$[_ +"P_P#1US7K]>0?!O\ Y*3\3O\ L+#_ -'7->OT <A\6;?[
M5\(?%$>W=MTV:3'^ZN[/Z4?":Y2Z^$/A>2(Y5=-BC/U1=I_5374W=K'?6,]I
M<#=%/&T;CU5A@_H:\F^ %])I6F:UX"U-L:AX;OI%4$8\R%V)#@>A;<?HR^M
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MH V*\@UW?J/[6GAF&,KY>E:+-<O@<DN)8R#S_M(?_P!?'KS,$4LY"JHR23@
M5XW\)/\ BL/BEXS^(.&:SDD73--D8G#1)MW$#I@A(S]6;WR >RT444 > ?\
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MJ "BBB@#P#_F\[_/_0/KW^O /^;SO\_] ^O?Z!A1110(**** "BBB@ HHHH
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M4\EU+6=-USXPZW<Z-?V]_ OA&9#+;2"1=VXG&1QG!%9TG_))_A;_ -AJV_\
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M_H8?_)*X_P#C==!_P@/@_P#Z%/0__!;#_P#$T?\ " ^#_P#H4]#_ /!;#_\
M$T <_P#\+R^'7_0P_P#DE<?_ !NC_A>7PZ_Z&'_R2N/_ (W70?\ " ^#_P#H
M4]#_ /!;#_\ $T?\(#X/_P"A3T/_ ,%L/_Q- '/_ /"\OAU_T,/_ ))7'_QN
MC_A>7PZ_Z&'_ ,DKC_XW70?\(#X/_P"A3T/_ ,%L/_Q-'_" ^#_^A3T/_P %
ML/\ \30!S_\ PO+X=?\ 0P_^25Q_\;H_X7E\.O\ H8?_ "2N/_C==!_P@/@_
M_H4]#_\ !;#_ /$T?\(#X/\ ^A3T/_P6P_\ Q- '/_\ "\OAU_T,/_DE<?\
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MN/\ XW70?\(#X/\ ^A3T/_P6P_\ Q-'_  @/@_\ Z%/0_P#P6P__ !- '/\
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M .A3T/\ \%L/_P 30!S_ /PO+X=?]##_ .25Q_\ &Z/^%Y?#K_H8?_)*X_\
MC==!_P (#X/_ .A3T/\ \%L/_P 31_P@/@__ *%/0_\ P6P__$T <_\ \+R^
M'7_0P_\ DE<?_&Z/^%Y?#K_H8?\ R2N/_C==!_P@/@__ *%/0_\ P6P__$T?
M\(#X/_Z%/0__  6P_P#Q- '/_P#"\OAU_P!##_Y)7'_QNC_A>7PZ_P"AA_\
M)*X_^-UT'_" ^#_^A3T/_P %L/\ \31_P@/@_P#Z%/0__!;#_P#$T <__P +
MR^'7_0P_^25Q_P#&Z/\ A>7PZ_Z&'_R2N/\ XW70?\(#X/\ ^A3T/_P6P_\
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M25Q_\;H_X7E\.O\ H8?_ "2N/_C==!_P@/@__H4]#_\ !;#_ /$T?\(#X/\
M^A3T/_P6P_\ Q- '/_\ "\OAU_T,/_DE<?\ QNC_ (7E\.O^AA_\DKC_ .-U
MT'_" ^#_ /H4]#_\%L/_ ,31_P (#X/_ .A3T/\ \%L/_P 30!S_ /PO+X=?
M]##_ .25Q_\ &Z/^%Y?#K_H8?_)*X_\ C==!_P (#X/_ .A3T/\ \%L/_P 3
M1_P@/@__ *%/0_\ P6P__$T <_\ \+R^'7_0P_\ DE<?_&Z/^%Y?#K_H8?\
MR2N/_C==!_P@/@__ *%/0_\ P6P__$T?\(#X/_Z%/0__  6P_P#Q- '/_P#"
M\OAU_P!##_Y)7'_QNC_A>7PZ_P"AA_\ )*X_^-UT'_" ^#_^A3T/_P %L/\
M\31_P@/@_P#Z%/0__!;#_P#$T <__P +R^'7_0P_^25Q_P#&Z/\ A>7PZ_Z&
M'_R2N/\ XW70?\(#X/\ ^A3T/_P6P_\ Q-'_  @/@_\ Z%/0_P#P6P__ !-
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M /!;#_\ $T <_P#\+R^'7_0P_P#DE<?_ !NC_A>7PZ_Z&'_R2N/_ (W70?\
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MX_\ C==!_P (#X/_ .A3T/\ \%L/_P 31_P@/@__ *%/0_\ P6P__$T <_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M+(V%11U)/85X1\%=<NO$'Q5U.[U%66\CT:.WGWYRSQM&A8Y[G;D^Y->M^/\
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MET/WUQ:VLL@Q_$Q0G]37F&CQ?VYJ6N:EI.B)X>MM(\.R6]];*P!N)&C;#%0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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ME5=H;+LW3\:WZ*0'":/\/;G2_!/B30FOXI)-9N;B9)1&0(A(BJ 1GG&*J_\
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MTOMY[F-:?$?PK?7L%I:ZKYD\\BQ1I]GE&YF. ,E<#DU;UKQGH/AV]2TUB_\
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MO_)@U"/S;9_)D;S%P#G 4D<,.N.M3:%XIT?Q+Y_]BWGVG[/M\W]TZ;=V<?>
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M]I=:KY<\$C12)]GE.UE.",A<'D5HW_BG1]+T6VU:^O/*L;K9Y,OE.V_<I9>
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MO_;/^)9_SW\I_P"_L^[C=][CI4MUX>T6^N7N+W2+"YG?&Z6:V1V; P,DC)X
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MI6I3";4=,L[N55VAY[='8+G.,D=.3^=/W+]2V\%[164N7KJKW^XHP^,]!N-
MN-;AO]VGVT@BEF\F0;6.WC;MR?OKT'>H=+\>^&]:U**PTS4O/NIL[(_(D7.
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MSS+O@KQTEYZKMTT[]^A7T+Q3H_B7S_[%O/M/V?;YO[ITV[LX^\!G[IZ5D?\
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MK'_@!+_\30%C[DHKX;_X0OQ3_P!"UK'_ ( 2_P#Q-'_"%^*?^A:UC_P E_\
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MR45\-_\ "%^*?^A:UC_P E_^)H_X0OQ3_P!"UK'_ ( 2_P#Q- 6/N2BOAO\
MX0OQ3_T+6L?^ $O_ ,31_P (7XI_Z%K6/_ "7_XF@+'W)17PW_PA?BG_ *%K
M6/\ P E_^)H_X0OQ3_T+6L?^ $O_ ,30%C[DHKX;_P"$+\4_]"UK'_@!+_\
M$T?\(7XI_P"A:UC_ , )?_B: L?<E%?#?_"%^*?^A:UC_P  )?\ XFC_ (0O
MQ3_T+6L?^ $O_P 30%C[DHKX;_X0OQ3_ -"UK'_@!+_\31_PA?BG_H6M8_\
M "7_ .)H"Q]R45\-_P#"%^*?^A:UC_P E_\ B:/^$+\4_P#0M:Q_X 2__$T!
M8^Y**^&_^$+\4_\ 0M:Q_P" $O\ \31_PA?BG_H6M8_\ )?_ (F@+'W)17PW
M_P (7XI_Z%K6/_ "7_XFC_A"_%/_ $+6L?\ @!+_ /$T!8^Y**^&_P#A"_%/
M_0M:Q_X 2_\ Q-'_  A?BG_H6M8_\ )?_B: L?<E%?#?_"%^*?\ H6M8_P#
M"7_XFC_A"_%/_0M:Q_X 2_\ Q- 6/N2BOAO_ (0OQ3_T+6L?^ $O_P 31_PA
M?BG_ *%K6/\ P E_^)H"Q]R45\-_\(7XI_Z%K6/_   E_P#B:/\ A"_%/_0M
M:Q_X 2__ !- 6/N2BOAO_A"_%/\ T+6L?^ $O_Q-'_"%^*?^A:UC_P  )?\
MXF@+'W)17PW_ ,(7XI_Z%K6/_ "7_P")H_X0OQ3_ -"UK'_@!+_\30%C[DHK
MX;_X0OQ3_P!"UK'_ ( 2_P#Q-'_"%^*?^A:UC_P E_\ B: L?<E%?#?_  A?
MBG_H6M8_\ )?_B:/^$+\4_\ 0M:Q_P" $O\ \30%C[DHKX;_ .$+\4_]"UK'
M_@!+_P#$T?\ "%^*?^A:UC_P E_^)H"Q]R45\-_\(7XI_P"A:UC_ , )?_B:
M/^$+\4_]"UK'_@!+_P#$T!8^Y**^&_\ A"_%/_0M:Q_X 2__ !-'_"%^*?\
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M_P#"%^*?^A:UC_P E_\ B:/^$+\4_P#0M:Q_X 2__$T!8^Y**^&_^$+\4_\
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M -"UK'_@!+_\31_PA?BG_H6M8_\  "7_ .)H"Q]R45\-_P#"%^*?^A:UC_P
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M(EG;R3LBG!8(I;'Z5S/PV\9W7C?2;_4+NWBMA%=F***,D[5V*>2>IR3SQ]*
M.RHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M)IDUP^^=5B$B.QY+ 9!!)Y/)^E=)X-\!Z9X+TV>VLI)KE[H@SR3MG?C. %Z
M<GW]373T4 >2W?P TJ?5GGMM8N;>S<DBV$09ESV#D]![@GW[UVW@GP7:^"-*
MGL;*ZFN4FG\XM, "#M QQ]*Z2B@+A1110 4444 %%%% !1110 4444 %%%%
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M (0'QC_T*>N?^"V;_P")K[?HH"Y\0?\ " ^,?^A3US_P6S?_ !-'_" ^,?\
MH4]<_P#!;-_\37V_10%SX@_X0'QC_P!"GKG_ (+9O_B:/^$!\8_]"GKG_@MF
M_P#B:^WZ* N?$'_" ^,?^A3US_P6S?\ Q-'_  @/C'_H4]<_\%LW_P 37V_1
M0%SX@_X0'QC_ -"GKG_@MF_^)H_X0'QC_P!"GKG_ (+9O_B:^WZ* N?$'_"
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M% 7/B#_A ?&/_0IZY_X+9O\ XFC_ (0'QC_T*>N?^"V;_P")K[?HH"Y\0?\
M" ^,?^A3US_P6S?_ !-'_" ^,?\ H4]<_P#!;-_\37V_10%SX@_X0'QC_P!"
MGKG_ (+9O_B:/^$!\8_]"GKG_@MF_P#B:^WZ* N?$'_" ^,?^A3US_P6S?\
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M3US_ ,%LW_Q-'_" ^,?^A3US_P %LW_Q-?;]% 7/B#_A ?&/_0IZY_X+9O\
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M@UX>\;^(CK.JWFIPW!C6/;;2QJF%Z<,A/ZTE\<7V9479,[RT_P"/.'_KFO\
M*I:;&@CB5%SA0 ,TZJ>K(BK)(****0PHHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MAQT/UKYUT#P]#\5_C?KX\3W,S6]KYLBQQOM;8L@1$'HH!Y(_KFK?@FS/P_\
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MSA9A$D6><;L,2<8.,=QSUQ:\!_&/3/'OB%](LM,N[69+=IR\S*5PI4$<'/\
M%0!Z+117D_C3X^:1X7UV72=.TV75Y[9_+N'281HC X*@X8D@\'@#/>@#U@G
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MU(I_\ ;W?JR7X[L;7XHZ'86=DEQ;6EE +?3DC^1_WK_(%7UP%P*QO$E[XO\
M$WBW3M>_X0:\TZ[LFCQ]DL)E#E&W*3D=1P,^@'I7HOQ.^&_BK6=*T'Q!9R1W
MOB73($CO#;J$,A5MRN@/!*DMGUSD =*D\&>(/B_X@\6V,NK:4-/TJ E+M+FV
M-NLB\9;#?,7]-O&?09I(70]JKYUOH8]:_:[2TU,+-;Q3*4C<94;+7>HQ_O &
MOHJO#OBMX&\26'CZV\>>";9[NX0HT\,*;Y%=%VYV]65E 4@<]?6CJ!B^.[6#
M1?VFM ?38DA^VSVC3A%P&,DGEN,>ZCGUW>]+\,K2WE_:0\50RP1/$LE_MC9
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MH70 FN638 HZ*JY.!Z\\_@!7=44 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MX+^,.MW?C*#PQX\T!=)OKK_421H\8SC*@HY)P<$ @]<<=P+4;5CU^BF2SQ0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!YI\?O^23W7_7Q%_.O(;C7_
M !'\1O N@>"=&\+7 CLC$#> EUD*(5#$E0$&&SU/;GU]C^.MI<WWPMN8;*WE
MN)3<1$1PH78\^@KH_A[#+;_#?P]#/&\4L>G0JZ.I#*0@R"#T-2MV4WHCY[O?
MA_%K?QW'@^YOGBCM[*UA>XC0$L(K*+H#Z[?PS6KXK\,3Q>*/"OPGL-2E_LQ
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M7M:\+>._&FH:9<02ZM#LM;?RV+2![A)&*KC)4;5 ..>?0TG\.@UOKY$^M?\
M)I'A_P#["+_^CIZ=X@:]\7WWPZ\"I=O;Z=+HUE+.$/)8Q L<="0B\>A)JUK&
MD:D_[*^@V2:?=M=I?LS6X@8R*/.G.2N,CJ/SIGBC2M=\*R> ?'&FZ9-=QV.D
M6D-W $8-&R1C(?'*AE8KG'!'/4"CKK_6@=-#4UOX:7/P^^&?C4IK<UUIMS'&
M+:S(X4>8GSM_M]5^7@@9.> OG/B/P] /@[X/\1>=)Y[K/8F+C;M6YG?=ZYRQ
M_*O2M0\8^*?B%\,_%[7/AI[33C'']@*JQD8^8F4QCY^ 3N &.G/;GO$.@:H_
M[-'AC;I]UYME>S-/#Y1#QJTLOS,.H'3_ +Z%'7[AK8V/&FE'X2_!LZ;X?U&X
M=]<O5:6:3"NB&/Y@I7UVJ/H37GUIJNC> _$'AW6?!VOW%[,%7^U8FC**/N[T
M' W*02!UQMSUQ7H_B5==^+7P8^WP:%)976EWBF&U^9GN8UB =ER!GEN ,_<(
MY-97@W6[#7=8T?1/^%36,CKMBU*Z-JO&!@R<J G3<0Q.>@YP::W(^R58_#,W
MQ@^(WB^?5-4FMXM,#I:;1N" .1&-I/3"DD#&2<_7K?V:1CPMK0ZXO1S_ , K
ME9=1U_X3?$OQ,D6A3:C!K1?[)L#!6W/N1@0#NP&(*^O<5V7[.EA>V'AG6%U"
MSGM'>\#*L\3(2-G;(HCM\AR_7]#&_:8A^T7?A*'.WS'NESZ9,(K"'A>/X9_&
MC2O#=OJ$UUI^N6J6]VLH"B5)B\14@?[0R/P'/?I_VC;'4;JY\+3:987%X;=K
MEF$,+/MYAQG XS@_E6/H=SJ_Q9^-FCZ_/H<VF6FD11^<SY95,;,X&XJ.2[8Q
MUQSV--6L)W,#P[XBE\)?#7X@>&+IXUNXYA#''G&YG8PS?DJBO:_@KH/]@_"O
M3 Z!9KX&]DQWW_=/_? 2O&/BSX1:?X\1:;:$+_;KP2+M7.S>=C,?^!*S5]06
M\$=K:Q6\"A(HD"(HZ*H& *2VN-[G@W[0,]U:^._"5QIT(GO(B'@B*DB202@J
MN!R<G K!TC5=5U_]H'1+OXD6K:1>)L6V@6W:-2PR8E&XDX+D\Y//'TZ?X[Q:
ME%XV\+:GINF7.H?83Y[)#$S E9 VTD XSBLRPA\3_%;XOZ)K]]X>N-%L-(:)
MW>5&VXC<R ;F4;BS<8'0<^II1'+;Y%:'PY<?&CXI^)CJNI2V]II>^*U$?(3Y
MBL8P>@^4LV.IJ'P?X@AU#X.^)?#GB[7;C38--GACM[I"7<;RW[D*""X_=M\O
M3!/0#BQ<:CKWP:^)OB&Y31)=1T_5R[VTBAE0DL63Y@""5R5*\'OQQGE[GX9^
M)8/A=-KT]C=^?<WZRRVGEGS!"%;$I7&1\SMVZ'/2CH'4B\-7NBZ5\6/##^!;
M_4S#->0V]R;Y%1VWRA7'RG!4J1Q6MH_P_M_B%\:/&%A=WTMG';7MW-NB0,6/
MGE0.>G7/X?C34OY?%OQ/\(:EI'@R31;*TO+2*3[/;G8Q6926+!0, <<]AUKN
MOA7IM]:_'+QO<W5E<0P3371CEDB95?-SD8)&#QS5+S)9S-YX3;QG\7(O MQJ
M4\>D^'].2"(QC!^2)06VGC+2')]N.P(UOV?M._LCQSXLTTR^=]CQ!YFW;OVR
M,N<<XZ=*B\:3ZQ\-/CE/XLM])EU#3]0APJQ[E5B4 *E@#@AU#=.F*O? >+5)
M?&OBC4M5TRXL&O@)MLL+(,M(20"PYQFE']/U'+;[CI/CYXCO=!^'R0:9,T$V
MHW(MWD4D,(\$M@CIDA1]":\LU[PQ=_!>[\*>(]+U&>66Z7-Y%D $C:63'=2&
MQSZ9^GK7QS\*7WBCP"#I$+7%WI]P+@0QKN>5,$,%'<\@X[X(ZUY3>W_B/XS:
MAX;T!]#N+./3 $OKDABO.T/(20-O"<+G.21SQ0@)O'W@.SO?V@;?2'NYUBUQ
MOM,K@#=&6+<+[?+WKZ/TNQ32](L]/B=I$M($@5WZL%4*"??BO(O%NG7LO[2_
MAN[BL[A[6.W0/.L3%%.9.K8P*]GH7P@_B/#O!W_)T_B7_KUE_P#0HJPM,ACL
M?C-\1(;(XB;2K]F"G@$[6(_!ORINIZQKG@OX[>(-=L/#=YJB3!X$VQ.$.[8=
MVX*<_=Z5K_#WP;KO]C^,O&'B6SE@U'5[&Y2"W9"';>"SG8>0"P4*.O![8S"^
M'Y%O?[CSG_FV\?\ 8V_^V=;7B+P;_P *T\ 6.OZ1J\[WNO6J6TJE-GE1R 2-
ML8'.?E5>>H+?2JO]A:O_ ,,]BU_LJ]^T_P#"4^;Y/V=]^S[)C=MQG&>,UZE\
M2/!^H^)?@CHL>FVTDM_IMO;SFW"_.ZB+:Z@?WAD''7Y<=:T>WS(6YX[::KHW
M@/Q!X=UGP=K]Q>S!5_M6)HRBC[N]!P-RD$@=<;<]<5WWBS3KCXH?'V;PO?7T
MT&D:9"2%B/(P@+$ \;B[8SZ 53\&ZW8:[K&CZ)_PJ:QD==L6I71M5XP,&3E0
M$Z;B&)ST'.#5_P ;-K/PU^-LGC*TTF;4M+U"+#B,$#)0*R%@#AMRAAD<CCU(
M774#(\??":?PE\,/M.HZ]/?'3[Q_LENJXBC25E'?G)" D#@$G'<G5TO1A\-/
M@;J'BG1;^<ZAKEE;#Y\ 0,QY*D<Y =L'U J]KNI^+?B#\#=:NM5T!K61+E);
M..%6WS1!^?D//R@_>_B /''-709=9^)/P2U+PU%HSV3Z3:6Z6DTF[_2Y$8DA
M<@ ':F.IP7':ET8=CB]2\$WGA'X<Z#\0;#5KA=5N+A9),'&P.&92#U)XYSUW
M?G8O-%C^*'QU6&[G>Q35+&UNW:-0Q7-E%(5&?R_QJ.YUOQ5XP\%Z-\.8?#=T
MEY8S@22LK E5R%#*5^0 -R2>PZ=*['PSX:O=$_:4BA6UN7L;.PAMENS"WEML
ML43.[&.H_.K5KOMJ+6WF<K\3?#2^#M2\,>&M3O;Y_#4$3.TT48RS-,YD8+G&
M\*RCZ8]:]A^#7A[2M#\+W4N@^(&UNRO+GS(GP4$*X'R%"3M?DY.!GCCBL?XK
M^-;G1]6.D:QX).N>'9K=29F5AF4YR5< @8&!V8')STJC^SMH>IZ?:Z[J%U93
MV.GWLD7V2*?.6V[B2 0,@!@-V.?PJ4-FE^T-H4.H_#X:I)-(DFERAHT7&'\Q
ME4Y^@KSR[M9/ 'P'@O-$O[@7/BJ2'[02=OE(JN6"$>N0#GMFO7/C;:W%[\)]
M3@LX);B9GAVQQ(78_O%[#FN,\4>#M4U_]G30(K"TF;4-,CCG:U\L^8ZX8,H7
MKNY!QUX(ZTEU]4/M\SCM>\,7?P7N_"GB/2]1GEENES>19 !(VEDQW4AL<^F?
MHW1_A_;_ !#^,_C"QN[Z6SCMKV[FW1(&+'SRH'/3KG\/QJ:]O_$?QFU#PWH#
MZ'<6<>F )?7)#%>=H>0D@;>$X7.<DCGBNR^%>FWUK\<O&]S<V5Q#!--=&.62
M)E5\W.1@D8/'-6B.AZ[H.DQZ#X=T_287,B6-M';AR,%]J@;L>^,U\_?&ZYA\
M2?%FUT*6^BM8+"Q;<\K!528HTHR3Q\P\L5](U\[^%_ L?Q(^*GBC5/%EA>#3
MM[&VWJ\);+XCP>,X12/Q%1NREHB]\,]7^V_LY>+-.D8%]-M+U%4'HCPLX/XL
M7KS.Q\"Q2_!^\\:+>RI<VMZL*0* %VY49SUSEQ],'UX[/POHNI>%M6^)'AR/
M3;P6-SI5XEK)Y3,)3&K>4 <8)*NWXU+IFD:DG[+NK63Z==K=-J(98# WF$;H
MN0N,XX--O2Z\@7Q6,/Q=;R^./&?@&UU"Y=9M3T6TBFN"-S9,TJE_<GK76_"R
MPD\%_';6_"EI=S36'V=CB0_>(VLK''< D?B:Q[;1M3'Q!^&<ITV[\NWTZT69
M_(;$1$\I(8XX(!'6NNT33KU/VI-8O7L[A;5K8A9S$PC)\M.C8Q5.U]/,E;?<
M<-\+^?@U\00>GDQ\?\!>K]L/#\O[.F@V_B37+K2XVOI72.U4N]R!(VY-F0#U
M!W'@''K@\WIUUK_@72_%/@N;P_<W5SJ>V,2HC?*%W L  =P((P<_G4M]X?U?
M3_ O@O6[G1KF\L]/GE%U920D 8G+X<8R%<<9QCCW&4]=?0JVWS+OPDOK"R^.
M5C:^$;N^.D7L4B2)>!5D;$#/A@O!PZY!%=9^S=_R$_&7_7:W_P#0IZP_!$UQ
MX@_:$TOQ!:>%YM$TV59=J+;E8U_T9UW%@H7)/ZFNF_9ZTV^T_4O%QO[*XM1+
M+;F,S1,F_#39QD<]1^=3U'T.B^/W_))[K_KXB_G7SU8>*[RP^&^I^#UC?_B8
MWD%PB[3DKMRWYE82/4 U]%?'6TN;[X6W,-E;RW$IN(B(X4+L>?05YW8?#R2;
MXC>"[N6U9(9/#]O?7"N""LMO"B8V]OF\G(_VC26['IRHROA[XANO#/P-\77^
MG/Y=V;F*&)^Z%P%)'H0I)'OBN/,^E:%HND:_X?\ $=T_BE;CS+J'80L><D$,
M1SV# DYW'MFN^\ >"=6UOX+^*](-E/;7TMQ'+;1W$9C,C( <#=CJ 1GU-9OA
MG7$MK33_  [-\)[;4]8AE$=Q--:?/(F[N"GRM@XW,<#&3[:2^+[OR(6WWB>-
M/%6G>/?B-9Q>*M5FTSP[%912H(%9B&>%7.!@_,6;&<=!5GX<M'XDT/QA\/WU
M2>?21";VRG Y"Q3*<@'H'^0D=N>Y-7?B!X=/@;XI1^(7\*1:SX<N85069A!C
MAQ&$V< A2" 1Q@C@=\=U\+F@\1:;K%]#X%M?#!E1K>UN88 AFB<<KG +8(4D
M@;3QW!J.@V</^S_X%L]3N_\ A*Y+N=+G2[QXHX5 V.#'C)[_ ,9KE=!Y^%GQ
M/S_SVT__ -*GKL?@9KFM:#K\O@Z?P_<(+F\>:XNI59?LP6,\$;<<E% .1R:Y
MS0]#U9/AE\2(7TN]66XEL##&;=PTF+EB=HQS@<\4/?3^MA]S(OO!Y\,_#CPY
MXWT[4ITOKRZ.%4!1"03M*GU^0G\1Z<]IK=C/\6_C:VAZA?36VG65B)%2+^#]
MVI. >,EV&3W  ]"&^+=(U*7]G3PC:1:==O<QW9+PK Q=!F7DKC(ZBDUV76OA
ME\5H/%4.CS7]C?V"*$0,H8F)5*%L'#!UW8QTJG;F?J_R)ULO3]31_9]TW^Q_
M'/BS3?-\[[)B#S-NW?MD89QSCITKTSXCZ]XKT#2;2;P5H\>JW,DQ6:-X'EV)
MCKA67'->:?L_7<^I^-_%NH7$'DR7&))(\'",TC';S^->^4G>R#[3/"?^%D?&
M?_H1+?\ \ )__CM>G_#_ %CQ'KGADW?C#2TTO4//9! D31C8 ,-AF)[GOVKI
MZ* "OF?0_P#D>/B__P!@[5O_ $8:Z_XB>*/&?@/XG0ZQ'#=ZKX:EA^2SC)2)
M6V;65F53AMPW L#P<#OC&^&WA76_$B^//$-U82:>/$%G=06J3 C>\Y9B1G!*
M@D#.,'/L::!F#8\_LJ7^?^@O_P#$4GQ0A^T?#WX7PYQYEC(F?3*P"L./5M=M
M?AO>^ CX;O6G^W&YDF$3ED'RC;LQZCKGVQWKK?B%H^IW'@OX8QV^G7<KV]JP
MF5(&)B.(/O #CH>OI5*S?S0GI^(:5H?_  JCX\:7IMA?SW%I<VFZXW@#S%*-
MD$#L&7<![#K7#RWNE>+AX@UWQAK\]OKC9:PMXT9D<C)V$X.U>BCD8ZUZ]XTT
MFZO?VC_#\HL[B2S^RJDLRQ,47/F @MC ZUY[8Q2_#35M6T7Q-X#@\0RRR?Z%
M<309!Z@%3M;<I!!P""",=>F:VU_K4OK]Q[3\$/$UUXG^&L$FHS//<V,[V;S.
M<L^T*RDGN=KJ,]\>M><?'VYO]2^)^@:/96BWIB@1X;5AD2R/(<J1Z$(H_.O9
M/A]"D?@NSF'AV+PY-=#SI["*(1@/TW;1TR%4X/(X!Z5YQ\8=.UG0?B'H7CS2
M=/DU&WLD6.>)%)V%68\D D!E; ." 1[@%O<2VT+?@?XG^)D\>Q^#_B!I,%C<
MSI_H[PILVG;N ."5*D# (Z'CZ>Q5X#X6;6OBC\:+'Q?-HLNE:7ID04-)DAMN
M[:H8@;F+,2<#@?AGL?A1\0]>\>:IK0U.VL(;'3V5(GMHW5G9F;&2SD'A>P'4
M4Q'HM_>VVG:?/>7\JPVUO&9)9'Z*H&2:^?KR34_C_P"-[5;6S:S\+Z3*P>=^
M"P)!;G^^P48 ^[_/N_C[+J+?#<6.DVMQ<O>WD<<J01LY$8#/G ']Y5KAO"/Q
M1UGPAX4LM%L?AY?NMM'AI,2+YKGEF/[L]2?? X[4A]#4TN-;C]KC49)QN:&W
M+1EOX3Y"KQ^!-17T:VO[7MH;?!^TQ?OD .#FU8'/X &F?$:RUKP5\5[+XBZ1
MI<E]:7$:_:8TSA7\ORV5L [05P0V.O;CFQ\,--UCQI\5K[XB:UIKZ?;*A2UC
MDSRQ01@+D#("9RV "3]<'1>0=R+P]:+=?M*>*[-?W:S6$T>5&-N1&/ZUR7AW
MQSJ7PGT?Q!X1UC09&O+AY)(G+8"LR!"3Q\R84$$>_KD=]X5TZ]C_ &FO$-Y)
M9W"6KVT@6=HF",?W?1L8-0?$?Q3XO\7:S?\ @/PGH,R0B40W-_D[77 )RV J
M+ZY)ST[X*Z+T'U?]="Y^S6C_ /" ZE*P(5]28#CKB-,_SKV*L#P1X5A\&>#[
M'1('$C0(3-*!CS)&.6;Z9/'L!6_5,D****0!1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110!Q7Q2\':KXY\+1:/I%];V8-PLL[3[L.B@X7@
M'N0?PKI]$TN+1-!L-+MO]59VZ0*?4*H&?QQFKU% !1110 4444 %%%% !111
M0 4444 %%%% !1110!YXGPZU"X^-3>--4OK>6SACV6=JN[='^[V#.1CN[?4B
MO0Z** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MI]GKUA/=S,4C@CG5G8CJ,#Z&I)?%OAZ#7!HTVM6*:DQ"BU:=0^3T&,]3Z=:
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M.=2)4PS8)&#C(]_RHZV^7W@=Q17$?\)G/;_%+4]'U&>WMM(T_25O&E8;2&+
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M  S)'[KQ8S&+/6T4>;T].]>L>%OAI:>%M4CO(M>UR_2WC,5M:WEZ6A@0]@H
M'8>W'2K:?#W1H_B(_C-3<?VD\7EE-R^4/EV[L;<[L#'6M+^\GT_X*:_+\69V
M]UK^MFOU_ \UU>'4M6^-WB:&'PQ8^(_L]E!!'#?7"Q+!$R DJ&!R22>1TS[U
M1;POJ&G6'P[\/^,;2*39K,R?9W<3*83@JI/0CDC%>H>*?AO8>)M9CUB'4]4T
M74EB\A[K3+CRFECSG:W'/^>O%6&^'^EO'X>5KJ_;_A'Y?-M6><.TC8_Y:%@2
M1],5,-$K]U^=QSUO;L_RL<IXKDA7Q98>#?"/A#0+R[MK1[T?VA"JV]O&S8(1
M5'4GT]1[UY_"KQ_ &_CEC2%H_$P4Q1GY8_G7*K["O9O%?P[L?%&LVVK+J>IZ
M1J$$1@-SIEQY3R1$YV$XZ9_G52'X2Z%#X,D\,K=ZD;.2]%\9&E0R[P0<;MF,
M<>F?>B&CN_Z]Y/\ )!/567]:-?FS&%A%JOQU\1Z?<J&BNO#B0N#Z,P!_G7&>
M#9YO$FK^#/!]V=[^&;JZFOT/8PMB+]3BO:K?PK8V_C2Y\3I+<&]N;1;1XRR^
M6$4Y! QG/'K^%<?\.M$4_$+QKXD^Q26R7-[]EM_-0J7"\NXSU#-@YHAHUY)O
MYINWYBE\+^7Y6?Y'I=<G\4=+_M?X7Z[;!=SK:M,@_P!J/YQ_Z#47PS\*W/A7
MP_>)J4:1WU]?S74P1@P&YL*,C_9 /XUUT\*7%O)#*,I(I1AZ@C!J9)N.F_ZE
MQ=I7[,^8SXLN1KW_  L7S&-HT9TC;C^+[&#_ .C*ZWPSHZ:7XP^&MA-$#NT2
MY>5'&03(I9@1_P "-=L?@_X</@%?"1EOOL*W7VH3>8GG;_KLQTXZ=*W[CPCI
M]QXJTK7VDN$N=+MWMX(T9?+*L,'<,9S]"*TNK_UV?ZMF;3Y;?UNK?@CAO@QH
M^F0W'BJZATZTCN+?7;FWAF6!0\<7'R*<9"^PXKSV;1M-_P"% ZYJ_P!AM_[1
M36FVW?ECS5Q,H #=0,$\>]>V:%\/;'P]XLU#6]/U'4@E_(\LFGM/_HPD?&YP
MF/O>A/3-5V^%VBMX'O/"INK_ .PW=T;J23S$\T.7#X!V8QD#M4K>+\E^#7^1
MII=^OZ/_ #.OMB6M(23DE%)/X5Y7<:1IL_[3L?GZ?:R9T47)WP*?WPDP).1]
MX8'S=>*]7C01Q*BYPH &:Q#X2L#X[7Q89;C[>MG]B$>Y?*V;MV<8SG/OCVI_
M;OZ_DR%\%O3\T>56*E=#^,@88/VBX./JCU/X=_Y'3X7?]B])_P"BJZK7?@]H
M^N:WJ.H'5=8L8]4 ^VVEE=".*=@,!F!4Y]<'(S6S9> -+L=4T&_AN+PRZ#9F
MSM@SKM="NW+_ "\G'I@>U*&B5_+\(M?J.>M[=6W][3,#X*?\BQK/_8<NOYBF
M_'2-)O EG%*H9'U6V5E/0@DY%==X7\*V7A*QN;339;B6.YNY+MS.RDAWQD#
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M7UC4;O4;)K*XGOKE96*'N"5SGTR2/:LK:/Y_BK?F:76GR_._Y'->#-*L=(^
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M_ECFJ;]Z3]?Q5B$GR17DOSN>,+H>EO\ L_\ B/5GLK<:E%JKM'=^6!*I$R@
M/UQ@GCWK:\6:U-X(\43ZU*?*;Q%X9V\][M% 'XX(_.NLB^!VA1S[3K&N2Z>]
MQ]IGTV2['V>9\Y&Y H']?>CXI:&OB3Q+X,T=;*251?F>:98R4BA1064GH-V
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M?WUQ>!A#;KCH%!SDMD=^GOD):I-=?^#_ ),;5FT^G_ _S1Z=17CUW\5]>C\
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M+D@'S"20"%S@8SR#5?Q[I4.I^*=#\::KX1U35M&GL#;W>G?9R+JV;<61FC#
MYYQUQ^E>UT4=$NQ5SR*Z\(V>M_!?6[?PIX5N] GO2)8[.Z!$L_EL&4[2QQD
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M:^)6C:CX6\':YX=UQ+T?VK<30>7;209^?<P.&)]<#/N<5L1:+JHTOXKH=,O
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M-M:(UI<&1X(PID"P @L1]X\GD^M<AXMO[SQ+X2'B:Q\+:)INCW.JJT5Y&/\
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M=")J^JV=E-,I,,=Q,$+X]CVSWK*^&/B2^\6^ ;/6=5\O[3<22[A$NU0!(P
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M.Y4F3G/S$'C Z8KD=!TY?AEXKLM+\6^'[*]M+S4&.F>(HHU,RRN>%D/W@?\
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MD=Y!*P\L*B[1MP 1P>Y//I5'PM\-+3PMJD=Y%KVN7Z6\9BMK6\O2T,"'L%
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M&<L>@ZC@\F@#5HK)TKQ/I&MZMJ6G:5>+<W.ELBW80'$;-NPN[H3\ASC.*UJ
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MNKR5(8(4+R2.<*B@9))H EHK/T+7=/\ $NC0ZKHT_P!HLIRXCEV%=VURA."
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MUK6H+2\0*6B=7) (R.0,=*W--U2QUBQ2]TJ\AO+:3[LT$@=3Z\CO0!:HHHH
M**"0JDL< <DGM65X?\3:/XILI;O0+Z.]@AF:%W0$8<=1R![$'H1TH U:***
M"BBB@ HK)N?%&C6GB:U\/W-_''JMW&98;8@Y91GOC Z' )YP<=*J6WCSPU=Z
M#J&MP:K"VEZ?,8+B[P0@<!>%./F^^H&,Y)P,T =#15&#6;"?0(M:%PL>GR6R
MW0FE^0",KN#'/3@]Z;H6NZ?XET:'5=&G^T64Y<1R["N[:Y0G! /530!H4444
M %%%% !1110 445DV?BC1[_7KW1K*]2:]L$#W2*#B(9Q@MTS[9X[T :U%96@
M>)M)\46US<:%=K>06UPUM)*BD+Y@520"1R,,.1Q6K0 445E>(/$VC^%;!+W7
M[Z.RMY)5A1W!.7/08 )[$^P!- &K162?%&C?\)+%X?2^1]3DA,PMT!8J@&<D
MC@<$8!.36M0 445E:+XGTCQ%+>IHMXEW]AE$,[Q@[0^,X!Z-]1D4 :M%%% !
M1110 45E-XGTA?%$?AW[8C:J\1F^S*"2J 9RQZ#J.#R:U: "BBN+D^+_ (#B
MD:.3Q';AD)5AY<G!'_ : .THKG]:\=^&?#VG6E]K&KP6T%Z@>W)#,TJD A@J
M@MC!'..].N?&_ANT\.0Z_/J]N-+F<)'=*2RECGC@$YX/';% &]17/Z#X\\+^
M)KDVVA:W:W<X!/DJQ5R!U(5L$CZ5KZCJ-II.GS7VI7$=M:P+NDED.%44 6:*
MYV\\>^'-/\)P>)+S45ATNY ,$K1MNESG "8W9..F/K714 %%%% !1165IGB;
M2=9U;4M-TR\6YN=+94NU0'$3L6&W=T)&PY Z=Z -6BBB@ HK*;Q/I"^*(_#O
MVQ&U5XC-]F4$E4 SECT'4<'DTD'BC1KGQ/<>'H+^-]5MHA-+; '*J<=\8SR.
M,Y&10!K4444 %%%% !1110 4444 %%%% !1110!Y;\?= U/7/ <#Z5"]R+&Z
M$\\"#)*;2-V.IQGMV)-<SH3_  ^UGP1XDUCPKIRZ;K*Z.\5S9,YS"H7!91T(
M) RPYZ9 ).?2/B/XD\0^%M#M]0\-Z,-5"SK]K4;BR19YPJC//(W?P^A[>,6E
MK>^+O%GB;Q5H?AZZTC2VTF=94,9'VB5HMN  ,%BWS8'ID\FI>S_KH4N@SP)X
MT\8^#=#\(F5K63PSJ-U);PP[%,A'G'S&)Z@[G;'/;ICKU7Q&\?>-O#6O:H]G
MK?A^VLK%T\FRWH]Q<*Q7JA)8$;N?N\ D<<US-QHVJ'X7_#6$:;=F6WU&X::/
MR&W1@W!(+#' QSS7-:[H\]E)XFTK6/#&H7WB.XO?.MM11'(CCWDLV!PP;IG'
M\6<\#-]/Z\A=?Z\STS7OB/XWU/Q)X<TGP?\ 8X+C6]*CNO+FC!".59GPS=@%
M/7TZ9XJEJOQ)\??VNWAZTO=)LM2TFR\[4)[@QJMQ+@$QIN^7/S!<#&2"<XZ.
M\.Z9?I\7/A[.]C<K#!H0261H6"QMY$HPQQ@')'!K)^(.@6_A_P"+&J:KXF\,
M7>N:/J48>U-L[+B4@<%EZ<AACG@@^U3UMZ@MCH]5^-6IM\';+7M.MX(=5GO#
M8W#E2T<+JNXL >Y!4@'/4]<5VWPTOO&-_8W<OC"XTV\MR4-C>6+*PG4@[CE>
M,#@#@'.:XN9]+\._"*R4_#?4)-.U6Z:74-.9W=K;Y=OFACEER%7'W>_(SRG[
M/UCJ-O>>()X;2^LO#TTBFRAO"<ELGD< $[< D>WI5+=B>QH?$+QCXTM?B;I_
MA3P7):+)?6OF()XU.&&\L=Q]%4G\*Y_5?B3X^_M=O#UI>Z39:EI-EYVH3W!C
M5;B7 )C3=\N?F"X&,D$YQTZ+7+&[D_:?\-WB6L[6L=C('G$9**3%,,%L8'4?
MG7$_$'0+?P_\6-4U7Q-X8N]<T?4HP]J;9V7$I X++TY##'/!!]JA7*T-2^^,
MOB?5M#\+OX;6S@U/4[F2QN8GCW(9PR!<$] =ZGVS[5L>'OB-XJA@\8:)XH-L
MVN:':27,$\<8"N%]0, CE".!P>:X7Q-%:^&[?P#J6E>&+S2G.H-?/I4DC/(\
MJO$,*3S\P10.!UZ>NYHEIJ?BF\^('C=]*NK.VOM+EM+2*5#OER%Z#N0(USCN
M<#-%W9_,++3^NI-I/Q)^(EOX0?QMK?\ 9\^AM$Z6\*HJM)-N\M3@<@!LD\\A
M#TR#4WACXL>*+'Q-I-OXMN=-U*QUN$/#]A*&2W=A\B$+W)V@@_WNO!%2V?A/
M5-:_96M=*@LYAJ,)DG6UD0J[;;F0D8(SDJ20._'K6!\/K7P_=:]IL<?PXU87
M^FQB>YO1-( ES$-P^0D##,O0GJ<8-4+2QN^!/'_Q"\:^)$NK&XTA],6\\N[L
M#M$EO#QF0#AR,$@')^;J,56\1?%OQ9=:]KL_A>YTNTTS0I0AM[LIYMYAB"5R
M<G[I.%Q@8[US):XU_P")FB7GA+PAJ7AS6UN@^HJ-PA7YAEL%1M!&[=G P<8/
M.8]5\/VOA3QIK]KXG\%WVO-=W)DTJ2WDD17!8G[RCG(9<X!P011KH/34[+4?
MBEXO\1^(?#VG>!WL[=M:T_SMD\881R*7\SYCV'EMVYQ6;J7C7Q/XS^ VMF[^
MR_:]/O5@U"38%\RWZ\ <;M^T<<8K1TGP_P#V;\;O!1TO0[W3=.ATR5VAF5G^
MS-)'.Q1GY&=SG@GN.G2LWPIX?U:?X1>/[)=/N4N9[C?%$\3*T@4ACM!&3P#T
MI='\_P PZKY$VC^./%'@/X*VEW>+93?:S'!HH SY:88NT@XSC Q]:T=!^+FO
M:'K&IZ3XUGT[5)(K![RTN;"12LCJF[RR4X[$9QD$=P17+WUIK'C/X(Z=;6/A
M^\5_#<L882(V;I6#ARBXR=N$S]3Z<VO#WA[0/&%MK$?AOP#J.E7$.G2_9;Z:
MY<J9BA4QD-@<[B!U]2!VJ=[R:%&UE<QO$>N>,?$R^$=:\4-:'3K[4"]BD"!3
M'B158$=<<#&<_6O9OCE_R2'5OK%_Z,6O$O[2U;5]&\'>'&\/:E'<:!>D7$S0
M-M^:0$#&,K@>M>Y?&FVGO/A3JD%I!)/*QBVQQ(68_O%Z <TI_#IW_P @C\2N
M>=>%/&?CKPY)X8T75VLVT[6M-CBTEEC!,)*;822,9.=A(.>&[&IQ\:=>'PF;
M4CY!\0#5OL(7R?X=N_=L_P#'?K6;X?;5O'7BWP'IW]@WNGP^%(83=SW"%03'
MM(/(&-WEK@=<L>PS5>/P<TG[3KZ2NXV4=]_:CKGY57:)0,>F2%H6^H:'L_C-
M=='PGU%;5[=M7&G@3.XQ&>!YQ [?+OQ[XKR/X:CQ#_PI?Q$;EK4Z!]@NOLX7
M_6B;C.?;&:]YUZUEOO#>I6EN-TUQ:2Q1@G&69"!^IKP[X=ZCJ)^$OB/PM+H5
M]#):6=U(UQ)$P#.V (U7&2WWN/:D_AD"Z>IC>!/&GC'P;H?A$RM:R>&=1NI+
M>&'8ID(\X^8Q/4'<[8Y[=,=>EA^(M_H:?$S4+73K 3Z=J:P0O%;!"Q,LD8>4
MCER HZ]_J:YZXT;5#\+_ (:PC3;LRV^HW#31^0VZ,&X)!88X&.>:V=&EOO#]
M[\3[NY\*W>M076KJHLS"P6>)IIMS [3D <Y ."0>G-5]G^O(75'8?"C7/'&O
M.;WQ'>:9?Z--:B2&YM=F]921^[(7&"!G<".N,'K3?BUXR\2^&]8\.Z;X4>W%
MQJTK0!9XPP9RRJG)Z<M7&_!>SG;XH:E?^&]*U'2O#,EN0\-XQ*[^,+D\$ABV
M.I SSR:U/CQ?/IGC#P1?Q6SW4EK>><EO']Z4K)&P0>Y(Q^-*6EAK<I'XK>,=
M&T?Q5I6O-:G7M%\N2&X6$;70R*K9 P",,I!P.O-:>G^.?'NA>!;_ ,7^+_L,
M]E/912Z9!$J@F20C:6V\XVG<03GMD&N'U/3]7\76OC?QHFC7EM!?1Q6MI \1
M,DH\V,D@#K@1C..,GV->F>)/#.H:_P#LXZ;IME;R-?P:79R+;E2'9DC3<N.N
M<9XZY&*F[ZCLKF%H/Q#\=Z9XDT"U\:_9'L/$\:_8Y88@&MVDX3@8[LF0<\'K
MG-9TWQ=\<07TGA%K:W/B@:H+9)O(_=-$>/N_7!W=-IJI9:KJ_COQ%X-C;1+V
MQM/"*)-J%Q+"<;HMI8 8ZL(@ O7)/'&:R9[?QC/XCD^*<>F72R1ZLL:61@;S
M3$%QTQG;MPF<=ZI;BZ'HT/Q'US0O&WBO1/$D]O<)I>F/>V;K"(O-8*K!>O.0
MWZ&NJ^%6NZUXF\!V^L^(GB:>[ED:+RXM@$8.T9'U5CGT(KR;X_Z:U_K7AO6M
M*6;=K-K]F$>"C-R"H8<')$@&#_=YKWS0=*CT/P]I^E0G*6=ND /][:H&?QQF
MA;"9X9J?QH\2Z5X=UF"6:S?6[#619@^2,"+#Y^7N=T>/QK6'Q2UG7=2U:"R%
MHVGV?A5]2GBD@#AIC;AMI)X(#. 1WP1ZUSWB/X<W6M?M!7UFUE.-,O5>Y^TJ
MAV!F@)SNZ ^9Q1\+?"^HV?PY\?W5[87,5Q-ILMI;QR0LKMB*0D $9.25Z>E"
MVU_KH-VZ$<VH/JMM\&[N2"VMV?49QY5K"(HU N8@,*.!T_/FNS^#G_)1/B7_
M -A@_P#HV>N-LM(U,:/\'P=.NP;74;@W ,#9A!NHR"W'RC SS7=?"2QN[3Q_
M\19;JUG@CGU8O$\D942+YL_*D]1R.GK6FEG\_P!#+7^OF<Y\25UU_P!H70E\
M)R0QZNU@PMWG *+E9=Q.>.%W&DC^..MV7P]U#^T[: ^);2^%CDIA!D,=[*#C
M(V,,#CI[U9^(^H7GASX\:-XDCT>^U&UL;$^:+:)CPRR*?FQC(#9_#MUKB+CP
M#XAUWP)J_BL:1,L]]JRW8L2A+M!A\L%QDC,GMP">E8J]OZ[F^G]>AZ7\/OB'
MXAE\?-X2\8W>G:A+<0&:UO+!T92P7<4RG!X#=@05[@BMKQSXRUCPM\1/"MI&
M\/\ 8NK2_9YU:/+!]P!;=V&'4_@:Y+X36?AK5/&7V_1O >HZ/]AA+Q:A/<.R
M"0J4="#QT8XZGO@5TOQVT.ZU7P EWID4DE[IMW'<1B%"SD'Y2 !SU*G\*K:Q
M.YAQ?%S6(K;QQK$ZV\VG:1<"UTR(1X$CL[*I9LY. H8CWXK-LOB)\1]*U#2K
M?Q$MA,OB:U)TMQ&%\F9QB(-CMN9,@YX;KD$4W2_ &I77[-5U:PVDW]JWERVH
M?9I%(D8JX7;@\Y*)N [D^]4])O=;^(WBWP/91Z)>6,'A?RWOKB>,JN]"NX=.
M-WEJ .N2>PS1UL&EK^O_  "I\'=6\0^'[7Q#J\GV5]#LFEEU"/.)7F",5"'T
M+8'XU=TSXR^+;2ZTK7->N=)GT/4[AHI+. J)K5-V-Q ^8=R,YSCMD&J_@RRU
M@0>,? 4FB78NM1>=OM3J5AC*HQ4%B.C,% /3#9K&\'Z+HD]WIWAS7/ASJMUJ
MWG&*_N5FDB$:%CA]O & 1G) XSGFGU7H@=M?F=UX\\:^+M9\6^(/#7A 6D5C
MI.GO)>F906G7:-X!/3[V !CH3GM6_P#L_?\ )*+?_KZF_F*XCQ7<:GX&^*GB
MJX;1;V_M/$6GO!;/;H2"[JO.?]DA@1UZ>M=[\"+.YL?A?!#>VTUM+]IE)CF0
MHP&?0T1^%A+^ON/)].U/QEHGB?X@:KX->W6WL[P3:@LJ*S,HDDV@ ^Q<G&.!
M],]YH/Q9U2_\>:!%J!MX=$UO3C<*!'CR955PXWYY'F1,,>C"N#EU?5?#NI?$
M'34\.ZC='Q%<&WMYD@8*&WR#T^;(=B,=U'KQ<^(W@RZ\-?!7P?-/NAO]/D>*
M95;!4SEI""0?X2"./4U$;V7R*=FSU'X1^+M<\;:9JVK:SY2V@O##9QI'M* #
M+9/\7WE&?8UYK>+XT/[26H?V4]@-3VL8C)]S[+@;<_[6S;GWS7L7PRT+_A'?
MAMHM@ZE9?LXFE!'(>3YR#]-V/PKS?Q5=ZEX3_:'&MQZ)>:E%>V2Q6ZVZ$AFV
MA>3@XP1SW .:T6DOZ[$;IO\ K<XZUUGQ?X>\1?$#5_",UM%:V=\LE_YR*S,/
M-=4"@C_:<G'I]*[77/BYKNIMX;TKPO+I^F7^IV*W=U=WI411'!RH+9 'RD\Y
M)RHK"@TG4O[%^+H_L^ZS=7$!@'D-^^Q-+G;Q\W7M6+JWA:32XO"6OZ_X>O-4
MT5M,6&\MX@R21R#< #C&WJI&>O(J(_"OE^3+>_W_ *'LOPD\>7GC71;Z'6DA
M75=+G$-PT!&R0'.UQCCG:PXXXR.N*P/B;\0?$NF>/K#PMX8NK'3&F@\TW5\%
M"R,=V%RP( ^7 ]SBMGX-Z=I<6@WFIZ7X6N_#C7DJHT5S,\GG(F2CKNYQ\Y[#
MGUKE_C?J=A<7DFE:QX-O[S9:@V&KVV5VS'/R9 (*],C.>O'0TV2CDO$[_$6?
MXJ>&'U=--@UYH5^PHF/+7EL[^HSG=TR/2O0O&'C7QBGB;0_!?A;[''KUS9K/
M>W,BAHU?:2P7.0!\K'.#G( KS:*V\3>%I/ 6OZYI.H7B6:O&D*QLTJJ)&*(>
M.#AN >W':NQ\8W6J>&/B=H/Q"ET2[GL+C3E2[@A4L\#LA!0\<$;EZXS@BF^B
M]0_R*Q^.6N6G@6_AOK. >*;.^2Q;Y/D^8-\Y4'!(*,,#C.#TXK;6Z^(O_"(>
M+;+Q]:VKVL>F2/!>PE5+.4^X O!&,\X&".^>/.KKP5XIUCPGJ_C0Z5/'=7FL
M)?1V)C/F>6-Y9PN,D9<?@">E>D0_$#5/'_A'Q3''X7O+&PCTQ_)N),DR2E2#
M&!CYCW&.F.>HJ'=Q=]_^ /2ZL<?\*?&.O:C9:%X/\.&&"TL;6XN-4FEC#,5,
MSMA<],AD /JWH*YSPAXK\9^"_!ESK&B/:?V$FLF.>*5 S22LBDCU VJO0CK]
M<7/!^@ZOX(OO"7B2&POC%JD=Q;:C#Y#DQ?O6CRPQD+M,;@'J5/:EAT75?^&>
M]0MO[,O/M#>)?,6'[.^\IY*?-MQG'O37Q+^NH>1Z7XU\?>)+KQ9HWA7P"MO#
M?ZA:B[DN+I0P12I8+SD#"J23@YR *\Y\<>.=2\7?"_[!XB@CAUC1]?AAN?+&
M%<&*< XZ Y1@<<<"NG\4+J7@CXB>'/&W]E75]IO]EQV]RL"$M&WEE<'TZJ1G
MK@BN+UGPYXBO_ FI^([S2;J*77?$4-S':+"S.J+'<$OM SM)D !([>XJH[_U
MW_R)?P_UV.]\=>-?%VL^*M>\->$!:16.DZ<\EZ9E!:==@W@$]/O8 &.A.>U8
MWA;QU/X$_9[M;O3XHY+^[U"6"W\P95#U+D=\ ?F12^*;C4_ OQ2\4SOHM[?V
MGB+3V@MGMT)!=U7G/^R0P(Z]/6LR3P;K.I_L]:<;?3+A[O3]3EFDM&B82-&>
M"0N,GG'X9/:A?#]P]-/ZZ'1Z5\5/%.FWVL:'XDO-,OKU=-EN["]LBCIO6,OL
M.W@C ;T.5[@BMSX5:_\ $3Q7-::YKDMC_P (]<1RA5CC579E)4' Y'S _P#?
M)XY!KB= T_P[K-CKEUH'@#4]+DL]+G,%])/(X,K1LC1[3P20YQC)[X%=-X<\
M4:M\//@#X>N(?#US?W37$T,D#*R&$&>4AF&TD9X X[CZ&;ZAT/4O%O\ R).N
M?]@^X_\ 1;5\V77]I?\ #-&G_9#$+#^TY/M8;[Q.1LV_CG/X5]&ZY)-J'P]U
M&7[++%-<Z7*WV=AET9HC\A'J"<5X9_8^I_\ #+PLO[.N_M7]I[O(\AO,QNZ[
M<9Q3[_+\P73^NAZ[\-[+4=*^'-L-4MK&WNFC\T"RC"(R[!L9@ ,MM R?:O'X
M_BU\2/\ A'V\4&;3WTFUU$64D?D*#(^-V".N,8Y!'7ZU[]I4;IX/LXW1E=;!
M%*D8(/ECC%?.4.BZK_PSWJ%M_9EY]H;Q+YBP_9WWE/)3YMN,X]Z'\80UCJ>E
M^-?'WB2Z\6:-X5\ K;PW^H6HNY+BZ4,$4J6"\Y PJDDX.<@"M;X3^.=2\76.
MIV'B*".'6-'G$-SY8PK@Y ..@.48''' KBO%"ZEX(^(GASQM_95U?:;_ &7'
M;W*P(2T;>65P?3JI&>N"*Z'X)Z5J^[Q)XGUJSDL6U^\$T5O*I5@H+L6P><$R
M8'^[GH11_7X_Y"Z(Q_%GQ#\:7/Q0O?#'A"?3[(V* QPW@16O&PIV@OQD[N "
M,@5O?\)MXEM_C%X:\+:B;1(K[3?.OHXH^DPBD9MK$YQN0?A7"?&>]M=9UN^T
M^;P3J2:Q#(D6G:I I N5XSN 7##KC&3TZ<BC5V\0^#/&7@GQ9KVEWVI/;Z0(
M+CRP6<S%)%V,><, ZDD]>>O-+6R*T+J?&SQ#!X(U:]F2VGU+^U!8V6(L*BE2
M2Q /S$8P/<CKTK>6Z^(O_"(>+;+Q]:VKVL>F2/!>PE5+.4^X O!&,\X&".^>
M/,+/PIK]_P##K4M0M=)O%NK+6DNQ;20L',94Y(7&6P=O3MGTKU*'X@:IX_\
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MFV!.3@XP1SW .:XO5?#]KX4\::_:^)_!=]KS7=R9-*DMY)$5P6)^\HYR&7.
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M,D"$$J7QUVY W=">,\5=\4W>L6/AF]N?#5E%?:G''F&"5B Q[].IQSCC/3-
M&O17A^F>-_B1X7\;Z#8>/Q:36FOS+$D,:QA[<LP4<ICD%E)SNX/7/3U_Q%?/
MI?A?5;^%E22ULYID9AP"J%@3^5'2X[&C17@WA?7?C)XNT.'5=(U/2#;S%MJR
MQQJ_RM@Y&WU%>\T""BBB@ KDO'O@./QY#IMM>7[VUG9W/VB6%8@WGXX SD;>
M-PSS]ZNMHH .G2BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** ,_7-"T[Q)I$NF:U;_:;.8@O
M%O9,X.1RI!ZCUJ[!#';6\<$"!(HE"(@Z*H& *?10 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 5R3^ XY_BE'XSNK]Y9+>V^SVUIY0 BRI!.[//WG[?Q>U=;10 4444 %%%%
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MWP9\/V7@'4?#%I/=(-3:-KF]8JTSE'#J.F, CICN:NZA\,K#4)/";R7]RO\
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M)&P$J%)SU(P!QV/Y4^@/<[.BBBD 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MXU\2)=6-QI#Z8MYY=W8':)+>'C,@'#D8) .3\W48JVK.Q*=U<]SHKP^\\?\
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M6K2NUO$!N.T,IR/KZ5[!18 HHHI %%%% !1110 4444 %%%% !1110 4444
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M4Y/4'I7544+16_K03U=SP;2VU'0?CEXHTV?1KR=/$$GE1W$:'RXHG;)D)QR
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M]JE:V*:L?4%%5M-EEGTJTFN!B62!&<8QABH)_6K-!*U04444#"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MWT:SUB3S+V$!@P.23M(//);'W< XZ5Z]10!5TNTFL=)M;6ZO)+Z:&)4DN90
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MZT>?2[B.:*.9B3(.C'E5X 8GOTKGK#Q*VM^,U\3.HF'A_05D^8?+),(\8/\
MVTD/_?->[:I8)JFD7EA-PEU \+'T#*1_6O*OA[\.-0M?!?B2SUBW-G=ZFIMX
MA*0=JJI*MQV+-_X[1KK8%;J847B+QMH6C:1XVO\ 6Y+VQU"Y*36##Y57<< #
MH,A6QC&./>I?A_HNNGXKZN@UTB2QN U^^S_C\4/R/;-,A\+^-M<TG2?!6HZ.
M;+3M.N3)-?,PPRY)!!S@D!F QG.1TP372:7I/BCP_P#&'5)[/2/M&G:K.K27
MC'"1Q%@S$<_> R,>O-4MQ/8Q[KQ;KT>G_$22/4YU?3]12.U8$#RE\YUP./[J
M@?A4>A>(?%'A_P 6^'I-:UR;4[/6K 7;P.>$5E)  /0C .1[BIKOP;X@?3OB
M#&FES%]3U%);, K^^3SI&R.?0@\^M7[KP?K-UXA\#,^GR_9K+2H;:]<$?N6"
M$,#SVSVJ=;_UV#HSD[SQ)XVN?"=QXQ7Q'-!#+?FU%I%PJC&05'0#MZ\<DU[_
M *7*\^CV<LK%GD@1F8]R5!)KYN\0VWB3PKX.E\+ZOI0CLCJ/GQWN[(<[< +Z
MC SZC/.*^C](5DT2Q1P59;>,$$<@[15:6![GSWIEM=W'PE\5M9W7V=(=122=
M<9\Z/D;/;YBI_P" UKQZWX@\%?"&SN(M7\UM69$LP4_X\HP&+XSU)X^E:OAO
MP3KR?#GQ;I=U8O;W5[+OMD<C]YCG Y[XQSZU3E\*>+?$GPOM].N='%G<:-)&
M;2*0@/<K\V_()P#RN,^A]:3V^[_@C6_WE31_'>JZ=J&J:,OB<Z[!-ITLMK>@
M-NBF6,N<%AD?=;CGL>.:SEUKQTNE^'M3B\47#'7Y9;6-'/RQ;7$>6&.I)/(&
M0!ZUU6E:5K>K:?K!N? .G:0!82):R11!)S,5*D+GDA@2.P'J:KIX-\0#PGX"
MMCIDOG:;?RR7:97,*F?<">?3GBDOB#H5(O%?BWP]8^,-)DU.;4KG3/+\JZ<;
MFB!?:S#//0CKG%=-\)+G5M1>6^N/%PUFS:W7S+20DS03$C[V[D 88 @X;\*I
M-I/B_1_&GBW5]%T-+LWC((!<,NR5-PW<;AG@$8XZ_A3/AQX:UI?B)>>(;G01
MX=L&@:/[(O 9CC@*><9&[H!T IH3ZGK]%%% @HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M:=_R$(_Q_
MD:W:PM._Y"$?X_R-;M(84444 %%%% !1110 4444 ?$'C[_DI/B7_L+77_HY
MJY^OO^B@=SX HK[_ ** N>#_   _Y$&]_P"PG)_Z*BKU&NGHIB.8HKIZ*!',
M45T]% ',45T]% ',45T]% ',45T]% 'EVH_#CP]J_BL^(-2@EN+DA/W3R?NB
M5X!*]^@X)Q[5U5=/10,YBBNGHH$<Q173T4 <Q173T4 <Q173T4 <Q173T4 <
MQ173T4 <Q173T4 <Q173T4 <Q173T4 <Q173T4 <Q173T4 <Q173T4 <Q173
MT4 <Q173T4 <Q173T4 <Q173T4 <Q173T4 <Q173T4 <Q173T4 <Q173T4 <
MQ173T4 <Q173T4 <Q173T4 <Q173T4 <Q173T4 <Q173T4 <Q173T4 <Q173
MT4 <Q173T4 <Q173T4 <Q173T4 <Q173T4 <Q173T4 <Q173T4 <Q173T4 <
MQ173T4 <Q173T4 <Q173T4 <Q173T4 <Q173T4 <Q173T4 <Q173T4 <Q173
MT4 <Q173T4 <Q173T4 <Q173T4 <Q173T4 <Q173T4 <Q173T4 <Q173T4 <
MQ173T4 <Q173T4 <Q173T4 <Q173T4 <Q173T4 <Q173T4 <Q173T4 <Q173
MT4 <Q173T4 <Q173T4 <Q173T4 <Q173T4 <Q173T4 <Q173T4 <Q173T4 <
MQ173T4 <Q173T4 <Q173T4 <Q173T4 <Q173T4 <Q173T4 <Q173T4 <Q173
MT4 <Q173T4 86G?\A"/\?Y&MVBBD,**** "BBB@ HHHH **** .7\?\ C2/P
M-X;&H_9'OKF:9;>VMD.#)(V<<@'C /;T'>N&/QJU2S5;/7?#R:5J4>IP6ER9
MY3Y,<<F6+YXY"CIG'(//2K_QO<6%OX6UBX4M9Z?K,4EQ@$X7KT'^Z:Y[XE^+
M_#_CB]TC1M.+7L-IKMK'<2[089ED4\*P//<'..A^M"U?S_R'T^7^9[%;>(M%
MO-*DU.UU:RFL(R5DNDN%,:$=06S@=1U]14$'B[PY<Z?-?6^O:;):0,$EN!=I
MY<9/0%LX&>WK7@1UB+PSX:^)%I;:5:W-G_;PLX;25#Y,2[Y #M!'01C'(YQ7
M./ ]EHOC>T,^G3KLLV9M+/\ HS'S1RO;N>G'IQ3MK;T_3_,$KGU':>*-!O[2
MZNK'6M/N+>S&;B:*Y1DA'JQ!P!P?RI++Q9X=U*.5]/U[3;E8(S+*8KN-O+0=
M6;!X'N:^9_&UI_8^O^+=+T*WCM-.2UL#-#$"%V[8F)/_  -NOO2>-$TV#7O%
MJ>"1;?V.;.TW_93F/9NC+=/]O&:!+4^H=*UO2]=MWGT74;6_B1MKO;2K(%/H
M<=#3-5\0:/H0B.M:I9V'G'$?VF=8]_KC)YKRGX.:+/9^--4U"'4?#\EI-8HD
MEGHLS%$<%=C%3[!\G/4GN:H^/%TB?XQ:TGC0VXLH_#CG3OM!P/,Q_#G^+/F8
M]^G-)Z#6IU?BSXH7&F_$#2O"_AU-+NI+J-);B:ZN@JJ&/RH"" '*X8 ]=RX'
M(SV_B36H_#OAC4=8E4.ME;O*$9MH=@.%SSC)P,^]?.WP[TRWNOB5X%_M&TCE
M:;1I)W\Z/)=DEN1&YSU(5(P#Z*N.@KT_X[WL_P#P@MOHMBHDN]9OHK9(B<%Q
MG=Q_P((/QIR5M!1U>IT'@;Q[:>+O X\17*Q:<D;R)<J\P*0E3W<@?PE3^-4-
M(^)EGJ_C[5M*@GL#HNFV"W7]I)<!E<G;G+?=4#<01SR.HZ5X==R:MH?@CQ?X
M4O;1;"2+4+:[DLU?>L<+GD;AU&?)YIGC5-,@\0>*H_!8M?['-K:;_LIS'LW1
MEN1_MXS1U'8]UT?XEVFL>/M6TJWGT\Z-IU@MU_:27 97)VY);[J@;B#UY'4=
M*Z*+QCX:GMKFX@\0:9+!:!3/*EY&RQ9Z;B#@9Z"O##%H4/B?XAIX4%J-+_X1
MS,7V4@QY*QEL8]\U!XJT&TTOX6^!Y],L;&VBU&:!]1EN PBEDVY0RD'.WYI,
MXYQFE_P/QN']?<D>_'Q1H*Z*-7.LV(TYFVB[^T+Y9/INSC/M4<OC#PW!IL.H
MS:]IJ6<[%8K@W2;'(Z@'."1W]*^>SX0#^'KYIO$_AF(OJJW%E:0SYLFE"L9(
MR&&%&"F,D@@8]Z9=RZ5K_@_2-5T^#1=,OM(>Y670[QCY%X,AG:/<>I+8 SGC
M"GY10%CZ;M;JWO;6.YLYX[B"5=T<L3AE<>H(X(J6N7^'VH6NM_#72;G3+(Z7
M;RVQCCMT)/D[24X)Y/()!/)ZFLK_ (5KJ/\ T4'Q3_X%)_\ $T/>PNAT?B_Q
M#_PBGA*_UO[+]K^QQA_(\S9OY QNP<=?2N8L?B9>JUY;^)?#$VC7T6FR:E;1
M?;$G2YB09(#J/E/L15GXJPFW^#6LPM*\S1VB(9)#EG(91D^YK)G\%S6/A75_
M$&N:W<ZUJ/\ 8,UO;M+$D26\1C)(54&,GUJ9.RD^W^3_ %L7%)N*?5_JO^"=
M?I7BVPN?"NDZQK%U::7_ &E!'(B3W"H-SJ#L!;&3S6CJ.MZ5I"QMJVIV=B)3
MB,W-PD>\^@W$9KP+['<:E?>'+2Y;0%MCX2A\@Z^K-",G]XT>" )!QSU JWXC
M$Z:%'X:OG\-74FD>'3/_ &GJ$7G/<*VX*+=B1@X4?-SSBM*EHMV[O\+_ .1$
M5>R]/QM_F>Y7NMZ5IK0+J.IV=HUR<0">X1#*?]G)Y_"G7.L:99W=O:WFHVD%
MQ<G$$,LZJ\O^ZI.6_"O"]2M;&R\-^'/%%PVBZQ):>'[>.]T;564R-#U$D.<D
M/G(Z<_I3->L)O%'C7Q0LMQX>L!-;VAMI=;5EGMXFC!5H&! 3#$YXZT-6DUV;
M!;7_ *_K_@=SZ EFC@A>:>18HHU+.[L J@=22>@JK8ZUI>IR2QZ;J5G=O" 9
M5MYUD,>>F0#QGWK#\6QSP_";5XKN19;A-'E6613D.PB.2/J:\[\%0:/!XK\&
MMX<2S267PW*VI_8]GS':F#)MZMOSUYS4]7Y?Y-_H'V4^_P#P/\STO5_%MG%I
M5U)H%]I.H7\"+(+9]0CC&TN%+,V3M'/4]^*T)O$6CVLZ6][JUA;W+,J"&2Z0
M,689"@$Y)/;UKQ"VTC3K?]EN[U*"PMX[ZX0K-=+$!)(!=C 9NI' X]J?XETG
M3[ZZ^)UW>64$]S9V=BUM-)&"\)\H<J>J]!TJFK73Z?\  +Y;_?;\D>LV?C2R
MN_'M_P"&O,MT>T@C=7^T*6E=MV4"^JA>>IY[5LW^KZ;I2AM4U"ULE8%@;B98
MP0.I^8CI7G7ANQT6/XRZE)<VM@MXVFV<UN\D:"0RL'WLI/.XCJ1R>]6?'NG6
M6J_%;P-9ZG:0WEM(+W?#/&'1L1 C*G@\@&E9Z+U_"_\ D0K.[\K_ ('?'4[
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MGVE/,SZ;<YS[5\_>#8=!_P"$N\$S^((K+RYM$=Y'N57#R+-(D9.>K (JCOP
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M^Y3GW4 4DKO^NU_U7W@[I?UWM_F>YT4V.1)8UDB8.C@,K*<@@]"*=2 ****
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M&U?R%<A\//A7_P (T=4NO$/]G7-QJ<8@>TLX,6T40/W0"!NSQU';N3FO*?\
MAFKQC_T$M#_[_P W_P :H_X9J\8_]!+0_P#O_-_\:H ^BM#\+Z'X:CE30=+M
MK 3$&0PQ@%\=,GJ<4FM^%M"\2&$Z[I5K?F YB,T8)7\?3VKYV_X9J\8_]!+0
M_P#O_-_\:H_X9J\8_P#02T/_ +_S?_&J /HU?#NCIJMMJ::;;)>VD'V>WF6,
M!HHN?D7'0?,>/>GZAH>F:K>65UJ-C#<SV$GF6LDBY,+9!W+Z'Y1^5?-__#-7
MC'_H):'_ -_YO_C5'_#-7C'_ *"6A_\ ?^;_ .-4 ?1%SX4T&]O[N]N])M)K
MF]A\BYE>,%I8^/E;U'RK^0]*JV?@'PII\-Q%9:!8Q1W47DSJL(Q(F0<'UY /
MU&:\!_X9J\8_]!+0_P#O_-_\:H_X9J\8_P#02T/_ +_S?_&J /?['P'X6TV&
MYBL-"LH$NH3!.$BQYD9ZJ?4<5>G\/:1=:$NBW&G6\NFJ@C6U= 451T ';%?.
M7_#-7C'_ *"6A_\ ?^;_ .-4?\,U>,?^@EH?_?\ F_\ C5 'OK?#[PD^DIIC
M>'=/-FCEUC\@<,<9;/7)P!G/84ES\/?"-Y8VUI<^'=/>"U7;"OD ;!G. 1SU
M)/N3FO _^&:O&/\ T$M#_P"_\W_QJC_AFKQC_P!!+0_^_P#-_P#&J /IJVMH
M+.UCMK2&."")0D<4:A511T  Z"I:^8/^&:O&/_02T/\ [_S?_&J/^&:O&/\
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M)7&"2>?K4<'AW1;;1VTF#2+&/3G^_:"W3RF[\KC!_&OG+_AFKQC_ -!+0_\
MO_-_\:H_X9J\8_\ 02T/_O\ S?\ QJ@#Z633;&*^^VQV5NEUY0A\]8E$GE@Y
M";L9VY[=*AU70M*UV*.+6M-M;^.)MZ+<PK(%/J,BOF__ (9J\8_]!+0_^_\
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M_P#?^;_XU0!]/T5\P?\ #-7C'_H):'_W_F_^-4?\,U>,?^@EH?\ W_F_^-4
M?3]%?,'_  S5XQ_Z"6A_]_YO_C5'_#-7C'_H):'_ -_YO_C5 'T_17S!_P ,
MU>,?^@EH?_?^;_XU1_PS5XQ_Z"6A_P#?^;_XU0!]/T5\P?\ #-7C'_H):'_W
M_F_^-4?\,U>,?^@EH?\ W_F_^-4 ?3]%?,'_  S5XQ_Z"6A_]_YO_C5'_#-7
MC'_H):'_ -_YO_C5 'T_17S!_P ,U>,?^@EH?_?^;_XU1_PS5XQ_Z"6A_P#?
M^;_XU0!]/T5\P?\ #-7C'_H):'_W_F_^-4?\,U>,?^@EH?\ W_F_^-4 ?3]%
M?,'_  S5XQ_Z"6A_]_YO_C5'_#-7C'_H):'_ -_YO_C5 'T_17S!_P ,U>,?
M^@EH?_?^;_XU1_PS5XQ_Z"6A_P#?^;_XU0!]/T5\P?\ #-7C'_H):'_W_F_^
M-4?\,U>,?^@EH?\ W_F_^-4 ?3]%?,'_  S5XQ_Z"6A_]_YO_C5'_#-7C'_H
M):'_ -_YO_C5 'T_17S!_P ,U>,?^@EH?_?^;_XU1_PS5XQ_Z"6A_P#?^;_X
MU0!]/T5\P?\ #-7C'_H):'_W_F_^-4?\,U>,?^@EH?\ W_F_^-4 ?3]%?,'_
M  S5XQ_Z"6A_]_YO_C5<WXX^$6O> -$AU36+O3IX)KA;=5M99&8,59LD,BC&
M$/?TH ^PZ*Y_P#_R3;PU_P!@FU_]$K704""L6\\&^'-0UQ-8O=%LY]0C((N'
MB!;(Z$^I&!@GT%>=?M*_\DVT_P#["T?_ *)FKR?PI\#_ !)XP\,6FNZ9>Z5%
M:W6_8EQ+(KC:[(<@1D=5/>@9]/2>#_#LVOC6Y=&LWU-2&%TT(+[AT;ZCUZTZ
MY\)Z#>-J!NM)M93J6S[863/G[""N[UP0*^=_^&:O&/\ T$M#_P"_\W_QJC_A
MFKQC_P!!+0_^_P#-_P#&J /H*Y\$>&;R6XENM$LY7NHTBF9HP3(J;=H/L-BX
M^@J2Z\(>'[YKUKO2+69K](TNB\>?.5,; WKC:N/I7SS_ ,,U>,?^@EH?_?\
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MCX<LM0-]::#IL-V69_M"6B"3)&"=V,C.3GZFOGC_ (9J\8_]!+0_^_\ -_\
M&J/^&:O&/_02T/\ [_S?_&J /HS3?#6AZ-<S7&D:/8V,T_$LEO;JA<>A('2E
MTWPYHNC74]SI.DV5E/<',LEO J,_.>2!ZU\Y?\,U>,?^@EH?_?\ F_\ C5'_
M  S5XQ_Z"6A_]_YO_C5 'NOB;P/:^*O$VB:AJ?D3V>F+.)+.>$2+.9% '7@8
MQGOSBMV+1=+@-F8=-M$-@I2T*P*#;@C!"''R@C@XKYM_X9J\8_\ 02T/_O\
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M;_XU0!]-SV\-U;26]U#'-!*I22*10RNI&""#P1[51TOPWHFAR32:-I%C8/.
M)#:VZQ[P.@.T#BOG+_AFKQC_ -!+0_\ O_-_\:H_X9J\8_\ 02T/_O\ S?\
MQJ@#Z-TWPYHFCW,]QI.DV5E-<'][);VZHS]^2!39O#.A7&D#2IM&L'T\-O%J
M;9/+#9SD+C .23GWKYT_X9J\8_\ 02T/_O\ S?\ QJC_ (9J\8_]!+0_^_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 ?,'@O\ Y.PN?^PMJ7_H,]?3]?,'@O\ Y.PN?^PM
MJ7_H,]?3] V%%%% @HHHH **** "BBB@#Y@\%_\ )V%S_P!A;4O_ $&>OI^O
MF#P7_P G87/_ &%M2_\ 09Z^GZ!L****!!1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>0?
MM*_\DVT__L+1_P#HF:O7Z\@_:5_Y)MI__86C_P#1,U '?^ ?^2;>&O\ L$VO
M_HE:Z"N?\ _\DV\-?]@FU_\ 1*UT% 'D'[2O_)-M/_["T?\ Z)FK?^!O_)&-
M"_[>/_2B2L#]I7_DFVG_ /86C_\ 1,U;_P #?^2,:%_V\?\ I1)0/H>@4444
M""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** /F#P7_R=A<_]A;4O_09Z^GZ^8/!?_)V
M%S_V%M2_]!GKZ?H&PHHHH$%%%% !1110 4444 ?,'@O_ ).PN?\ L+:E_P"@
MSU]/U\P>"_\ D["Y_P"PMJ7_ *#/7T_0-A1110(**** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^)O_ ([1_P -*^,?^@;H?_?B;_X[7T_10!\P?\-*^,?^@;H?_?B;_P".T?\
M#2OC'_H&Z'_WXF_^.U]/T4 ?,'_#2OC'_H&Z'_WXF_\ CM'_  TKXQ_Z!NA_
M]^)O_CM?3]% 'S!_PTKXQ_Z!NA_]^)O_ ([1_P -*^,?^@;H?_?B;_X[7T_1
M0!\P?\-*^,?^@;H?_?B;_P".T?\ #2OC'_H&Z'_WXF_^.U]/T4 ?,'_#2OC'
M_H&Z'_WXF_\ CM'_  TKXQ_Z!NA_]^)O_CM?3]% 'S!_PTKXQ_Z!NA_]^)O_
M ([1_P -*^,?^@;H?_?B;_X[7T_10!\P?\-*^,?^@;H?_?B;_P".T?\ #2OC
M'_H&Z'_WXF_^.U]/T4 ?,'_#2OC'_H&Z'_WXF_\ CM'_  TKXQ_Z!NA_]^)O
M_CM?3]% 'S!_PTKXQ_Z!NA_]^)O_ ([1_P -*^,?^@;H?_?B;_X[7T_10!\P
M?\-*^,?^@;H?_?B;_P".T?\ #2OC'_H&Z'_WXF_^.U]/T4 ?,'_#2OC'_H&Z
M'_WXF_\ CM'_  TKXQ_Z!NA_]^)O_CM?3]% 'S!_PTKXQ_Z!NA_]^)O_ ([1
M_P -*^,?^@;H?_?B;_X[7T_10!\P?\-*^,?^@;H?_?B;_P".T?\ #2OC'_H&
MZ'_WXF_^.U]/T4 ?,'_#2OC'_H&Z'_WXF_\ CM'_  TKXQ_Z!NA_]^)O_CM?
M3]% 'S!_PTKXQ_Z!NA_]^)O_ ([1_P -*^,?^@;H?_?B;_X[7T_10!\P?\-*
M^,?^@;H?_?B;_P".T?\ #2OC'_H&Z'_WXF_^.U]/T4 ?,'_#2OC'_H&Z'_WX
MF_\ CM'_  TKXQ_Z!NA_]^)O_CM?3]% 'S!_PTKXQ_Z!NA_]^)O_ ([1_P -
M*^,?^@;H?_?B;_X[7T_10!\P?\-*^,?^@;H?_?B;_P".T?\ #2OC'_H&Z'_W
MXF_^.U]/T4 ?,'_#2OC'_H&Z'_WXF_\ CM'_  TKXQ_Z!NA_]^)O_CM?3]%
M'S!_PTKXQ_Z!NA_]^)O_ ([1_P -*^,?^@;H?_?B;_X[7T_10!\P?\-*^,?^
M@;H?_?B;_P".T?\ #2OC'_H&Z'_WXF_^.U]/T4 ?,'_#2OC'_H&Z'_WXF_\
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M - W0_\ OQ-_\=H_X:5\8_\ 0-T/_OQ-_P#':^GZ* /F#_AI7QC_ - W0_\
MOQ-_\=H_X:5\8_\ 0-T/_OQ-_P#':^GZ* /F#_AI7QC_ - W0_\ OQ-_\=H_
MX:5\8_\ 0-T/_OQ-_P#':^GZ* /F#_AI7QC_ - W0_\ OQ-_\=H_X:5\8_\
M0-T/_OQ-_P#':^GZ* /F#_AI7QC_ - W0_\ OQ-_\=H_X:5\8_\ 0-T/_OQ-
M_P#':^GZ* /F#_AI7QC_ - W0_\ OQ-_\=H_X:5\8_\ 0-T/_OQ-_P#':^GZ
M* /F#_AI7QC_ - W0_\ OQ-_\=H_X:5\8_\ 0-T/_OQ-_P#':^GZ* /F#_AI
M7QC_ - W0_\ OQ-_\=H_X:5\8_\ 0-T/_OQ-_P#':^GZ* /F#_AI7QC_ - W
M0_\ OQ-_\=H_X:5\8_\ 0-T/_OQ-_P#':^GZ* /F#_AI7QC_ - W0_\ OQ-_
M\=H_X:5\8_\ 0-T/_OQ-_P#':^GZ* /F#_AI7QC_ - W0_\ OQ-_\=H_X:5\
M8_\ 0-T/_OQ-_P#':^GZ* /F#_AI7QC_ - W0_\ OQ-_\=H_X:5\8_\ 0-T/
M_OQ-_P#':^GZ* /F#_AI7QC_ - W0_\ OQ-_\=H_X:5\8_\ 0-T/_OQ-_P#'
M:^GZ* /F#_AI7QC_ - W0_\ OQ-_\=H_X:5\8_\ 0-T/_OQ-_P#':^GZ* /F
M#_AI7QC_ - W0_\ OQ-_\=H_X:5\8_\ 0-T/_OQ-_P#':^GZ* /F#_AI7QC_
M - W0_\ OQ-_\=H_X:5\8_\ 0-T/_OQ-_P#':^GZ* /F#_AI7QC_ - W0_\
MOQ-_\=H_X:5\8_\ 0-T/_OQ-_P#':^GZ* /F#_AI7QC_ - W0_\ OQ-_\=H_
MX:5\8_\ 0-T/_OQ-_P#':^GZ* /F#_AI7QC_ - W0_\ OQ-_\=H_X:5\8_\
M0-T/_OQ-_P#':^GZ* /F#_AI7QC_ - W0_\ OQ-_\=H_X:5\8_\ 0-T/_OQ-
M_P#':^GZ* /F#_AI7QC_ - W0_\ OQ-_\=H_X:5\8_\ 0-T/_OQ-_P#':^GZ
M* /F#_AI7QC_ - W0_\ OQ-_\=H_X:5\8_\ 0-T/_OQ-_P#':^GZ* /F#_AI
M7QC_ - W0_\ OQ-_\=H_X:5\8_\ 0-T/_OQ-_P#':^GZ* /F#_AI7QC_ - W
M0_\ OQ-_\=H_X:5\8_\ 0-T/_OQ-_P#':^GZ* /F#_AI7QC_ - W0_\ OQ-_
M\=H_X:5\8_\ 0-T/_OQ-_P#':^GZ* /F#_AI7QC_ - W0_\ OQ-_\=H_X:5\
M8_\ 0-T/_OQ-_P#':^GZ* /F#_AI7QC_ - W0_\ OQ-_\=H_X:5\8_\ 0-T/
M_OQ-_P#':^GZ* /F#_AI7QC_ - W0_\ OQ-_\=H_X:5\8_\ 0-T/_OQ-_P#'
M:^GZ* /F#_AI7QC_ - W0_\ OQ-_\=H_X:5\8_\ 0-T/_OQ-_P#':^GZ* /F
M#_AI7QC_ - W0_\ OQ-_\=H_X:5\8_\ 0-T/_OQ-_P#':^GZ* /F#_AI7QC_
M - W0_\ OQ-_\=H_X:5\8_\ 0-T/_OQ-_P#':^GZ* /F#_AI7QC_ - W0_\
MOQ-_\=H_X:5\8_\ 0-T/_OQ-_P#':^GZ* /F#_AI7QC_ - W0_\ OQ-_\=H_
MX:5\8_\ 0-T/_OQ-_P#':^GZ* /F#_AI7QC_ - W0_\ OQ-_\=H_X:5\8_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1165J'BKP]I%W]EU77M,L;C ;R;F\CC?!
MZ':Q!H U:*0$,H*D$$9!'>EH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "OB#Q]_P E)\2_]A:Z_P#1S5]OU\0>/O\ DI/B7_L+77_HYJ!HY^BBB@85
M]0?LU?\ )-M0_P"PM)_Z)AKY?KZ@_9J_Y)MJ'_86D_\ 1,- ,]?HHHH)"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
5110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
